<SUBMISSION>
<ACCESSION-NUMBER>0001104659-08-065758
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>14
<PERIOD>20081025
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20081027
<DATE-OF-FILING-DATE-CHANGE>20081027
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>THERAVANCE INC
<CIK>0001080014
<ASSIGNED-SIC>2834
<IRS-NUMBER>943265960
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-30319
<FILM-NUMBER>081141206
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>901 GATEWAY BLVD
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6508086000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>901 GATEWAY BLVD
<CITY>S. SAN FRANCISCO
<STATE>CA
<ZIP>94080
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED MEDICINE INC
<DATE-CHANGED>20000302
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a08-26779_18k.htm
<DESCRIPTION>8-K
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, DC&#160; 20549</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;">Current Report Pursuant</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;">to Section&nbsp;13 or 15(d)&nbsp;of
the</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;">Securities Exchange Act
of 1934</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of
earliest event Reported):&#160; <b>October&nbsp;25, 2008</b></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">THERAVANCE, INC.</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as
Specified in its Charter)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware<br>
  </font></b>(State or Other Jurisdiction of Incorporation)</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-30319<br>
  </font></b>(Commission File Number)</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">94-3265960<br>
  </font></b>(I.R.S. Employer Identification Number)</p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">901 Gateway Boulevard</font></b><font face="Times New Roman"><br>
</font><font face="Times New Roman">South San Francisco</font><font face="Times New Roman">, California
94080 <br>
</font><font face="Times New Roman">(650) 808-6000</font></p>

<p style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Addresses, including zip
code, and telephone numbers, including area code, of principal executive
offices)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425
under the Securities Act (17 CFR 230.425)</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to
Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to
Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105627\08-26779-1\task3186222\26779-1-ba.htm',USER='105627',CD='Oct 25 08:48 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01 Other Events.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At
the 48</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">th</font>&#160;Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and
the Infectious Diseases Society of America (IDSA) 46<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">th</font>&#160;Annual Meeting held in Washington, D.C.
between October&nbsp;25 and 28, telavancin, an investigational lipoglycopeptide
with bactericidal activity in vitro against Gram-positive pathogens including
methicillin-resistant <i>Staphylococcus aureus</i>,
is being featured in twenty-five posters or podium presentations.&#160; A text version of two posters containing new
telavancin data, which were shown on October&nbsp;25, 2008 at the joint
ICAAC/IDSA conference, are attached hereto as Exhibits&nbsp;99.1 and 99.2 and
are incorporated herein by reference.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 9.01 Financial Statements and Exhibits.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="right">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.66%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font></p>
  </td>
  <td width="93%" valign="bottom" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibits</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:33.75pt;width:93.76%;">
 <tr>
  <td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.72%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="10%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:10.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:86.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Poster
  entitled &#147;Telavancin for the Treatment of Hospital-Acquired Pneumonia in
  Severely Ill and Older Patients: The ATTAIN Studies&#148;</font></p>
  </td>
 </tr>
 <tr>
  <td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;99.2</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Poster
  entitled &#147;Telavancin for Treatment of Hospital-Acquired Pneumonia Caused by
  MRSA and MSSA: The ATTAIN Studies&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105627\08-26779-1\task3186222\26779-1-ba.htm',USER='105627',CD='Oct 25 08:48 2008' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THERAVANCE, INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:
  October&nbsp;27, 2008</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Michael W. Aguiar</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Michael
  W. Aguiar</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chief
  Financial Officer</font></b></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105627\08-26779-1\task3186222\26779-1-ba.htm',USER='105627',CD='Oct 25 08:48 2008' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.62%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="10%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:10.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:87.62%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Poster
  entitled &#147;Telavancin for the Treatment of Hospital-Acquired Pneumonia in
  Severely Ill and Older Patients: The ATTAIN Studies&#148;</font></p>
  </td>
 </tr>
 <tr>
  <td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;99.2</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.62%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Poster
  entitled &#147;Telavancin for Treatment of Hospital-Acquired Pneumonia Caused by
  MRSA and MSSA: The ATTAIN Studies&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105627\08-26779-1\task3186222\26779-1-ba.htm',USER='105627',CD='Oct 25 08:48 2008' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a08-26779_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Telavancin for the Treatment of Hospital-Acquired<br><br></font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Pneumonia in Severely Ill and Older Patients:</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The ATTAIN Studies</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">E Rubinstein,</font></b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">1)</font></b>&#160;<b>GR Corey,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">2)</font></b>&#160;<b>HW
Boucher,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">3)</font></b><b>&nbsp;MS
Niederman,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">4)</font></b><b>&nbsp;AF
Shorr,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">5)</font></b><b>&nbsp;A
Torres,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">6)</font></b>&#160;<b>SL Barriere,</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">7)</font></b><b>&nbsp;HD Friedland</b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">(</font></b><b><font size="1" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">7)</font></b><b>; On behalf of the ATTAIN Study
Group</b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font>University of Manitoba,
Winnipeg, Canada; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">2)</font>Duke University Medical Center, Durham, NC, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">3)</font>Tufts
Medical Center, Boston, MA, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">4)</font>SUNY, Stony Brook, NY, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">5)</font>Georgetown
University, Washington, DC, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">6)</font>Hospital Cl&#237;nic de Barcelona, Barcelona, Spain; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">7)</font>Theravance,&nbsp;Inc.,
South San Francisco, CA, USA</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting,
Washington, DC, October&nbsp;25-28, 2008.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABSTRACT
(REVISED)</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Background.</font></b> Telavancin (TLV) is an
investigational lipoglycopeptide with potent bactericidal activity in vitro
against Gram-positive pathogens including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). The ATTAIN program studied TLV
for the treatment of hospital-acquired pneumonia (HAP). In this analysis, we
compared the clinical cure rates achieved with TLV or vancomycin (VAN) for
severely ill and older patients.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Methods.</font></b> ATTAIN 1 and 2 were methodologically
identical, randomized, double-blind, Phase 3 studies. Patients (<u>&gt;</u>18
years of age) with HAP caused by suspected or confirmed Gram-positive pathogens
were randomized to TLV 10 mg/kg intravenous (IV)&nbsp;q24 h or VAN 1 g IV q12 h
for 7 to 21 days. Test-of-cure (TOC) visit was conducted 7 to 14 days after
end-of-study treatment. Clinically evaluable (CE) patients were those who met
prespecified criteria for evaluability.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results.</font></b> Pooled clinical cure rates at TOC for
several clinically relevant subgroups including the elderly as well as patients
with severe HAP at baseline are presented in the Table. The overall incidence
of treatment-emergent adverse events was comparable between treatment groups.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="701" height="226" src="g267791mmi001.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conclusions.</font></b> TLV achieved numerically higher
cure rates than conventional therapy for treatment of HAP in severely ill and
older patients with comparable treatment-emergent adverse events.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INTRODUCTION</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In the United States, pneumonia is the leading
cause of death among patients with health care-associated infections.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">1)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>A recent survey of culture-positive pneumonia
identified <i>Staphylococcus aureus</i> as a dominant
pathogen for all types of pneumonia, including hospital-acquired pneumonia
(HAP), and the only pathogen that correlates with mortality.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">2)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Conventional treatment is associated with high
mortality among patients with bacteremic HAP due to <i>S. aureus</i>.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">3)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Telavancin is an investigational, rapidly
bactericidal lipoglycopeptide with a potent multifunctional mechanism of action
against clinically relevant Gram-positive pathogens, including
methicillin-resistant <i>S. aureus</i>.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">4)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In Phase 3 clinical trials for complicated skin
and skin structure infections and HAP, telavancin achieved its objective of
noninferiority in the all-treated (AT) and clinically evaluable (CE) patient
populations.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">5),(6)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In this analysis, we compared telavancin and
vancomycin for treatment of HAP in severely ill or older patients from the
Assessment of Telavancin for Hospital-acquired Pneumonia (ATTAIN) studies.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">METHODS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Patients</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Major inclusion criteria</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Men and nonpregnant women <u>&gt;</u>18 years of
age.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Clinical signs and symptoms consistent with
pneumonia acquired after 48 hours in an inpatient acute- or chronic-care
facility, or acquired within 7 days after being discharged following <u>&gt;</u>3
days of hospital stay.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Radiographic and laboratory findings consistent
with bacterial pneumonia.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Adequate respiratory specimen for Gram stain and
culture.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Major exclusion criteria</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Receipt of potentially effective systemic
antibiotic therapy for Gram-positive pneumonia for more than 24 hours
immediately prior to randomization.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Respiratory tract specimens with only
Gram-negative bacteria seen on Gram stain or culture.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>An infection due to organisms known to be
resistant to either of the study medication regimens or suspected pulmonary
disease that precluded evaluation of therapeutic response.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Documented or suspected meningitis, endocarditis,
osteomyelitis, or evidence for compromised host immune response.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Study design</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>ATTAIN 1 and 2 were methodologically identical,
randomized, double-blind, comparator-controlled, parallel-group Phase 3 studies
conducted at 275 sites in 38 countries.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Enrollment took place between January&nbsp;2005
and June&nbsp;2007.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Patients were randomized (1:1) to receive
telavancin 10 mg/kg intravenous (IV)&nbsp;every 24 hours or vancomycin 1 g IV
every 12 hours for 7 to 21 consecutive days.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Telavancin dose was adjusted in patients with
creatinine clearance of &lt;50 mL/min.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Vancomycin dose was adjusted per site-specific
guidelines.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Switching to antistaphylococcal penicillin was
allowed for infections with methicillin-susceptible <i>S. aureus</i>.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Concomitant treatment with aztreonam and/or
metronidazole was permitted for polymicrobial infections.</p>

<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Baseline
clinical assessments included medical history, physical examination, chest
radiograph or chest computed tomography, arterial blood gas in patients on
mechanical ventilation or with an arterial line, creatinine clearance
calculation, and electrocardiogram.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Components
of the Acute Physiology and Chronic Health Evaluation (APACHE) II score were
collected for all patients. Calculations were performed by imputing zeroes for
missing components.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Severity
of illness was determined based on each of the following: APACHE II score <u>&gt;</u>20,
baseline Clinical Pulmonary Infection Score &gt;6, presence or absence of acute
lung injury (ALI) or acute respiratory distress syndrome (ARDS), presence or
absence of bacteremia, and age <u>&gt;</u>65 years.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Safety
assessments included vital signs, adverse events, electrocardiograms, and
laboratory parameters.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Analysis populations</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>AT: Randomized patients who received <u>&gt;</u>1
dose of study medication.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Modified all-treated (MAT): AT patients with
baseline pathogen.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>CE: Compliant AT patients with a clinical
response of &#147;cure&#148; after receiving study medication <u>&gt;</u>5 days and at
least 80% of the intended dose, or &#147;failure&#148; following <u>&gt;</u>3 days on
study medication at test-of-cure (TOC) 7 to 14 days after last dose of study
drug.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Microbiologically evaluable (ME): CE patients
with a Gram-positive pathogen recovered from baseline respiratory specimens or
blood cultures.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Study end points</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Clinical response at TOC:</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Cure: Signs and symptoms of pneumonia resolved</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Failure: Persistence/progression of pneumonia or
relapse after end of therapy, termination of study medication due to lack of
efficacy, death after <u>&gt;</u>3 days attributable to the primary infection</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Indeterminate: Inability to determine outcome.</p>

<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Statistics</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Descriptive statistics were calculated for
patient demographics and safety data.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Two-sided, 95% confidence intervals were
constructed on the difference in cure rates (telavancin minus vancomycin).</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESULTS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Disposition and outcomes</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A
total of 1532 individuals were randomized to receive study medication and 1503
received at least 1 dose of study medication (Figure 1).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt .25in;text-align:center;text-indent:-.25in;"><font size="2" face="Times New Roman"><img width="663" height="268" src="g267791mmi002.gif"></font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font face="Symbol">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In
the combined CE population of ATTAIN, the proportions of severely ill patients
and older patients (<u>&gt;</u>65 years) were mostly balanced between treatment
groups, although more patients in the telavancin group had ALI or ARDS (Table
1).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .45in;text-indent:-.25in;"><font size="2" face="Times New Roman"><img width="691" height="195" src="g267791mmi003.gif"></font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
cure rates obtained with telavancin were comparable to those achieved with
conventional therapy across all severity subgroups. The cure rates were
numerically higher in the APACHE II <u>&gt;</u>20, ALI or ARDS, bacteremia, and
age <u>&gt;</u>65 years severity subgroups (Figure 2).</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-weight:bold;"><img width="705" height="302" src="g267791mmi004.jpg"></font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Safety</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The incidence of treatment-emergent adverse
events in patients meeting at least 1 of the criteria for more severe HAP or
underlying illness were similar for both treatment groups (Table 2).</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt .25in;text-align:center;"><font size="2" face="Times New Roman"><img width="624" height="237" src="g267791mmi005.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONCLUSIONS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Telavancin achieved numerically higher cure rates
than vancomycin for treatment of HAP in severely ill and older patients.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The comparable incidence of treatment-emergent
adverse events between telavancin and vancomycin suggest that, if approved, telavancin
may be an important option for the treatment of these vulnerable populations.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REFERENCES</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Klevens RM et al. <i>Public
Health Rep</i> 2007;122:160&#150;166.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Kollef MH et al. <i>Chest </i>2005;128:3854&#150;3862.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Gonzalez C et al. <i>Clin Infect
Dis</i> 1999;29:1171&#150;1177.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Attwood RJ, LaPlante KL. <i>Am J Health Syst Pharm</i> 2007;64:2335&#150;2348.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Stryjewski ME et al. <i>Clin Infect
Dis</i> 2008;46:1683&#150;1693.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(6)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Rubinstein E et al. <i>Clin Microbiol Infect</i> 2008;14:S14.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\rrathi\08-26779-1\task3186039\26779-1-mm.htm',USER='105342',CD='Oct 25 05:13 2008' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a08-26779_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.2</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Telavancin for Treatment of Hospital-Acquired<br><br></font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Pneumonia Caused by MRSA and MSSA: The</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTAIN Studies</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E Rubinstein,</font><font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font>&nbsp;GR Corey,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2)</font>&nbsp;ME Stryjewski,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2),(3)</font>&nbsp;JL Vincent,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(4)</font>&nbsp;JY Fagon,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(5)</font>&nbsp;MH Kollef,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(6)</font>&nbsp;MM Kitt,<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(7)</font>&nbsp;HD Friedland<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(7)</font>; on behalf of the ATTAIN Study Group</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font>University of Manitoba,
Winnipeg, Canada; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2)</font>Duke Clinical Research
Institute, Durham, NC, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(3)</font>Centro de
Educaci&#243;n M&#233;dica&nbsp;e Investigaciones Cl&#237;nicas (CEMIC), Buenos Aires,
Argentina; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(4)</font>H&#244;pital Erasme, Brussels,
Belgium; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(5)</font>H&#244;pital Europ&#233;en Georges
Pompidou, Paris, France; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(6)</font>Washington
University, St. Louis, MO, USA; <font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(7)</font>Theravance,&nbsp;Inc.,
South San Francisco, CA, USA</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presented at the 48th Annual ICAAC/IDSA 46th
Annual Meeting, Washington, DC, October&nbsp;25-28, 2008.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABSTRACT
(REVISED)</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Background.</font></b> Vancomycin (VAN) is the standard
of care for the treatment of methicillin- resistant <i>S. aureus</i>
(MRSA) pneumonia but is felt to be less effective for infections with
methicillin-susceptible (MSSA) strains. Telavancin (TLV) is an investigational,
bactericidal lipoglycopeptide with potent activity against Gram-positive
pathogens in vitro. We compared the efficacy of TLV and VAN for treatment of
HAP caused by Gram-positive bacteria.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Methods.</font></b> ATTAIN 1 and 2 were randomized,
methodologically identical, double-blind, Phase 3, clinical studies. Patients (<u><font size="1" style="font-size:2.0pt;">&nbsp;</font>&gt;</u>18 years of
age) with HAP suspected or documented to be due to Gram-positive pathogens were
randomized to receive TLV 10 mg/kg IV q24 h or VAN 1 g IV q12 h for 7 to 21
days. Test-of-cure (TOC) visit was conducted 7 to 14 days after end of study
treatment. The microbiologically evaluable (ME) population consisted of
clinically evaluable patients with Gram-positive pathogen isolated at baseline.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results.</font></b> Pooled clinical cure rates at TOC for
ME patients with monomicrobial infections are presented in the Table. Patients
with mixed Gram+/Gram&#150; infection are not included.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="682" height="154" src="g267791moi001.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conclusions.</font></b> TLV achieved numerically higher
clinical cure rates in ME patients with monomicrobial HAP caused by MRSA and
MSSA.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INTRODUCTION</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><i>Staphylococcus aureus</i>
has emerged as a major pathogen in hospital-acquired pneumonia (HAP).<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Methicillin-resistant <i>S. aureus</i>
(MRSA) strains are now implicated in 20% to 40% of all cases of HAP.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Inadequate antimicrobial treatment of critically
ill patients is associated with increased mortality, and this is most commonly
due to inappropriate treatment of resistant organisms.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(3)</font></p>

<p style="margin:0in 0in .0001pt;text-indent:14.2pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The empiric use of vancomycin has increased in
response to the epidemic spread of MRSA.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(4)</font>&nbsp;However,
vancomycin is less efficacious than <font face="Symbol">b</font>-lactam antibiotics for
treatment of invasive infections with methicillin-susceptible (MSSA) strains.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(5),(6)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Telavancin is an investigational, rapidly
bactericidal lipoglycopeptide with a multifunctional mechanism of action
against clinically relevant pathogens, including MRSA.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(7)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In Phase 3 trials, telavancin has demonstrated
noninferiority compared with conventional therapy for treatment of complicated
skin and soft tissue infections<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(8)</font>&nbsp;and
HAP.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(9)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In this analysis, we compared telavancin and
vancomycin for treatment of HAP in patients with a monomicrobial Gram-positive
infection at baseline from the Assessment of Telavancin for Hospital-acquired
Pneumonia (ATTAIN) studies.</p>

<p style="margin:0in 0in .0001pt;text-indent:14.2pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">METHODS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Patients</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Major inclusion criteria</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Men and nonpregnant women <u>&gt;</u>18 years of
age.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Clinical signs and symptoms consistent with
pneumonia acquired after 48 hours in an inpatient acute- or chronic-care
facility, or acquired within 7 days after being discharged following <u>&gt;</u>3
days of hospital stay.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Radiographic and laboratory findings consistent
with bacterial pneumonia.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Adequate respiratory specimen for Gram stain and
culture.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Major exclusion criteria</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Receipt of potentially effective systemic
antibiotic therapy for Gram-positive pneumonia for more than 24 hours
immediately prior to randomization.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Respiratory tract specimens with only
Gram-negative bacteria seen on Gram stain or culture at enrollment.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>An infection due to organisms known to be
resistant to either of the study medication regimens or suspected pulmonary
disease that precluded evaluation of therapeutic response.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Documented or suspected meningitis, endocarditis,
or osteomyelitis and evidence for compromised host immune response.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Study design</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>ATTAIN 1 and 2 were methodologically identical,
randomized, double-blind, comparator-controlled, parallel-group Phase 3 studies
conducted at 275 sites in 38 countries.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Enrollment took place between January&nbsp;2005
and June&nbsp;2007.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Patients were randomized (1:1) to receive
telavancin 10 mg/kg intravenously (IV)&nbsp;every 24 hours or vancomycin 1 g IV
every 12 hours for 7 to 21 consecutive days.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Telavancin dose was adjusted in patients with
creatinine clearance of &lt;50 mL/min.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Vancomycin dose was adjusted per site-specific
guidelines maintaining study blinding.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Switching to antistaphylococcal penicillin was
allowed for MSSA infections.</p>

<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Baseline clinical assessments included medical
history, physical examination, chest radiograph or chest computed tomography,
arterial blood gas in patients on mechanical ventilation or with an arterial
line, creatinine clearance calculation, and electrocardiogram.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Test-of-cure (TOC) visit 7 to 14 days after last
dose of study drug.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Analysis populations</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>All-treated (AT): Randomized patients who
received <u>&gt;</u>1 dose of study medication.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Modified all-treated (MAT): AT patients with baseline
pathogen.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Clinically evaluable (CE): Compliant AT patients
with a TOC clinical response of &#147;cure&#148; after receiving study medication <u>&gt;</u>5
days and at least 80% of the intended dose, </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or &#147;failure&#148; following <u>&gt;</u>3 days on
study medication at TOC 7 to 14 days after last dose of study drug.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Microbiologically evaluable (ME): CE patients
with a Gram-positive pathogen recovered from baseline respiratory specimens or
blood cultures.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Study end points</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Clinical response at TOC:</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Cure: Signs and symptoms of pneumonia resolved
and no progression of radiological signs</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Failure: Persistence/progression of pneumonia or
relapse after end of therapy, termination of study medication due to lack of
efficacy, or death after <u>&gt;</u>3 days attributable to the primary
infection</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Indeterminate: Inability to determine outcome.</p>

<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Microbiological evaluations</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Respiratory samples were obtained at baseline for
Gram stain and culture. A sputum or endotracheal suction sample was considered
adequate if it had &gt;25 polymorphonuclear leukocytes and &lt;10 squamous
epithelial cells per high power field.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In patients on mechanical ventilation, acceptable
respiratory specimens included endotracheal suction, bronchoalveolar lavage
(BAL), blind bronchial suctioning, protected specimen brush, or mini-BAL.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Two blood culture specimens were also obtained at
baseline.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>All isolated pathogens were submitted to a
central laboratory for identification to ensure consistency of results.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Susceptibility testing was performed in
accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines.<font size="1" style="font-size:7.0pt;position:relative;top:-3.0pt;">(10)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Statistics</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Analysis was conducted on ME patients with
monomicrobial infection.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Descriptive statistics were calculated for
subject demographics and safety data.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Two-sided, 95% confidence intervals (CIs) were
constructed on the difference in cure rates (telavancin minus vancomycin).</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESULTS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Disposition, baseline, and demographic characteristics</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In the combined population of ATTAIN, 1532
individuals were randomized to receive telavancin or vancomycin and 1503
received at least 1 dose of study medication (Figure 1).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="652" height="221" src="g267791moi002.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>In total, 329 ME patients had a single
Gram-positive pathogen isolated at baseline (telavancin, n=164; vancomycin,
n=165). Baseline characteristics of patients in each treatment group were
comparable (Table 1).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman"><img width="644" height="150" src="g267791moi003.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Among ME patients with monomicrobial
Gram-positive infection at baseline, the most common isolated pathogens were <i>S. aureus</i> and <i>Streptococcus pneumoniae</i>
(Table 2).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .3in;"><font size="2" face="Times New Roman"><img width="662" height="191" src="g267791moi004.gif"></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Compared with the vancomycin group, a higher
proportion of <i>S. aureus</i> isolates from patients
in the telavancin group were MSSA (Table 2).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Outcomes</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The rate of clinical cure in ME patients with
monomicrobial <i>S. aureus</i> infection at baseline
was significantly greater for telavancin compared with VAN (Figure 2).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .3in;"><font size="2" face="Times New Roman"><img width="671" height="291" src="g267791moi005.gif"></font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Numerical differences favoring telavancin were
also observed for patients from whom either MRSA or MSSA were identified as the
baseline pathogen (Figure 2).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Safety</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>The incidence of treatment-emergent adverse
events were similar for both treatment groups (Table 3).</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman"><img width="624" height="182" src="g267791moi006.gif"></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONCLUSIONS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><i>S. aureus</i> was
the pathogen most commonly associated with HAP in this collection of patients.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>Compared with vancomycin, telavancin achieved a
significantly higher rate of cure for monomicrobial <i>S. aureus</i>
infection and numerically higher cure rates for both MRSA and MSSA pneumonia
groups.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font>If approved, telavancin may be an important
option for empirical treatment of HAP when a Gram-positive infection is
suspected.</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REFERENCES</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Kollef MH et al. <i>Chest </i>2005;128:3854&#150;3862.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Rubinstein E et al. <i>Clin Infect
Dis</i> 2008;46:S378&#150;S385.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Kollef MH et al. <i>Chest</i>
1999;115:462&#150;474.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Klevens RM et al; Active Bacterial Core
surveillance (ABCs) MRSA Investigators. JAMA 2007;298:1763&#150;1771.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Bodi M et al. <i>Crit Care
Med</i> 2001;29:N82&#150;N86.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(6)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Small PM et al. <i>Antimicrob Agents Chemother</i> 1990;34:1227&#150;1231.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(7)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Leonard SN et al. <i>Pharmacotherapy
</i>2008;28:458&#150;468.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(8)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Stryjewski ME et al. <i>Clin Infect
Dis</i> 2008;46:1683&#150;1693.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(9)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font>Rubinstein E et al. <i>Clin Microbiol and Infect</i> 2008;14:S14.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;position:relative;top:-3.0pt;">(10)</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font>Clinical and Laboratory
Standards Institute (CLSI). Methods for Dilution of Antimicrobial
Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard
M7-A7. Wayne, PA: CLSI; 2006.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\105537\08-26779-1\task3185535\26779-1-mo.htm',USER='105537',CD='Oct 24 23:23 2008' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g267791moi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi001.gif
M1TE&.#EAJ@*:`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````"I`ID`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2).*%,3B2M.F5YQ*A3I5:M2G5JM2Q;JUZE6O6J.&_8J5
M;%:N8M&:[5IVK%NU;\'"G2NW;ENZ=^V>U<MV;]Z_?@/W'9R6;V'`A-<>%KPX
M<5S$C2,KGOR8,66\EBL[QKS9\&7/FB6'_HQ8D$1!8E.K7LVZM>O7L&/+GDV[
MMNW;N'/KWLV[M^_?P(,+'TZ\N/'CR(^;5LJ\N?/GT*-+GTZ]NO7KV+-KW\Z]
MN_?OX,.+_Q]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]^]<#L-!OI97$_?XQI%]#
MK01P!3:"!+#<05<$$.!#`010DR""/*C1%19BT^!^^RW'E(&L$)1@4_B5:*)\
M!0802(,*1@1@0Q$V-"(VK002(D*"!)*A@!+2U.".%A7(0D%.E1`A"Z:QR.)R
M'.[7XXE01GG>@`A2B>`5"PJTXH(O"A35C0*AADV,!K6"9(`%'FBF?V9BLZ5`
M;<+)5#0$M<+4@V06A%H@`[6"Y96FH79-G&Y>80J#?%(XT)=A'KF<*5?P25!4
M0&+#"I+7T,CA@7JV*!"9UPPHY*<.2FGJJ=X5N`*<5$;(XD"N!O]0@D`OIK@?
MIQM:D>>B!D;HWXP)'JCD"@&$V"&-L7+*"G\!6$&J0;J^6N6!P6H8`+$]QCID
M01%>2VVSMR)XJVG[Z=ICL,<2%&H`>Y#I9)9:&@AKCRDBNRTK\**J[[[2Z5<A
ML=]^RV>#2;;XXG[/CIGMD[!NVRRRWP;:8H(%^]>@0,1ZZ?#"!8TZ*K#R-LBI
MM<:62I"O`Y&H,*TM>BSO?IGF>ZF7)LMK$,7S"A2JP]ORZ_//SZ5XI*35XDRP
MM?X=K)^3">]J;Z<!6RNLP50#V2Z93H_9,ZM1XTPS"TYFF#6+/?Z([-*MVGS0
MAZ6.:E`@:I-9KZI`UVTW4E8.5*W(UI+_6[7"6/ZY\N`G;PWQX3@;7:K9V&1J
MZ8!8,WSV0#$/N+?:'*)6(;<,;SCXL2EJOJ"TG/O9MMHB>CKXSD]KB.'=L,>>
M$]U05VE:NQ5CH[26&R=\LH0N#UETR"T>K70KH7(:>4'1B/KP\!'S^BL+&2+,
M=<)FNVV%:=$$F/?GIQL>[\ARQ^AVA([+KO[Z+WU/:KV-7PO_L<$6Z*S"@20H
M.3;$HG9ZU\4+()L,E*!5%=!,RRL(@/83HA&E:&HC$U*!9E6Z1O5'6KJBGNX<
MQ,`-ZNAAOVO%U;S'KK>I#FY@B]"-B-64K+'OA3`4B=LZUJ#^]"E:`6+<AR((
MME;HBD'^NM[P_PJ6.VR8(ER-4M$/M09$)/&*!<N26)9\B+J4,4Q_@5BBM?9`
ML^WI;3^2JE.YVA6@98D/;EDZHGXL%`@DQO"-<(RC'.=(QSK:\8YXS*,>]\C'
M/OKQCX`,I"`'2<A"&O*0B$RD(A?)2/9AB4*0C*0D)TG)2EKRDIC,I"8WR<E.
M>O*3H`RE*$=)RE*:\I2H3*4J5=E(DY@);$^!)2R=(DNPT;*6MY1E+F=92UOV
M,I:X_.4N?=G+80)3E\),9C&5&<QE.K.9T$3F,Z4935Y.TYK5)&8VCXE-:GJS
MF^#4YC?%&4YNDO.<YDRG,=?)S'&JLYWEO&6^6DG/>MKSGOC,IS[WR?_/?OKS
MGP`-J$`'2M""FL@*'-+/@:RTK!N]TCY,"6,`H!`_#=+*HM9KSX::M:`\)4A2
M3@FC0?O)%"<Y<5=D0N-]4DJUN*7M/1QJ(PC%]#@K9`IN(QOI/W&:LYYVJ3[6
M:U"F.+0J4G',/4)]GX9,(S0[<0A-6'H0"P:U!S1!L4]#8I2<7M<G0>D4CM7R
M'=+XMS_Y'`UK40D`G11V+<*QIX-D?18"J3=7BS4+94);&-S*%JO3K8!O1KQ6
MNK[Z0A3V5"#+XE,5YQ.J$#F/%06:%]S@I]%B*95,@$V0]QRF)BL52&)V#:VU
M6$9:MQ)6?6$UK7X:6B+Y6?9B:7J6?ER('KC_6H],7CL:X#C4NBKUBGA^\YO8
M%$K;T]J-IV+%1K3*.A]8ELI)Q+I?C/3'W/,P#F68M9G77(6:`8YL1($3K=DR
M.B_-Y=2XL4NMTU@D/OI<;6%I/6JW8&K9N`XNMY["+!=G6"T_'<IXSRU5Q@9W
MA?NA5W:&)=53;A0AD=IG7:8)E:1TY1^65M<\(G.*S;*+*T]U"&XABFW#$$BS
MW*6I@(VB$)7`=N"[J;=;*F)9I>9#+-$BRV^'90_95L"E<WE*M]9RXN%NV*P<
M"C!,;D30"DI`O@NW^,E0AHG@HDSE*K]DGE;.LI:WS.4N>_G+8`ZSF,<<4"?)
M"LL1B:W71B*(^XF8_X\?LN&G$I)4A5AA!<NBE[R6!9[]E`!/8.J86A<26?3)
M577=V6&`FI<0+3;HKP/!EJ%IE$$\I4]/4-`/%RWXJ?-*9UP1VK1%^KLYDM3*
M?7?\[&C'5*D"!1HAS7)%A"3&*?)JQT!V"L!0/0TK7BM00A&2+E^_H^J+L1HA
M!2(A*VK(,DCVNDJ96H&#!Y)G)35*62;3%9J/TD':T<@I@7;*%%F@H^NM25P:
M(G=7KVJ0`NN.JY9RBI']E29(19!B#T(-73==(W;KSEE-F;%]C#VF:Z@,B+#2
M$8O[!+PC#=G5W$E0KR.+D,EJ[-U@"I5IYDLX1&N'X!(2\D&TB#6>"1I6%/]J
M+\LR93].?VI(K7!L=&`VK7A9@=D[F]$&]?<K>5U.07B]ELY_=W,J18MO#VQ%
MBF0JJ5F3*5JZXO'C6J@\?Q5WI7\M<E%AW609="%/*X!YMTRA7E]7YU8(N_#"
M-\CC/,'-J$/*$PNVSAWB8DGEG^KH45D(P@V^2NV6'52`4BMQY1+<.=TJUT#V
M4/6:(^_EG4;<Q(YL[,,WK6R-7W5LU3SYI#5\6TN\[5%-9:9KA.K2!3&%R097
M/J;J)]-OMGQVEKUQ@:O.>AG=<`LI:W'O+'M0%];LO'+M,!,L6VWGKB]"&)<Z
M`[OZYF.:N8$TW`6"F*M'47><K1P.O;YYWZ0H^YW_6$TJXRH)CWA3VWBVMH4`
MM,G7R:U-DLCUQK`$&CM-0E*;[+<#A0/!;=H05WZXI6NRQ32L(G#842H(E2^%
MET29)CDSE#+"HFX&`5>IDU,*8B91(7TKY&,+]20(M!S^0B'>93LF:#8$4R'Y
M8G\*LBZEQ7E2Y'T4IEL=HH*7MR][$'?Y,W>=@B?RQ2FCTBTCTR[@H7I:,PBV
M-B9@@GL]DGL20EWTAX#6X6XJ4E*=@GJ01R/74R?`AB5:9$4L)W55XGP>!QTT
MMS(B%B/7("D(XS$DTGU'`V`68U$]%2-1E#`OTGV*(X)!E#`(=8.H$ED+EVS<
MTF3/(GQ/\T#/]AU/^"0>_\<"%+1!%28AC56'<D=WW2&(VT*()Z-WAR9VAB,A
M(`<O'61&UT9_UG$DUL9SV!)8>!8Y610`LR!Y,6@VH6(%>V40KO)H099G?`5%
MG*<\2#)@/U(A:&(@"99`I](C&F>%"K1URY-1;H-$JN8=0K9&25AGHK=J?I@G
MB[4=>I9RXK,"6U<N#=)T!O)3QS8F@;,_ZS)WGI(@!A9V4SA+^=8A3@$G(440
M;<15&B@N@>)$\@8G"#5M"G,-4&!@;80DT!<OD/6&(B<5U+8TBD=I(K=P:R<E
M4W8-"W@0G(B1<?<@_Z@IM09_T\$*!F8MU7<0,99N23,D\[=V*M.`WC%EKS1/
M!?\RBTCF;V[20R*24Q*Y?"P@9S2"`)+"B>MS=1=!6:A61SP8)"9)'A17$04B
M:C"%=RB1D>JCE!=Q!9(&;V06EF(YEF19EF9YEO9A9C"VEFS9EF[YEG`9EW(Y
MEW19EW9YEWB9EWJYEWS9EW[YEX`9F((YF(19F(9YF(B9F(AI=@FA=([YF)`9
MF9(YF919F99YF9B9F9JYF9S9F9[YF:`9FJ(YFJ19FJ9YFJB9FJJYFJS9FJ[9
MFF@9F[+ID5)(6(_7F!NA=,B6$%@H$;K9)RSAF#3RFQ.1(;VI,\A6F\G))A[9
M,4%1F\J99EK(G!@1G1D2G31!;BVT5D_&`OTWE"DY?(W_N0)6E82M\%=-L74^
M='-6T'\=<S\ME!""8"1$,A7+L8$JH15)"'L*08`6Z9]Z<V>8^&Y8H8L:TY(I
MXTOX22LWYY/(,A-M1H]$`@7IB6920:&O5B?DJ3/IF(\,PA5?F!`MA'J"@)Y_
MB!`HV104^D5!(3E1.5#SUY"1%GT)L3]3R2H$,3,:4A!BZ"46`J!B%"H$T:,*
ME*$J08<"T1]>A!!X9J"P5A#E-A`R>B4$P9,TRI(_RJ(S<:/H%FGSM*2?4BGU
M)R)8.1`'<)Q8:GTYQ6=EPC"$,G\[`:80X2>1,BD6$D&:HC<+^FUULB`Y@J0O
M)#E,4:5SAB.>)FMZXJ05&&B8_UA6;2*D26J0L')EX:DH1"I&+-F;7'HS6V,X
M%#BC!W$-I,@EV,EFH:BHE".H[24(%$4KI'@H"K$B$`&D^R.G<"(V)_,3K/40
M'.DA/4-W<=(\6$(+"&)#!>(X^4,09XHQ`7*IZ].`2,ENU36@-$*M(A*>6@*4
M\`*D&(.CW7HEL&I]I=H1@@J?6'8%1LI<B)H0K`"LG@HO&+(ADOJM83*O*G&>
M&EJ!&;('TT:M=+<"J!<(]GJE#D&K%;AM`H$(G8JF-T&A&QH1;18F*2DX:Q<-
M6[-L89JKNH.PZU,@,O4@4[9ZW.*1%^:A#;-&A#JR"A0@D#HF;60G:^8Z+;&G
M4PFHD_^:J1Y)K5<@`.HXH"W@8*K#ICVHLC$QJ(N"K7#ZJ;"R(V-Z<B(ZL+IX
M:0?G)@BZ?.&YIS^AE88:*2:#KAI+L%1Q%3>R-305#6$'EC`TE)1#(K)ZLRQ)
MLCC2I#5Z(S1U,E+[()!:C;"2/G6;$BU;J*X*:T#"7)NJ0&$TH%9Z,^<UM7!2
MIBB!K]0F/E``+Y.+JFY+L!++FR^ZM$3B2ZS0`FBFMXO"F#(QN`O!%%QRN5<*
M@O2B)SD%J->P`MB*6N-X*;.EEF_;I@<!IP?!II'XM=C0/`G5)/S#J8O"L2`A
MLF%WN[/%M+"FJ?!7-OFBM&OS7;_+A1!ZJD3+<*G77@SSL"G_@V:;N[>[J3M&
M*K,'T;8ZP:5&6Z,YNHDIJ3)UJKI,DC[KBGKCNR\E&K666Z4[`KE#FKX9LH$Z
MRBUHVK+SR[F`FQ+MBQ"VJJ>Y&\$TXF"06U8L$*XT\FH8A690<+XK`<"!JS>M
MRJ,6PKO*!28@C+ED.A'<JB<J9[.JFQ.352%68&!]N[1V`F0.8B=PXS@`:WU3
M92<__&Y*=Q5>0IXQE[_\`C8JF"#I6BE_BR":U5'X8B=6W&DJ:&R`6B'%@F5_
MVT."L*N-8ZTC<7H+X:PZ@XE*%P"F0)Q*AV]22CT5XI46`R].U1]X$E5,P2EW
MHH)VLK:EZR<\]J-1=6<G@R9_Y51F_W=%#J)BZ;.@4:S`-_-9"T)[=F+(B[(M
MY&;%-A@F(]P3J/%J:#L0^>,?J(<E,;,H91)5KLLF%D(A'KP^UT!['KQMN$@Y
M4:$Y>KH:E*/+>M-N@3/*85(0HNJUP/NX'%MJ:[,UN8RUN7S#J'$%?*NX%&+,
M>AIH.:P:`7+!I1O,*]DG6*LA%N(G"(NUW44D"T*<"H1EY@66M'<S'M+,8A'#
MLRD4PJP3]^P3^8P3?M(=^QP1L\MFL5S/!%U'XUK0")W0"KW0#-W0#OW0$!W1
M$CW1%'T=BC+)E(,%D&20HBH(Q_G/?D3.'FDH#!'/D/1(4.K1O:LW%ZTG6(#!
MRGP3HB,Z:_^S$)`E(AH=JBV=HSE:*3==O>D3<Q,RTU.VRAS[QPM1S`)7S<Y&
M$>P<TQZYTSO:'/H1L`/6DW[\E`PZQX!:PTI,1X$PR&W6,^>I@FJ+$$+FQUPM
MI?V!&@?@NE5"=K%'GH*`"*HCLA/"R6;RR0)A)#/&"I%(QRJ6)57H0PY&06DU
M;;M7@=OC5`/Q9S2AURIV$#EHUF97N`H45;BSS&H]$>3&K6#\=CE+@E8`V?'#
M'!JWN/N+9/7)VH"<JW@-2"E\RY@+PP6LJ/.'DE4*?#QZ*.W*+67DN#.Q/T,"
MOHKZVX>\P#<C4N$L$`+P:F7(H3IAL[,MJ<8=JN-<5C=<$;1J(9'_K(638F#-
M313`EJ]/$@@MX,("883R*3RDNT>2(X;58Z0P7"C`B:DZ,R1"&[AM!-ST?!-8
M2T$F7*RD'(I)$\N2,^`B*P@RH!#U#1,1^S:>YJC"[;1ZXE`7X:+MQK%7\,E?
M;1-""J9_!L`-?*-`9L#*'4BLY4.^EL+Y[;XB*E6#UZ0H.3(#V699@K$\D>#-
M*J:=^RM+"G-68`(=G*/GE<!%:GTALB'P8G`XT<+H>\RTHIPPFT455V"P9)41
M8;`*A,$B4LWG191'08GT,BM3N5=.PFMM1*3MJ[Z#%-8E]:4!W<#)O<PBN34+
M2&%5>A6&0^<W`:3^5M_$S>>P(J,RB7K4_RO)8W*B52*2'RX2XSTFE7S5_NL0
MY%Q@0"*GM"T1@FK:.V>H>]S:2`&I&N1$)-XSD0YMM/)75_'H,824[R8BUXV]
MQKN[1[X<7!ICJRW)K8``.\&JD\(IKK".J$J3K`;KYMLXXG,%6@XK@5:UEK(U
MKIZ\"U%@!*3"ZYC#.6)>_QN57\VMID,B`[["QZL4>D:C9XZ!03W?86J#L=U'
MO/LD4^J1WHN%A>N(6%C>Q/PDVUT3DJ,586>S)9`^[B@A`SJH-IOH&;LH&0J"
M%8X2[YX0;CX01:XNE%.CM?GM#/'@P%O41=&RL@N$6T?G_.ZB_C'OR!U(_2TB
M`LZ="C'$HZNXU?];X)VK.UK^J;.>G0.;\_9-*S?/122?XAHBJ5;JH@ORP%?V
M\`_:NXX+@19\I^_]I`X^;;>M(2DY[<,M/=[:DU`Z\D-Y%1$6VQ&_1U8QE-N"
M+E,!)(1RVKJXQT]!+G?:H;*;H%)1`F'DXI$-?VB\P`J*H.@2"(BMY?[#Q,$.
M+H3,`GM@W%C/$<@>>>]V%5`P8_!W#7;?%`B%)YL(%5^/\<LG,E.%6%!1D%7:
M(^W:CU.+]$0QSA9_WW52)I=VT'LD>!TCF0X\,L<YF>`]^VJOSM@>V02B$%PJ
MG&6B^L,O_+?ZF+KOWS71:N,LA=]-F\U9)PAXS[K)^\-9)LF?HXM?T27_`?L:
M\=/48?TQ(?[/,2@I$?4=X?W<O_[LW_[N__[P'__R/__T7__V?__XO]!:&^L!
MBFLN3&X`<0W;0(+7`@@BF%#A0H8-'3Z$&%'B1(H5+5Y<R.H*"Q8($PKB",6C
M0Q8$.9XLF="4%58-KV`+A++CQY"M"`H:B5'GS@`R.0X$B?*E0RLV![:Z$N"*
M46P^?R8,=/2*`"LY![*RPF+I42L[O3IL!9*A1@1;'0:-^O"*U8=:'P;=(Q#C
MQIDT611]N(=C(*8LY&)KQ?3K8(P!6"JT8B4`P15#6R4F&*`E8!9I3;):3%CS
M9LZ=/3/4&NUJ9FP!+`<BO3"`44%#&>*L_!KA_PK!"4T3M`+%)-O/G]<._"WQ
MBFNW@*]T'8N<8(FF5T1C$Y2Z.#;E5BSWIH@S^L*Z2%TG;'5PH,&_"@,ICVBE
M2\J%UU:,7&UQ^\!`*R);OLLPO-Q6=4L39&60VK#KS*#^%*(MI0,3&NHXA;X+
MKRG>"*2P0@N]:L4^J+H2!#T)7W.M-8ABXVZ@U#9$T*@,+^QLQ8'\FH@T5M@;
MB#:&3C1+(18FBZ^A$UETZ,1`OON/N\G&.Z`AYB9:*D*&@HO,(AP1&DZA'FU[
M+DJ@D.NO%5:N`]*KQ5(3B[0`RBOH1ZA*FC%,-]^$T\3R>CQ1S::8X@NP":M4
M:,&A!!$,,_"NM#%.G?]2^W/`A%A05$L=CS31QZ/LW-)0A5RAU-&'%E0($0\=
M"B2J-F/\ZK?Y)AUPHX]2RXP5HW*T="*#L.&SM&M<K%&KVL+SSS:YSHPU6&$)
MT\J4C0132J-/CZ(QIJI`TG!1MJ(U;*WH1LKPBAF)Y'18B,Y+:`4KK&U,4I+8
MPA6XG$Z*MJC6>F+42F\S;0K2AEHI`4TY)1(1,'HC:W0BL8YJ;%M0.P()3"M,
MT1.H@+VU+5+H2G(2/(ZL"HNC(P>F#&*//SZKRM;8ZQ"AF(@$BD9`/_+P"C`7
M#"O%E%V]EB:0@TSH&D'*ZU73016]4F*";`I+0Q;$BPS2?X&D%#-]%\KMZ=+_
M'F860!I=@E&G_KX#*;":&1JWE6N.91`AK`)#^>;Q,IMIIG01G+#'HP/HB6ZU
M[X98D&A3IM7#Z8:F]T02<;.7P9?&U1';J^^&LB&.(^8N;>@\[/?)EUA@6%Z?
M+;7S[WL+-1>P(4=W6=N#M$L*I\\G9-(*5Q)"/%RV@K9UMZ&I!MG,(IU$ZD$.
MK:I+<-;Q)I[%'54K,N<?N[WQP3T46K*A(9-/DZ!0B_<WHE$UMSK@'S,5B_E9
M-S?TQ\<=4A6BQO4+"R>D#E+T_(MHIWYMA3J$>B2\L&=H_*:0QA723-22\#"E
M@$UYV=+XM\#-8$8P^0E$]$S$FWB9Z#L"?%%.H'0J_^AD)GU)8PSNAA6`+*$*
M<(YS#5;:@C'V?-!?1EG!==YSF7G=3W*`,8D(F1>1BAU%71-IU-X8=+4>,06#
M@B(?`TEC"F!ECR!T48I@-B*`QA`-=+9C8!8IA)05"$`I(;+"`5@@+M:E)B9'
MTQ94Z-:3KEPC:UQ!(]<X8I@*3@Q[M4),'!]"FJ0<S8^DD=^)WL416-5GC#GR
MGZ4,LL8*_O&/D1E*W1S9D"MJCT8],9$C,7FC`45'DCWYTQRS8D32C"L``M#*
M7RJI15:VTI6<D1^0>OA*B<S234VD947H1R$P60@RN01F,(4)$:D-TYC')%`Q
M/Z,S9#;3F<^$9C2E.4UJ5O_3FM?$9C:UN4UN=M.;WP1G.,4Y3G*6TYSG1&<Z
MU;E.=K;3G>^$9SSE.4]Z#NL\8US6,"M73ZP%``I$RDJU-B6CC7QJ.&P<4$K>
M54R[\>V.BO'<8P)0Q3T:96R*60A2GE(BZ"2E<!UB(W\4"*1W#6]RJ,SG422(
M/KI5!3P0A4+\ZD:WHYD4.$=SZ89`6<*";,2?KNEA2H7E'PX>4X3R3"02KR'!
MHD+N*!F3&<`8I*+ZA2N1>%2;`%E1`J/$9%&-.IX/;6D3_('F*&X$T]\`N3A#
MW8I6O33<"2E)-5;LK2Z!T(U4(\+6/H'.98S!EKZZ=!/2X*HD-[34]#Y"D;`(
M1B[_K."-ZA8[66P(1&=,D6Q"$+&R@ES%*CEI7T8YVT[:K2^)IBWKN19EI:?9
M9Y9"!!E6RTHYMNZPJ@[54>)R1J3*K3)6/=OM@]*F6+74QH-]XJMM<!<(>['-
MILW+X4`.(XC"Q6H/OMWC<2#KH`&RY&O8>`]D`8F>_1VG*J;02FNX^$1&&8M:
M6!&O1V#6$58@<7*"B$92W%G)?3XQGV^\27*="!0BJ0E8B:3.40TE$N0]B8*"
MA6VED*N0%L`U7`;,J[?^2I$ZA@LC*G0P1+97D04!DB+<O<I0,BS@..EMAA.Y
M(E>Q85]:#65O&GD1LO1*JTM*-R<VXB"?<OI`F^`XNNQ$_W&N"$LW"[]-PE:B
MFQ!76CO836:6MH78+&6@)JR2SY:X?6+F:$@2,(W4>,]]$5R_#)%8]BTB9I9K
M:T`RG(UF=(THRPQRQJ:V^B!V/$)<@4`$(4.!C`LG:[%.C7)&K=5:#R%O`];U
M&#-I`'5(O^!=B[7"RDY""N*?7>[@:]C:YDD1Q%@-?F).!,EB85T+)[19M9A1
M/2C'?>I'@U.(TV8MK`VSN</<BQ%O#C@B1%RD7$`)FMXBHFS(564/>;K;OS9=
M(X'4R431"$RVJW:3M.Q3.C;YM8:L+;'Z>`3'_;E5MA4LSIC!1'+`_7)J&X+$
M7U/97S(!Y=!8/:RP"*2'N(;NI?_L=#[38@XT%H:SA8"KFN%53!!="`3$)6X9
M%R[*SZ6NR/E`?.'T7/!NYULS[,SSDL=\)))]HH^JC;*_MT*N5],KN?72\IL1
M'Z^__&R5:A15[\>U@J=>!6_`P6._*F?1/TL#,,%J#6R"5/A^R<6RH7JMGZ5%
M&#3"KK>/UIU3IH.W-FQ)-('Q)BX`R2ANKN&N(&0`.Z,(T.#8@$):-**[(P,&
M.;5*^W<:">[GS1BC_IH%L];MS598QH$O8D&6ZERVA<@;,QL#5M9Q:>>NQU9%
MTU'@#M?,;+%S![16K]'@%<X6QX!^Y&]VR)2')D?9@*91P^[/2!J4KR=^FWCO
M:ARHF[3_D30"!]AS)M)PFF1E57]D)".#-G6X%SWS%MEPAX&G*<[(+=2$9H\)
MP0Q*[!+6PB]D!2?995/B6CR?)K\_<SS)NPV(1E1BEI!*>=%"4$,7Q\#KC^;>
M-Y#F3TA]D]6/Z)\0[#()\/,CQ+,_^+.C)&JJIB#`.J.+T1JLFS(-T$JXXHDI
M?D*GJ+,04D.F"MP,!#.F:,B_WO"26^I`#$3!%%1!;T$S=1*]%83!&)1!#`04
MK\FV&FPL&]3!'.1!'/3!&P3"'?Q!(0S"'BS"(31"(E3")&1")'3"(X3")7Q"
M*8S")JS"*;1"*M3"+.1"+/3"*P3#+?Q",0S#+BS#,31#,E3#_S1D0S1TPS.$
MPS5\0SF\08R8FS7"PSS4PSWDPS[TPS\$Q$`4Q$$DQ$(TQ$-$Q$14Q$5DQ$9T
MQ$>$Q$B4Q$FDQ$JTQ$NDQ!&<P4WDQ$[TQ$\$Q5`4Q5$DQ5(TQ5-$Q514Q55D
MQ59TQ5>$Q13DP1?$H83@J1:IQ:'1#%K<%(=(-UT,&&%S+,_@191KO&)BC8LH
MQHI0IEAT1OT+%`.I+H%!D$VY.)+PH=73C`D1JA%!#'4I/)+KBIA;B/5AB2]!
MB$'S#`34"=?ZNBL8F[Y[$'##"/N81H58NYWHQF?D1P*9A<O*+5J1KH$,!'4$
MCT$SF91CMCTPR,)KC>LH/.9*N9G#B?^HJ)F7N(90P9_"ZX*6&)M!2XN"E#N7
M*8^H^,CIJ9F(E`9:`<FC,`6'3(MF(1K+L(E92`EX?!*!3#E=W">T@PE!V`.R
MZI<O2;Z!C!:1I!+5(4J@`$I_@4>K`"H]V8.60(VP$`^1O)]0D0M-@X[7292?
MM,CW<,B@1$B@D#3OBHKP:,%^9$O"0,IJ5+[M@*SJ8+O*$C^S6`SE*`DN`:H_
M$;^!S`Q30(B2V#/'>(D&"8R4*`GV<)6TL(*_H)B;]+UVZXJ96!F2`PZ!H)&4
M*,@^&0I6>)ZB7`NF@!7H6)=)(QFC*`FK&\?#7#EL6!)6R)Q,&PC1H)COZ,RA
M2[`]NTM*`PS_&/I+\6O-S+R"S!&-KLC-)7D):'L)#5&=?6S+Z"20E'@>Y#P<
MW/`.`D.(KJ!+A,$)R#H*R\BLX-Q+S_I+1J$X"7$?WH1']!B20Q,Y]K0)W4BO
MY\0-@6P%P=P*NV)*A7"C\;C&TC3(@8P_I."+X9`SX("5A*D/NS--Y9.0@GRT
MX:#'PBS([C,^1-B*H2C/^+L)ZNK0NQ0;Q.RHEW"%K@!/G2R)TU&=E,BOX)3.
M&&41,]E.[I0*W83'PVH[ZI"+[4RQG@**O]PS#6$%+`BZPA0[+KD5#J65'N7-
MP#`)X\A,Y>L=',))Z&`.WH01&E$.1JO2*]VK21O0OXP&U\H@CS`;Y`)5M,R4
MT"A]T-^,4M<"**+9$0YUA2JUCRME3(]8#/:PCS:*)&:*OY*0K)1`3JI*"1S3
M1!EE5*_P2>A@C?'4$]5!4_@$R_!TGYP9M$CU"+FSB9G#AF@HR!35R,I"4X%H
M4]&AKLDZU9]459OH2Z;,5")IH3T8"MY$CILK1\5JMU3KG;*<L4U]U:')";X0
MB>DQO`LUS3Q11[88DC_1#IOHNVX;TY\T2`EMB:U`R)6IR)2#4ICPO1EC2(&X
MU71,RD9%UT;]UGMYG5P<EB;1P&$QO72EUWK=IG55FV6TUWWEUW[UUWX-"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g267791moi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi002.gif
M1TE&.#EAC`+=`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````",`MP`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4'M>BTJUJM6K6+/J_"2I3:0VIBRV&MNJ
MX-B/9P^6!;D685J6;P?&C3A7KMRW9,EBRXNW[=ZV>!/6%2N8X&",ATFZ\LN0
ML=;'.DU]:M,5D]=H%@,$8*&9Q<#-'P4%$"00-+8KHSNVXGS%;&ILFEN*)DUP
M=D74CEFP6"LZ=:O.F@/\!AY`(.?B`U'3#E"B[&_/9J_HWJC<(&K6`G$W%%2B
M=</8*TV]_T9HNCKD\S:C38X425+[]I@NFA;M/;%CNP;O#\?/7^#:^_W19Q`?
M`7@'GEH2T6*6?_S9YA=@#"ZXH':U"3>0;@429`)R_I7`(6R<T79:AK"99AI!
M5Z#FG5L2,E:6;2BF9MYT"`XDX%_^/5ABA#@:QF-_>_V8UEDW"GF@BRVBIR1)
M;GQE6664M:',19Q]!IUI&+)`VG/7\;89B:M]*9!MG%5IWG6OZ9:EBV5:*!IV
MR97IV688>B=(FP?=2:>-<OI')VLE<.9<@1B.F1I]@7*8Y8IT4ABG7"RD6`*D
M'\(VJ9^_K0CCEV/1:%:@"+VYV8MTCHK--7)J69`@@I0%A:I[6?]8(7;/@58E
M-K>^6:B`OUE1$*&"CMEGK-+=FFFL6[XFW9YAFJGLE[2I62:`2U9;431?2:(M
M9=M&@I%IK8`*(C:BO9AL:\<>:QMJV9&V*7*VK6NA=HYF9R&-O_%A$(P;EH;<
MK2=>Z-FQN`Z<X7/$8G-*A@(V?&@`>Y#[,&E7F%!6=?5B8X*(Y9;[6:6WCBBR
MO<M%:@)L4*A%HEFJQ@NQQ.[*.)YKT!FW8FGH7C&H=[?VN^//H'E,$&@(SV*"
MP>@RK'1K#D>\6LS+G3PBJ1<C1Z^LUF9]D2E16N8U96Y@9*R)W@6Z8KB>W<ET
M=^1&VC;6FT)W10D4JSHW:;J5Q4)S!>W_K3??W-TLD'@EEW9EI&\:!.9G23>.
M[.._00VSQ%1+G&*P5[LFHG2QAK57R(9?6-R=B!BZG,XLO%JS89[FQYW;:F.S
M1PD12T<QW0B!CJO@]+45N''_!B^0SZ(5K/B5!B:?<+HO1_YXG*^5A[OMI^&>
M-ZY\:ZT]8NQUU97GF4&',,+"6LB\XP2/N-OD/\M;]?M3%P2%\`FO&D`@_N8/
MHB!7L$KS_^=+F,.8-C%L$(AB,NL?J^!7K]^T96]J6I&'?L6A/SW+0)Y9UNKD
MLK*^C48T$7.9Y&#D0<:XC65@(A'`D`,>\$2N@Z$;U_B(=K`:$O"&P&-5].`E
M,P;."VO;"Z)$_Y31-:]0ZR%C,U#*R&6OSPUL.JR`'>S6HK3"G<9N6*P;WM9'
MD.M=+W::*\VE3`0=6`T->3A+8P"=Q\8"NJQRJ[$7_+K(J!0E[G.5`L^=M%0L
MTY5FB7O*3\`N!#@I,LUMU*->0=BE.!']A53N.N&M)DF_@E6J-%'`9!IA@[X:
M)NN3V)B?'\=U12U><1`%TQL7A<C*AVQ+6Y*(S[=2UZ70O6D/`4@9ET)DG$C=
M2D4J8A]K6A&WN<GMARXJ4##K9QCFM*:%/$S1S.RUK+6H*%B_T>72),:"/01+
MA".BS=%P"9TW57.1Y7P6%?-H-5G]LH;'W*"?!`>\R[G1-YM9EB/5=_\YWEBL
M;[XT7SYQI4SPL&9N'+KCKP+J'>5@<S-Z2I:6L".@@VHF6@5J!6I0*8U\BDL[
M4;C7)5M)4KE`R3)3P@C_^/>6_OG'%#KSCPE:$U,;^8\@>[BI1O_#/W*URJ8<
M^^D"\W33O135,#UUZ6E$I-&?JJ5_#X)J<JQ9EFC$5*,^_<]5M[J6Q=1T3`ND
M)VRV=+:;]A1%M%'J7NI34Z42<Y_^.>I=H.H_5KE+$*A<ZUB<:M/^274U8K7K
M(FF3T[%HJE5GW0O;CO=6PTB56(T%*\6<4U/!UI283..K8,%JKHOQM:2@Q0;7
MW..>2&!F)>D++4U6<\2K)!8DRR*//%4V6]7_VI8E;G@2V%H2V=OZ-BE7B!A"
MU+J0K_[VN"?!UBLC`0KD.O>YT(WN3HCXM4BT5KK8S:YVMWL1;;TGEMP-KWC'
M2U[!0*DKQ"BO>M?+7N@2$9:7::]\YTM?(6[K26&KKW[WR]^K8.N[D?A$?P=,
MX`(;Y;UML(QU#<S@!CO8)ICPGK;R^^`*6_C")&G%2=L@8`Q[^,,@KLA[WV/:
M$)OXQ"@VB!N\%Z44N_C%'P;%)R0CXY3"^,8XSK&.=\SC'OOXQT`.LI"'3.0B
M&_G(2$ZRDI?,Y"8[^<E0CK*4ITSE*EO9P*N)H%^D<[83`K9M:A*$-&S$91$1
MZD)1:*@[=1.%$W8'_T-UTPUQKTQG'D,THE;BT'#.)=H[EP>BO"P1#U4HJ[#"
MTZY_N\(I`EWG1N,X3/,TE")K12ZV">)HP,NTY7`F(SG+D2"N2&()F>GH4KMX
M/B2:VY>=2+<`EJ@LFG'%ICG)N=$0>LNO(9_H2"564_L:RVIA3:%L%DKQC<9V
M4BPC_6Y4H#NQ-G6?CG2>F2.0^>UL(9W1$EQ_S6WLLFI90+02_V1U+.T<ZTN.
MPX:'8.TF$F5H3[>V$F`&^<U!NH5_J`G`T1[;[7Z#EE48TDR*B"F8O3G13VWB
MLSG!K.E<N9NFJ4GUFAV96H)>>R(`E]/`K^OOCC\%LP%'W+85(CU5"JQ^M/\*
M@*_V0U"\10_BL.99NP=VEO&=A9?F00S_CJ,;N7K\YT;!;+YSJ<"+L/PYD#;<
M6$@4B*`%)Z/0.R$G2Q/#D))J0YV)%=9M%1RI>\2P0]\XT,>>$Y#SO.@/9M6K
M.L-OLKN])&#ONK9=O%?I>*CG(W^[WA\"=IY#8:A`-CO;/[OWPO_%GG0"?),S
MSO8]),;PC:X[S[7-<:I@E<PI^BJ^_;+YJ`@^=8J'O)0E+R=!.+[RKCU.%R,U
M\%Y*<RURSGE56G$*:1[T\:+W\><1AWJE_,<AG?H0([L(2(,97TG?/GNK>I_[
M"I.^43IC?E.RB:'*!TQ:\JRX\[(V%CY4K/1Y;S[_EOFW=CD7-HAKI"7K%?DS
M@5AA-PHE*#U;)T2S>P@*;1>_?,V5)67BGOLV)!`Y)0BF8%=X]1E2<SR.!40L
M\$^^Q7AF$WWZ%U[)!WV$9UNN%B0_HC]@%2OB,R@U$RS0]7R\-X%!Y'.UL7/H
MEG_/Q3Q.\R5M(G4!0VT$0T,\HRK2!UJT9WO^EX,FB!1ZHF<J6"8LJ%V_D4E%
M@FT?,ARF(C%9%RM/5UO:58%FTRIC1E0_&'3]UR9V%'[B!2'`5R,28A?.05^&
M-3O@)S#3E(4[H5''D2A[TVMLJ"0@]R>+XH-S"'<KY5?%(B9YV$JB$H-R^(<X
M@8>$2!6;<33KER)0X'B'__B(=`>)DCB)E%B)EM@1UG`-FIB)FMB)U\")GOB)
MH;B)HRB*HPB*GHB*G:B*I'B*I<B*IAB*L`B+I5B+MGB+N)B+NKB+N3B+KZB)
M[$6+O#B,Q/B+KGB,LFB,R8B,J:B,S<B,J^B,T0B-Q5B-N8@3F@@-HJB-W+B-
MU]"-F=B-VAB.WUB.Y`B.U\`*Y3B.Z;B.HJB.Z`B/YMB.\>B.F2B/[(B/[VB/
M]#B/^GB/_/B/_9B/_"B.WHB.!GF.\YB0[LB.#/F04[%>`[F/]8B0!7F1%IF1
M"XF1&ZF1#LF1!%F1_AB0)"F2(3F2)DF1*+F2)]F2*JF-.9&)UC"3GTB3,RF3
M-O^9DSBYDS7)DS?9DT#YDS(9E#I)E#Y9E$*)E$IYE$QIE$XIE**8E#X9E4OY
ME%4IE5:YDYD8C%G9E5CYE5<9EDT)EF,IEEYIEF1YEF6YEFK9ED)9B/L(D'+9
MCG.ICG49EW29EW:IEZP0"'W9EWHIBGYYEX09F(6YE^K("M9`D(>)EXB)EWX9
MF3DYF(+YEX%`DX_9F)IIF)R9F1%97J3HF:+IF*2YF8@)F.KHEZ-IFJ79F:UI
ME]:P"J\YFX=IF:P@C[<9".]HFXE)FZ[)FG,9DV@YG&PIE=:0*!LB`+")D]<@
M``%`E<5)G-?0="Q@E#>IE<:9G=;`"@(0*!ZBF]9@!3#_J(ZK8`*)$@![>9W:
MB9TZ>9UNF9.?65[KV9/NJ9[M.9_VR9.<89><49_2F98`BI2H@I[0^9Y,:0T6
M=)G7()X8HIC6P`("@"'0H)[TB9_V6:'W"9_8V)`'V9$>^I$>V:'L^*#/.91#
MJ8Z;8:)1N:(JVJ(K.J*Q"*/D^)@R6HXTFI?6@!HSR0H%LIWW8Z*<\:$B.J0*
M":)"6J3Q25YY"9$ABJ1.RJ'D:`U-)P@SJ7(N6J-8RJ):.I0?&:4OVHDUBIM;
MJI*>F8GO)YOE69T\:@7?J!M?>J-P2J9R"I`6&9,&>J<!.I/]69-6X)Q08)<;
M\HGBZ4SI6""?J'*?R'.ZN:`%_](9-#FH?WH-X@$%TZER9>*@07D-J/%^FS&A
M+JJ5*5JI;&JB.VJE>/J?8KF5ZQ6=K'JJ/$JI@2``NLD*@\H"I9")NC&H5W"3
M^08%UYEO5C"3J-%TFT&LU=ETLXJH.;HA+*"8`ZJ.#9AONTJ4E:I!`KJ)-NFF
M/DJIJ_B@5A`(WWJJK?J5<`F<OWFNJTF7_8FKRGD-H;H9C#J336<*#[H"T\D"
MNJD;T&H"NOE^5X`J`E`*FBJK[MJL/+JK!VL-XG&94KJ84=ETNSJEVQD(@D"Q
M@6`*@>"7[1@()K`'G[BFK[("F*FI_.J;Z7JR)BN*ZQ4-(VNN*.NRJ,(".1H`
MVZFM\_\SD_.CF$$ZL]OIG(+ZG-Q9G>_'ID.[H`2;2Y6JF$VGLS3+L^&)GB2:
MCJP@FP`9"&Y:,6RZ"A5;L1A;L0[KHPIJM9&B<HG)&59+L"^+KBFKJC=AH12:
MIZ<*H=HXH/:DB3N;CE9;LGWZM*;("LNBCJBACN()K4U[F]>P"H@*L=7*J*-*
MD\BJJ?=SKZDSN>_GH$\[H==0"A$JI1':D]IZH?F)H>PYNJ);NC09C*";NF^K
MNOZYNF\;N+H!BJ4@'>W*&=JXIQMRC\ZJ&9K(NX_[N+@DL#H:NXR:F,ZZGP!+
MN%+:HS;YNS]JM>_W*JHCL&9J`G;)H\U*G?=XCXAJNJSKMJW_^Y,;:J3D2Z10
M>KX"B9M!JHWYE+&[*[,(BJ\2"PWH"3&9:+4K``U]FJ\F(+`0*IL-F)X).\`_
MNJ2?B*S+2Z6Q"(I#&:H^BK`]6I,1S*1'>KX47+[DR%X32:<L:;X7;+Z:*V<?
MFTM^V[3BB;,E>K<RN;-!*AW]BJ\+"L.K(`#>]*\SZZPR><+6,#^)6J(V6HX<
M^Z]7(``V/(TK&D7/J8VKX*915)W:F)K:NL%2G+XEV<%V"K=8C*IZ2K,]K(E7
M,*H^&Z37@$O@J28.ZJ:0"[@$.KB,>KLTRYUL&JMQ3,0%>K\$NP<$.W0!X)R:
MX:RQ"IZB6JBC.IT$.ZY:K)9L*Y_B_[K(6+D"&Z*8],NFR3O)<@NPF;C'[-J[
MQ_JC9)S&>KJ?9DJ@R#O*`>#&+2JOD>N\FL''F@&>![N):UJHOAK+"'S(6>R3
MY:JV,`NS2.RX$3JLERP`C-J'"MJG27P-@9(Z>YRO!`NA`KO$W6&_!+RK"[N\
M"BJ3""RQV[G-B@G)/VN3J**(4-O%C*G+YIRV>RF1:WO.ZVR7UW&/@+*N\ERB
M:PJA-ES/!+N_1MNOA=QTP2K!TO+-)+K%8RP`E%JU`L"F0\RFW<S-VUF.$`K(
M,RN>!*N_*K<9O;G+[!R<.''+C!R6&2N4(7V3&?NQ@ZFQ\HK#4NJ7T#"8?;FC
M#&O2SMJ7LO_YEWB;F"B-F1IKTV2YTCS9EPQ+TI:;H:0;ND:-JDDZ7N"[U$3M
MO3\)U`\;"-!@TR$]G=>\TNF)U3(]L=U,F3P*GHZ+TE:MC54=TG\IE&=]UN#L
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M>YO?FY.8*N`#7M0'WI.9=P6!L`K7Z;>6.YT,[KU)+5[YO:.9E],(OKHO[=\4
M2M_]O9V>&N(Y*M<7#KZ[NIU4&^(UR0HC;N`L?N(>3JLI\MZ.F^%`.=+N>==1
MBJ!3V\1>2L%<VN"FK9+P+)#@:+6@W8^9N`+.*I+;W:4;B:^9N`=/WMWDW:[;
MR="%/8^/'>0760H_/LZ=K9NW>P5]::\0J<%4K(V5VY<P?-HONL-+;J0K++`6
M28[C/-KI*`#/S8]@'N@V:KW3>>7,+:/2_R&*:-[73/Z2FLW!!'F;JP#G*^R7
M#MZ-@<##!GG%!.[GHA@`#EZ3XXB9G"CCVQN.F/O@"%J?&/K%KENA,(RIGFJZ
MJ4[JI!J>-@S.0]WB/<FC+DZ40WV3RVF=,SGJ;+G$V)JQ5)Z.,BNH8*V5%1Y>
M:ZGD]]OL.PJ4+JZ567WJGYCJM7[MS9J4'YNM03WJH][M")J.2RGLO/[4*CWN
M37N?5!GL5A"LK$ZAP7Z@UX[%X:JG+#J35A!%N'P3V3V7$^K#UB``5,MEU5FS
M5[`""NI-9YJH^:J@422X5_`J=NE->U"Y>0FN5@`%<6P%W5'Q31ZV+/"M4`O#
M#^JQ<'T__@JN+/\?10]/KYF;\@B,*@JZ`E\<J3GJ2]VL)I<I'C7)\\N>(E80
MN%&.H#+/Y8)ME_W^C<$ZX3ZJZ-/JF>K<F$DODT3_\XE^YAX?GKXDP=^HY4K.
M"J_RQ0<<*1Y?W1D_-XL)L6K*Q3R:P_CJII'RB6H/D&SOPDGOQ`M:+!O?31Z_
M]?=:[XW[9O_L33POL'1CIO4.!=2;\A*OW$F?]$W+V7GIPQ??UA_+IIROLAU=
ME-P97"Y\P)(\X5R,*I_HZ0*/*D&/^LRNB>`Z^X<*G[9ZP/<KR>$)GOTN`.,(
MP^"JI^[Y^DH^G?]<`NKHKKBZ_"DBJ![[_)IZF7ZKB:Q@`F1?[<VOB=;_*Z75
MB?Q.6?>'2OLIL@<+'O`OWY/OK?,WR0)4&_)U;-M*+=_>]-[2H9C(#OZ93O[@
M/_V%JHD``260M6LL6%F[$NA:P8,!"#(D:$TBJP`+6:U::/":1(<<-P9BL=%:
MQ5(L"':4N-'*E8TL%%K3R"KDM4!6KLE<.%+B%9O6!+!J2?`*T((#KUUAV5(A
M*Q,$94K4"#&E1*H@%_*\!@WI5JX1KZVD.C(0*RLA"9I\.I4@-K9MW;Z%&U?N
M7+K8%D+;F%5D`%8R>WZULD<0BRO0!'BU1M%4PHHP%4)C@7'%08J!&%_;<\6I
M1H)X99J,:!4O"T%G326N./K@2)I6.F^$UMBJ_S6K,A,&$H`Q]5>C+A$^SDO0
M,@N3-SGCA`S4\5'-7S53S(OW9-[&UE9=M'ZQ;U[?W%4"9W7%96"OTO7619]>
M_7KV[=VWU_M:_E<H?3L>=0G29,W@SA,2]BBQ%8P["RE!`@@$I(@BB^XC!%_C
M:S.G#BMJPNE6*<Z\[DHXZ)H(*]LCD(J0V@PH\CR,3R]6]'N)/]50VZLEC"##
MJ`374@3+.8*N6R6[5:`I)3J^4EP0HT!*8ZV\:]YCTKV(U&*%0HI2XHF54OI*
M,B6*^AKKK!YY@TFXR/HZB#^.PLK+N.;VL.D[I6X2(">7ODL(RN)J$DZSD5;<
M;DJ5]G"S.ZI866$@Z/_.%'.A"(NB:28S17I2)T2]RFDAD:`Q`9J4RDJ0!2M>
MLI0W2"%=JTE33T4UU?8B'34EJ_!;""0KMR-Q*BNLX!,HZ#9RR$S"9H5F-IA6
M>W*A/3@S0;DL&_MTHT-O8ZE8I%HJ!2J@9.U+4S,EQ<I/K\0#JKN5Y%3H5:;.
MZI!#5JMJ\]&'TA2IT>"F@LB$!,7K<BI5]VVK4N6R8FTTH^J\J:'.BFOLJS>M
M@8;#GG`2KM$2;\KKKXYF*ZBTC*<C:#(Q0S(OL1(^,BL0*%I2;BP/4^K.-S8_
MLLF@'8M[RMD!EX,I2!*9\^I?35-+\E@H6!C:BA7FI,TFY?@L!0I<(SY)R[S_
M_N6W:JNO5J^5J;=V2D?CC&R.E=)FXZ_9:U8Y+<F,08.(IHN*@PFC?[N4V,,.
MH[30.8ND)([AK05"MV/*S**I;IE,;"[ABKR=UIJ7`T_R4*09[+KKG4\D.G.C
MH=C-(?,2G'BLL?C2-2^L4Z5J5&^G/&NX:UV"`E#'70*PH+1ABE"B6T'JS:4K
M<J?JV)IH=JE,WY'F'5_N;DR]YF.%NC%YT"H3KZ=Q8?I/HN0Y%RD_PWWO:;8K
M3L8M+*<<NJFB_MY]<M'46Z<*7]_,+_9T^^^_FOY(=R*\K`*%;TE"2J"I:Y0@
M1#&I#D5`P[#CF<AWP*,*87BG$L`5Y`J945Q"?L>=_YF8[WHL"-*P5/*IECUP
M)^&C77,D^#NC\.X@2)/?:G(7H5NU2CP;P0IB+.658^4D@O\!E87,MR3\O><N
M#8*:L_YUG=>0*46@@L9V/$-`Z="F/TR,HEX^1\6"*2M(0/D<Q2+2K/E@9$<B
M^9<3O6(H+?DM,684R4LZ)!RJS"@KVW'*W0@(Q;R`BH]X,8]GYJA%)3ZQ08!L
M4!$5N4@C(C*0*NJ0MO+"Q/A8J3]7>@UP$@/&O%2K9ZOAI'FNP\G$^'$B7L$D
M'A-RR)NDI$=GC$BPKGB0+*ZFCRG!"Q,3`TF@V%%[T9'B=BAI'E80T):.1&(6
MRQA)0MH1D8Q<5:O4LJYI2O^3FM>T9C;?5\UM8A,D/>%F.+'936V*LYSC-"<Y
MU9E.=J8$FN^$9US0.<]SUG.=]+QG/8=GSW;R$Y_]S&=``0K0>*)':Y438T+3
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M5I3,W!%L26O9U0*6MK1UK6-9R]C:HG:PI>7B:T3K%FI^)3^_F^-`8?3/)RWP
MGZR+5.ZT62'E4B>KM6)NO.8W7;!45YWZ:5Y^"G7-4@W7O*::IU@ZQ;SJ"FJ@
M>!KH4?[B*L*M,S:V+"IUB!4OZ>8W+/>YYT^\&\ZRS!<:5C!!M%IUWI1VK8*T
MN5E__M6S*\)-PHZ]+889ZI&_)BRDUF@6,1T[X>#\)*%)TS"%=?BB$0>'/R15
M,48YO+!#E?2\-W;/03MZ./VN6+?K:]R%=1CCD+78*Y^B__#./HRB&#<Y.#%I
MD(<U3.*N06;()UZ9B!$:XXCB!<D-$E1";US5ZTE,=\1Y&.V09EPHW%`B0^N.
M3(97BK+(3%+Z80'ZQ%,[A'CJ"G%JE0#*XK&VT3``Q-DO9&H2@#W$#\U9R3-Q
M(+5G%IR&,)ZZ1DF(%DOBS*_3&M%/V(@CGN;X=#R2OC*K:B8F@MQ*J'G%<:S3
M<U=)9>0E>W9-JX?'ML_@:S.('N&Q/E5@5L.$.(*^"9R5A6;"$!4DXH'"^1:R
MBL5U.M?LTL^R$8V[OH7ETQR1%7Z:_;&8L,`$DM8/\T*=K+K*V0H/2G%8&A<6
M,@Z1P88=34+(0KE5,BI*O2P.3_]8?8T*SG`CIA@9;4+"XP65*]H;.U2-S8.2
MQDSNUKQ=5&,@AI5KF%@^C_*4A%ISEI0L2F:9+@Z2!8+#^1(2(=9;"I]$QZ?V
M-6C/1D%FUV2]<_00\I&>*=X^:1.M'/80(=$"X49BA[*ZM9D@)3#*A^HKN<=H
M)`"GJ1`A!:ZCR"EN:WA1$&9N=/*.4"Y%]ZD,R92ND%5$CW@BMPRB5J:DB1-0
MXS.?.2>_C,CN('/,TL2/99I"KU5<H5"\<A:SY%AQA8BJ9G@:N:2@=Q5<A2<D
M2$9--P\#E6K9^>3SBY2=!8"7G4$>)=_2DS4`AQHR`7AX'4*>059DDOOL+`"I
MSTL%YY?_(-[W'HT+-,Z1W'=56//<^,3]*8*^*>%G+V1<>E/;G&JL9Z0/)&YF
M/DF'`G"E+?F$2O/5WL,6M_FTA&F:9#/+YQ62++P*.$`$'XI?'K(B*R1<4H=;
M445,%L%K]5<BFY>45>B]WK.E(-N4(`J+\]*QA>H.>$.-@>@6O@D<E)M`WS@4
M]#..I=F-6_F4H4`(0/F9AMH-F9D3&ED[$:2.C7B<P=@($YNP%VN;9[,,6FF6
M`6(Q89O!57L91)JP50*Q(-*P$)0.I*FQB#J^(^P7E>(Q#%D:J`N6GGB<"(R(
M:<&0!3&1WN@0CS&%A<LZR.A`E=E`H["<L#F,V$@\@-F-KMF__Y&;NP)ZH2_:
M&K2CD#ZSC`2Y"2N(MBK,P$;1(..A&+1K+13!B\5),8KYLJX),ZHYKZ"JH>52
M&R2+.,5SEO1[">F[DY-I#5ZA"O?)##32F_0A%4UDNL^#/3&<BM$318YCDZAA
ME6FAL81Y'3E1CMCSQ``@H!R9*_BI$+]P&D]QFK]8M3VQPK0J/B3D.8$R.3U!
M'Y[QFB]+F-6K#F9!NA`"-4>QL&64(:*8M]#H"0P!Q9LP@;U9%PP4(1&"H(@8
MDO<SF\3`&::`#8TCG->QPO7!)?3Q$Y[H13PLBSG:1C?!JWLK+#[#-.S9-Y;P
M$VJ;D+'HFT8YDILQ0X53.QXCC"M9BO_B@3?E$Q'`4CXW&Y]]N[7Z(*4V5)S9
MF\4]@"U3F`R@&*\1(HM<XXL$24:Y*1[?$!'ZZPD?C(_&N2`5H1C*T(OK()V#
M>TFGJ2UC1,+>@A,-A`I<J1Z6<TK:X)#F>SDYT\6,.PB4##Z:DY5C`0I\(93F
M,`].Z3Z[L8R1]*6Z>9[6Z!261*23"(0O0A^.F#V%*(LK64@YTY25L(V.N8V.
M2(NS2\&NT95=6IJ)A"3#?*2_ZZ85T1(Q!!U=DATK<@K0L;Z;L$.)"):)`*75
ML#[>NZ#0L+ZJ&(C0O!0N>0GM&<VPB+M("01-H8W4`1U(`9U("8^KQ*]2R!?4
MM`9!L*78I(W_T$R,^./,_=*>X0PHSTRN!)DPXC/*(TRORJ2-E#&4%NH0NDD,
MD\029S')07FE?.D2L2FE0`@1.<I-R^22:2JF\#`?#P1.@AD4ZV/,R3Q-VF@T
M5IE-!4/-)>J2RER1%BE/T.'-4NJFT"3-=1I/4SS0=;DWG$HUCG(RG**R*3,R
M+(/0EN(RAM(R(=/0*XM0FF+0SR*IYC2^:-"I!JVL0KS0D"HR'>K0#<-0%_W0
M&`W$+8/1#=4I#[51A!HSN*(UN;*KMF(KJN)1(!U2(?71'OU1(TU2ND+25Q-1
MXVM2(CU2*5W2(&52*HU2)<W2*]52+/52-`'(KRLMEZ.8MBS3,373_YSS.5;Z
M.7QSTS:%4S:5T]=(4S)5TSLETU`24Q$S4SVM,C0%5#X=TR?EN36ETS?=TT3]
M4T%E5$4]TT9=5$?UTT>=4T.U5#RMTTQ%U$.-4TZM5$P%+?/2GU$EU5(UU5-%
MU515U55EU59UU5>%U5<M1D(5U5BUU5O%U5S5U5WEU5Q5P'YIBU8`5K805K;(
MJV*UBV`=5FQ`UF-=UF955F.-UF0EUF>U5FFM5FQEUFNEUFW55FC-UFX%5V\5
M5VYUUF\UUVD]UW+55EHUOG&%UW0-UW6E5W6UUWF]5W*M5WSE5WW-UWA%UX!E
MUX'=5W_M5X`=6'=5V(5EV(9UV(>%V(B5V/^)I=B*M=B+Q=B,E=BAT=B.]5B)
M)8R/%=F1=8L\(]F31=DCO+V49=F+-=F6A=F8Y:E6.#29M=F&?=F;U=F=/9T`
M@`*>!5JCS-F@)=JB;8^:-=JDO;&A5=JF=5IL6-FGE=J38MJIM=J=1=JKU=K[
MN0)!.)8`$(0K0-:M)5N2#=L#(0Q!$(2R95M5H=D2((X`"("Q;=NZO=@#.;0`
M*($`L-N^99+?B;0K\-O!K5BXS=NU)=S$K8M6,+>J5=S'I56:90&XA=S*A8NX
M15S+U5P1C8)#R]S-A=RW!=W1-<;!*`'2M5SB0-W5Y;FH9=W$[=K7E=WS@@*Z
MG=VZ;07;O=W=C:?_S^7=WP7>X!7>X27>XC7>XT7>Y%7>G6L>OW'-5@(D7')>
MZ8W>SIA>ZZW>PP(8[-U>[7U>3<E>\`TLYXT.\N5>8C)?Z"VM]*6E4%U>DVK?
MYXW?-LK>^76*ZU5?^<5?^\U?^NU>_A7?[\7?`*;>[B7@\RW@[YW5P?6G!O:O
M`<NN!XY@Y2JO]RVHJ7)@",[@">;@#?:G"E;<"A7AG!IA'#7A&T7ARK%@GBKA
M%";A%S[A%I;AG:I<K?I2+L5@]K'AJ)JN(>.FI/+@!U[@%58D",;A@-JAL++2
M]T'1=CKB(HT7R\6MS\JMR!(9ZUL!:/,4WJKB^"@PP@`_!Z2/D_,MI,PM_R(N
MJ"Y6X]2RABPN$&N3'3/6K.JYM.4A#CBB#0"3XS).+,L-8@TFH7@)A(3[8["R
MLP+Y"_(8%@G>8!!&XT7*80W.)PQJ'@^39'K!/+)0JG=3E@XN*D<F7(MPX1@V
MB%62QXI*3TUR*3V\ELP`R^-0FE%>J4>.IQF.83&*C)?II3F4*#*!SI<ZCOJB
MF)``1%MN*3^>TB[54NC@#[6S*@E2$!.%%#(*BD=!NPZZX24&95J^GVPN4K2J
MB"J<B.HPY$\1D:S*18EX'#ZDYL*S&V].YJ4:XKZENTV]5#LE4V?L(YI1&4?B
MC&KT%&M;R?=+#)LX$8@LO(0!U4Z]9T#BYG>:U/^%_E1\!KO$<94Y[.<GJ\1R
M838T<V/KB@BR>$JKPR5[EFA/%:X:9N257LI.:1'[(^.2T[Y!JA0?:K6D.`MC
MB9:)^)2F86GFVN:'QII(]N1P`@R7/D-=3)V6H6EX@4UL#CWZ5)2B!NIYMEMC
M'F&Y5,A&JQL6E1&F\XR>/-,]J9A1@UN0<;%8QFJ1$FI&6FL<'40^<;6SX645
M(Z.5$TRQGL40PK**"("R^)UQN>5;1N8GCF=RXKCE$A9J8K\["VA]))H6`2?6
M_(NA4!1B^69MKI^V+J+,]FP??94`.92RLAUK28S'SL=H66Q&`8QB\3]E?F*K
MKMLIYF,J1B(6B&/#4`C_\3@?568*N?&X0KR/1\)%8R/C/4;NQ.1L_%GCVH:L
M1FP)0#EG7F&)D+$X%'WG%.FT4M,+/6[NY);MMBWD#+;I\5[I':(7JO[@\%[N
M4R%J\U:+\LY%>E1O)@:K^G9B]BY;47YK6>[O_X;A66[O;@YP`!]L_R[P!#="
ME:[2SV[PPW;P+=7L!R<K_1[P]X!G"I?P",_P#8?PS8;<>F9H,[7B']-4AI;F
M%753:4YQ,15Q-I5801C;S,U=9)5QMS"%5I`&MH@&&L_=:276'W<+W5W8D^Z/
M(JO3*SOQB49RR2)Q2SW1$WWR##U4E'9?Q6W@/#M-W"`<SJG$N"6.`H7@3R.6
M_YN;FD[K9$@)VT;IM,$S[NXP&6"#G-\$8J6R\"/,,[YE"[S=\ZC]G;EM"[EM
MBP,17&QX6;P]M&+-LV+]<[V-V/?^+PO3<BJY/90#<^?Z8SQ;H'U#FM,.<\##
ME8+XM&NKL\C\C#5[&IZN<^:L7!'VLS'"1=_QBE7@Y2YK*4T1YJ-3"5TICE5H
MBD!,0YC1"V%F98VHC\KA#+9^V,$@CF*57,$5A!(H].T.=!9`UIJE6<1%VJ@E
MCK657&P8C$)WV`K]#*S;MSD:CR/C;EMG4,N0L*1;#H:#,FX\,<YH'.G[]>O[
M,N6@YA!E<"0V"#>GG4EL0T=TJM'T07/R1E(!,.TYF?^GPVQ=&Z)%P0E(P11-
MP8G97*-K^]$[-[X#R79BW=NYI5G!S7;598N]=8L#&0P]A]K3?8M%9]:L??3#
M3HZ2V1V"=Y]&#*=&0XHT)Z=UK`J6,13"<<^20T_"N8]FSAV3:+LA*C^T\OBK
MI6TBR>5R"9$;`1QJ+I_9&AIH8$(4I0A2ZZ4K$,!$%L,@&\*_BKN].!;+?K,:
M:OLB"_8^=MB01?F23]N0Y8.Y/9!J']O`'703`/2VF-QB-07/E=@N/IQ09P'(
MT!@2`3GNG@^F8(FP,U%2"[-<*K?0()R*5A)"PYL8:3578X6'>R2V0:W"IB<.
M$6F0-`OT@:_E^HKD.HL@@0C_2H.S;6-,FH@V$1D+A-1UB5<+<F:ZB3"*\HL.
MY@DTH&=UAFV%!#-T%B#6VRMY1L.&S@5WL&4+05]Y[R]9U_V=P'?=<?_DBK`"
M2U.]QF.0O\PA3=Z?:,0A:_NT<BG%Y@GN6Q%``)F*;3F?F@,(:]98!1!H[=I!
M:RP2(A2(D$6@A@D=&CR([2+&C!HW<NSH\2/(D")'DBRY\=HU5@A3KE1YT"7$
M:P%D7@MT96"`0%:NS%192D#"/1%?(K0R-";#I"P/0J.I,^&5*]>,0HWH,B70
MI01;KFS*@E73EU:@L6(!Y2O#@D37+C7I]BW<C:T"L*@;H!6VN5>PL:"[ERX+
MGGNQ_]'%FY$N1T$!!M<5I/%*X+B2)Y-D>_5R2A9DO[*XQL*4P`![K.PIV'3G
MP557,+/*VEJITJL#.ZM<Q6)5UVNK`K&RN73JS:57K+3,2K;G2FM66)6U@G;E
M<\QL*5.O;OUZR.05*5;TK!+RS4"=K2QG?AOA5H<2'7X^B)8YJU7PF;^DN!!:
MYX,[:^:7R6KB06I!%XA!*=GGDD#EY:=010MM!V"!V$D(UQ4E7"&(8'DMEE=?
M@K12`@N"",)""1>5$(!&<Z%XD6*#(88-%'=AHYAC<[$P(8YN/;A>@=9`HU9=
M*L4D'GQ(D9><1`W-%!IZ\LG'W)._!0+%2YKQ"-U_%96UWO^2#@GX5$57$#@3
M2F@)])5VVS5T38YMNOEF1@PU-6=N80V94TU6*#04<`<%4A!Z*JEDYU$1"26F
M48D*)!Y"PSUD%9KXJ20>0RZ)N=(J)C"%D"DK(,1H0H%$9%MM:,YV#9UAH;HJ
M-'"ZJE%?&"&FUT5U72@C7S("!IECA-V(45]VG5)K`#7VQ5.(KRI[4:IUKEJE
MD%9"M.=*E'H6''W/I@0H07[J]"VB_\54%J2R%161>,V612=JPA%';5BF$%>6
MH*9:4P*2@VJKTK+]^EM2DCURY]Y_G@G$RG(+#H0O3BOE!*!W!,.6IGA("039
M>2]!IF?`LQETQ1X4VRH1PI@ZMQK_>P4+#"&;_[8I(D8PMR*(*1?-/'.O>7DX
MHXA[P#P+S!G=G!&&0N_L,IS=K;R>@R5/1:!F%:W0E*/6F")@15TN&7":&[O4
M7%W3#K0QQ`>):9"9$E4\E$%0M'3R551U#''+2-MMMV5<L54IDFRI:N[>??\F
M7;Z"`S[XTWP'GG=L-07'>%MW2SXYY7!!3CCF>B-^N>:9*Z6JXH5OVMG?FH<.
M.E>K<,RY196[_F::<\N^-.T#SVY[[6H^"&&/L>_.X\!*X[ZC0Z\;?[SKP:\L
M?-G#-__\[=#G'CWUT_^>>X3(:U]=LYO2Z;VVW;,:_OC@JRH^^N6/?[[ZZ7^_
MOK/LOY_^__;UV^^J_.3/WS[_^_NO/P#S)\#X$=!\!82?`<''K_LQ$&#6&QY*
M>A=!WSFO>KZ[H/2X$T&*8+!Z%2Q0W1@H(A$91FBM*.$(@\:B7@V-9W()6@I)
MJ+,2SA`C.(M9"5O80(PPSX-E0TG?/BA$AFR0B%PKXNR`*,$C^C!ZK=LA%#V"
M$L]MSG$00=`*G&.%%0B"=56\2E-&$YV43(DK-IG6YGB#*1:$K#:0(1!+SMA%
MA$##;8-2HQ==$D7`Q"A9,P),72[21[NX2$:*^56L8%48OB"K,;GJU2%)]*NY
MF``OBH$"A^BR2"CF47-GQ&,@LL@"*S#LBYT[Y2?9$ABBI!)QO?]1E7,$-17G
M0$$JDWKCZ%;5F]!1,8J^Y`@%I7>-*U!IF`O95E(^F*8>#L<]!!)(*2!3(&(Z
M4W>@2E"[6&&"IEBK751A$$.BLKQQ/I&!+[+115[4H5P9IB]X<:>&"DE#PO`D
M9SPIX3W3^:L8U>A$-Z)5BSB4LP82KZ`%(A)_5$*>9/*.@QGTTS';Y2=I0E0_
MJ[,/;C06`)69JEK%?$K$T)8EW14TA+_\)=_>IZ^_">`J&VU82K4UD/_LP2$K
M-1VG2(<>VC3J:SI5U=8&DBB$"()/:KF4-<KHH-Q@#8'KV^,D38`B=&(CG_GD
M2[+J8LE`YDHC(VH%5[&:,Q+U\U?YM-'_7<"Z%["6Z*3N`R"\KE&"+N[AIW!E
MSC7V4+`!;@JFF:'7IX:2'JWTQQI0`&R`^J:3G4YEK^C!UTV)HE*3GC2*331(
MMV)#INF-4E0!@(81#X+$V8R4/S\4&T/`Y)YAUI2#U+S8R.36(Z0.L9SW"\!<
M,;0A7Q'+,<=J!;*(9<G=EJ`$-.1)55>47'SB2IW%BB=D:#6C$PUTASW$WDN1
M="3J60$*O,FN:%<RVCTY1%3X6=-*4,-!,PW$;2\-D'CT]+&Z$,<W`;/70U%2
MV<IVDI566@M!SF(J5H1L+48YUS5*P8(5U`4*#%YE2F($QZ]Y2I782DY4XD@@
M1UT%H>825>A`_TI%/4)1DX[D4%NMNJO!^&JKB%2N/C743C^*%<47N>IBP&JK
MC&0HBOUE"6*7\B>XH8=/EGH7AQ?<X`<7LRR+88I"='/,N$TY.6@2$D),H*_W
MS`1UJ@G=&+VXWY,&<W9;ZMU6D$2I]<*Q/4I\,\066BT',20P:RJ0;#O#V@E:
M"V(E6QO)%*8\#9;X5QF1AG-]:]R-P%.Z`<!5.DT\F'IB!,=F?2ZM(+/;2C^7
MDPW]-!W5XEKB(`FUZ:UIXI`T0:5TTR6E--OJDO2ED,G$H0CQ[GT37!>V*8=/
MV"O>F'WYUORU9LL$V@J=,!.6`U-+EL[.C8^"NB55H5$ZBTUJ`)S3%_^.60N,
MF;%&U4"V*IN`+X&K*C0M4D2B&\OHJAEQY(A>3+1BG5"=-&:!"8RUHK/NEBY1
M>.2,(@-%OCH5/Q$Y34TA0[Z^-@K)4DFV+J%-D[*,,FP%:Q?$%9)1^H8-CG6>
M\$-ZDY_%>D5E+&F*LED2;%]>ECU2V9:@-EOFF'CFV&:!`BU'29P0Z><FY=7S
M080"Q(Z5I7<@J]+0>X0F-.7U<<P>HGYW^.C$//I8O95+7QYM`EE)]5@\D0:Q
M!!F`80F718\^T6"HVN.LO\C34,>SVQ"RT5FN6G;[>=I#SD)+G(_GY6M.R)F3
M2NK1#O.9:0&M-6P305'?6J$1X0]*\)/?[JS_W+*FA%S%D4(06C[L3WICXZ,$
M)R?/;/'"=LF8`$;Y8,2MP.3@?I<5LOU@'S6*3Q5?C9).R;@H>FB>0C.:1TY(
MPYOU?F8V/&%>D&\SY=O0JX81_O%]S\`?Q^TLN+9&:3@/VM3K+=SO$CU+S+*"
M*Z`<4YIZB.KK\AO0(B<A<U=)71DLRZ06V#-GP;W@=5_%RD.QS-;KX`,]E$-U
M1Q'9FN[\B-)P#>\H8$.P%_`T%&7QGP0BCT$Q3P+^T$2,U^09(`"*'D5<&P?"
M!NXD1^"1%$E%X`0>3TR5SF2UX+ZH3V2=W`NZ(`O.H$PY1`WF(%?,#PX>4+.D
M(!`BS[#Y8/\$$!'^_X\.2I8-%D@,-B$,ZI)-/>%D!6']M-P&7J$59F$`:F%M
MH2`5?J&_7-?;C2$6;J$9DB$70H\7@N'=3)'^4='H-0[UX93?T&$53<SAY*$=
MCAA"L*$?(LT<,MS$\-(;ZE_H'*+$'0XB+LX=%N)T_*'K^)_M_(G"],5_$$38
MH-$9_A#&7%1H%)-`")C'/0C'L(+U\4G%C$5#:-OCE(Q!R)<)"L\:0B(M8L>@
M@1HF5D3L140CU04:T@Y_C!*"L")49*+"M$1PI.+?_(EKZ1W@]0<K^)P``ELM
M2LX0]A7%^=1YK$)6-$[YR:$,7D4S#1/'>`6H1(Q_*"'VO<MY2(IIO2,:B?^3
M9^0&N14A^U0C/N8(P76/-60;VYA%1$A4P0G.6UF+M9S-5*#:QPDBFJS"1QT3
M:!7;JI!&15U#A:W*<RAARBU0/B)-RX$+2AC%2Z7'!QW;<CP4;QS,4B%,T6E0
MAD%,4+%'1)A"1O4CK#6*5-!9G976],QB1_YD28AA\Y"+GIW1?U1-23+'@46/
M*92"06`-1&E'2V9@&65@/R*)J"65@R@53Y:@$_DD4.:(&WJ1QU380C1D-QH.
M=%S!*OR(ZR$)^VBB@OQ&*8S("];C2T3CX[!$+85*8$1$F'W*O#AB6!:F9/P8
M^UED4:A.0`8'ZJ@258`707*%0)9"T8'.:"!.1NK_1EF`1G*\WTYEF!7,$1@=
MUN7]AF'VRS*14U1^Q9:,9``(6):XHD0@14S8AC':2H&LTL'4%YVE!'CH#FU9
MC7/PFC'I3N&M6GF!8@528VH^9T@TI^T4'55T1DR4AFX*A-!MQTMF&,7E)I4X
MA#0U1#2.$H1`94)TX\7$DJR-H'U!#&K=XII`YZNLX`X^RY88Q=EL8UI.BL=A
M9,%LYB#67)TQEE*P$<-Y%T,>7)^H#[G5U9&$Q9D-))W0IX5ZQ#4^RU7:!+GA
MFD">AF.=1IO]Y\2<QEZF5I4)I$LE8DLM18LJH>IH)<YA&(,FH<I=J)M<EFEE
M8SJ29`;>5Z&DQ'S`AWPX_],&54PF7N+/4<R[)%5Z!<=VH9F>(,5+.DX`VA:.
M7JA0$IV#U$4I>$87(:4(0H54]%J@Q,>06E01@<534H26=4Q(T4>`F%Q6UB:X
ME>DY.F!/9FF;C.5IGHI"Y,>;E@*@5$K!7(6;M5Z"?$NB^(8\[LVTI:.D$D71
M/01ND(N5=HXJHE&>605A\BF?(N95@MN2Q(1`ID845A.!/DVC#A5(;8K<0)C5
M7"1FR(U!'I/[Z4M"F"9%#A.V5)F8@>J$2"+$3$G0P1%L9B*ZQ*29-BOX!6HF
M=L>K*H>7+J#8((PP%H4QAHDX[AIF"1JH.:>P0J=\_DZEUN.0&*.0?-_'E"E2
M/?\KQH2->)[%?^HI=WS)R:#HR!C$=N85O;;K:@X:6(ZK2;`/PQGLLR8LPBZL
MQ)5HPL:AP\B4PC9L;BS5P4I<4Q"LA3+LQ0ZHQRX<R"*LPWX.QB8'R4TFR0HB
M">I4QY*/QEY'&L;L)LKL+]:L&KXLN<ZLSMHLS98ASV+/P.)L=IPF'P8BT3KB
MT3)<T29MT@KM<QKMTD8MTDHMU$ZMU6*IT[K%T&TMUW:MUWXMV(:MV(XMV9:M
MV9IMUA;FV:XMV[:MV[XMW')MVLXMW=:MW=XMWN:MWNXMW_:MW_XMX`:NX`XN
MX1:NX1XNXB:NXBXNXS:NXSXNY$:NY$XNY5:NY5XNYF;_KN9N+N=VKN=^+NB&
MKNB.[IL,1L_XC/013?(=6NIV1.NR2$=<00ZQ6%6MT(4<35RT0LU`$O1Y1'5Y
MU>IBA#2\KER`Q._:S`@AKXC0KN_6[@N%A&,<KUM(KU=%@^J&!'#Q&%X`5_*2
M!.YB[_#Y'O4>'_3."/&*Q/C&#/"2KLM<"(O)KNLJWUZH$(<TWT74S/)M[X78
M[_+!+Z/9DZ&Y+[`$7UXDGRNHKPFMU8S`[_/E$%XP[XP,\!7,`H_Y;P/_7OW:
M#/`:6D:<`@M%;_I"7_9:;P'GT/*1;U[L056]+O*9</#NP?8V7^_NC&$<#?-Y
M%0O4<%2L\$=L[_/Q[_"=L/FZ_W`$UPH"RW`!:W#^YL7\LH)'#&\,*['RT;`,
M3W'O6O#YLJ]U9"^+?:\-12]>8!+]9B]8/?`#ZXSY\K`@#,M:R2Y8*;'-7(@E
M9>^-P<@`<P1PG5`.DW'O.0;\BLD*%PW,]-Y>R/$;?['SWHC_LD@A_S$3IW$;
MW]@L&-\@3U)&8))&H&[JRO'.[,6-8,@)1;(;S^\9UVXA;V_.$)\?U[$H/[(+
M>0C,[,$HURXEUXCS(5(MWW`%SPP4A/(0SW)4^#(9[S$IYW'V_M,5#.\I\\4-
MS3(AGS$?1`/\JM`@>\BDW0P7GU"O)+/Q<3$ATW(?:S&<@/+^\G!BY''M>O`0
M@W.MX/\,&._OSN1P"AG&-,-*[=[(K\@R6/4*!PL-']3Q/5>:"A4R&N.,[))S
MI:5(\BIR\M4(&"^P-5NO._-%59&0)P^P\=TQT;AQ[`H-00>-[$J#'-_R(\,O
M/O/8"'VT#Q<-_&*R.FOS0YNO-:=T\*[0S<AN(1<?1[QO'</R0'4R#AT-+!]R
M0`<P1:\P\3F?(P,U!]\N2Z>Q-A>SZ<YQT<`PB[0"#',R!(NSA/S342\RCZT0
M1=OP(],Q[?Z**:RR\U[U15@!'C>R;QFQ]2*2Z_+SC=%Q1;,00?.Q(#AQ`;-8
M4]_U6$>Q\3$PB]&Q5<_O0+&86\L%8&.#57N$H9WQ)].SS@3_32D[LNF6,T`7
ML"OL,$@[[S4;-F1;-D'#,='X,3)C`Q^\+FG;L4]K\#2376P',CH'-$_?KDVS
M$!T#]32#]6'KS#)3M!O_<^UBLBF;MCEG,5?'!>X6=CO-+CJO576Y,20E+_>2
MMCL_<%K'\W&Y<F4CLJ'!6$9/VF7O3`RQ<RW3L%.GM@PQM-#`L`WKME/[L27Q
M@<S0=-%X]'YCB'_/#//B-!I3]U6W0B#P#'I;,QH?33_GM67?]2!;T@@]L(C4
M#'"9PC2;\6N+M<S,+Q\(,&>O]5Y(\X++D`TG;WHG.,S\R@@-"Q3\]WI+.(;[
M,GMO!$ZW4QRC.(63D"I#=(9#M@R!_W5SNPK924[ZCL21`Z$NEZ^KW-#=,+=<
M0/F;&#/]CL1M#SF6+ZZ4"^N68W"6?SF8A[F8CSF9EWF6MGB7/W&:NTF22Q_Q
MMKGO33%)L#!J2\B2]S"=%[%)U,@\2?F;7X>;PZZ9IZUA$[&7U_GS_1NB)W&*
MX#$2]W"CVS'_/D84"W:=5Y5)$7%PES6C&WI%M^YJ1[JC0SH*Q?FC,WJ=FQ4<
MG^]>J+,-[<4!'WH2+[+O;;6H5SJC\6^##[K0OJ\VWQ!$F$*/?S,H9V^Q6[,9
MES'QA;(.Y?$@<[*3VS1U#\T_Q;:A,?3-6'6(#'OO<?"(@#`9G[*QN['/U,A>
MR/=B*[8."?]"+_,%LLOT0&V[(*BP_RJR?!]T&P/X#)ET:XMW;0O4IPNR+W\Q
MM;M0S!QT%(#[M,<S&//QS'"PLIM[,Q^T?0L2.&-S5LW0SN3;E?,Z?48%#.$[
M#T-\+Q\[0'?Q4Z^P5G/O.2NR)>$[/J5(,Z\U0!N[#\,O'R@S@./U(@>-/,/,
M6OFR2+O01\,\#F4T7M/R5-\N4:]U>-?NT3!&&NO,SU]T:CMOTJOZ7<LQ6(?R
M*J=U\`ZW/.\OLR,US/,T(M^84;,8)CTV<B_O5XLXUMNZQX=E@-,0)M.Z"N.0
M$6,U#Q?V>[]US&PS:YNQ8VOO(Y_T18#=M2<WT1M\9]-N>7MT1E?_^R,KN!>+
M-=J?_`IE_E$3-X[7>T_K=8`K]-R']>?#-Z6C\2<[](+K+^(7-AIK-,0;=U7E
MMFDK-P.KM>ICTJ^0>-U__#SA=,6[LQ]/>&@S<PIY\H17M'5W+X*/B#FW]^#S
M./%C@Z(S/1/K.[[/^`+GM;G#_>!WOF][,&-H<SI56B+0K_4GO=ES.'XO]AT?
M]--+_?*?=UQ??=K1+M</L'_3+D`(NM+JBB!L5["U,HB-X4&"K1@*DBBHE2D^
M!$]A$ZAQ(L."@E@T3/@1H<*.'R4FG!@RY,"3!A$>W'B0H4*-,47FU+F39T^?
M/X$&%3J4:%&C1Y$F5;J4:=.?*;&9PNF41&I5JU>Q9M7*E*#/@5O!AA4[EFQ9
MLV>KMK*)EFU;MV_)0O0I%VY=NW?QYM6[EV]?OW\!!Q8\F'!APX<1)U:\F'%C
%LP$!`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g267791moi003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi003.gif
M1TE&.#EAA`*6`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````"#`I4`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O8,.*'4NV
MK-FS:-.J71M1F:EEIMPF-!6M8#2Z$$TM;&5*D*!$/06U*MA*4,C"!@5S5(R8
M8^'!-!4S;.S8,$3)%?T2QFR0\D/.#1MK%@EZLF6"HT&F/OFX\^F5;2*UD10;
M,N%(;@J"BO0I]+#8"P4%8!&@^&N;PJ\4A,+"=D<H`0P6WY@<VQ46QR\*=^ZQ
MU?"'WEDD__R.C3CWB\25@V>AOB+Y@=[;&[P2X+S"5BR@1)R.[?W'\!&95Y!_
M&0EG60#Z[2>?1'M@)Q!_],%$FT+1M-$;0::TH0Q!=1UD2B83*E1=>=$19)]M
M]DT&WV4!9-?91/81)YUX%3EG($2S?-8B-BFN^.*/`L5W'V$*O=>C0\X)>=&1
M"!'($'U,1GF0<S+V%QV302;48P!19(F0<Q$.6")X"_&Q(T0H!K#@EY.15^60
M(@$WD!NR83)8*Y%(DDD;F-2U&R@"?1);&QT:--M>:@K$@@F6T5="?0^R0)R:
MDT(F"''L#52<FM>1.**DP]TY''W-87,IJ*4*V(JC8Z*&*8WQ!?_PJ*8EY->J
MHFH.U^BFD%VG:Y`E/*J>(";P8=V.DH*J7BO027K0I:,*E!P+M0Z$ZH$L[+$C
M?L1!8>FFV(9:'J:0C=HB@*L.)YYWPT6GJJ,T6D=N8N!&2J`)N;*'J6'"T2B<
M<8KJ>R6\FDJ*KZCJ^9KIL=;.BXV9QM4'H*GU2BOKF0&8$"G%HA[W+\8TNHGI
M*3R:(%Z_%`];L:11$(>MM*_2*URU`?^JL'CD0<M"EREORF-Q,BI\G*2#);H=
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MT':.1W?CX+C"WJT`J"2/Q*90`C'%A/"$"6R8(A*9<"!OL/$)2?0&$Y&PSZ'N
M@S9)8<]!1`.@"/&W+61%1QJV&Z"I(.<L_"CG4H&0EV%:IK=2K<9$U2G?VF['
M,#%ES3_L@AU\_RB7J4M-ST'7J>'I3D>8`)S/5&J#GN]@5J)9S:>(F6K%*>[D
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M9Z)HK;)7NA)M)Z06PY3O6M2I;EYAD?H!J66(!2I`5K-TJ%K0C5;'M%*^+#R8
M^J?<"DBJA5Y*C-Z)HOP$Q,T@I2>4')$3+221&VS@AD?!E&!O_D3!2)",%@G9
MH)8"BKT2#.8:M(KH-^]''+-VTW,TJI883U:"%Y8@<7<MCUNIM3G>$4^B_(*4
MMFQ:D.R))X2-A-;/XH56093@?"\U#-WTYE99><E$:+O"*,,92(O^S`H\JBO%
MSB<(S89V<F."3+"&2+C_B:R&?775+AT[O;S_SM4@55KM;<5HUQ>:]J6VD52.
M+#M"P)ISAP'`76?I`YUEB9:VIC*M)JE5-&V2AUMX',BE3M,K<BI*F[/:[7-%
MJSC@ZK6ZGDS0>2PGSQZZ-F3+PF<K0_G%^7S'5]*,'<UPV<1UB39J5OL:-BK4
MP*LUD&N]$7#8L#&V@SQS(-%H9@Y+J="+JI-RD,(/9P1DSHE=\[A_E!N!`O<W
MH2J.PP5[D'+P!SG`!0_$@269.'.'6]T%=J.MN$8'<3H0$I,0DN6B4?34Z3P>
MB_!Y&]NA-N%C/1&6T<@?GH7[IDAC`KZNCU-NK^U,R^2_BABU-[46S3!KK-4Y
M-L,E')],]8B^CK*Y_X50%9WK[F;2U$W.QN=,LT=;J=V^Y0QDN)*&9[L9Q35I
MY(`\DIIL%A@).DA-$H/9S84$)9ME($1.`\8::MI5'-N0:J505D^#AL,S,\7,
MLU]4:2%15>AC"?!.G^Z,TA)EBGA&BCT#-!<('S4I@;0L6HM%FYQ?O;A"4C,Q
MIZ9?FU7-9DHFRU_M.@VI:@@U_BS6V!R^`KZ*G>HQY91>+@N2D[1W[8GUZTS0
MX:Y*!<VZFC9/7L!>':NQ'2US1[MF[N;/>_Y7D$^?!FZEZG:+49NL(ZH+6<G"
MF#9UMLN>[7?6M,*9OY+M8LB`"MZ-%/?]=K6KNO$WD^K*^$8B;)<!=^CD'/\J
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MX*/DJ'ML*6D`S1H'4722#:F2A@4B+'FI7O,'X236EA'90W[F=X!!80HV$B2Q
M4W6R<R>P173V\7FF0C.(X8#<I8"FHET)P1C<`1J4\8`K%'`-.'/7UX%WQX#P
MD1Q,U`JLL#\%00N0MX)15QHB*"W^IW?2`H%.Y2`B""V6@D,%\8)LTQE5=RK<
M`3F=083:M5X0Q2/*!T4RYWX(6(4H<7!*=2RHTDVODC30ABGVU2B6D7#8Y&Y`
M]2HHYCEUU7\4TU:BXFXW$C-[XV7GEETI!8:XPE"GDBFRHBQ<^&<FDQ_^U2Y!
M!BKM@RUF.!R/0C*#XX<&_X,=<1B(0X4OV98Q>&-?8(A=N_1L9W)N:%8I>7@F
MY-:(X::%`&B%J*@2HQ-CG%5(0,9_EH1G%+4P<&0;FL,V.6=$*^0B?,5F?!-8
MTI)]]G=+@70IB#!"AR@XPB$0MYA4:M4?V2=%H=4ZZ_-*5]))J%$LUI%7BZ)E
MZM1!"V<"3_1P;U6$TY%SKK)1L8.-3QA>+21:V;-9'Y<]=9-S+F1.J9B/+!$>
MUU=Q<S-G^+@\I15G+7(J=)88185E-[90G;4\BV4;[X4K-I4[`SE;+J870?)2
M=?93AR-4`X5:?J%O\+4_MD8Z?K$WUD4CMQB1<N,R__*,5X0QO&-DTE).X>%I
M:O\"A!:V,5AF?8JCCT"I$GC(7CWT.;[#5_A15^QQ'!1X'302!:W"C^^(3;65
M-)NB%R'DD*Z4+JW#5N685';&'M97$*=@:YX2)JQ`?R2T<0RC)#W5(&V#CMK%
M1DB4*N0T?L\80KIH46'REF`FEWTV?CXH<B0E;H+9'GC84RU5F`0T1N2TE$$9
MF2;!17A67JS45NWQ85)X?TO5*G:V5OA86`U)9,W#DF]B,H,D0I&W4PB71Q'I
M'3$%3E_T'OH79"I&DH'57OK'D6`6D$+F9CPWDO>W60\U$-MF9?<C'W)V)V-8
M.BEYF^6SF9(YG1^A.(=3/X35*<XA5T;9/LW!'+U9@4?_%(N8A'XUYH4!`TJ&
M$0CUX0JT))$]!&\-HTKMHUE0`B"*E3),Y$IJ<@W4<R6;!DIQY5^S]5CKM$FN
M-D+"J4G0]4J_*4H3(R.G,B![Y8.UPG604RWEE2G4Q4?GPIB&M6HB"AU42)TF
MVA`::5IFHH[%1A^;4BK7M2_/$E0ATRJ3\E(9-5&BV2^G<:,]!C3X1$G%=FWM
M%`"8MVF^TCH']Z,X4X\Q^BN4!#2[XD[/27AY.%C=U#DBZ50%J7#P>2S[YC($
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M^'JOYYJIK=JO_OJO`!NP`CNP!%NP!GNP")NP"KNP#-NP%.$7TP=\(G&#VP>I
M$#E]I%H8/JE]!R$-&#L2'-L0-Q01&*NQYS&6//*Q6&%]U;<3*#L9>\"OTN(Q
MJ:&QI?_5*S(;$B[:IMT$J1IQBIU1IS,"/JCJ'90(@"-2$DF4>8PH$1##7;)2
M3C\Z)O*G%?(6J#)!BPM1M23+4.*6IG>X,*`G$^A(82FX@6PG>%,'D2$4)!CI
M=UESA)C%`B2S>#DKF<?)@4SV&MP%>7V+&EFGMWJ+&%MT$/)7@BCZDVW63TO6
M'W=;%#<R,8%+<\?Q?1[S<A"8N2H8N%^'N-+A=)ZA):5%BY%5;,MH$/]%MEO&
MA6U%IR`3;I[83@REB?16+K\F&"24+)P$AH$3'NTWJL35AG_6G'CHD+Z;9H;X
MA]$T+EN(63.G+@<CLB%54=:2GT3+%6O)A<>I+0E7,*48'N+_`E2\!HI=!&>@
M:&6@@E+R(KMXV";2AG]'\QHO11.`B4\^ED=AA&%4R6W82#MQE5K.$H^GE)YZ
MM4>@6E\/$IMLZ1W8R3".]4%JY1WG4SY(5I2W`G^@^7B/ER;O:T1R%QW^@<%:
MH3DTY(J"=$2)TSU?)A`K$#+)N6>L="7P"&4CZ:?,&"\=:D4B"',0^4@])I9X
MI&VXUA[>0;]0E6<HHI$&K%WE]#^VL6,A29-89H<IE$>7RJGNA!WTT25)2TFC
M=+H9V4ESNF8T)TY6],-=9DZ3LBD^$Z3683)?5#0"Y+Q<`5P9!RVYV9(E$IP\
M"4[:LG'.6)M]+%$+,KT-R<8ONK=,_ZJ3C1%&ID2V%CA3TA@P^7G&=D.!EW*D
M/<B,E+*82\9;LIMBY]5LHXK`C=A&'K5.JU,?"Q/'TF,^J?RCA-54\J>0F?>^
M$XD=_*A=;K45D=,YR8'*)[97^/?*MMQ*=74%/,..FN)E-OQ0B(6UKM(>Y957
M9?3)^(>I7.(V@(1C16A%^U9"I!5)`;=C66<D:"-H(U+%%L6G6,Q/$X,\K-E>
MS$L\:O9AE<,"F.-F>6LQ:5PYI35^I<4';FK(\U08G!@OQ.(5PY&:D5N2;M92
M&3/(*8./GH>_][R_</6C>230W+>Q`U&6N(P^X0G&,6%+!6FV$7);^?DFX4:!
M0M*AM\4Q$_\S9CG7C?QIEUIF@(-JRG[&EBSD.^P$PS4LDSW4EYVER!XU".3\
M>?K"97YJ(*:\Q(;4%1='P-XES*5BG7?3''/G1#`\<Y58-/8,G>H+QAU*7$_]
MU&Z:NM`50D@CN6,;$\P"-+WBCRYZU=8VFU*K,^];(GDMRN_FHESVDF]"V*2Z
MUY,BR2\45&<BN0(U<!7M;,U980-XO7_3?2(22GG-.*FEOEE!1L9FIL?R@CQ5
M'`F"*V@#4I#4HX2#V`_BI+K#.Y4]:`I1EO(A-#W&:T_LLPXKL*!=$NX<E'F:
M$=KVN!,QW+]-L,@M$;Z=CR[:W$:'$M*]W-:=L=>=W=J]W=S=W=[__=W@'=YH
M(1B"(3OE_1CF_8#GO=[JW=[I_=[H'=_L#=_S+=_N;=_T?=_UO=_ZW=_Y_=_X
M'>#\#>`#+N#^;>`$?N`%ON`*WN`)_N`('N$,#N$3+N$.;N$4?N$5ON$:WN$9
M_N$8'N(<_MR$\6PF?N(HGN(JON(LWN(N_N(P'N,R/N,T7N,V?N,XGN,ZON,\
MWN,^_N-`'N1"/N1$CJCB?>1(GN1*ON1,WN1._N10#B>E6MU[L1:=5A9K?7^?
M9WE4WGNE%07C=P6NX%3S"Q&6-T!&I"]:\GGCU^7FMRIA/GVE97E10.+6H;C@
MX]03^-1G'MH^2194W"L+(K2#RK4E/A&3_X0?F30E1OZIBFZX/)T0+_L@R>WF
M.@&CG<&R:&LJ(VNX,(B"J\(8-XM#'QOJ?+LYJ+<F#=>RF63IMO?H8R7IX]%O
M0W,>C?ZIC0[KLHX0A,XSEQ'I3/'H=6I+L=-2S,)%#-$JDRX=8ZEABF%_IV!:
M^H/JTI+:.9FR`(5L$ZCJ=JZ/>Q`[G:[K`Y(0O6R<GK8FT>`OKQ>IBGYZ[&8=
MX/Y\N03O_;8J.T/BC6L5>`3KDYXJBZX0*"ONJ!M<ZJ8H)J(>8&4MJH4B#:="
MK=`@DQZRPA>IV`&)Q1TD_!2`LUYC>,[$W"<82^NIUF?QS/$@VR4(IT#H_9$0
M0KM_L07PW:X42?^%/%3[&I;TT0.9[-1>)!1U?7FCQ<DW)H@0])J"6;ITXC,J
MZ+@5\ZF8<9,N[BE>R(GD:0UGTH7TJ5RK/UI+[TZ)]#V_$+=.Z:$-]&%N+0(=
M<.N"#6..HDFC\PH_1."GP8H27.7R[V6$=G`?]Y[CZK6GLE$Y[X`_[M(W^(+?
MJ2/K+D%;^$L?',<7]E&1:SM?6'C/\JOB]I'/L1=,[T4O]DXE'9[_[WA)4<`.
ME.(>^IW?).1.)=RQ["MO]YUZ*^V^2U<00W>/$$^?A&CU+*E]%1*O*,EI>87M
M@Z8?J&U;'JC_]C`#+`\XF%`8\E$)*_JM<0J(P=JIL:,?E$<E.Z8/A1+_TX3P
M;1LDT_TPHUFR0[H(5=XA[ZF1H_UXE/UYFM[KO2*Z/$3D[XPU.41\CQ.HESB2
MX?*<OF$`T0K;0((#6[$HR$)@P8%7"@I:B*V5H(>"*!*<"!';16Q[&%X4="5D
MR#U7/!(\%3(BMI0BKZQD&%/F3)HU;=[$F5/G3IXT+6K$.%(D0:$DAPX<*8C/
MRHQ`!RZMZ+3G5*I5K5[%6O,GS(T6'[H4ZA"IR)),57[D.#'K6K976P5@>-"F
M6)DLHA6DVU;O7KY]_?X%'%CP8,*%#1]&'#BDRRMY9;;BVNH*"XX2[R;&G%GS
M9LZ=/7\&'5JT3JX\2X]&G5KU:M:M7;^&'5OV_VS:M6W?QIU;]V[>O7W_!AY<
M^'#BQ8T?1^Y:X&F).)D7?)YUHLCHH4LO;YZ\,/;J<;/;O*S]-TSNIIM'[QY<
M4(#&+":O9!&@\L``<`G:MXE_)\*<=!VG/FBRR1)RK[W_Q+/*/04Q*K"]G!I\
M;R8#%4)0M\;:BZA`*"*\2<`"YR.J0!;XTTX0$NG#J[&/.,1&/YI<Q,DKGE)R
M3;^W"**0P?0J?)$A_B2;"D:97`Q@1QY'RQ%%)7DZT:>\3!0O)(:.PD:A)%O$
M\CZ<]*ML)(DXXD\CBQ8Z"Z.7;A(3*,GF6W,6M+H4Z">9I)(+.AS9;/)(TN:C
M4$:M8LHS)BFA"U3/UO_F&PK(N6(ZD-'YA"0.RH+T4ZC.C1PJ4LN;\,OQE$15
M'&N@`B5R3R-0U<)I5,D:,P6;4Q.-`B2'(".Q0,@DQ8O/,P'E"E)#F43*HE%C
MLA1'R48L;=""3/@5-_LD.X@%*$J#4:')*)OI(#!!+,Y$!>/S4:`<*=2OA"U%
MS=!'8T7E*)"\X-)6J>BH5#;+744U*->&*LOS7C/=@P_$*YO=R5(6,U47.OD(
M`A4Z$U:ZPE>"6<MQO0Q!A+&$DS8JM$KW%HZ21,@0KI*BH_@C66(MW4L(/H-J
MC4C98O.M*<EZ[9,/+/RF,W&A*^TS$8H1I1V1S0'1C4GEB8EM>"9XAX::Y;K_
M(FNLI)<Z7AHU7&G65&BAARY!+)BH)"H*5AAN=+AZ)>+49U<OTD_I%A':@U^1
M<(TBPXB:EGM*CF[&5R8H.#J*;'.GG%<L;!/.&DVL-4VH0VYIGKEQU`ZJ;F"E
MUZ[2T1*;M'1QD7),^5RD.R?V1)OIJOPFFZ&8]/1\ZQUW)1C);N5PM&7?UW*;
M%O\H+M!!ATENDGT?K6FBBD\Z+CY[]3RYGB&;*,D<WZ(K;H*B*912I!J\B&S@
M^:8)^(3^?O=.@4"E\-B+S'^6>OG)I`RRHZM\Z5;SD5]Q?OHAJAY&J'<*^9$J
M?SW;W=OT9R3^&09S\WL9`!$H$?]!1E3YTU:(D"(?__T]#CAK<@E,G/(DO.A(
M)GE12_XH6*3Y5`957Z*)\I#B)H-T*2I^HP@KR!0>5QD$+&")69F"%<(&T@2$
M0H$.=8+R0R&NJ841:47=)E?$SC#Q7D[\2E'()J>*5$2%5+S)QAPWI;3UI(Q@
M1&,:U;A&.^WD0HLY8\$8R$8ZUM&.=\1C'O6X1S[VT8]_!&0@!3E(0A;2D(=$
M9"(5:<1%-M*1CX0-'*4VD!+,T2J^4E2,^K::``V+;1M2T!0KU,G[7="3-SG6
MA3(DH+0IB$60?(R'#'0I5\:G.M@+94%`6<J9K$>4O=D:KEAPBL+XRE_%*5;#
M7+0U/=7+4KIS51PYYK2OG/^0(96$I4X*E<F:'/,^MM.*EY`Y,+H,C"H46=-R
MH!6[F80I3AJQ'Q0OHA8NHDDB1YF.\XZ)1:(,)!!289C?L@7-WOWJ=A09&#F%
MU\[GN>Z7V>0=.Z?$J.L@:G)`VE]P6G>GK+`'G;8J&>30<L%`T.HL1Y&4B3#H
MP18EBC(:R9$ISH0K)2K+HZ3"6-(F!Z.-BN>@J-.71$.5D98)5"NP@ZA-N!E4
MAL!H6M<2)4$95-!(E=&<0=+;5)?$$*16:6^5>=:/3D0VIV7U>]C@7C4!]4V,
M=%6D1)F,4VZTT%\U3:594NM;*?/2`&WUK'496E)==YWN`:JK$X1.":XQDQ5P
MM%O_6,MHD`H2*[B^U8=LI6J=!E6OP6VJJ$.EC$OV0"*+B`0_-N+/M:*6I[[Z
M%1NSV.1C&Q.KH?0+H:MEV8@84A*@,NRA5Q7LI=H),=P6:FU7<"OCWF:<R@$%
MN#RA%!1))"35?14C8?TK57NTKH&<`G:#PH[L=(?:YK6QJ'/-*\$64EM>-15Q
MS2/G0T_!4DA"JJ=R(^USK_6U`+``F\39W[@>:CJJ#@JVJ?OL<E\6*N$RK#K1
MK2Q>D>(J<&ZU<BY2'L)<A-ZL:=8*#BNO5C58K.:.;<"/C*R$0]S/H))5<L@!
M&,>V!<&:49.[I-+2_,1G78-@=YJ^Q9&-!_(P#9**>MB"_])T3ON0'T$F&@!L
M1:M<5:D,LDU^K]13.H_%9/T)\%;1("#]J->PZ7'8I1B487"9Z5CH.!G*X:.R
MU,I<P`;[Z,2[X=E*PI(HH%#D?:5YDCSA6A*5M+#-0:FA01+Q$+-.='D8D7*P
M7,@',07T(6-I#!Q9)TZBE(32EB2._0#Z)3]%4XM=JAM7.-T0>2HQN((ZC1@'
MS1B[XNZ-J@S6G$"-S%F9C'"PD>:KA3WLY#A&9+M&#+*)O6QFXT9-/6QVM*5-
M[*WT=MK7QG:VM;UM;G?;V]\&=[C%/6YRGY`KNS(1#SDV-!>?\`I\@,YO=3*K
M22+E))S;MK<<$Y)2_>Y?#8L6U/\ZB^A['BB5W+H?*X)MQU4Q;41G/)$I'LX4
M`2'<AXV"*H.@)K:%LX9SIV7F%I^KJ$QZ,UPY`5*`ND2B=E_[((C`+`LBO>8@
M-V17;SF-BWX$D=O1!:#"8NH?,]*DQBR$PW9.8$B5_F,'PQ!&N$)5R_%-&PS+
MRMK'G>((UX>>1IT[3@Y97>2Z[:^-'H\@?$A;FLF*PB9-/50Z)R0S"8IO2ZW-
M7&NCG7L))2'F/#<VRG)%VY:NX*3'Y!IY$^Y2S<V@I#1)K$P/9L>;37=(3>M%
MD2&Z"XE4DY0O4_)KG)GY(MMR?"G/4DN%>SLI"**>QJ;N8GM\X8\^IT\1V,I`
M9O5?0>7_3/I&F\3LSE:>H#9<O8OXGI+Y6EJF2]=`KAFY_,YYS>+4]EJMV*OM
MF>2(I%AO%=N&=#>FTGY/F:H:GH;$;J62R&#&=-=N6X;+2;,@HI"MRLV,K*U@
M%D%,`3*;!XZ2UO>CF6FX+1N27DJ23+N4H_FXIKH727$,LHDM3D((FXH:G_N\
MIKL"5I"&EB.O!/(307`KN."];T,LAD(P(W*\M6(^B4@NKRJ5G\@9C)"J/MH:
M`0P4GLHHGL$Q"ENQRHFL8HG`U4"(BG$,_"`]F_`*/RF4)&D%](.;O2,(V*K!
M"Q2L-`,4UD.A%;R__SBZ:KF5B:B>1)"N02H6SC&G*Z&Y]K(V_[^RK>]@,/_+
M#6^Q+%!),PLR(HZSM)BH&^.3DGIAIO7("[]K-I.S*TA!-R9$1!5<0?9+,YU3
MMB)JPJ:J#%YZPZD[FP0RN0VS&911/A[;#83AG#IIMRN8P3RDI3U@CIV9/R"S
M/./KOS?<M@#X&N"C)6D1)9'QEOH)NGN*B_[JKQ,A)6XI0RH$H[>(CR@0F<D0
M&M+CE!&9Q3!1+:/[#_;X13+JMQ`IFC%<FA=:B]:;"F\L-Y_HO>T8QT::O<X0
M1`2Y,_,(QW9$CD=TQWB4QWFDQWJTQV*4'U.H('WT'WZ<'W_,QWT4R'X<R'\L
MR(`DR(0T2(5$R(5TR(:$2.H!2(D\2/^*9$B+?$B,C$C(F$B.K$B/O$B0S$B1
MW,@H^TB3#$F4'$F5+,F.9$F-A$F2C,F7E,F:I,F;=,F</$F=3$F>7$F?;,F=
M%,J>I#.=\,6A^<7X0,JE')&D=$JF5,JFA,JGE,JJC,JKI$JLG,JMM,JL]$JN
MU,JN!,NO%,NR#,NS)$NT',NU-,NT=$NV5,NVA,NWE,NZC,N[I$N\G,N]M,N\
M]$N^U,N^!,R_%$RY-+M[1,S$5,S%9,QI8P&T.PKVP!'^")12*Y_`*"/%ZQ`$
MU$RV4`MN-$5@<2#_$(BP(8@-0<"J$`N'.!!B[`E9:PC.6T>^F,W&Q(Q,HDR.
M0PC-A):_<0K_A-H(%@M.>/H;.WPA@%*GXR2JC;"@BX`YBC((<2$-5"D@`$HT
MCJ$>"J).[?1-\I`1L1B3ZV3.=S(Z,"R_Z)R<7>DU_[@,LC,ZI"`3YF0;ZYPI
M,<&6*)NG[$0*4YBG/C/.F]O.KF@5$T$GY2PUDXE/-9&12SP/R(`YZ[R5Z*3.
M.*$1VT22TO*9*&/.U8REV)RI")6+,[F7H6"?X`22F>HA.XS-^V3-7.-0+%)1
M:^O,Q7,(!XS-\.%%C%H.DU$PA.!0HD`GX'S1]3&RX.3!U"*J%(K-&$U"X/S.
M,7.>+_E,A"(FKTBM'A(3Z80VL$,A\IR5).V*,.70&HT3+1W3NR@U_\NS4O+$
M41*9/Q(-TBU=KA/-SD&H30L-#$49%&89PL[A39``+V7931ZUM.^$S]W</5?C
MQ3,!0[&!")/8K)TK(4=#)3BYE+KYTI."(4?%TO5RHA%%G+MA5$V%SUGAT!-)
MBI>X!C[QTY>RCZ(KC3[](:`"NT4M4Q&53U)[)S\C*G&Z&Z#218)`Q0TETK!`
ME5*KOIU+56@#DF$ES?Z$)S)E3LO$4\XH)WPY"Z0RN/`AN?!$'9.`F#)%EQ^%
MP[&"MA[Z$7A[P%'CP:Z8T;@0&_G,)$4Q55[\D1:]5M9INN;P43/)O1_%56)%
M3R0D43(A4B-*PO?DU"NMU3"=0&XUMLN2V.2N>-9\<0BDLM(P;0Y.S<,6U=5\
M83EH&];>+-7UZB$\K%;/:$(BP@9SJ1-$Y44S"0EB`J&Q$"9',]2[>=@]3`I_
M9513]1(D0M*E`@MV<3%_^0E>M5G6%`1W$9<(Y536--F:S15<K5E1)=)/C=D#
MDI.BQ8;\*ZID;-<U5-:,Q88-5""I%8KU85H1U3,@2MJW64]3Z5J>$5&F]0H0
M@H]T0IT3]1*M==O8I+2A@`H@`:"BI=:498T8-2-XY`O&E<U'-<]1(J9S^I5R
?5-P\NM/DV5@WS%R=V-S/Q5-X$MW2-=W315U""@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g267791moi004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi004.gif
M1TE&.#=AE@*_`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````E@*_`(?___^]M;T````("``A(2'W[_<A&1#F[^^,A(S6WM;>YN9S<VM[
M<WM:6EI"0D+%O<5K:V.EI:V,E)1:6F/6SM;%Q<Y[A'LI(2FEG)R<G)09$!"U
MM;4I*3$Z,3I24DI"2D*U"`@0"``(``!*,3H("!"U4N9*4N:UC$*U&>9*&>:U
M4K5*4K6UC!"U&;5*&;6,&1",4A#FE&/FUF/FUA#FE!#F&6/F&1"<YMY*SF-*
MA&.EA)3F6F-C>YR]&3JEO=YC[^:]C.89[V,9I6/FI;7F0N;F$.;F0K7F$+7F
M<[7F<^;F6H3F6CJ,&4*,4D*]4A#F6A"$O1"4A'.UE+6]YMX0A*40SJ4I2A#>
MQ;V]4G-*[V-*I6,(2A!K6F.]2D+FI>:UO1"]C'-24BE20DI:$$*$[Q`0A.80
MSN89$&L9SA`9A!"$$&M:*1"$O3&$O7-:4@A:"!"$O5)S4N8(4N9SC$)S&>8(
M&>9S4K4(4K5SC!!S&;4(&;5:4DH0I:40[Z5SA-YSSJ4QA*4QSJ52A-Y2SJ5S
M6GLI(1DI"#&U[Q!*$&M*SA!*A!"U$&NUO3&UO7/FYK6UO5*$[S%SI:6$[W,0
MI>80[^89$(P9SC$9A#&$$(R<[Z5SSN:<G.89SG,9A',QA.8QSN89,6L9[Q`9
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M__\`$``A"!`($``(_P`!"!Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M*G3IU"C2IU*M:K5JUA[4@#!M>N]@T-`="D8=FQ#>#VXFDTH
M1@`"@P(T2(S0*H)``0($TLU@L0$)`P4)"$C`L8$`NX;Y5@S0"F\#G0?P"D30
M*L#=O"0KM'H+0(.``S$S>`:=,H(`!Q<3""!0T,'AA!`$8(C(0`"#B*8?YQX9
M66Y$R06!<]3,V3-AB`=:05AY;]4JKL[Y@06AA"R('0WO<6TN5F%LQ0172_]$
M(%M@A>.F=52L(&!YZQ"D-<:V?*""104"#$2HW4HGA>.U60;`>24%8)M`%X0@
MDW@L51`?1<F<5E!]"M7V3D0')/!@0Q&$<)N![H4467^_^1:>@AVQYUX"%$@4
MV0@M\<,506`L@\45`H6%Q1!=K"+0%=T)M$H7.\!C4%@]`)`,"$G"1H($`B7`
M!00):'#!0!$TT("``+3"0`4.-$`8909<L)P#,&;``3X<0,"870"$:5``$(@!
M)UT&$'`;00Z$4`$A$-@7)0,.,!!?!@Y`H,!`"1#*&0`6`H"H91*,D``$#CQZ
M#V4(;"AI"!-<)AUC";SC`&F(NFE>90@$<QL"#A#_@E`"=9GZJ*2)"@K`I0Z`
MYP`7D!*`CY=Q/I9!90(IIY>6<!84#"$)-`!!?`]@RAF>!#S6"@D)P,IEM;T2
ME.IY*Q(2KD!1.!`/IN"E>MQ`R>6)6@8C'("H0`=P2AI=C8[P%@.;S=G*`[#>
M1NB>8'+&CPZ)QA-E916((>BX^(;@0`4-[`FKH(UF.E!M<!Y@@;_Q8<!LG`"\
M,T+("(Q@*$&P0F"/0`8N`$``)"S7P*D`/%"708A^*1`#ENX:,`#%G`Q``2&0
MV,IC74(-0)8-@/?7`1.$&`()6"K=&I72OEN!M0*]TTJ>CV%*VI_G`@"!F%PX
M8!<%'!!``,]!O\O;C`)!_Y?6$``(XS<(@.LH4%I8I&4D0H)CH1`7`BA&@`8,
MT&.E0+%!0$_D=VG@`7F`!?"!!E4#(%D`#9#.EP"/)1`"L.*RGOFNJ<M=T`B>
M,Q`":S>?AH`&@`'0@082;&Z?:A<@T#3F)%@6FUT,]$,`90)8QD]<HIDXD`XY
MFS>Q`!RTT@IH&FB`0`?5IQP7`PULO8!A-AO$W@4,>'!@G.:[9AE[]"C?`0"1
M84T$'$``+LC#=("AP($,]*_V&.96`@F!`1I`B!!P8#*LTUU_,*:!<''``!U`
M`#XT()W<U`9JVV)`6T;`%_:TP@("@!$`/*"!Z36F11X@`0(,PR4`,J"&?/GA
MW?](M!K18"8#<;&``_JA`25RCB`18&+]0D`YP]SF'>U)EOD:0YCYM<(!#\!?
MR]*G@-W5[T"QF9EJ-K.[H0G@0I&Y@`2`AT%I[>XMY.',[B1@`!1U1@/'2I\\
M2'!%`<B*/#.KC=ZZ1,C&V`>)=M%!^ES#O@.-"(`,8E#F8A,J`.P.`I!#C>E\
M0YZWW8\@->1"!4F$Q(Q9<$`3Z"!?./"9WA6*=0+!W?0($`(-0<``K>"+`\QG
MOS"21#L@$`@\N@`X(&$G+-4I"P#"@AUX=&<>UTE(6K[B)/68[H*=X9W=[D*B
M\D70-QD@@6)(@"+3<&8$>3&-,0?B&@1Q;4#=:XT`I-/_%L)D`&JQL0\!2/0.
MPNC.H/VP#R'>""F&!@@`Y.$+!EZ#Q!Y*JA]2PU((9"60==E%-<L)@`:64X$0
M+,=U&654"!YS`(L!4`,PBHP'),70!`A(`"1ZJ"=YIX'^*!(`O(P@[PA"`LQX
M9FCN$8Q`'G"_QN2REH8!C0-(`)IL[4H`\8L-:&))F`D,QFWINP#O(K!(`)"`
M=PCHAS<!,%&^9"`$=D$B7SH$I0[M:2#O\-"`#J0B`-ACI0"(!T;W^IAXN%0@
M"N@@)EEZV.7-!Z+ITUT8=1=)N$+6,GT2R%D%\M:W,)"F;\'8!O`94I/>S+15
M6DXKAAHETF%R.0<8:9P,P`]^_T!`CU<R'8E"D-LVNFU/<=&L;]BI610I=:<&
M.>YQ=Y@LS%0@G_#\BF$$,LQD`""JUQ5`B^Y!`AD2`)QD+0DR"7(/:G#%<8:C
M)@"`-!8D[:`+03((%D`@C(5,(`10:BD1P;F:MYG3=/OH'`85(X![(I$S$A#`
M/6*37!0EB&99?(]U^_0NNI3/GZOA4NT@(!CGA<##T+-L%$A@ERAT$`*-@9*X
M<J::$'RU&&XI2+3*=YL-8+5W(<UB`N)Q'L(H\#$*%,-541,A&=(2=@!\94-O
MRCL(<&V8=R$`*(]:$.)VQH^2LML]![FG"_BF,5]I!7P``,\#Q+9U)*"'0,1`
MN@9<0/\`]FF??0(ZM=U=Z"`,`ME`R&.7B`)`DF[5(5L%#<4#V55]-@,1C@O"
M'JFI1LBN0XUJ8HI3L(;QL4X^8&TT_9HHO&9;$;QG@MT:8X/,F')36^#][M:9
M$)FG:9A2;)?ZPP%1`L"V=J-T?PI0:=.Q%@%YXEU^SBE@7T/`R9A!Y3V/*Q`,
M?/">BF8D:%I!.@Y_U36$H4<O`8`?44Z4`!8520'X5@#X[N`YS\QF>K,)I![L
M``M*\)%!&L>06')FLY[LK9X(@0`+:#9X)""E.HO+V1!P)C(ZL&I@,-,8T`3`
MM/I<U%0)DX`.&X9CC8$:%T;*;P885`"C90`)+J1G&/+%`AW_9``#+#"S%0,K
M'AH@P3Q2[>^!6#$"W</9<AY``F"5]#&&P<L%'[TK$J!F'D9/<C#V'!<!\58@
M"R#!`<W*.P.5=$\T)H0%[CH0#:"(R@8B0,515+/F3GO,98Y3"&;^W50K)G4-
M6``"/&YIMWT87XVQ-5&#1YYB,)W44#HP:%/-=?5]*(LZWRM)`4L0U\TT2BY-
M0'<!F/1+8CJRD24Q`#S=9\ZUS\P"$/+@!5\0*V:@'X=/=(25)T]&D\!+#$"`
M8GYGH-DT5`P/Z"D`[M%K?.,;B:VH$L"'.US,!)P!MRT\4#%SW-SC0S.U9"KL
MQ"S5D98C"B_3ML/D#`"DR[#[&3?)_W@!,%\CK1N]ZNZ.>@.'(^NLQ3N<N^0W
M[Y+;#,`I!`$>Y8#O8F!"=VD?&M`L`T$`]^1E$.9J3R55(6!=;9==A&%=@V<8
M%)<!H'%YED%9D-5Y])$!BZ0\[A%SU@5CCT)G!G)X.;9S`H!D!$$!@.4Z:A9I
M229#QS$YF$0B3M9ROF4Z;&9,P84T`JA9]Q1SBR40!*@7>@547T9572(`!4!F
M)&!=`6```G!8:@<:%5`,H'%Q```Y]F%FA&<0O@5#S<)Z?\8Y$D`"ZM%9GP)!
MAX9%)GA:*$A2!K!X4A,/N!091Q<",14"_T-G3G9I=[<`=Q<I%J!Y!R`8X$,:
M.M`/I#97!O_P%A+8.[?!99)H'C7$6J_621D@(!70#VP&&C!&8$MW`*^79$1T
M)>P!7,(F;+Y!17?13N#1=<NF('B8+&0'<=L"&B/0#TNE&-@&`/W$;1("0$U(
M>B,Q;LD$`-L!`.8V32"P#`#P'(X#)(ZC'3W`#\\A;P)1`,@$#]YH)//@'`;A
M9-X$//SP`$]'9@K2:/\F7`4'+6;53NUQ',"6;`11&_:A>S?3<P;1)W9!?3`X
M=@[3#QMD:#'6&#/W4'J&@1C('J'2%BW2>"2`#Q'P.P*P**9Q5X(A7;*E:'WU
M7"D5)976(5##`5?B3AEX71H`&KVF.R_#(#/T7W'R&6MD$#&G(>;_9!HA%52]
M(R9+>':@01X7,DZ04B\%(5<`\&:@P05^4G>7`U)P@58#)Y+`8AB+(G@H:1HU
MAU<+E'/=(WT"L0_]@90*I&8#>)*<DPQGQ0_VD'00<'<&$@4`L#F@H6>J40[9
M-7,X<P#<Q%DQ%AEI`V<`((4'4`"I\R&F%6U=@@^B5Q#`-'@"T0'#(A"&T6>3
MQVM$)$!YTE"!1T?Q>`#)@'^:A1F;,P_R1Q"\1`&'*!>*%@""(1T\YP"$$5TI
M.4*@H6V$P7VAR0$X69`("!('P#>"HQ;=(3A@P!5-$A;0.$UI`0)8(!T$\1Q=
M,2-AD8Q\4FH(4%0+0(,`U!BA-Q#``1S\_]`8K"$<Y!DE27<0?8)3QV$@(6DW
MM4%(`L&4J^$:8<08CC$0"^`9!``GE0E6=O$\`+``3U2/!*!B1TE+;O%52'17
M$2"%`F`_R[$;6/08!O)XKN<`KG$!QP%]KS,0$,"??!$9P7,`;X8:!<9TMG8`
M\!1#T$D0N[-0`?A4..54U!5<GM&$^U!+V<6>E.D9>($L;E-40JH_V;4_WBD&
MGC*%F/-$DX$/J\$9Y.%OY'$;#5H0.HDT6;0;[EDV@J$!>+E7>N<S4[@BK-,6
M!-`BFR,@/[0:<!(;?@<`%B"%!*`8)H87^8%'V"D8^W`M$&H8$[JE$3:D/T@S
M7^IJ5F0>;W8:F_\90/.)%R$J%R:*%R-`2W<1)DUW&0+!#RW:"DU8$#7TEH!$
M72XF/CQJ/W(A&!#8/N`C*(WA,(Z$.:-1`6^V4IX"$O?P(*3QJ05`&@]R#R\*
M0`E1`,1Z#\2ZC9]:$+7E(@,!K`?!#\FZ-`/!'G+Y$+?:$,$:$07PHO$1K11Q
MK;N7K<**+[/">!-QK7VYJ1!!90EQJ\&:K@:Q,P-!;=DAK@CQ(-YZKP/!K0<1
M'_X*+PL!K@3AK@%KKP)QAA]32P([(0!+K@/!E`M[KA,!KP[;$,R&$!2KK@I!
M&@:;%3-!;=KCL1_!'GH7$\+Q$0;29MJVE2)[$E.H):E#(AL1`8(1IDG_X6(M
MV[((4*@YNQ'YPK,N@0`0Y!$'$`!"&P`1V[,I$GOAU1'=$I%*(0%#J[146[56
M>[58F[5:N[5<V[5>^[59FP`1X#`%,0\1`+4W$0%`"Q$!\(,'$`&Z8A!O&[<`
M%`$MUZX%91%J"[9\V[=^RQ-9VAD*ICX8>A,G2Q$X6V@A.1#V,(P#H4`R>Q!8
M5&H/\1V:^K>8F[F:"Q/'92`<)147VQ#L&!&&`8$001[AMKFJN[JL"Q$QA$EZ
M^@Y9NAJ"D0$_5QL&L$@@LJ$#E!\<XQJH=E5:$A=W=@!M(5MW,0*Q`4BQ85FF
MDVQ!)S49I@&B]Y:L0QJ3(QKZD6I0DP#`ZQX__\=HK]MHAJ$!870!9\4YT1(7
M(6*\!>8>KB$8_2$<T0N>TX,74]NZ^KN_6DNO$[4<M5%GM[&:]O%P`X-$"(B.
M!/``VMNVN`0`==,H:9D?$6`@)(([%9!@G!$7<$M%'>P;/6@8]E"A428W`7H8
M78J$%8P/K*%H+25VM?$6Z)A2JM$ZN].V+G4`-!0!7S%5!%-JPU0!5[I@.L22
MOG%Q6.0>V%,E]LB_3OS$5$L>;C-.K.:&"((9B<<>*C@@H"*\N^)2\^!23(,:
M+25*E<8/!!EE0N6.9@7"PX4BXB,07H>:S&=<F&&I#P=;$0"%@#6Z*B5IE3>,
M7/A2,M1KOO5%D^&\KO\8CQ%D?$;5Q%`<R9)L%09"BA/E26^1D41(=H@'<=.:
M12#YQ2^8=*I!QJ^K7TG&7[G%(+[%RJUX3T1ECT(XF,M6@`KBN0.1`0:@`?OP
M&.%+$"7U@B$@9/,PC-P70`:P#_C6:_?X&KY6;"GJ24&(99-<S=;\%+:A(`;W
M58<&P5C</0Y9$#\FRE<%:3D\>:38'^F\-.F8CLO,.P''QE;FA5>&2G:\R5?<
M,Z:UF@&`4EQ,P]^)=$26GK'!@ZU``?;`(FH,0*2!@6U,;(QL5H]\S11=T4KA
M9:CA%V-UA#QIQ7E<$#/\SX&%2PI``D(&F-TG(:BL6\F[QLCE2?G7@[/,I!'_
M3828L<OXG)2W?&-:Q<4^]\`#88>%]9WX(7K'O#S`Z!XDL,J\$STW%3S_-6S2
M+,>P;-%6?=4^\4/+H3RPH\E.2"5,A8*=],E`]IVEG$L:\`X">DF\1R)^40SD
MH6(,\A<0W8,+E0$(/)HPXQ:F`3N3PP`14$.+!D\28&&^;*Z0)VD2PGLR9!C&
M-$S[46KM@P%YY)>VTX/?<:6>A!F)B]6>_=DV$44.4U("$M@U%RT?)E(AA;P#
M@8YT&%B,5P`0L`\K(Q"A2<:3-S1B:37@M-2:Q5,F8@'?]2@R.1FKI9$.P!C!
M<)\:8#/&"TQJ<MA;7`&N)7DS526BY&2ZP@`&$`RQ_\@``Q6+'/88@CTT=4/<
MOE'<H+W>[-W>[OW>\!W?\CW?]%W?]GW?^)W?^KW?_-W?_OW?`![@`C[@!%[@
M!G[@")[@"K[@#-[@.9$?Y0,\$I[,NTSA-00\^[#+DV/AY5/A$:[A&%X^&Y[,
M$CXY(A[B%V[A&Y[A*<[B*P[B*H[A,)[A%$[B+7[B-F[B-K[C`!CB)&[C'?[A
M'9[C,E[C/?[B+3[C$;[D3-[D3O[D4![E4C[E5%[E5G[E6)[E6K[E7-[E7O[E
M8![F8C[F9/[E4AB+"1$`%5`!#[#F:J[F]O``<A[G#_#F=&[G:][F%:#F;+[G
M?AX`]L#F;_X`@?[F;%[G>_\>Z(@.Z')NYXV>Z(_.Z(M^YY`^Z7,^YWO^Z(6>
MZ(+>Z8%N#XK^Z14`ZJ/^Z7+>YVVNYVT>`(2>Z7!^Z:W.ZJ]NZ8M^ZJDNY[B>
MZ[J^Z[S>Z[[^Z\`>[,(^[,1>[,9^[,B>[,J^[,S>[,[^[-`>[=).[(<>`(OB
MX-B>[=J^[=S>[=[^[>`>[N(^[N1>[N9^[MJN1&TC#QR0OQPA#SJ0M`-A`"4+
MS!(P@YBXWS2KH0Z`R`>!``0P6B?AFLJ7$%IR$0RP=`2A[C]8<23"#W5J$1R&
M'L2R$Q(0\0[Q0A;!#](RL`#C`<:T`:T0#.*3W1\@$1_P11K:"@C*:!)`MP71
M"N#_5!#L7E8/\0`-P/*-AV(6$!^HTPH+<!R8XA%>9ZJBA$7Q(Q*.#1''EA"U
MH1A3`N!TL5KXT.\(87(H$2UHGA!(9/,.`4.>V5RFE/1=PFQ().\'H=FQ,74Z
M@3JI>Q`,5A&&$0)F*<=-Y!IV(0\"0`_'MB>1X>X(L3.3LUKYBT35BA#L&AX%
M[Q"F42CZ:"`<@'(KV3LO)!BD<4H9L1N"2QA9J3=O.T\*P(%3P[$5/"'%H"N,
MT42Z<OKB4L"<SR45T"P<I"KRP"4)0('\[3HSORNX[T;-(K:Z4MCF(?K<9KN,
MD@'\</MZ$_KO\K:$$?H*8"\P#U2P8R\)P`\9,$\+$0'%_T`",^^HSXLETJ,]
MKD41D@<UDY.L0AP?$7!``8#\P`S_\?^B[]\S\/_^TH']<,+`UW[[\9$``"%/
M`8`*&0`DR)``P$*&_`08/)CA@(*$#"U>!,`O`@(-#1AN$.`Q@8!6``((F(>1
M@0:,+3%"("'/8H0`#"LTT#"AYL(`$0XPQ$=")<N%$61NB,#/Y<56`A1Z(*&P
M:04`$`1$`.#!:5426`%8(+I4;,L,'1="@)`,0`0-K3@8N'I6`($06T_B%/``
M`(.Y=?7NG2M`P\`&!`PS`(`@<`B%!P0X("```0#!"UN%N"!@P5X#ACT*$+!P
MA``.),>>1IU:]6K6K5V_MDF"`__#R)$_+%1<;*$#`1?ZA;`<&D"#K<0O"_B9
M@30!#7&']YZK]*[)W@3@3K9XDNK!N88%0%`=@@##`^);AHA@0"A#OK`!6,](
MP,'"`_@T1/8(H)4&#LPU_#Q`@_N^6X@?`P8$;[@0^FNN%>:VBFPW`91J*K*2
M$I,,0P>;VXDAQ0HHBJ0'O3IM)`\8"D"#^69"#P$&%%IH)!)5FP`]G@0X,*_$
M.I./(!+P@0NQ]X2SR*R%F+N`KK!2<R`J`!YXYZ<&0J!JRIK*"0$#^@20P+V+
M,B`A/Q;!.PF\"D)ZDL``0FA%*>[$."@$CPXP8+XS$YP21@)*<@R\>^9*::&Y
MUA)`I@S_Z%%*,:\$$.K,R?CJT$M))Z6T4DL)8C-$K&!2B(%^L(H@0\4,4HRJ
M!:E#+-3)(@B!3`$0&PD\Y0PJ,TV1T+2((S='&@&`\CK(*($#)CK@G@.$M8@T
M\L2KH)4&?MJ+I1"6/!-&U[@0()F3A.3MI]%^XHTJWCH5@*JF?E*LIBE_@@DK
M3]T5X)UH39WO)(.LHFI4`)1##$SL&"J,H5!=!:]8!8XU>%B;Y/RHGP8B:"5!
MQ>2[#\2%-!!RM2F]:J4?08-9"$R((@2@N874NT@!YP"X8##]D`-``6.%G1G:
MA>2!3$N+$B"A5P`<T*`F"&P\.<%)6153X%=1M:@""#0PD\"+_Q(H1\4X5WQG
M.^*H<JP5"@(@83P`3F7(/`!("#K7+!<B`3C%NKPG`FLOI;MNN^VNX+Z%&`@!
M@02XL)'O&0,`VB#'HJ`L8Y,\T`!Q50E--01"?,V:.C,9/C-I`#ZX$(!Y2)C/
ML?GL`:UTTRTRVU<2#("`@=4S$J`F$M8K,,/70I5'N>T$YH"QGT/XB1[?M5*H
M@BB?H\HJH6.OBGG!8Y;,L4?C2B``A2000(=]']K>@HN,!."=I<$&3S'32^\\
M<Q179Z`!T)_4_CD2'>A<-?<AJFQLX93[U]<,Z#H2D6ZTNZ98!GB4.5_I=A>!
M),T(`"/P':':(B"(#$=LDP)3?A(`(_]6I6IIX1,03@B6G0,]S2/QP)5%IL0U
M\4R+`+TJ@+(8,BA?C<8!T(J"<Z8%``F$H()W`V(0A?B:!V2J*@)"FP;<133E
M7.!^%_/``[:R+PWL`R?>"U7D$",^Q5DN39?3'/T8@D(XS>,QJND-0Y)AMATV
MP``+V2%Y;.>:`!&"<2H4@`=:00)OP<P!(1A(D^:&/$):12\P6=Y.".`!5OTD
MAPY$0#\,@CWM^>LB#`L18N1!@LFAI@*8-`G#_N0S@(5@`PR!3&LV!D>BA&`]
MLT+E=PBP'I3-9(HL$\X>;8::_=B,+S-*@`2HID147E!2RN&"H,H5OO&%8#.A
MV@P%"/3)":#_B$".@5,"0A`Z!D!DA;X2`"D90H(+6"1LV='`&Q-#`HBX$D.3
MJ0`#(C5$>M:SGGD3&U]VAQL!Z(8O!H'E7D)0#N%@;S(G654(MC@^S1R$`5CY
M)!@)DD+<_"=&VP1`,GJVD`=4P*,?]:@Y+U@>L:%M2*#QCDUNZ1K#],@R!A`7
M2GZG$'IL10PAH,!:&)"2;RJO>34A1+P$ZI65C$"=?-%2`!B@%^54LA^3X=]%
M(%#.A6Q`H:'<S`$Z"E*/6DN:8CH)/0Y"@I)D@`'L6AD!NH@:]^F,46S;7]\N
M9H"?P"6`%RF/SO1SP,O\A`)<]>A.S/H3,2QS>XJK@%<6P+TC&4U2_U)<47-^
M$BHL+JV`^R+!""5T#V;.R6IW6DA-M],6<(;.B((J)UO(12[\L<117Q&J/64[
MV[L]H!\74LZFEOG+L1$%2U[)&^LN)AR^3:88&<HB=\`3*EJI:9J@'.!%YZ.R
M^4@Q!-?%;@C4"8`84E508J/A.)?4'O>LQ`#8`:U^^/@S$J3DC^2BRK<P9(_A
M:("SAJQ*"&JRV)V,!!_8`8E!^*(7?>F`G=OK'X:4ID4,9?>Z`H`31T%Y)CA]
M\D3$J4F3MB,C51)MCX+R&?:Z%*KX:8"6M&,(U!AR@?4TA;-P<7!=%+(U_1A`
M.E)CB%7DA:V=.,:!7L)6Z80T,$*!AR\7X/^`B3TR'7X2(,E6`\Q^7`:`X[9*
M0QJ(((Z2193(C."V,6+4?$`3'-[,AK9G1O.DSG1!W]AP;]SCC8.N,T/G&.=!
M'GRFU(R3SAMY1(H>H3!&")`@7G&G?F/1,GOF`A<'CIDV$8;-2:88H`G")25-
M4<AHXN&K`S4E00=@3E.J^9SEG=(J)&(.`1]C&@QU23']$@#B+.(8B!"9R)X\
M(\#FTAR%)`#+D8$T`H#3FII"Y"1)8AYWPND8#71`/,(A@0#W%I;(_*3:IZ'`
M=2,C)+H08!\<\E5M6)V8`UI*`1CP"4,2@`"J(&0G!:E)!FIR#P1$"MYK(=$!
M,K#/B&Q'WW_A+@+_9H0`W<1(F+.6=V(JN.Y!IMGA#T<-O6=$@8IPM.(!V'=B
M<KJ0=W0)10G/@%[6W>X,T#=&&8]1O6.F<GK/<WL**8`$O")PU=!\UNAN"0(J
M>-Q=OB8#/UR+1.*!@,GJ0"D1D(A-DMZT#`3*)!(82``0,)`'5%P_^YB:WVPB
M@79KG0)<?\EZ$"+RA$=<Y3O#P#P+8BWIN:;CFV9(,61BD0)@X)0'*$:7I!ZR
M^,W:=ALI2H+%@G&;10`#A_^YS:H^MP]"W/&/AWSD)2_;!CA6MJT0_.138P^^
M6%Y2F#\S`R`->8@UG)X,6)'F5;]ZUK?>]:]_/00XD'G8U][VM\=][G6__WO>
M]][WOP=^\(4_?.(7W_C'1W[RE;]\YC??^<^'?O2E/WWJ5]_ZCQ<0<ZRC_<[<
MI_O:OT_XK?-M\)=?_.<W__;1O_[QLQ_]W_]^.K]M@/G77_[WIS_^[9]__N_?
M__H'P/X+P/\3P`(DP`,<P`0T0/VS#P)HP`:\O_'K#/J;P'VHP`/A/@IL/PFT
M0`L4/PWT/NY3/^N@0`KT/@L4P0G</A6,O_1[/Q$,P??K0/GKOQJL/QNDP`[4
MP!U$01Z\0`D$0A\,PA7LP2*\0!TD/R%40B,,0B8,019<0?-;P/QSP/MX0"MT
M/Q?4PAB,0BYLP2ST0A@<P1;,P0ADK+$(@#1\@/\T#(`U5$,V7,,X;,,Y#`![
MD,,[G$,\E,,*R,,`X$,][,,Z=,-!#$0ZA,,YM$-!5,1$9,0U;,1%=,1(A,1)
M?,1*E$1+I,1+U,1,Y$1,],1-9$0^M,,X)$5$=$-[8$-43$-5K,,_A$-6M`=4
M?(!8I$577$4\Y$,VI,,*D$54S,5$E,,W%$8Z!$0\/,1A=,53C$517,8Z;,9:
M=$9[8$9:I,983$54M$9G7$55S,99W,9O=,9!E,4W9$1NA,5JS,9$;,->-$4U
M9$=MA,=LS$5#U,4WE$-I7$11;,,'*$5^W,<^+$:`%,AA-$0WS,.`#,:$/$9"
M-,AH=$0V[+GKD\B)I,C_BK3(B\3(C-3(C>3(CO3(CP3)D!3)Y.N)B/02@$N-
M"G"3D;R4&<&[00J`78I)EJ3)FEP^#_``G1.C&#DTU@"UU>"'8;/)26F`C&$`
M"'B`HU0WS:F`[1K*IX3*W2.`2*D\W*"]U(@`SQ.+K(Q*]P@`D.&)C/DYT5A)
MAL@`S>G*M%1+R4L`8R(/!A@T"!B(M7"1'XH2A.@FBX@B?8,`[."'+CJKK""1
M@NC+N5R("I"`!2"ZG<F`OIP;O`Q,=3.KR'R2'ZHZ%$&`!?@QAI"'NLR5N=&Z
M)UDYX$(`")B1L@N9!6*`!7"YB]@`W8@`!J!,07,ZI_&03>&W%3.]M>3-WIRM
M__+(/`5HDY^P!P\(`'ZX![08IP9("'T#%LN`@(J`@-M@F7MPD](4#532N@`P
M`!CY``28AP)@%8`AA.*!J85H`$)0`'Z0(FA!BP0H`"F"$=.TB`_X"P^0B`-H
M@-$[3.,<%@1(O5;8I3:QC`58@.W`SX-!@,YQ@+FY`&AIA>.\AU98JUQQ@`9X
M`'[0)I,\`'%*#.:$@'+0J:70.=\TT1.=+;ALA1F)`#'9):X\B$-S@)IH2XMX
M@!692IZ,$;%Q`'DQ2\1H@$B1F^'XH0#PB.C,CN3INR?YBQ`H2Z*0`+3$*QO5
MH/IY@`L9B=UI@(W;#1A9$GX@B@;P.-30`;#<FPH]R_^6V(Y[2#TU=4L4A=,X
MI9L$@`"Z0L](28"C7(GMD(`N"M+$Z)^\'`Z.@1$$@*<V!=0$\-"%4`"G7`OP
M6)(B<8D.;9H5:<L&T*N66+?6,8"Y,U2+0-+$D#6",("-R`"=(X"?,%*+:$R>
M:)6Y&POL9(_-P`A9=8D5R0`Q@(!!:A8Y]=5?M11"R`^A;)8H@)8+XH!!2E7]
MV*=6X"#$Z4N&&(&G*#A4HE.@6XAR2#`/J``7R3E:K57%$=23:P5$/8@1>!'+
ML!AGM8A6F,L.L)8&\)L-BH<$")2'L0@'V*>AVX<*M0@)2":&L(`*;=&E8,WA
MV(D&,#F.ZDE@==B'Q0B8L8C_8)"7!%B1`_`N@E@1?O!06:V?!.@<PK%8\A";
M5MBG7G6`4[((I?"`:O45EF#.*8W665N(#Y@;.\4(#9@;C%U)1:6/-@59^LA8
MDW6)0XO4&8I5QUI-334SC`@`\$@`%TT:"\!6B+7:AR6$^H&`/3C3A2B&U"L&
M`O"*%"$1`"V*-H71<!-0%,F/]K$)L8$8F[B`G,J`U$L`.\T;=6L%O<A;GE2D
M[;@),X.`OCN4BPB`SHF`V=M1@:'0HE#:$^&H:;T8SAR!_'``@&N=HC`]!$@:
MV2S:W/P95)I+!G!9`MC-JT5=.:W;/4%*%'$6A8"`#FB`<KB'=*T*C!.#!HC9
MLXB4_QFUB!P%&!*Q`'KP@-T-F0LUWL1`WOZ)``<HWO[9@.5M&F>!@#0<U>%M
M`"ZHV@6HW%UE-P^)F!=A`*WQ48:(@@N=V9#A``@H3YFCCP5P``CX4T')/`E0
M6G^E@)YL@+F!@-P=.']-W0`68)=P5-5XVMY<3"]Q6]8(@#<=X`>&8(UE#1"I
M6]_42CIJ#<.,X`U^X'?83+$HS0_FX!$FX1(VX1-&X116X15FX19VX1>&X1B6
MX1FF81,^@`HPR0I@N[_J*@ZU!Y/,J-.MX=_T*,["J[\"XJ:Q":XRR0VR"2.F
M/F1IB7E0BY8X`'L08I[@**[ZJXNH`"X]3.9+@`<PR2Y>BO\*<+K?XQMSS0#,
M,$N%6@"TN-"=B4L((("%98C]N,HAKJ<1\``#;8"UW0U=78`&>-"EB(((NX<+
M,%"T@``P#AG#8`@*P#KI.P`N<``#6*O]W`?/.X#U-=`1J-J:%1*TB.,X'AJS
M;(4XCE]53KYW6%_Y/>2BB!CXE5($V!/A.TIV_=VX/=Z+,-LC@;LC@56"2-6C
MY6-[<H`Q78L+:8!1-8F,;9JF#0#J7(JL?("F!0`,,-?GDU>72-^+LACZ<(EW
M:-C=$*SG/`NCR5SCRP!MK@"?\>6%B`+-P0`+:%[A"V''J@!][9P*M@@%((J[
MQ:LJ1L\NB=!D/C.)1=JS&:1RNPC_W\V(8MCC!("3>18-T&V^;VX)]KV("]#H
MB#WCSIF0BV!H&S.^!)XAI=#9[^'2F]CF;MX]I5R2'NW5D!$KBT`]@*$'(+X'
MH@!HA98M!,A8=%7?<18#<)TU<4(`>7@`"'``!H!B7R%0C-X7`%X^CGX)Q2%H
M@IA)EPA:E["H@]!F]"01^EP^GYV'G@S5`\`MF=8]SAT.[+B'\:B`"TH/%V$`
MSK6\"!@!"NTY@`;3)!;JN\F;RM.`?:)DQ&Y-DVA3N$RZ"N"`"G*`C;/JKI8^
M,:"]=EX('>@F!W`10S9);\TYHXD`_MP+T\[IY+MK5>W)*!4-&`EJ-1:)"\G<
M*U7EZ@'9_U%>"P>X(=JP%B[8X\*FFZ_TT0T@`&-S`)UI8&8V2\B-D9Y;U@8H
M7W/&*V1NOIQTB:($U61;"&EJ":TV:8MX!W/U7(Z#Z^!K`.B^T5H%CP98H/3&
M/;EF&:JPJ`>XH-G&V7*FJFSC@"1I*>*F)VT:YR.)2:%<L1^+WK'8V[*030@H
M9+7ZEQJ=/O$&5<5)6X80@Q\;V/#^H9^,Z`XY;>1CH)U]TX?AB`<7/0D'/J5<
MBR!=$=SN;+3MG'?0G/+8C25]CY`6\$JA;U`5.'.-`D^NGXB\`&%)@(]:-P)0
M@`6Z8.;3[I;@`L7!<:9PN7[&")[)V8<&51'V/>X6-'[3`.34X?^N0CTGIFW:
M.,\GR6]$#8:^BVJ+X(*"&?,OD>\>GY25H8Z?\*&F6:D\WIWU52&ME(=#&P$>
M5SX+SS'OT>FD(00S'>^+N&.,H(#];H4?0NGBHVZP[D[M;`EN%C[X98_M"@!\
M`-^+2(9;`M`DP<^S6&V&^),TQG.ZT4\Q,(P+->@)@`SYH(?=Q'*&T`'(X(`-
M=XGTR(X[/S[(<"''@@P!Z616=8`+:(56+W;H3HQSC@?ZN0")Q@VL[KWN`'#F
M6$H'X79@/N=9YV/EA`U?\\U+=X]W<&!TE_>)1/2QD.+>K'>QR/=YY_=^]_=_
M!_B`%_B!)_B"-_B#1_B$5_B%9_B&=WC_@L\`T//BB)F)PL#7[+#XS60`HGUX
MU0#95@#Y5MCO/`7YZA4+-H66`["`DI\;^@EY`O!1LYK(I]UVP7O:<MWC]O80
MR(``?EM="%A8M(X^.BU7?W5K;^>]!=7?0$8E"+`8J`88#S!B"#@T4/OQCC^-
M#)^)3J=J`":`[4"`0X\1Q8W1I7``+V^^J(86MC!,W846C%L*(OGIN<-8O2I5
M^FB%,>7ZYY/?*DZ/AHMJ9->]@;UXO`\`,TL`:7ZH@W#+$C5+C]AOK!>+Q6^)
MK[^DLF2(Q"2/J2&*"@A8*X[WY^LY=2^')[^(PN<`E2T;RP"ZL-!YYSO<B;^(
M$=`WU`Z^HPQK_]Q8``JG$Y.L:R$F@)Q2=,E_":X9)`?XH;LFX`*_B&`O"L0Y
M%N:O"MZ>OA7U%01'M+%`L>_YW2PF/G4O$IMI`$,1_-Q#@&K:!VLQW9LV"0-0
M6(S`[_F]B$H_3.PF_AQ#/;2@>(;H`"X0%LX%B`0`!A($4,%!P8$1,B"`8(%@
MA@;T($#X((9?P0<($W+LZ/$CR)`B1Y(DB"`#`P@1!@:```"!`PT0*GC,X/*C
MF`P>&R`HB*!GR:!"AQ(MF&%C00T!!C(`FD%,T:A2B3)H```#/84([1%(6`$"
M@08""U98$)8F00<K![9:.O4MW+ARY]*M^Y&>3I-663I@$(7#38X8H/\F?+<0
MPH0#`QL6#-"J8#(-=B=3AA@!@0>@$$8X0'O@PH*.7"1X3$!@;<($'/(2C$"X
M,NRBK1@0K-!``\T(>P%(0!K[-\>4`R4#:&OP<4?3K`LF:`7T@(:F&8[N!F[]
M.O;L<06P?4@P@`'%"2."#-#5H_&!T+6S#]J`M@7D!0F,+0@!:$((8L0G9+"?
MHSR^M:<=9@3T!8`&]QQD5%8#PE;50/=]QM)Y"=0WD&D`)',A``>$L)@##\@3
M00`1A("1@RFJN")EW$4@(`#">05C0O1YY(`\!#T0#(L])B#9`]4-I!9'-J5&
M`%H)'4"`6QPA$$6/[2T)@`4CM')E*P00T$K_8%&^)6-S]PWT`'(/$/==5Q5\
M2!9Q!B0Y)'Y>RCEGC_P(Z1@`/W+4RG($$2!>!%WF>1X#%TY)$`0ZT&E=`TTR
M=9.-!87`7T$DD"5?:IAR%.FBO_'9$09"=CH4A$-RQY(!K1&`0``!(-#*6.:Q
MZBJL``2`#T=JCKHKK\`Q<%JK$,C'@`$9!/!`!!>(NAAM$8Y`HJM(*K1JJP@0
M$`]!_)S7ZV1AMBH/%TB9-BL"!G"85I,"4-#J`ZVZ)4``%;C;:FTT<AL5!`P<
MFP$!?9ID[[T?(4M0`JP=T&<%%D3QYD`)+]P:PP-E,$_`%5L<U3M-<<A/`!8P
M$`&E'%U0'S\16(!`_\0.,]P`!A?710%*$2C`T0-1H!S2FB\I['$4%MST)`,6
M[!P8IRX75?#'(%6`FM%-._TTU!PEL&Q)@4:]X@:""H5`RU=[_37888L]-MEE
MFWTVVFFKO3;;;;O]-MQQRSTWW77;?3?>>>N]-]]]^_TWX($+/CCAA1ON9:`\
M47KN5(P?3A4%[!4`07V!%FJ4H_(T:U<%/WUT0`.*?G1/`^(=W$`#RTWG-S\/
M),U1!!,XH`/%'TT])#T->)`[ZA%&['9+#MQ<4`$1L1SRJ!6<=D\"&`@@'IYR
M9?CX6Q^TYX'H`$"@DP(-H$6!!QR-D&-=#$@``<`.]/[1^`JUI<`\_&([$/\'
MO]=]P/8'%O19!O<<L,$^[`>`YPWD'@HPX`$.-H*!\"-G<.M+`@Y0@4^Y#V3S
MB$!HN.7`J]SD=7&)P.:H%[``B&LW!R",I@ARIKJ\"#WW0`#5`!`[#&V+A@2Y
M1PWWEJ^$<(!\ZDE51[;W$0V@2(;A@]M[:M2P'-ZK`D!,C1@TT``'""0TUJ+)
M/2`P10CP9R880)_W.M0``SA`#$LY0%7$0"3U5,4!#G!4&QVPG"A,L7UZ<4`K
M4,.`$#8%0UILA5@ZXKV(.,`#]1&+;APP@OH<8`%3;$#M`/#&@G2&*0$HAK"L
MD@!"-(""3&F`&O$SG:\TX#0$60!K4N+&KDELB@[_>$=(2(B_!HS`.QUIQ9L6
M*#&=S,0CY?!77(XBR)58((:1RH`N"X)+=/EMA_OCR*F@^1$Q)05Y:KL'1X@(
M@`L(D%=X]"$E"1:66#F@`!)+I@$"V:'P#(E@B_334II3'P$D@!\XK,^GEI0D
M`3Q@(&XB"+R&=*$$=8@#K0DA04A`N1^*9YSN:]@(Q,,5@HR@B`#8%I?0P@5/
MGDJ?:<F+&V$YD&BR$W3S3`MJ<*.T$##`G`#@24<.H"G0:;$G#+%="N."`1@A
MH%FEDEHRHZ=,U@0@AG5SYEV`652/%&"%3`%FVBSZ$I?(U"";@8"C>D4!"$AQ
M9A(+#$QN**!68&2"^5E*_P6220"+WM2@S[QH)&7HD@M0"D5_*D@1HPD`;3'E
M-1YYAU\!0(_<^+48$V@G)15C5H*\8R/3&X@'^HDAY%P@KO;8BUX!D#.G=B@!
M%X#LA4Y2'DP%@$<<F>CG`BM-NPBS(!$XXDNHUL*TX`=_&D!-`IZXMR1ZA'\>
MH>:>F-;*NCD@@_9H168P,C78!JP"`95DDCA0'P9P"76(V8AH"S*"I3`@+SH0
ME$JLQI%W-,@D*%O6@CI2@<+N1E@Y\<@"A+O,^!;D`TO)P`6TV``MZC(*I"'(
M!(HAL1"NT'/V$-#Y`!`DU]XD`UR`"!>VU[L"&$"_^UWF1Q8[D'<D\U(@V<@$
M(O^LM<S*9;88\@T,/6)BIN!1#*5;XZ":B5""4!>;OXU3;9@H0X"I+0,85C`]
M$P+C3ITKQ0#0+::TV9&[$N10M0)`_7@H27MT9,C%>2DP@9L?`1.$'I+-%@,X
MBR`E?7:;E$).T91YH5:(IY(-LUY:!)*ZA+!9>TP+T4#":)HF<6$IC`E*:5U+
MH^9\1%\`^(!X;%.0>>@8+JW-\P4NH"5)&X``6DOO1RY@8P7SF&Y<F+%GL\J1
M!&>3<3V5FW.4!*.G\"K(21'(@A52'0+6!IO\Z#"6.R2?'P,@"K1)#TLB]TJC
M6&7.M:$R3&OC%B7O]512G51"DB$@!P@X`;Y9K`'FUS#_Q50537ZRSW).96RM
M#(=2T3P5DP?2CT=Y)98=W@"N"?+DA`0@@QW&5`8(,9D5CUIK!*%KH;LDQ+XA
MM6$Y[0B)'UTCQZ%M2=:T\@B@BK@01,!"CME`A%QB3@_`T0'S*,#4FE4,2R>@
M``=I5@8ZL%<`^-A_"8!`.1J&CWCPX^4W,4_)$V#D!)"`)@DHU3T$X'/,^&DE
M%8B"!S:BNV34W`&L)(@$N%3RM/X7`1D<""HE!BN00T#?'4(2/^S!@&``A80%
MX0!_WG%86]$'Y`@@C(<\;)"-A`"M,-G(`4@0@`1B8`1>33:]:QB!@QM)U5!G
M@#TG(-*!I%LNS$-`1!WW4X[8_\R\%CJ(D!I=MPA.Y`#S3*"%+*1M.C.,Q).-
MFYL\'_KZ7*!0"3@YMP[6=::A\7*7WF,&^$/%9#2D?]FR.EH21H@,7.@>#%B`
M#A;7^S<=H/<<:@@".'3\E;R>8,='@#47J8#C2V#3Q"\(`[QJD#UVGSGY@F4`
M:B>/)DW.*%_6N<9JP[0`D,\P;.RN8AQE=5;9Q]\Z9PZ.G=WSQ=4#+,#EF(2_
MO45$4,1^J9C$711_!$!51$'DV$<`WDU5,"!09!'J-``7?""<<40#N194<5/<
M5`7J?*!$;-H[<%(&B-_:D!78\,/!G4WTO44RR&!0D,FB8-I'Z(8(D000AD1W
M!6'9:/^8U_!;5&6/$3:A$]Z-A81-`L35$U:A%5XA%F:A%FXA%W:A%WXA&(:A
M&(XA&9:A&9XA&J:A&D9%OAE@OJB$2%A3V!P,`\CA7"3`6N1>9312062,<"$`
M#`[/TW0.#*J8<'T$Q^"8L?R-JXR$((H$!=0A`.:-SD$`!MAAK_!3!6QB!3P`
M)AI$F96-:<1#`FP:9<S9`73:6_S3D(#,:QU40MP#L[E,2R"`JV68YB5$0X!%
M0O"#N?!-J$2!`$A5D:@B2Z3.+0[)`[8-!-!#`#2/*5V,V6W-,D8-!%`9<$34
M;TB`U[$<:ZQ.*G:$$KI,"'33D9FB2#P605"`6_4-K7W$!HW_1#(.!`E\HMI,
MWD6Y#$7\EEQQ"8:,$3U0T:/HST"0QN"M!0RASILTA/I<2`9,@(LYBH.5T86$
M2M(EB><01!2PAA8Y@+]E`#U(T5XDSI!]14!^F571TG*TQ!2QQO3T4H=TY`7Z
MA$Z@CILA'%FT5S\!#`%0H<O,8T(,X0^&D/)4F:CAC>G9QW]]1'8!U+DX6-U$
M##M9C`;(H4*A!2>EA3N-A03HTF<TP%HTAV?\DU@.Q#P(0#)TR`4T230RB5,R
M7KJ@A4`2Q#XH!@Z)QY\97IZEU%@@E0%(%@1<W0=X'00L91XM!E"<1UHARDP.
MQ%\$A@"@8\,$UCN\AP>L!`0LGI,T_V;`A$`%[L11RM`4<9DXB6,"V@VT99HU
M'8P8<!PT,4XNQHUK7,P!"$"D$4"Q$`0&,!=*R)J\T1E&O(-N`9QY%<?BL,6%
M8%!Q7$@$`<`[$8QX9):E`$`YG*9)S!A;+(;J],2I,4='B,%85!(%((<<E82,
M1,@%1L'5O94]6.<[U&#``&5!D)AK?$`Q$",H)H=NY4W<@43"C4"C?(0`^.0`
M2>;<:)'+Z`#5>,";2%>>N05,[-$;*EV39,!ZOI1A8*<\!);-*%JN'-QZN=:#
M#<D(+$!H;E-]5$!*5`6:Y<N*$DD-5F*^G,EY+,!_-4=?F&.,\!%V&N"'Q:3Z
M:.9Q0(VZ@/]$:KX$Q85$;G5$,L3FW+PC1]1F0932B;XE1Y``PP%/*Y"FQ5B9
M"BF1/Z&(!@@$/X1,G0V$"2H3``0#-B8$/<B7G3P=HD`5!'"I![1IPW221VS+
M"$0!7NK$;"D&B@A50NQ7K-S<$<WE=Q02$0K<!19>E2F&`]@85AG%VCF-?/I)
M??Q<>>)B1_`@WQ1`4@)43N)(2,AG/,9-`S9-4EI;8Q"&JY:;=PZIIOK$7*%D
M!0@$L`'`!B#$D$4A7C!'!:[5?'H$E&[87C@`QM4JJWGG!F@*=\6)!RPK6/J3
ML8:$QUA@1Q3`/G@$`@A8/`3&[1"$:SZ-`(Q><`0@"0V;U.C8R?C_361^6,0,
M7A@AW+G$@S&FS:Y*X\%I&1R^Q(AJ3X.@T8CZ%_CMAHP,'HJ42@:8UDMLA!.)
MAPXX@&(D`*TADYABD030TD!\P.8`WI2NA;243`.X%72@Q8&Y!0$LZT'`4J<&
MP`00@$O5602,*`4=P`@L*TSVA\!A9W&DS&ZXF:(>BKEF*0[UUJLL5&WL)^/A
MI]U(:7G8R_:MBE0!);O.#:\Y[:X\13",0->VPLAH#PS^1YY0!%H4PWXQ0))P
M`8=49F"^29"\QV<"0'N^AZ.0DMJ:G]T6A`*(@80\P+("@-LN@.,@Q0%,`$7T
M$RNAT7[U208NAQ95:EZ`SD!80(6F+7_T_TM'K(Y)'.(/<82@(`#BIB6Y>F[`
MR!2`.L`%"*FV?D0\Y,7@J8\B\<<>\<T$`>B5H*LRH21'7))ZM$+J<D"3(*'<
MT%+7!@/PANT:BDTW2H6"#H61Z:N.@L0X'DY52L4!&(#6+B_WVL4]5&/WAJ_X
MCB_YEJ_YGB_ZIJ_ZKB_[MJ_[OB_\QJ_\SB_]UJ_]OD4`9(`$Z(`$,$25LLUE
MV&/5"+!U($`1Z1S#R(Q19&G%Z-SWA80>,A;_M08#&Z&K_&_@)(`./+#1"$`&
M1$`$%,-",'`%A"+9W`,^V`/O2H4"Q-N`>!)/Z-QNM,21N%33.,;'!$KC)41F
MF`2?7(8!K(4L$O^PX;P#/GQP!JC4X>`P"$.`@UX,\8[$39E-I88->2B$*('4
MYAH5MV0`6[FPK233X-$98^5KX>1=0@SCX8!,'[9CQ2Q``O:$J_1PV8:%TJ+$
MN,F0002H#*UH<E:%)#)62D#`W$H@1<"@(2NM#*D.:O14'K<&5TU`LW1,XAI%
M5?0)!O$64XQ%WM(86E3<SR5;!E2G.:Z.SRCRE9)%8!C:I.YI!5?,&"]9?>Q=
MC20)KSDAR,96$\8R518B0&4F1JSJE9E3*KH%`VP$#=X'-LG4?1K$R#X+2Z1F
M!^CADKA%Q&%$/+B:'"F&`FCSFR@OAB&HU"!%Z@CJF';(),4(WD&S#$W_)4:9
MXK8X0+`"@(M=CL6&Q*MPP<R(JC7%*D3P!$SU+U-RYKTL\SL0IUZ6!K[YK`CU
M9&J8\.$<@&.\\IS4IAOA$6O,)D'H0`9-HW,F1$4);CW*VX44X7.RA&+P6F_>
MI*U(JJ,\0.UDUIJ<)U/Z;)GAVD:<*4K;BF.Y\6*M!T'DL9@51#$5!"%`B9/X
M'X:45T<0JM%PAJ393S$`C(]95%%:H0#8<`&-*N`H4BL8``8O2O56\9"@Q;_J
M`-DAP,G$1X2@AF'E!XGXFT;H8O0-VL'YLVBJ!P%D!L/-VP%\%W]=15J?#'6Q
MG,\.7&_2V'^]0Y?4D(7B<Y?X:'!8)W:I#\-$_['3"#.QQ11!$@2C7>'U[L]0
M%P[B7HP'R.F7%D2W,EY#58#GS8,"*(!XH!U!1)F:IC,/"Y<#*,#`Y0<3%L0O
M3:FC'$`$<,:>DJLZW10!>&(I1I!B**_XM-F;S&6UGEY0KS#/%L0"V))1G&8#
M"-M8-`!*ON+7I*H21@'%?BI\/@YNDUL3AG9\]K-O!`"L(@5!-1F&=%C1`.%R
M%X3_2-)++]"0)5"N-1GI:EJQ(ASRT/=>"N"148J-_:)G<]MYW-K^/)$;]U%"
MB404Q-PI82?1CD=/;%6354>=WC"'`/6>N.E2<L2[6B$OLT58Y\T#,,Q=5@QF
M[RBX+49@3,1&-X`Y=?]GQD'$1C0L1-09>A.$/""'>;1&*U!,`)S)1`]$:KZ6
M+KU7A&#GOX9`K#1`F?FXQ#3(3\$$-B5V]IK$"-S$DL99O9@$X_@,<",U1SRQ
M?R.%Q^49GA*KT:A)DYB&Z>)V`[!N02!T%7I`8*#/X3@1:AP`!Q`TG;R*I&D)
M`6#I2ZU9HA426L`$ZC0)>(Z'^@1Z'\HS6;,<[\Q?&?UKPXCZ<HRGH>;OO^Q7
M:)ZIM6UZ\[TZ'Y_3?B7)K0]>8/*#!*`%YZ(I30+4HX901G+$9[MI?[C8FVB9
MT<#$EA`"PQ$M'DFZEH3`_/B:%KZ6`8B!Z0K.41``8%#T_:I(%&PO2>"C%*__
MMQ6K8@2X<;G'^QD6`$/+N[W?.[[GN[[O.[_WN[__.\`'_*X(`,$7O,$?/,(G
MO,(O/,,WO,,_/,1'O,1//,57O,5?/,9GO,9O/,=WO,=_/,B'O,B//,F7/,77
MN\"GO,JO/,NW?/I2"G]$$(?,0\@0\4B@X[D<P#+/:N/4Q0$0:$A@HLW'GI(T
M65S]?-'+1<@0:.T0<X>DB$!H]<K%(="[?,#8XJ8)@$N`)`;8Q%JD3EXZUXQ_
MQ"(B`.W]MD$LQ6.`T$O`Q8PE@W5^A[_\1$2LQ"**A&J%4WEO3@`$6=!\ET#T
ME(/51SJ]Q49`-';2QF70,\N1.UUL!&WLK/;@:4<T_\6+3*_5+PH"2$"S_`1M
MZ`!JK#U0Y.I`B$'?ED:U6,C=%TP&%$`J4LX'YR]-E$R'3(=`5!]"N'K+5-Q"
MA$ST*<K!4/-T8,M:N$H_C1WZ?;!"X.'WH<_\75V\.`<_5,!T<)L]Y"^W40[_
M?:/V=,@[W*!!%(,$$',$4&##?*MZ7`9-$/>&S<Q""!?UZP!&U+A"_#SU"X2K
M`#N&V!TX,9#?$@1`?("0H(`#``#X!0!PX2"`"`<S!##8D"(`!`<0*(QP$2*"
M!`#>$4``0(R"#`\='@QP\N##E?P:``APX%Z$"BPK9H@H\R.`#`4<[I29\>"!
M##H.0%Q9P2>!##X!,`A0+/]#4@9,C5;-^13`/845`=SD6(&IPP/S;GX,@*`L
MUP0**R"0!Y9N7;MW\>;5NY=O7[]_`0<6[)?M1`<)&/B4<.]`!`@'(4!XT/#`
MXX%T[3E(.N(AA'B(#\;4H1%"4H/W8L8$0"@H`(,K70-8D'AAQ6`(^`%0+:8V
M@&*Q(SR5QR_9XPUPHP"`@`#H:ZX-85X&4!E`@H<5$F=@D/MU`].ZDPY\\)0+
M=Y\*0:LV&(5I``G*0_M\=Y">[H\1YC6L@#ZQ])@,2HLJO`3B.@@!"C*8[P'K
M*G*@P/$(^2B#!E#RB4**6AFJKE;L46Z!@S)4[;*)"-!HI!%\NFXD@]YY*B8(
M*.#_9P2F=**H`;52C`^"]@"P0*$'1GH,/``T4."\V`#(,(KM`$`Q"@IT.X@W
MBA1P@(&DZ-JONN3\BXH+JP;$SL`*BGEHP<'03%/--=ELT\TVHW@@@G?B2N"Q
M#"8H!@+:&HK@1N6D8H!/BF"+TJ*;(-!!`N\D4$@H".ZQ,X`*07J*Q:=X8Z`G
M%".(``,`.#!P`45O#``""3Z:J(&KJA/R)@D>FP!+WMRCJP`$8FJQJXT@4$BU
M*"$`*LH,]B-/.6$A4.!7))6KX,.&)FKH5X,BX&(DBFI:=+*)J%,-`0@RP'4>
MM@[R(*P&)$CJN:X,,NC%GLZML`(('DJ@E0#D(6##,0_2_VR$<!FP5,J#[GFL
MW8IXV^"G_Q)`[:`"3ZH@`6N9(@J\>:S=EB)YZ`D7@@ZG1=(@31^6P*,,$EVT
M+(HJ&[2AFB;4>+K'5$,9@0D3(#:^>3EZT^>?@0Y:Z*$MFJN!F,3$28RD(H"R
M.BY<2R"!*ND",K2DHK".TD8!T&$^`&0MN,"&8*,6T]5Z"J8Z`IML:5UI#S"W
MH7`/8.VR`BR[YZ`/9%I7RWX%M#,^^`"8A^:##!]*R)@Z:(B>!*X%/#2;BF(V
MJ2EO@BY#E6A[#/*#,)B)MF4)/X#/`U`$RR"/=8O'J(;T?<X`W20N;F4,#XKS
M(!1)3WTBP=VE#`!S%<8[*J94J__`@K`HP-(GG;[ZLD\+EAT;6H)C,BRJGO#U
MJ%.ZWH%W<T)I*Z>`SQUZQ_3!I2U*2(12)UK^^>FO?V@&'F+`W`<>N[FAS1/E
M&*/HH"$WF]?&KN4`O4E%.1&01SE\<R4)H*0!R3C`?^:T'0P\)4-K`8#:I,,0
MBN@+,A$(P(M,^!@452!.%F"*&!)`B!2F9E-AV1%%''"2!2`O``%@P`.B$!.)
MO","B?$@`+AV``$\+#$W\V%H)L6E'C[F@E-YBA.SYII)M>(``8C"2BJ$``D\
M@'KGDI.2OH*!C"#@(11ZAP,"(*E.79!EFQ,`\C["``04@X$(8``?-Y`DS5GD
M-[`[R`[_#Z(O)][0`P_9W,3:)JEPM2T"Z:K/0`XP)7L,RHD(>("RQL-%##0J
M(PE8P$J>0B]3)84`)O2.%D$5E0;@ZS_(B\`#EI6`?SG&2)IIB,F`B+0&G-$B
M7PO76MHXIP:$KU<G.4"T[!=-:4Z3FGS!4FXJ5Y2>.(]@&*D(-J])&><QAF79
MO(>1`""LI&!3;\[CYG18AL[IH!.;U8&.WA20%*`X#YSO3$9^#L*/=CJ/`?,X
M0#@)II2`ODR>U:EG`KB9@'H>E"+P2J=%#Z(`O5%FH^F,9T4KTI-[N.R=[I0H
M=$YZCWK"DW+"0XA+#V#1CSAOGPV!UTJSB=.0UK.A]K3I1.%E:BZ9PC,W!TA&
M-KO24\0Y#Z`-R2?+.LK-`S24("!-:#6QFE6M;G4O&.7J5RGBLHI@YRM@11-%
M?W8[LZJ)-6MUZUOA&E>YSI6N=;7K7?&:5[WNE:]]]>M?`1M8P0Z6L(4U[&$1
*FUC%+O:P`0$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g267791moi005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi005.gif
M1TE&.#EAGP(C`7<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````">`B(!AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2)-.;&7JTZ=,GTQ%4TJUJM6K6+-J16FJC22O8+]B:D61
MA=D`5P1);%5"+4-!)<@RO%)"X)4`"EG@A=B*Q96:@@3)W9BV8*L`9NG^Q=;J
MBE^W`EM!,3NXX)7%"P_ON2@H0&5L=Q5"V?NP+XN(@EBH30T9)-J(AULS#B`;
MX[4K<A%+#/P9M6>[<AWWWDK45"2OD;Y*2HX\TG"&`4RDU8O98>?J">_6/JB7
M;&"%@;8K_SR,'6;GYQ4#D([L./'?PVCU1A'8V6]W@X?1$VSUW>+=S_TAI-YN
MXB74V6JTC12=;]@=V-%U]!68D%Z<"2:0;MA02!Q2F1R'"5@?B@7B1!IB@R%C
M:5766"MRD3?0BH/Q=AY^@N`V4&C8U$C?7RGN.%!@V)VB8V0L0'%0C9`%MIJ%
MO#7V8X`$%19@6FZ=8I9J$<K6XT&-60@:8N5)\YI=OV%3`@MD49;CB3>>!AQ_
MFREYXV`PLL>86RS:2"9_7@YYIYX9DL8?H#E^)QB?3\H&Y(T):@>:6X+P\=F@
M+?(!*694#H1A88^^N&5LB*Z)YXI'_F4IG37*52-:/$(6S9:@L?^XQV*"F*#F
MHY,61FJJ3C8&9H9QD;JA4,9Y)<E7R2EW+')31;2@0"7L==U]7[9'EHN!WN7F
M824X9H)L;/DUYGT:(B:NFP.NZ5B9=ZVK%K8$)9:N@XYJ:]9LXI:G5V+J4I<C
M"]VJU>Y]Y#E:$'7JD76%K80R=N9`>KFE(<%>$I3@A0%`<1>KKQTV7[88UL>"
M"=">:]>9V@IT7WT&S\NQ6V!21Q:&U)58\V\..CCQ>OBV>^%?U[QVW6B+8:C;
M86X.'(`I:]J'\\71IGPPF"%3;61?MJKE\KI,<[LNCP#C5O#%FIY&+UYW,=T>
MCS'S/"Q/K7C8QH=C"43WW%XQ'5%W@NS_,:;11;^78&RSO?NT=V7^^!N...ZL
M\E[1/HXOBN\]7&N#TGTI\+>@M04:EB>GB>;!H]M5=-*<FS8;V]Y])LWHA)OH
MIF%C?IF;"3.7?F1<9?_LNXN$$^X@?8?;;CSC>SD>J$`FK"#JY]?>JSJ$7?[[
M5VJ;.;8:EF23Z?V7:RI\^H7HHKL8Z!T/GJ"#^85OV5XXIB9YX>37;V+@OF>(
MN_$5>]_>_=CP6V[.-SJ`Z>=M->G0<I83B69A`Q,+9(X#'X(8<V'F:!@\C8M.
M(;2V7:]1W3->O'ZCO'0%H"ZR0\C75E>0X2D.00)+7+O699`2_>@LQ,N-7Z3F
M+X3X"GUNF]SC_R26O,09I#,6TR`&K];!!I&M7B!4&`FG.+_(F6@ONIG1?U@(
MK_V,;'U@A)E@C*@_<4D+;>NI5;G*)T04_0I"<%Q?8B+VOC0E+C56A-`5+]2M
MC=4/:0(9#<1J1Q`D^H5D411BXX*(0)S@340ODIM82!1$P/TN?8*[@J68!,;/
M;#%*>Q'D\D:IO$+21G5],5(A_6(9+&GO<Y!)C)(^<\)"/FQ36.H+;7`#F77U
MQBR!N1B;7E2[3ZH),=ZY3`MU9TD``B\`F]D/V6:DQ<7!KXCS*Q?D\.(B-0$R
M7`;1#EQXY#F#:<]MVN&EIO0(E],8#5T?&Y=?GFDX&*HK4^_['M)T2?\\F)5O
MEOF3YV#\:!#:X,6@.<R?`0-UP$;&I"MM.,YQ/C$04!@+67ISENX&\K`4?A.3
M:]I,]7(6PBW2Q8YVG)\)V9C"&3F3D,\C*8*D.%!IZ4M0?[NF#NVB%FG(Y5X$
ML<(9889"PW0T4'I3GAZ).9AW3NZ9'_P@9/P60YH:CUS8W*-6JX88R&2,BZ_!
MD?#"2+QNU="F$*,CME9J/]ULT45QE&H`U]>P+=[GJZ,<'EL[]5$W:8A%)3.(
M"<P*L*0%X!2*I*)#X<:8QA($;R%J`T6L2+I@_E0U;X4F^585&;0(8C23\BQ0
M%YE-+.H4BKBYDKH,0YG[M`MI,4P26@!9D%K_=O8*K)":MFB*VL.H<I#\H:/L
MR@,OI%UF3-KJ3`@S=$'S7?)TG'V>IJY@"@VU*S77[&=J_#I4ZK&23AWMCJ.`
MV0J&Y:@$V?/<9O%#F^VV:2_D^6%;,1O6]OH,MEO4:VK1*5INGJDQ?_6LB4@&
MK&#"3)7C,JMVNAA(LT(A<R+\U4(7NMBA($<Y;9@@1([:2M#9Y59]60R``96:
MZ=1&,JP,9`']RN+`T@>8;5+-=V&*HFX-]#'%^Y%CR@.L56)V=CL6"!\>\Z,H
ML&`/N3H3:XBT4<84:3_M:4V-B'Q$TDCONUC&U#Q?W)H17^/#`':+<%Z<X@S-
M;KNQO!(RL0%A:>RX_T51QA)<5K,_E15UF65V,F;0[!B5N0G-3_Z<C-_S8TB!
MSLOA;,N8_R6=/K_X+T`5=)KUW*;M>=B4U^(=])C<.;L0N,)!H0.&/T114)N:
M)AP6"EV\*J&ET'@H.#JUK%N"B60AI]2SSK6NUZ(7]4!X(Z.9W5&HM>MBAT34
MD&T#KHW-[&8[^]G0+DFMD\,<3$3[VMC.MK:W31`WC+H-F>"VN,=-[G*_+:++
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ML^8KWD6]?3_AFAD<Q[.,KH+<C4XLU2-GO=A*JVR1O`[/,FE3G@6%UN69TF;7
MZQ37YV*ZC`[04TA[O._=!)RO\L9(HW<FXK`]^R(2XX,3K?@0.O?XZG6KX\[\
MG+3B;B&B`TB4%[GI=>Q>XZ1TO5@9Y%5C`PJ\NPO_8M<,8Y0"L/8LU8V8,GGU
MF"[-?CH;W4EEYYT4I]YAW'4RD(7-0@>9@H3\]TIFH38)<DR$]CT84GV?5UX:
M=&5F$T(EUCGVY'VJ<SS9968L-'_+`SP+"'+-]X$Z$0W*06V2@`G1(!4H>((S
M)Q%[Y50>!5+_9T\R98%6Q1_SHU*F-5]0%@#S07F:-8.TMV!8%1EX(DQ81&`N
M>"*(8$1P]3=_45+65!G8-406XQGPH8,OF$G\`5-`^&)ELG)V!'2.,U;^Q").
MQ6`@F(8V(2)L"!;'@2QV9Q'*`S#Z5X?3PTH1&(&OM(>NA"6WDE9-A44HE(1_
M%C$@)4TR^'Y!6%AJ0F$__V)6HV1%`R(-#T-;.5)GG55/?N92C*(64<`[OI(:
M=58?1%0SV40RJ'1E%J1QI@(ZTY)+:/<]8Y@YB[8OTM&`N*B&NF@3$)=NS'$L
MRB)Q&/$LA/A<_4=6)$6`5G474S$D-E1"1_A'?Z-$3B17>F5X1`<^_])9?(`Q
MWHA^]O,Y+=1$Q&-#>V(\H*6-P`5Z.U5[3,1^;]=/S[-%`G0A'V-7BF5=`',B
M?3==2;>+``D3GR`BT)=L=--0#*$A5O1Y^K-:;&$DE\,8GV=2Y<0YWF<%X9<@
M-*-IV"!4,W,ZN7,A1I)?ATA,B=B..I.16O-G#'E_M$6'%<A<M"-73K9<06:`
M?O\V,S,%/K2%>_@GD1I4B?=B,#=$3BNYB8GU/7[C9R_V=A3R30M8B6T7D%1Y
M$A(545AYE5H9AQ9A0EBT+;VF2E#EA:X'0K$E0H7W4SS3>CJ47'_4>AA4C?-H
MA#>">QY&%XT7*`<%7ZW7.[37/B,7?.OX/ANS&(6G(7"1=X/$CU\IC87X*^.X
M+G_&>*,A9@."57(1!9SW4\4W)K$W.QFT)K]5E:0Y$E+1"M%P"M&`FJK)FJMY
M@AMA<]GH;UKW=0M'%E]V0,/Q9?O!)4HGFTHWF\`)<+-9G&IW6;YY$*(4G/$X
M',[)G,")D!'H=<=Y=-39&!=$<M5IG*79G=XY+,M7E\O_M1,NY!$B8Q8<^9WJ
MN9[<)@WA:1,L@I`6P2+OR9[V>9_XF9_ZN9_\V9_^^9\`&J`".J`$6J`&>J`(
MFJ`*NJ`,VJ`.^J`0&J$2.J$46J$6>J$8FJ$:NJ$<VJ$>^J$@2I7R&:(DFJ`5
MI#*0=A#YEA!IQQ$K"A$>IEQ99"YE<V<E>J,#VF?WXDHH,B3]H4Q"QBE&]%G!
M42BQ8B.I0A!"8BC*9!K7PBG54TA2\H<FDALSHS"GX8$XNJ7\Z6BF8R+GA9T9
MHA8X-J9LIC6K)"9.MHT"=AEL<6/;`QI&,F-5VA=1"AJ0!FFR(4Q:@Z5<^J<!
MZJ5FZE]X6JA,Z"B)(W5HHZ<?_\:)\E.4A<H:K#09O1$(KQ$%V"%,5_I]_`>H
MGHJ?"U.HRH075E*HW+,:VP@%:'HCU[.F\L,"294B`R66JO&J'\0?L\!E-R2F
M&Z<^?2J.0/JIPKJ>!\)*W&.&HIJG.HH;&GEV2)0?QFIH@+F-`<0"U\!]#=@7
M?5IFPD%8_'<Q.X0S;<$"@1`KPWJNW2DG1OH>[[(:P8$G`-4@7K(B`D,G5\";
M$:)C-FBDZFJN+Z(D[2J%`U4QZAJLZ'JP")L2]?ELA:>=/V&P.%%!Z8D1#3,;
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M)(S:M<)VN"T*N"!A&H8)(!WG&9EC2`OKG;$VIO)#'F1*IL@Z$'R01G3A"KZK
M1*:Z<&6+IHZ[M5C$O*U[$]VS2UN++H6J,2^29Y[S&(?"39C_E:?@&Q[NQ"(:
MA(I?ZKJRFQ(%A+1$(A"!T!AZ8[CJ"Z8`RK%KHHUT**>3BT*(FV<8E+_/BPTK
M,$9L.G[88`IUD6)_$QBG<07S\1LLQ[F]],#4J#*\ZA:JNK;K9*CYNZPLM`=9
M.KUK6X!]RL'K>Q+D51[.B"8DA%B)@;AF^I]^@J=`FF]TJS)%IKAB=@6SLJ:<
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M]%S/]GS/^)S/^KS/_-S/_!PV5V`%`3W0ER'0!MW.!^W.!RW0!3W0#$W0$+W0
M".W0$]W0#9W0%/W0&CW1&"W1"AW1%'W1(3W2'IW1'`W2'4W2*IW2!CV>GJQ"
MG0H;EMQ"\_]I$7B<=11!LZ4QTY5<$4AT#==@#4`=U$,MU$!MU$3-"JR`U$Q=
MU$Y]U-<@"$0-U50]U59M#4I]U4^MU4`MU57=U%\-U/RQU6"MU:S0"F6=UDXM
MU6H=UEV]U%P=UT@]P2\=3C'-%Y3,)7FMHCQMM#G=URH[$17[$%`2$8XQU(B=
MV(H]U+FUV(ZMV*R`!4C]V(^-6Y2-V&`M"*Q`UIP-U8&!V9UMU=?`"FQ]V8X=
MV:;]V#62VH_MTG5=$'M@HVL!V/$HTQ5!VU,)&\A+$;G-%_X1`-<`#40MW$)-
MW,$]W$D-U\:]W,A=W$1=VLSMW-)]W-;0"IL]W=%-W<=]W<VMW=G_;0W1L-G9
M/=Y)C=;>W=W9#=WHO=YGS=WD/=U"3=>OW287D;(200LW_;$^#=@Z;1WYW=\-
M`>!S8:URW=FM$`BAK=;6H-D)SMFE[=9Q'=7<#>%ES>`%[M:DW>!A3=IM+=<9
MWN%I[=KS_6$5XA^W/=@.@>(!GM\O"A%8P.+_#=Q"S=TTGM0V'ME"/>,VKN,\
M?MSW:MPUWN,TC@6;'>2CO>-'+M2X)>1('N2"@.!,'N5''A@YGN16;N30T!C:
M;>1&GA9%WN1@'M^TG178;!"SEQ%CSA##61)I+JA+D=_VO1LV#=B#P-]V?MN`
M?=B+/=E;?0UCS>=5#=I`S>&BW>=;[=6%_Q[H3VWAK)W86=WHCH[HBC[IHRWI
ME`[H&:[8@)[H(@YJV"5RG>6B:>YQ>\$Y)_%O%4$7]4W;^<UT/CV?@[#?>"[K
M%'$7YXW=W4WH[WWKUP#EO$[>T)#5N#[LQ^WKQ/[=&;[KV:W4Q[[>0NWKRH[<
MFNW>SJ[=8NYL[`*+"H.IG:(C[1PA0)K(H$$Y+5[?EX<BL!,%<.NF+Z8W)H8D
M14PJ6^8D->+F#6'OL+'7AJ'OEK';@IWG+,[O!)?3+$[@(/[4C4WAG)U;FZWP
M86W9&B[::7'A<3WQ%`_6"7_Q3HWC$3_9JWWP@=[IIB9']KNH8XJX6)NG,FF%
M)G]YA-L1M9JEE_^[MCKJP!9KNE4ZNFL;%[]K\B+?2JMNTWC.W_/YWX#=VX0-
MV,6+Y$">ZZ,-USW>]+@NU5*_Y;F>U56?]40=O]--[5$?U']N]5V/W,SN]&/O
MW%+M]59>]=.^]DR/Y/)]:HNC&E8(.^,EPZ'X?6(KPWL+NG![<#O$9,C:O#>T
M\B>\J)5+)P_\A):,[P)WVZT>^4=_YW\]Z[5.X`XOVA_>\8PM"%6>^4@M"-$`
M^D^-"`T/Z8Q]^JA?Z1I?U9D.\E.=Z:T_U3]?88TB-A<2N63:9P,,NZ[./=3*
M$4XWJD#,^#FB^X-*K6N&,PYCJKL;VYPA\!!SXH#=9`67WRT`XZG.XL#_'>W3
M72/-3NPM4.W`3N3DO]Y+?O[PO=K>K]V!(-F_[NRM,/[A?]Y78/[U;]S7WFR_
M$1O<A#8`P:)5`$'8!`5HA>V*0(+8H%S!%@#;0$$L("(<V.H@-HX=/7X$&;)C
M`!8<"5[!*-&B019[2DPD:")APY0<4=J\LK&BPI((1?Y<^%/HQX1#C1Y%FE3I
M4J9-G3X%N?#:-6M3J5JM.C7KU:FLL'[5"I;KV*UEQ9H-FY;L6;9JMT)KNU:M
M5[=QT<K%6U6OW;,-H?X%'/BGH**M('(L:)!P0HT=!1%.9#`AX8F4)1NL+)AH
MXE9[&G_FG'CBE:*4(39V*/JQXXF3BR8-"E70_V&GM)D:?LU4X-/5M44SS?DT
MN-.#5[U6/7XM^?)KIK#L98[<^%6X5Z[!E9Y=^73D6+Q&WZX]^156XKF'#S_[
M/'CFCZ&O/V_-,'KVYZ]XIP]?NT_-_?W_!S!``3MB83<`8WL*M:84;.HWIBQK
M,+>E>HLP00F5DLHJ#;?2L$-6!.DP1!&M^G!$$SL4))H3.01+$+KR8LO%#?DB
M$<090V2Q*QM/-+%$'D_T:T`AAR2R2"/[N^(EJ%JY4"D'EV*2MR6;1`K"VZ@\
MRLJE4+KNJKVP\[)+Y,H3L\POUP*Q*C#7I*Y-:%A)CDTUVYPS33K+E).J$O/D
MTS@R^YPST&L"N1/0+O]=C+/0.ZOB[[:)'F4,4DDCI7122RO%]%)-,^5T4T\[
M!?5344,E=513,ST*0:<,2]`VX*`B3;@GD\)B5J1B)<[65%E0:\:]TF+%NEY9
M80$*0L-:R`KE\*NKV:M(VRJ0%TTAU"P;R8/1V4!LO*O;KH3-=BU6GJ-QK&O4
M\];9:X)4*@!WWX4W7GGGI;=>>^_%-U]]]^6W7W__!3A>5X$J:4E=LTQ02Z6P
MH"5AWK`T2N&D)$:*CP",NR(GZ`+9XPIEI?OPO:I*<%&`Y`+AU:)!RTQ4.S`_
M]`HN08R=2I`]H.'U9!:J"J0505M&#[L2?[XS43C/=#F^E8%F^JK'OBLZ:D;_
M(3ZR:JNOQMH_51<\>"@&'Y2-:J$2$7NPLD6B^*@H:^-UJFVO43;$N#4<&BP6
M0`P`+K=+8H%007X-=ZL=J\+VFK8+MZIM4U[\,40X&Q_1QW*W\C%=N22W'"UV
ML^:\<\\_%\JEORAL:N"D-#H[)%P;[%JHX5A_6+B+X8)B*FQ?OD)04[P0%"X6
MK+""A9@'_5UEZWI7-%`9];JBVN8-;]-PPGU.'D\O'[,>>4'=R[Y[[.;3WOM!
MEQ=?T*E!1S]]]:_>^K;6?_IZPK!CSY7^"MFVR@JO]$]KCV.Y:L7_6.25`-!E
M*WT[E]X"]Q4[385_5`E$(!YXE;:1SUEWD=$"@36X_\DI9T<:G(HI&@C"=;UO
M?2=$80IO53`+R<9"J0.)"472BD'8[THVG-#%JL(_;,TI9],YVGD(`@V3;2=X
MAK,.B.ICGC%![1K/VPNO?K6S046#B?G)CD;T@\7M!/&*X)$9%Y=XKL>-$3R-
M4F$:U;A&D;0/2J9#"JN$`\./K`XX,HP*'%-%1X^0;DMM4XYUI$B7"`[K>(XK
M$*%844"X_2Z08,*1B+:".&(%HBJS\9]R]M`51N9$+#?JT"4_F"-S:4@]H$0E
MB<#U25:>:Y6M+&4)V3A+6JHQ27]9&W&F)*46$H>/'<GE@WYID]GIZ9`?(]_+
M_K2HM>RE6N6SWIN6PPI3;/^QFM6T4_CR9(T]52]/0314GIX9SC8ARIO,1&,M
MU;G.SKE1*?$['1YC.#]?\D:>?1SF9?`7RVQI\8)L^9`",\=`$);%@B#,X$`W
MV,&PA(RA.BJHAC;'3HI6E$CNG-@]/:)'H[0""_FTXX0T:I.1*F:.3['8>5X6
M-8<FS:7/8IG46(:?E1)-4.2Q:4R5-TZ5]I1[.:TI5>;3M)QN"VI`%6(^ZUB1
MDG;.,*_;2!UQ`LR'%,04&7N-:6P3FZ<6)&VGRXF!6F&@CASF%!+AR%,)-!O'
M>)6%&:.-10H24J-@-(XEA>?$Z+F@?'YU*'X52C#_"#D128ZP3R3/!P];,Q4U
M#BW_&8SHXQ[J07[^R+"+O>QB)PH[;+"PEFC%U=9ZTPHH$(@C)4F,"4Q[6F#N
M1"&4XNB6'./9T:P6,9Q)2&C3^E:/%,RW2Q&=P5S8RP8MJ8;U7%5?05I,;1;M
M;]#$3C1:<(4H8.&0Y`S4XYJ+O&Q"UTO=W&Z97!1><9Z3N]KU[E[2N2HEA>2I
MAT%M05I!,HUDS":O5<@>H*#4H>1$CA"A+0OEV%O''(9"+"1,%%@K&MJV*JVS
MR<WJ5`M,5_&6M:=E*X'Q"YL&O]'!PH$52$MZGY/6;Y\*Y4JPRG6N*%`W"B_>
MY#_K`JW)]O"A;XMH(!_:'11S"%T[WNR"R.H1QI2D,;%"_[(T.GN9@J%52!8Q
M\)(WJF';UI<CI1U)69<\5B85C*Y-X>V0/>O9#(_F,+81L$%H@RL_]K?#[U0J
M7@7K).$BEZ\X=-+%6F#%+3+'BV*D"A]:@(7J#KJZ4>CS>LJ8:+W4JHI?U$_=
MS`A$,D$Z:4ID-'K,.>G]\/<C3M[H;+Q:$"/#]S&YO7!G/2T4M.[A,80!M91K
M:]NV*D3#I*E(0KRLZ\#(\=2OV["L9]T1SPQ8V+->79M=]^9X.HR7=A8F;XY[
MOSOCKP6,(ZQB(_=B%[?8VU&X]F+/)>YK1`%$D"5ENIO#.'475K'M]I"VX5TC
M2=:[0T'&$"M27=;<\II5K%I-E/]*$IS$,#LPNV92KJ=L6\\>)@IC_<@*TMIE
M5$M9P8#!%9/&^IO5D;G@-D&=A@$^ZHW"\):RB>U06M`JD/9UQ"6ME7`B4YL2
M7*,%43@!SG5N`IWG/.<\]_G.>R[TG!L:"],]-*&Q$/2@`WWH0)="TX?^\ZEC
M89,X-:^9!$$H[)9I6^2E4RM:D'4V&97L85KO;3+V<0IG6-2N(6EB<B)W^PZH
MJU2^+4[DN_;30!@S9:W[?2L3*V.#N(X2*EA%#+R0HLS=UFG=P]T04W>^"Y[#
M?Z%%4^.\UVBO:MI@(RYP>!6%%[U%+'J+QHX$:A6]L>+%W_YV-5<_E=D[;2RU
M7[VYR9C_XW7+6"[^C"R9?,^AN@U?HDVU:&TN>B3``J;Y&S5XEE+N.I8_9<@B
ME57V?8/2BW5%IBMUCLAT^L07'UWI8.QI=X;W4J!AG=/I.>3[O?)30&M'/M:1
M_[/PD__S)=___]>:Z.LHO&JJ`E0NWI@Y:KNA?5J13RJ^<!$$;GLQP$&Q%.D5
MR($L<9,L<LLL>QN+RF$HS&$H?`/`$C1!HPBNT`.]Y'JV:E-`*#G`VF"N]/(@
ML$..*[@V.^DZH0$:<NJNKN,F$-E!/[%!KSN[.D$O(%R753O!)EPGNU*;Z9LA
M*6RC$-.^TL&"$N.LTFF;'ON6AV(%N&"6B*(QX[.**T`$WL,Q_R_4,3,T#BP`
M)<MQ)=ZS!A)TPCL\02CLJ,U;E><+"<TK*3^,H1AL$!VJO_QHJ4-,CDL:/S.2
M$?X;%.KA/TG+M.^H-$5L$ZZK1*=YQ$WL/SP$13S40Z\AP.&"MJ48!$+L/!<4
MO1&9-RV:-[$`P4BBQ7&[P%OD"G3SP!G90'XB)<I*)5S,K%@$QE#:Q:FPPU!4
M1HHZ.=[P`EA)F):SIRM\$)A;+AH$$T$@ER$DG"/L$FA(IK.CL2*TAJW#1DXL
MPN^YKK,S.W)<PF6$QQ(<Q<`JQ19<Q7O$OE-T$I#J0H8"/B\$Q]H;J!%"L=UC
MP]W+,1$T/H=R0\HZ2%F*QXBTJ'F$G_^&21`+L<@%P:6+5,%W@HJ4LC1$I)Z0
M]+-&[+-6."I,)$E/Q,3U4\DN24GYDT263#N)M,DUHL@I_+#:D$;B^+REB#F>
MG$8&Q(L>>:7#&A<%$C?$82CL<4-1BL.X<,@5(Q$X)+<YO$J(O,FM9*,49$%[
MA$&PA#,\.QU5W)(9[#J'XL:524<]Z<%S^L&L"\)S').VY!EOE)DDE,MWY,J^
M3*.<=*]ZU"6RK!*7(\PLX<>GG(H`VK'KT$7C(\@5.Z@*-*`0Y*"%?*ZG1(3(
M'+YD],O/Q!K`!(F\NI5HU,)JI,9\+)V^,L3\2\3WJPZ3_*).7$G"(1/^,\?:
MW`[Z@\VA8DG_LX/$F@3-X0Q-`21%9QM,?4R*5#S,B,FG.>,P5]Q%6#S&N7@N
M8AR+RS1&6LQ`S,(VI'RWZBQ&6,J1#B1&SR3.]!229NQ#4W2?OJJS%QQ+Y;P5
MM,PZM?1&G@([<'S+YNH9I(&FN5Q+[EE+_?0N<W)'X53/!5U/XPPL*AQ-"(T*
M*]P^I\""9Q1*$^-"Q6Q#7ZRW<2F]#B*-J%07&W/#-0Q!</'"<7G('VM(]&30
M&!4,T20*/N0K^$1.?)Q/^>PHC@#)H$F_+KI$;LJ)/;A-Q^0I(0Q2IGF<H!JC
M_QR_H/H>'5S2-ODS*54:3$,J[=BT[TLJ&073(:%1(A/,XFK.OS),__I4FR:Y
MFPJ;#5>P"4`BH0=DA0@*@/]!(I71$0HLEPQ"F6I2#BNX@AA+'`FJF1"%3'9;
ML0=$L5G4((74(!@-TTD%KO;ZRN1D1?GIR(EY3K-\%).B-86PS_`")[0SU4"H
MG:LP4.Q"+_VIBL-ACN9(HC`!0O"BP5(M0BH%.P2EP4^DU%\-C#'MB,R#BI_4
M5#5USJ=(A$#LU!FBK9,HJWYT0^W,$+T0@*N2(JH0!('DBP;RI"?:'\:!D[B9
MS#ZM3#.$U(%BR()BU,F15&"%US9RT,&04*E:E2]#BNMSDI=+30RQ%;^;N`LK
M#MV</W*1#B0"(E2-F]ATTC[;/[BY38\1'O_T"`1L<3]/_+'\X\U,DX\9>,GQ
M>%C=5-!X)=EEPZ4R74$>10JR.5.A$,3-$#7'2RL^"`DOD]-@#!'@PXKN8SWK
M0!G6T[;#^J`K`-3\*<\D0M0%ZL6"O"SL[$#(>5K(>=>2+5GVS-1CO5J]VM3"
MW%K$C(K<LJK:RC`N64M<?:*VP1E"^9T"V@M=]2YIN@I7'10XR1TC*H],BLOP
M$E!O--NN6U6XU$N]Y4NJ)=RZFE>=O%=8@=,,+9T1JU=^&\J/>+4K>S#1J-84
M!8LW(9&L$#[U:TRLXYC"*23;X1EIL1W.#)=O94,54TP6G2P7):&I+5Q@%=:`
M%<LX8DY,=9^6A1__3TV*'R6JF/JS_K0>)64_YQH>V@N3O6#>2-Q2()W+YS6:
M2\12^QNWX`VJ+I7>JQC9V27<VLV,]KQ=KG4*ED56-.U:PR71HFQ7WTO$::7*
M#EF<K.Q%S`I/]^46RVQ,K?3>_B4V2VV0Q]6R/NS)+;RCR`6.:QS0;5045>B>
M==S/<`2[<>Q5<QS0Y^)&\#G'=NS5P?5?_P5?TD28\?7:\W599DU?-^/0U(L+
M52@$/DV@QD1=.2Q7WTLH_6W=45K4&99*V?U@&0WAIA+@RBA@IEC6TYP0WZV2
MUMS$UYR.57B%0H"%I,$_EH29CSW#F:S-.K7B<[G.EX0&W]1-X*1))OQA_]`,
MX2$6X;KBO"1&X"U)TXZ0A6M8(>FL11U+MT(HA"B.!>L$')R=I'/=SE#JX\<<
MY!EQ2ES\Q:85SV&LSE,ZY%;RX3->4*M=0-T-2TS>41TM2QQZA55`"BR0B,;"
M!JO`!E(V95)FA4&@8U2>"EC8XUBNBE.V"ANA93I.Y:DH95UN+)3D95W.95S6
MBD(8-P`UE+TMPK[-NK]M+EY5PNZE9$H-XAQ-64XF7P-VXU/4XT)8A&WN9CW^
M9FY^A2@.YW+VYG/6XR@&9W2.Y52(Y75.9W8V9WCFYG16YWJFYWG>8X-\**=<
M7>U4U\PD(>QYR$F.9N*<9L/CFB)6S0,VX9_XJ/^/>`5#*.5'H>-9J.BB"`0F
M7DE!X)WSB.4H%FD'EHXJ)MB0/41HJ`9BOMC:S$TLWMB0O#\LYAG:?$EHGIB"
MV;C.$K7;RCA];:<,&RM@NPQ1>XF[0PRP73S3$)#'8+RTBC74R(G#>*K7.(W5
M&=0"(XTU)IB3I6:LM>8UY5VT:5:/H.,ZOLH.5`61#ND]GF/:"]IL:ZS#LH:J
MF-_6553?FTH-C.O&B=K&,>@8V@VFDK*MAJ^X2Y_>X!N06S@M0[*/`RV-D*^!
M,^,JC-,(XS63TNFD9NS=2JO3V#>E\$JN@<:Q_L/X#.MD?>@V&E5HPL^J@.*V
M9FM8`!,(3B\)]BXH)4?_6^TZ`O5&V_9!W#YF#\8XMKJ;@I`X_!*S8_,<RL8[
MTB&=6%F-U2@UD^)JV4@,4ON(Q`,P(C[KQPNV_U(0HEXA7%+C+%3HU7QCI?""
M$8OC5DQ(%:6*>XYB=[[G/EZ6I!VH,B0A_#A(?\;<UB67IX3='@MLR64KQ[,(
MLO([5L'7XFPXS'[NQ,"RSI(\GF"ABPL0WEJ=`2L0MS(,^;+<U_@OTMB-PBOO
M72)AKX'.*E%QE17KU?Y#CFY)ZJT&58@%0X@%'-=Q'H<%!PZCAOVB1=--.YE$
M(V_B2X3-<1-R+M+>FZYLTI@[ZE:(4S@\4[B;"_\<MI*CZTLVU;#<"Q.(@*ON
M_P"!N-HBJR[OM]Y0B5"CL`O[-XU*XYU4;\9UZ-(9X@>/F!&[6?*DFT/2P"N`
MI$A6B\+!SJSX5@^-I$16]!"!9$4NK*,DQD?W\WM#OH]PM8C0;-8Z\^X.;<Y1
M[&"KM50[L-4BC("[:@').(W0\L=+/.U6M:W*#2O(N^F6<P"^9#.]U&K.9!C?
M0]..BM8V%&4.+[<E)[AMR[P-4-Z^SV4J0F86'V?>2YR^%52C\J+VNS6K[+^`
MJXFHJ@H;8)Y>N]^HJLFCC`K_#Q2GK343:ON"D-F@C7)7,[83/:]>\;]JXWW\
MZHF)AA1>MA4&:+XHQX-DQ/7MEAJ&0$%6J'3EBW5E6O\>5I<#Y\J7G:$]\)PA
MID>V&1V,GX'J<PJ@KA)^K=#&Y;XNUD;Q&R.&M6*4?K^65LF,W<28/L2.I>DG
M8OE,H_:#CM&$)NU[=]FR]G7TW?7!XI&[V&L0>E^$:JQ?/)'Z1<KO)*R_C@M'
M7?B`ES&)UWFN'.U<Y_5-!NM>3VT6!_8Z$O;JH2:[9$NZ#-P#I56Y9'92=78:
MA/8^D7;!S?FL5\\Y3USA6-PZ)_G:R//W)OK5E>^%'$,OY.^"]*2#5-VF+'RE
MK=N&+'!WO72\W\H0MM$KP5'Q#?K`4N(LH?%)&]Y,"W(K)O*7#`0^._(N'OV0
M+/TB/_WWNWO+'TZ>WUV?-YO_I\C=SL_]H<>0/H=TJZ#..Y;%_"5^M=!.0#[4
M2C?&I17/\6QTNI&WZC3/ZL1ZVH](2YX0C#]<HM!SE1-\?^U7V!BQL@^?DZ=+
MF\/+_%Y_K"-']2A0##Y"L6M_+R#>;2)N[)]4\/W4J]EVCP0(;`('$BQH$%NK
M@PH-TEKH\"'$@5=87+MFK:)%C!<K;LQ8D97&D!Q%>BS9\23)BR!1CFQI$II+
MEB8QLMHH\R;-E#IC[IPY$B9.GA@#"(IH]"C2I$J7,FWJ]"G4J`(G/FU5M.F5
MIE83,KW"=:F@JTNOB%4JZ*M9M$GY!,BX\MK;N&[A"KJH<N[=O-=@7MF+%^[?
MN()`_\K56_C:E9J`#0>V*"A08\9WP]I=;/FPM59]#W/.&&CPY<B6`ZB5:OHT
MZM2J5[-62-5I*R]:RRJ]TI#IV::Y<=-&BJ7TT;!8*?;$:/QCW^/*EW^LR_QY
MQ\3*@WH$+=1G1NO79=+%SIVFH.?B*SX>/YYHZ_3JU[-OGWI/B:K`@\.>'[$W
MTE;V(>Y>JE_W?@]=T190?EU4(()N.9?@@1DQ>`UDE35848(46L3*6P]J>$UX
ME6W8H%VLA/>A@25B"&*))$:8HH,M-CA8ABZR6!EI[MEX(XXYMO>:5EC,YA1^
MP07H4']F!7G?D`L)IQ!P7TVTW4Z:]823B"!Q:"6$5YA2$O\K5ZPH2#34<0>:
MF"2%-=UR'8$WI4XBEND2AQVR&1-Z.MIY)YYY1L0C4U8YE56?12;EE6Y'0D06
M@(D>U`H+M+'`J$""M"59:'>Y*=IA?,'%0@"F7&0%%*RP`!E(@9C0I15T$8;I
M7XE1VIDUY<$%A99P!>*EA(%8$<A%E+&J%S12PEHIA*`->UB->BJ[++,W\NF?
MH0_YJ1N022HTB+4'"8K4MD?]=Q!99>4FW)-IFHN15=[U=.DUHWX$4@GAO7N-
M%<G)6Y)Q:BJGG7G*85@1<101%PAD%1$,(:GWPDF2<2)"*93##^-;49W-6GPQ
MQE%=$1]LT0HX6[8&`<K4(!XO1"C_;B$7U"TV8>%GPE0$RDCBI20^V-=%1%46
M"`L2;@H2-&3..#1,7;3BX<PR6N/P6Q2198T50,-UA372^6JSC#@3G718,:+X
M8,XJ9SPVV18_JY1F6HT\UI]B#^2%R0HM.9;;D1:E7T()937W0(].1=R;'G4Y
MYTRL8&&ENQ\%4!E&`FQYD5?Y$H[86Q)W])EQQ+5+:TCU$C>XY2$9'KB:@F@=
M^E!QE[TZZWF>;6/=4<4N4.RS5]7R5F<)PL(5SZ*,#5M_%>@U8#`-+R/QJ\+4
MJ4HLO+71J-A8B&+RR%M/_?7M8K3"10=?Y/RF?CU8?8.K8G\^L<>CGVSK[;N_
M[.OYK9U4_]I-S1`[HEVI+O+\2/UNI)*N4A2^E0MUR#E.X+ID)0$4C%.<@@8K
MVC(@%C2J(M)1EU#(0CB48$%>4,A<]PJFO?"9#H/8`1WIR),<$[*D8N][(0QO
M!!_Y`*D^U-)*[%@6D6^!Q3[?NAL?3!>SK7U-044\8HE6=#SC^45J0/D7$C<D
MIR@JC6FTTM74=I6S+.Z!,(K!&HJ4F+0BPFB,0PM;#-.H1O7$[RBTV)]!$E%#
M1?7P1RG#X7`,V)%[I3!6,-$CAUC(,*$9D%\+.V3$!#D2=BGR0G+2HPO7*,E)
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MPY\S>X>5'.84<!L\("`5B)%21"(2ES#J)2IZU$B@Y((&1,PC&ZG!1F[$%"M,
M89=2B)%;_C1U+_UJ/V,JK=DY$V\W#!3_'=%&S6BT02E>"(#TJ`J7HW4U.QY1
MZD7SZHE\J;20==U(*Q`QN4A\HHF*09_Z_!(>\IDH._]B;&*+"=;)JE&L#ID6
MM.9XQSY1<[/^20@T"%N*T7YBM,DH+6E-^PEET.$)J2TM;$L1V]G*]A-T2(8G
M9%N*W):6M[O5+6]Q2P?>>L*HQCTJ<HV+6]W2`;6T?:YN44L'/42WNM"%;3*F
M>UWK)J,-R<CG>&02,:TF4JO\I"QZW3=#(-7T*"S0Y$X+9;^<TA<;;!T&)CZ!
M"?SJE[_[S>]^/8&)).!7P`7&A#`P86`%(YC!PYC#<!,L8`DW>,(,IK`GVC#A
MI.85KTKU!(4Q_S$'"R^8Q/\E\8@O[&`5E[C!(CXPA6&L8$]<HA2>\8))&=2*
M%J"41<'DJ!E;FMXAN\^R1(*-9NOH6;0-(JWTR]LE:G--?:*3RL81+$;&R>'D
M)I6<Q[DGE1'1"BMC!!'P-(]WP8M5A06N.UJEF#.U!5>!H*=WA#)=*'G7+#LG
M!,^TR0V?(_5>B5BE=U>YPAZ\,E/6D$7/V.#=_/RD&43AN5%V:P6M`#7IA`QZ
M.%6)<WN7>5/YZL_)2/%"#B?UR]!<:I>6T=0?N^OAO%[&6*9\"RV'N9CRN%HN
MNEQUAH1U:\_8NM<9D6PE$65HX:1MT)KNG>U0P^SW#KK3`G&V0>8\%?_<$?K:
MV/@?:YB-'T)5FR"=?B]7R$V014OYTW9DBFQ,+212*QDL/65.._'EL'SS&SR,
M*T4;BII<<?[Q<E;J-YJNI,YX.I:>#F_8/1%^G$0NO)T4K_@^XVR0L&0E7-B(
M@E@P.17-1!LUCR(461:]I$:MK=/D@K:W"<7NU0R:45Y:]_PZ7;^=IXWD3OI3
M0#F;9+6>];/R-@H/#]H5AJ[TG3F6D1@K(N"`MR&_V$#:1GN<((^"T9%-=^C3
MPZCU%I4Q[,<N.:'?Z_&6Z5RGWT9(J'/4NYKSC@^@Y`I7.JWMFG-Z*C"?>6J6
MQ)6Y\4W;WTXWWO.G]JM8N]VPB;NTXASO)2?_M,F=I#RW[BW7J?V5+G]D.#TO
M@NHW*_S-9]H\*T2X9M*?B?3G+93IK%(6=-OMT:9K_)T4_^B1=]O<?6MF0;RR
M)$#A/C6V*4@K[$X[Y>_>]]N^>]JD46Y/=^Q/((OOY>EV="0U)7C&MI1SON^7
M5@H/4\4&=D9R/>REK4C7(/FUKC.SF?47RWSH%[+&]`/7L-3/*WYS&>,M2ROL
M`=R]'39``4&8PMUD!:30V?,=WNXQV]YHG$R-#,I]1?T@X-WQ7O.IV\K]2?'E
M1UG%&0G63F?5&]%9$YDUQPK.TPJ""3>QA"E@"5;!4YOM&YE=G#[IH#Z]WAWM
M3=ZD7*10&MZ9PK*8_\Y5;%KP-9,%(IH!#N'@=1`'AAM:N$Q!.!M9`,K(E`6B
M)9X`S<YZO1O;;-^A`$E.61X*)A3^,%W7U<S80<X;&HC0=!U?T)79A=37E<C5
MQ*'6T&&<`!D2X1^105-44*!I&")F65-50-YE@9I3_`:]`5!7\%0>H=Y5_525
M=-YOL%[E--+ID5<7=!XCD0XJ;9Y%^.`@IB*S&!F3D!4.Y1!LH*'2&1WF!8>J
MN1]<'-;]*59C]=ICT5_[K5^ZB)\7J9(IP81(B5\9X:(@JJ(SKF((>@LC+@3@
M)=.HE5I73*-K4*(*9I/##8[$T5.7%$C"U1/EN!/"317#]=OIH2-SE-##N?\3
MZ,1C/,&C.<8C*CZC/LI=T-%B00G=/_KC+*9@&OH/&_;8B>1A@4C4V&6=V2%C
M1MRAP_BA2I14'HK1TY5='C;C/G:DW$4CTI'@T*DA&4:>;D0#0OF/3Z%.-/!1
M5SD'($7<!A&2)QY<5VV37(WBY.#@4^6C1_YD>K"BMFBC0LP`?#$%)]F;)RTE
M-BZ%]^WB^Z42_<$:_1F._>F:^GT?5^$B_)E2+T%E^@D3_2$;4)8E&X'D,HFA
M61"B0))D+2(=_DQ9-JD)3S92J]652U+9OZS@7N8@F,UE/I%77BJ23YJE84I%
M&`)D0!+D6J;DO"GF0`[*09H4*WB*0GI&'#X1(&[_#=?U&!Y29"X^)&:*ID9V
M'4<>)FJ:AE`:1#7N$%&"BRM@GRAAQ6L&'S>.Q4HJTCQB52P!DE>0G@:]V51I
ME3UB%=74%8><#E459FHVYZ"@I4RY(F?!HEIRBPF6))'<XK`EI/A!9&(=RR^*
M7R"$"5CB(3&&YE0&$C->R56:$EDZ)WSBIKMIQ4CFQW5"IENVI4KBFS>V9`M"
MD)7M$<8E7%^&H^C8H#<VS)D9Z+SPY5_B$W/&IX2Z1C^BC2,&"OXX1<E@A1R]
M)?<M'4C)R$\8T67"H6@&S69N2"#8X49.I-*\:*\L"!]FYA_&X6E.*(XZQ&HB
MGT@6W2SR'^V$TA`*D4*9_Z2'1F<E6D,@!,"9343B>(1_`E*LO%FOF&+IX:65
M`&A$(FA?EA<FPF0CN1ER1FB.YNB.KMN%0LLU^HVBO9<@$"#R32!3%N110")3
M/*45@,\3M07/',]=0A8K]:*@#@]H)):AII]%`FJL0(95W0IA>`FO9(05/,8>
MQ"C2`,M?R-^KE9]>?(;]'2HQH5V9FN69#D0BTD^/;A;B)1YK#M!M1F;F52+%
MV"1&[(%<\B`W,5(,8D0@T*HBL=-/@4:O(@R]^`Q@7,,*L.";X6J_,&N_D.FH
M2FABZB>W$!18K$S+'03?82<UGF!MR(RH/(Y?P(6J$:IH=@^-+DV*<DU$MN@4
M2?\'"YA"JH!(N%;DN4((C9:F9U[#>T:KOY9JD%:G_T"+GPU0MK(FH`B"+":4
M,]FI4G;C19S*Q)G`YWF$E`05L(;.)B(G30;.)X8*P'R/2%C#YZC>EX9><0B"
M%U@IM/JK<P(L0J2IA5XCWX3@DB1"3GEK?IK%+8)/)C*IU("?,;J:IJQG)J[G
M;Y9GZEE0TX3L7!!K5Q*ML(GG^>E:O[ILF<+LJ8I@?3XF41`I%%@ARG0:MG"K
MW-PG;AI'U(2L(.0I[^#+,-;57?J5.SZ'(>T@2'C)L1*,J.1BNY@"-'R.3)8C
MQ`&2"[89G&&MXDY%A2;%AF82ALHF0L1J4THBG1K%@(3_*..$A+F6*&+0*(K2
M:-+>X9E\QF=TR-*RWX5\B8R:71^.7=?8*+^*ZN(^(\Q.+GWF;I](@V/"I>Y2
M*^;F9@)U'EQ0J67H45_9Y9G99>=!$.DE;YNU;.V2*G2.5=>*FH^BJMD>A#1M
MKT$\)2ML1:;,Q9]FS]8-*J>J"OIB:O?0%:ANJGFN[Z9RI_P^CWJ:[U\(P@S"
M+_^^Q=5.+WQJ;6WB7-M(;E+`S9S6QJL^YS7('@#"C;[0Y0I9V3A2670L[YMT
M4.>U8YARE0'-HY79(YE)+P#_Y+0R9F/B9[7V[H<";PM_ZS5TD"`D`MPH+-P$
MK8FT[D6FJTKY86>:U&>V*V5:_V378633Z2L0SVX)1^OMQEF'+N;.KLQ#%*E#
MX*SW(E]<`J`6N\QU#&:93.D&6VG'$HYUZ,7#>&GHZ*3EU"7ID/`2[R/,BMP8
MTM0FV4=NY,WDY@VSY3$?X[$??]L=][$@^_$>_[$A\[$0'K(B#VE8U/`@U#`J
MM<*JK$KL3C)@6/(D"QLF7S(G$X:M;3(H4TXHCW()>?)BL4K4KMI7(JU8BM__
MOO%A:NT(7N\+K\P6WS(NY[(N[S(O][(O_S(P![,P#S,Q%[,N8S!S7!R#NB`%
M/R@WN3$L.^/&T%#VVF<U-]-^)%T46S-NW,987`$-A\4CBS/<8($0.]TY^XPZ
MX^LZM__SEMJO._N,1\6S$%=F1)8,0A)QCQEQ1_7POKYR2-+NM4K%5I!2:6`@
MFB(?0J#%MPCTV1($?B"TJ:[;X%$T-LR"[0BPVA3P)%*C@.34`/?>P^(F+T/,
M)::Q4Z604X5I<-;5<!XO!EF5*![G4WEPF$)SWQ1%4N*(J'8<IQ6:;<*=%NKT
M[[6,X;U&]3[%XB&$%4"@1-R-HQDU1.M-IT&![#W:[&BM='X6=?;)PEHG"_-'
M[`2/%PR"##\R6E</_2HJ+[YO\OR+6T,=><8UB,0M71O6I?8OV>DU^BPC_H8J
M5#0@<)S%%@J>S`T0[6S%3.4/89/20A=VR$B@\P5L[3G?3.G_G"!$066O1O^U
M#&4_X*)9V[DY=F=3WT;W24B+M`)'XJ#D+&OO9TMNL:]*L"E6L'#Z*CYI\`LZ
MLWF(,'20!`J]Y$D3IB&VD9MVW%FX*5&K6P1F1;EY8%'<F7XH]P'*#T(,VNZ@
MQ>_,U.X<VE=TFG-+1'J@V\%^-M\$U-PT'LJDMD"<L/9>LU&4+11S[9%:;WWK
MJ':&K_V.CPX7<;K.X=BMB$0F8QX*`B+<*S^/%!)_U(W2STX'++D4(,NIG;>1
M2]]=8-IHH1X[#S;4R^XPK!Q;V^_P#02*=J0DA&878&MHQH=[&T2+16B+=U%/
MA5@DM6O8N))H*"V+]14G]'UW:Y+B_R7Q"L+GI5!4M=D82TP9=Q4:"Q+%W>"1
M3PY.?PNX02#*'=Y,I8V%-W?SJ5W?O9V%M^8.$>`I3.'OF(+R#1Z0#@3'V)FE
MB;EIU`_N<??L`=^,$Q`(SF=77%]'9U]M.!.)VY1N:*>QE2_1?NYWFE][NEI6
MWA^O@64J#TNPS!_5+OJJ`?1E/0J1HD6C"-&58_7>^%_?9?A/JUN&1[?^DG=!
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M@6(B@DJ,F#9SW?.V>91[VJ>7>W,+>S<?'=O/`OM/?56N9'HN*MW_*X^=:"R)
M)BV1+F1@?'^CU(Z);N9OI!(??@`G?$&\D5,\\4!'_<;5#J"_/0.;HA>SB34`
M;AAS(NW/]IPT^="#*>FP\089ONE/EM:R?@K/++++5.SWN$$/>E72Q="NFG=6
MY=:[VHJ>9_SBXEH?([XF.J68O2NC??$CDT:CMLS7_%(@L.0+NLTGDUS6[0$M
M\[1?`3EJ>TE<$/U7A&Y_.YIP,$!8NS:0X#6!!0D*NH+P($.$`UDM=/BP84*)
M$S$2#"`(6T>/'T&&%#F29$F3)U&F5+F294N7+V&VO%(B)K96K6)RA'D3ILZ7
M/%\*POESJ$NA,*\$N`;-X-*F3`5"=2J0_Q6KJ$^Q7M5Z35#6J5^E,H56U6O8
MLER;;C6[U1JKKFO!>JVJ]NS60'7C7A5$EF[?I@&*UA0\F'!APX<1)_9XA45-
M6CZ-YLP9F.71EX,@5XX)U"7C@14)@G[8]6%ITX)$FRY-.G3IU%Q996P].K;L
MSP];L2[X&J%;U;\AZ@9>>J-BX\>1)U>^_.-,F\]Q1H<^7;J@H]*Q4X?>Z@JM
M[-^UY^8(GOSS*SS+D[<>GGUT[M?;AU^?GOT5^/2Q)[T6F]78_?[[LRK`MJRQ
M;L`#QVHKP0,CJFK!!P6$L"WK_N,/0`#)"O":*S+$T$+^.G3KBK8JW"]$$_DK
M<*\3-410P(@4C/]0QAACW'`O&EW$T3_`F.O1QQ^!#)*Q`%@(P`0B`R@!R2.+
M5+)()HEDX4DDG322RB61+'+*)K'D<DLINTPRS"J9+(',*[<4LTDPS_322C>E
M=!/*-M4$4TXTWZRS2CKY!!/*/\.$,LX\`4U3T$`1_5)+0A-]DX5"&374ST8A
M'1322XD48%%,#8UR4TJ[S"S(44DMU=1344U5U559;=755V&-5=99::W5UEMQ
MS57777D-LBCI5OJ5)<HH.XG8G9Y+Z=A@/0+6I6)1<K8E:)5-5KEE5:(VVV:M
M-18D;4<2%ER1A-VLUW/138RQCNRS#*6D.GKOBI3L.\^F=I5E0:&.K+/_]UV%
M<&IWW,7Z97=?>AOK2%]121(D`(\4\E<E?%N*>&"1%%HOWZ&X"X1A<O7U:&%E
M[4NXWHOEC<Z^B[&I5Z<H#CXIXWFQ69AE;*!(N-^/R>6Q9HW3#5KH:0^F.5N'
MV96F9I8:`SI:=G%J++=H.5K/Z&AI;LQ>04Y1*>&EF19989:N#IL[ETSAF20^
M=#KJ:YEUFGKBCDZ95^JRPQUO7KE9>G@]=TL:*N&W4;+.Y+'IG4_MH1EO?#&P
M6;A"8I/F-:&CA[%A>V-L!(D<;Y)RVSOKE5C`">;2@[6;W\4_2K@5SU?"'!O,
M"3\)]I8&=XD/R3\GR5^36=;X]9A3:JSNRU?:_UIRUCTRQ=XKNIX\\(,]9WE>
MT1$W5I`]HM.W=\?!WS6[HVA6.=SI.*(=ZO.Q.WLHI[EU%N"ES_Z66X)!DOVC
M<N]%O'[[XR6V`,+O?LGZ6L+T!SIN$=!V-JD=Z6[F+WL]<"1=B)O!O&8^L!7.
M)U$[VO5PPL!PV:M[5*/?Z-[%N?%T9`_,"]\+824>ZPB%!7O@`^H$N+\96N=U
M)>,(\$(B0Q[F4(5!W*&[`A$P=F'LB$4$R0.%*)3_;:U8413<M_`VBR,.904"
MI.#J=MBL[Y$D=SUQ8<N&0K/NI`1^TB,CQU!X$ON$Q(TE:5K`;N9$Y-E.(2&#
MPA*-I:_(?01P,#3DN?_JI[4SSFYU&PS<>5[7,H[4,22E:T44/$A)+!KP)F/\
M"":?8[6;N0Z$7O-("_]7/#2V!),BI-P/DQ<WU25N==QQQ;LXMC17[F]O'='<
M%WGIP'NELB3/\^`N*PDU8IKD;T*YPBT/&<US^:20,H/8&<5SS9L-D5\LD^'[
MSMBNN%73=\(CYT@R=DVBY9&0B_S6(F?(,6QR,S?!BV<WE24(MK5MGAV$IV6D
M@<R04-.=0*FG-!&:4(4NE*$-=>A#(1I1B4Z4HA6UZ$4QFE&-;I2C'?7H1T$:
M4I&.E*0E->E)49I2E:Z4I2UUZ4MA&E.9SI2F-;7I37%Z2.XPYIP@\60Q1V+_
M2=%-TIW9VEO7DDD839)JJ?>Z`A_PV;*<3I6J/FIJZ]BY&&B]C7K&42/#@!G-
MZPC%)U>MZEG1:I1)#A(*19/<34H@Q=(M+&O[6M[>]/6KD@GSK:TH3L;2URY\
M>8\CTJ@7Y][:.J<&;`^CV^F\K.;,@P$&=?*2Y,^()T!0>D]AZ=R9)&D&F+N&
M;FDGJ]E-*%LL6O`NE<M,ZVMAF[SH<80/>#0/+!%;1+]-,IO&;,[8W(?"W)6Q
ME%H+X`2;U;80\M:10I6J%_N7,%,4L8P@(1]T4'<WL#F3NF.;HW'+=T(]BF1O
M10EK;-&;WD8^[[`JW)?E^H=<P*X2N8K%62<YMX<]_RXL?9U=CW8E1E@QKE=@
M)^2.!_]83WO1Y+_-\2`V:.*RE7%SEMJ5W7SF];!(BG*6RH0LSW:FL9^JE\1I
M]>U1I`A9J.KLPXS\6Q'M!4JMBC>1B,.MSE:I-272#*H"G./4=*+CTR*6N;D[
MV^@TIS[RT@P*4?/@V8:;8^]&IP1*A'+_,MLLJ&+/M27V\FM%R:XY$KEJ4JR:
M$B5Y9LZ%<'(9LW*0"?9@25I9C23,[->:3.2.)-C-PW3J4:)@$YTD]KHX0Z?1
MVJM&09=OS-K5V!^="DC(ROEQ]PIR5K^<:4WC:L2(''/A4*+%38^:U*4NH*E1
MG6I5KYK5K7;UJV$=:UG/FO_6M;;UK7&=:UWOFM>]]O6O@1UL80^;V,4V]K&1
MG6QE+YO9S0Z:#Y4W/Q4N#V,#&Z-`IZ4_*3FP7VE,)[\2V)GL\<N(I47S9D05
M:)D5JUZ*7K?O,!U#G]7L;M)VV6+.:Y)6L&*\?(,8?J56U,%<M[7Z+4G&\FUL
MHP%-N^3&8ODL,\.6?5K05`[,3>(VE.EBO)9,9'0<A<PYD77Y)D"VS$%-(=1L
M`F6(/)FTR,M,&;*J4)[O<R_G0I9-FW!\ISZU^15@=O.=BYCG/Q^Z/`E:\WBU
MHL<&[7@[W4-NC$>'FDL7.B\AWI@+KU+D!ON8*;(IO*EQIVGW9#E/]+;*2:YY
MH/#_D?HI""K+-++]9T`IG2P%+:JT08R)%]SYSJEN<W+#7>#I/:`.>XI/*I*P
M?S.^\H"E^KN)2]KA\2J:@;DSW99Q3YV]F^/E:59HU%GMN2DV=^33CM72X]=\
MX<7QD0=-=S%2,X3KJZQ^@>>^F1MSK,]]N9F7B.CG!N9E=)<:CJ5JF5*67(>*
MKG=1$MN1)#ZWDFR&\1+7X[PE'CCT])4JE)?KX%#&GO&AY[G=YH[<2**QGK''
M.K7<;_XAHQB_:YY/O&,K04(>].`_G"^^_.WPN`HR1(SM``N2B(^LCDQAWN-;
M$@8*2@9:4`S."`N6ZH>'A,+@+$^7,DEL\"70WL.SQNS#_]R-K%XN^:"E`1FM
M%6A";L3CBJ9FTB+.:;[F/*[F:BZ0S3+#L@ZOSB)FE<9N9;KN<1JC")ME_78N
M:^PCW"1M[@B+XY1OT7Q*T'P/;&`O8/YF*/@,DC3P9^PCT&JP"JGO>F:FCB2'
M7/;*,LK.)MIJPN(/VS(-TK`![BKM\`;JW/2*^C;(N)K%X$)("X%PC*!,_=3H
M#RWO?Q[(SCHBT,K&W6)P@P#.^_3OMPPM@&KI:HPP"H6OS<`I\AYG$ROM##T1
M:BZH!D]N^*B0ZU2Q$'T/S;X&S9P&;XX,N1"-_\Y#>#Y'9Q"!"J^FF;;O%H^K
M%69!=:;&=2`CC70.$U/I%,.0$/]K2>*Z11`T#QO43?P6T"8"@;YRB68,RX!<
M36)V!OKFQVETSV,ZJ6C\:8@(YY[2[`0M:WO:29AJS,8.ZP;K#Y\T)N"$<&7,
MKQ7TZSVZ@!?9C@\=:8,.ZYM0;P)#D+F":Q::0]I*1YS\SQR';]"HSM*RT;W*
M3,1P$<.XY\,`1["\SA$/DA\73:Z":?TL)W049[!^*\\JK;:PH1NM0W/0*`J!
M#%_VAKEFJ;4.$F#*#L,.9K[NKID22>)@C^)V:E]B,8R:R!25Y\#(C)%ZK?"2
M@S,0(_$FJLO426BPTC"L<E82SMG(DE3`Y2N)+2S+<BW9LBW=\BWA,B[E<B[I
MLB[M\BY3\3(O]7(O^;(O_?(O`3,P!7,P";,P#?,P$3,Q%7,Q&;,Q'?,Q(3,R
M)7,R*;,R+?,R,3,S-7,S.;,S/?,S03,T17,T2;,T35.C.NTT5;.EZJ8%`@(`
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g267791moi006.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791moi006.gif
M1TE&.#EA<`*V`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````!O`K8`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.5T4Q%.Q4UH2F#51VVBJ:P52M!7KT^U2EV
M;,&R)`6I_'I0+42W#\,VA)N1+3:[%>G6U"L0[=`VD0"W:</5H*DVGPI*:N,P
M4N!(K1"V"D"9,HN*5P)$WB@H`-^<`:Y$9!&@:.?/!DN$#GGZ;@`HHTM7C*(9
M6^O)E[6NCKN[:X#<&2D+_$VQ%6G*J%VVQD8<&VFDGP@3+"PP6AME!3,Q9I@)
M,K8VF+JR_P`>>?/#S'K-F^][UK!G6@G7WYW/ONM`]0?EUW<-W*#\R,_1)Z!_
M]Q4(T7\&#JB@;9X1I)]M+(@F68+[$3C0<@@Z.&!F#65(WW*]=5C@@P29$F)"
M)U*XX(`!SH>?A@=E%IF,%:JX'XDKUF@A<Q*^F&-.F$1"G1N!8<*5,I%@LE@F
M`@59'2:`,8F50('Y)N%OZ$&(Y4"9_:;6%<>!%9IJ$5K6EVJ[=<8"F0R2!IM!
M73;(W'B4@4G99EVRL!F6M1T786Y^#O3;<:X%4$)_V+!"F@G`6?9<:ZW9R8);
MXV4F6IY<DJ:G08(<=V5NQ!E7IT"=66$"<6JNABE!:IH@FJAI>O_6G*!T;LH@
M<FVNUEQGAE)*9X.::@:KA`,%J&II,J8JVF]0&"I?IUZZ)EIGD@K$AZ9@BKF'
M0'GR->BL79;@EJ1X5D:I;,21UJ6$)HY:4("=1D9M@'$B,MRO5[!YT&O-`A=N
MN;_)J^NBSI4&:8.2)A>3=@,1*1!BV%A'##;1<05EDXR9$LE5AE6LT"GC"41:
M62'3F"6CW&[:Z65@;AM@R).Q@HV)7\HV&6H(R_;R98*XRJ!:(<_I5F?WDHKN
M9<;Q7,*V21NT)H.7BNL<J)>6-IEHXP$XZ5U$8W/%M,`BRB.#W%J]-<RU16IS
MVK)]?58)$C[:X!XP%Q1J`'RX5G-?M8W_S=S>!0MT:-DBF[W>9+:A7/+:>[XJ
M9U\1>GVEXX"7O&DK/M\\M4&K'0R@P<!>6;ELBF_:7.>R$=3B?:%MUMGG(O-<
MLM2<PZ;Y9+!K[K;F?K-@PG![7[TYD$).]TF2,T<""L7%._F=)*T<EIAAD4A"
M77Z[M7AU*UE>2&]MFK\>^)Q?H5ZSP)]1*VID)90P'.5>>R9JT83/*;*XN$G[
M\_L("9(EC?1R7\C4!\#4X<8\IYF?@P*6)=QU+6#4VA^-;A,P['U*?^+C'-)"
M!"WT8;!U(QM?<P+$AQ0![UJ7R9D'A;><8CV.A2K\&X/*TZ`$KNZ#=('6O1`(
MPCX=380;U%/W_UPHN2MXL"""4`W_PM<WNVVP:K`3VH7D-$*=729R!&RB3:(C
MC;XL1AEM8))UL`-&KC`,&T6BPR>F=Q#PB`=0!C0!W"(T+L\H,7X"JQK0CO8G
MM>AN;6KA%>K`!*;"\0=J7JM4Y.QG-/[%CY!/W%_^SA(:0N)Q?/':VLH(J34'
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MC6$+];=`M]P-;.>\I?!,QC:CPN8V8C$6'`M"(X+DZXI!FR`5G[I,U:T3;.>[
MU2)A6!YO@75XJVL:5"%*G&8537AW(2<R7?K3X363ER]]T%$O&:#-A(QF]&M1
M`(`YP[LD%2=GE%@KP)@8ZWRB%='!F$`8=CR="N1XH'#L9;&#Q,&-+Y@T&JQ7
MFI.O:?DL7T`S01>S)CYY\LV:G`/+RTBG-,?_+0M4Y!$6JX05JL'US(^'6D^6
M*O7(X17W+H,[:8M>I]:!:9![J=-A[,HGL!FMS8C,#=J%X$:X_W5UAZUY5%];
MY[<>0M2S!=P?JU!FR?B]UIW8?*US2@#?5[JRD.K)G'.O25W[Z;`UGEW-;`6B
MN!*X@I&O@:Y!]A"`/700G?G382M\>UK:.;%\+I5M)-%FU+.YKVP]VB]._'E9
MP'Q"$@)M@RF@-#V'EE@2RS/(\2`6L>KYISEWA&6TQ.K*@HDIK"VBY]!B>%PD
M:@JDP[&=G*`%VUG!ZC<_Y56(SZJE=]5)3NKJ<01)Y2:_IDY+;](2;!VD*;J4
M-#.TXRB(Q7QC8@G9_VB?\5*:L-6W3VKTR&RM9PCIR5)!N70SS2K7;=5[GS+C
M\))7.)69X,KD_U1RSJ&!E[HV(RI;W3%=Z/IPI1^TKBM<-&]<CO0/_ZC7,A$+
M6F%&M<!`W;,KSO-QC3:+K%O"X'3.8M8\*2FNQ4.L[^YZ(B;\M;"18B?+\'/8
M+FDFLA%R''<M&]AB>[:TITWM:EO[VMC.MK:WS>UN>_O;X`ZWN,?]E'@1M27:
M58BR)S+4SW+*UPD98D-H="J1K+LA]VZW271-9J-^F2$])K?`MXT[1[*D:PPY
M-D.V;*,2:?$CKKQA1R2^$%UG,"7\WFE%%CGPCLOZT<3:=*Z6%05Z>J\WC?_F
MYJ3O1<]RV9(@/M.;NDS$W<_V:US%S`V?7TO<S[Y9O4P^N1%Y5F=U677'Z1UI
M5X->V)'BF3DAY5VLA5;SY3"]J&MRL]&E%<OT`O7-DY%C"NOY\T?G5N$>3_M0
M(-B@FRDP@<R!0G_=CK;;TG#00A->"6UCX>%0VG)7I"\CL^9*:DWT=9`*F7(!
MI:?6@D]^=2=?_"XJID_U5WS/F;`T#P?Y2$+APZV+N-ED!S;1!+CQ>=4;YA"E
MIOE&AL&5!R_;H@@S]IK`7IV*FQ5=3SX,O5SMP$?*7LT#K[:;CZ_KM*[1E(^-
M>L<=&[!OBP%3+WK]<<^ZQ`=]/'WXUN.GM^"%ARG_M_KL7=ICE:K<WURZ"Q89
ME(V-=UQ1X%[5['S6793YACJTUS5:MKMW_ZR#A0V#\#@<%WP&2!2O@4[04GR-
M8U\Z`SI`HW/-5ANG(R%=\BS3%S5[Y$Y4XU'$MTZUQ5>@UX%_9$CAI7,FD%K_
M82ES\X#+UU5Q4GS,X3K!8D@15G.X<3H=:"+691G_UC.7DH+.80(<J$RC(SC`
M,1[CX5+W%$E)I!9X!1>%=(!4*!3SES-PIG_IIX2Q0DKN`U?]MT"4ACKG5'WV
M\Q78)RBCEGI2I87FMW681U-,.#,Q%""S\!L/%W"O15,Q=%?PPV"1X59GZ'W_
M5E2%92Q?2(A1=(7^-X@`_W@9I]!@`]%W55B).Q&%S>>"ZH4ZU34\7X,6)T@_
MQV)PP`,YHG$M$5B$*C5[S(1<TQ(YV8)6&W1_AZAS1F0>Y3<VX4>+@C@U8A.'
MZ315[A4X$W89U[(L<8-;(L6*-Q1!N;@;A`A1BB>!?L0";Y)YBU-?O,,[EMB-
MH!$A`+`I>1)"HF)$QX<-S:(:>Z(IMM0MPP&"=Q$H5%5/QV<LLF$*OK,;516/
M9D*'^5)%D$,:J:1>Z=@W>+B$#,(Q?E(>?M).GZ5OZ(B'N"@GXTB!#Q@:.4,F
M1X-F1U20CN9-L[*0_*$I?/,M1=,9&GDNI;$KGG*2^AAMWAB3,9$B/L(>-2D@
MQO\Q9"IRDP\B/.6!DSO9'COB(QY2(^IA2PAWDS:9(.;!!X(W(3`R(D!Y(U*I
M(PKR($GT*D(944/)E%YIE%\Y@S(YEC21<1FA)N/A?AJ!%T"!EKX#DQ3A;$,!
MAO&1@,J!=F29EVF!E\7A%]<F%QWAET(!F`N14GIYF(B9F(JYF(S9F([YF)`9
MF9(YF919F99YF9B9F1(!%E[!F6C8F6'AF:(9FJ0)FJ;YF:@YFJ>IFJE9FJVY
MFJ[)FK(9F[0)F[;YFK@YF[>IF[E9F[VYF[[)F\(9G,0)G,;YF\@YG,>IG,E9
MG,VYG,[)G-(9G=0)G=;YG-@YF@U137\"2=[9G>#YG>+_&9[D.9[F69[H>9[J
MF9[LN9[NV9[P^9[R&9_T.9_V69_X>9_ZF9_\N9_^V9\`^I\"&J`$.J`&VIY]
MIID*NJ`,VJ`.^J`0&J$2.J$46J$6>J$8FJ$:NJ%"@99<(H0@P3T)FA`AU!;<
M]'`<>A&I0AHX`Y<=P7`*84H;QU)7T"QC1E07]Q*3P6HU=Q/!YC0CJAO"Q:(#
M49`8Y:(GP:+_*!"`:&]!>A#1@"-]U0KPD:)KZ3]+2")F^1%HQXT104^IUCHE
M-2CI-!.DA:(S(9C2MW&X4C:QYQRW"!?PAA(X=J2"8&Y<=@5=P#>20RJQF"EA
MAH<2):,0\A4L<SFH%3L09"M8_ZHP5KIP+]1SS\<U<%.-<2-1=,1ET22%HD2#
M:I&"8!)F7/)AV"`N8(*D[(%R:>,OL>1W,K%XWN,VKI$TIP8FAY5(;N9IWF2H
M$LAEID@L0H@[DEHL(<8]!:@0%T<OE_IN,.%D1C-T<\5@8#,I8!,(DY0UQ2>.
MGD%!F>I*`#!T2$.D6G6G/_JHA2DG5[-E(Z0G(<1A[.==[#I7XPIU_G,B'(<<
M,%J7;@8^K#-)(O.D*=$95Y%5VXHZ>D(;Z+,<V(I,T$JN1-=)-Z.N1*<G@68W
M8RA$`6!9"=%"F7=@2-B/L_H2_":C02,(\<>)]W$N\0@;IN!I\2B,`\1Q(70B
MX<=\4_]HKA&Q'`"DC+:Q?&336BU56-4GHON#B84FIQV81(JDA`2AJLWVKWXC
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M"K4RP6"_.S7:B+U]`5RF]25$B&"8&C0A=+7;=SBVPD249B.3H5."J$1RD95^
M]A)K$D7BXU841&7EE;0&J7M&V(K&D885-8Q;^KS2-V0`,H+#V#T7V'3UN'NG
MNU>JTVN19+COI'%NRGXN,J8`FQ*3$2LN171AE5$.S'QM.!PQU[DN&59-ZQ:G
M.X&5`1P<^T.K",1HBA+0TJ:;>R^,<HZ5AH=&LW41B5L5Q'#M.B@GRKD&^708
M#+U`'"SKF"LERBM\LR9$FL!K@V>=D3=]ZU'?6ZY-RU)X>").5H@B^SA:C(E5
MA8?SRR`V6CCN9,01^7<2&<'[F#)!_YNC&QN[9[QCZCLK"*>CAT-IZE$>F'PX
M?K0>?($6?J')]Z$?FWS)7WP@GUS)%X+)`V$*J$R\ENP@G*S*<06D??'*'?(?
M/6D><KP6Z:'*<G'*.\(U[UO+1`3+QOS+^G$[KJP5?BF8AEEPI1S-(H&&`>NH
MRU:.G&'-'N&RTMS-STO-WAS.XCS.Y%S.YGS.Z)S.U08%7]/.[OS.\!S/\CS/
M]%S/]GS/^)S/^KS/_-S/_OS/`!W0`CW0!%W0!GW0")W0"KW0#(W/VERY?`#1
M$GVG$4W1$RT(%8W1%YW1'+W1'FW1(*W1(=W1(_W1(GW2)(W2)IW2++W2+EW2
M,*W2,=W2,__]TC)]TS2-TS:=TSR]TSY=TT"MTT'=TT/]TT)]U$2-U$:=U$R]
MU$X-TNH<U5(]U51=U59]U5A=;6H*E3_!EUIMS%OY(\*6RUBI<$`,%F@MF*`(
M?"3BO%$9'Z2"AFB-1*B\:R<U$-<`D[:"$?XC&5^#QU^JS4%A'!SQ<I[F/\2'
M1*(Z;%]SK,Y1N7O]-7<JJP?1CK3+R&_+S0.'I>1WV(0J.7,J,D-SV75VV!RG
MV6;A/WU=:`@!V.SVPJC*$'N]%(2]EOZB.B)3V5[=%*LM*`7Q.WW*)>D3I+W-
M+=Q35\ZQV]B&VG[1*50%:I(!DZV02A-L5<1"JF9A.O=!2,2$BY+_S2KMC$#A
M;1O<C2(+X<Z>](DNVQ_<`TN?R"6&*B_C[:>4[1_SS5+M?1?S[35>T<ZPE*D;
M"Q;^S6RL`L270B*Q/1:HK2#UA$0C"I?`?2%?DD,O[&WU;1B(LN#O8M[QZ#3;
M/6LT%7(P2:K^,BZX*-^PA.(*,=L;#DM^VJ_0E[OE02RV`N"];8%P(0!M(843
M+MSD[>.)Y#H]@JIO&VWY?1_L/"W)<:.,#;#%/1"SP.*Y'2-TD=\7GN#;IN&=
M^>1>DQQ'3E5AS#FX;19C]F5Z#2`M'LJ;`C*<\L*N[2!=D^'56"Q3[MN/?2&+
MC8Z>9!"+#2AVCBBY$07K83.H6KMU#MXK_VZ55Z"QPG8%T`TG(^K<;3&BM>WB
MW*(7$3YP%\XU_I.@4)`<7-[A7`);"C0<9J%Y+=,WE6XW__K.,WZ+MB(-C2WD
MXH&LGUC;_U;C,V*I5U!RLLIZ=..RN>?.9O4UOG[I_/T^7Y/DR&[GJXX0J(W'
MH<XMHOW>0+YLH6[M9(8CK9#GSF&Q8;$[=MYQ&DYF8+ZQ#_X?N0>%JJ/</E'<
M^`@YS(;F_M$?4B[L;H[N37OH7>[BJ7/FT"[@LBT9J92$S':KA+YP+&7D,&E-
MY$$74OYK&A[QTWX?`XGH*>MIGA8A8X;EVK;IK&Y57OZ++US<'A\4A7@Y,`G<
MJP[KA28OZC$ML/\=;W`AZ9_>M.8!!8(^ZA_N'%T4USZ^UX9^[=_>ZD2O<V8F
M[PT7[?-NW\8]S$K_;$\.DT//X>T>H\A]"A7>;=$N7.2G,"R.QPC4'U6_%)+.
M*F_"SMWMWM;NSM5=1)0-X._"C@<AZ^$]3\1>\S^(WB+C]=\]?G_?Y@/.I^`]
M^+/][]S\7?4-V$\N#:+:SH%`$#N_;)+2CDIX^4EV^=(;]?T>HQ#O<:-KV*%Z
M\YDR*&U-HYU<H\-:]%D-$UN_XH*-Y]X(\@X1\8^Y^><1^ZTO$KK/U;M/;N[^
M^\(__,1?_,9__,B?_,J__,S?_,YO_'H[>1+AUKC&Y$K1^Z_-]C%O[L___Y@K
M(TNX7YBOSQ2V;Q1?#A+_3N?\+NK=SY@3S%*37>6&^;Z4EBT]6?;@3"JD4O,Y
MM/\I^RP`(:@5-H+8!!$4=+#@0H*M$C+$YG`@E($*"YHJ*'&A0HL)!VX4"'&A
MQH8,/T8,65"APXQ76*0D*7+DP)@06;14.?"*3!8G9?X$&E3H4*)%C1Y%FE3I
M4J9-G3Z%&E5FJYL]"P;`]A*A5D%6J1[<8U70%9\%7[;ZBO#*P;$?6:Q%^W(G
MU8\N!;8RT8JLWI4]XUX=:]"JS;M6/J9-&&#@X*P*_78%[/7QS8A^K^R$R!?;
M98*4">Z9NU9PP<M[,&HU2)$@YZX695[>&S@S_Y2-:P.3E?E0ZF[>O7W_!AY<
M^/#@5#=CONUXY$W9RT6*5MF9(66L9BU"1WU<)>;J#:F?;/Z3LN?.%3%GE8XS
MZ_GL9A?BGEX[XOGJY/5V=EW=.,'N0SF[ARB\AF@Z3R3RB$,P00479+!!!Y^"
M#)OZ%CMHOX),^.REC@HTJZS*XLOJ),9D@VXSBUJA3;<.)=SHP`'7<BF]%5DT
MJ,*WQAJ+NNDN^V@L&+OB4$(<URJA/!/Y&U*0ZJ(X:;_[O"L1J"C[*V@/UT;"
M##:37'RP2R^_!#-,,87:#R[*1!.0,8>\HLVF:#+CT*K^&,/NI!(#2Y,_^4PR
M[*KY&%*M1AHM!-$DR/\$S(Q+02DC="'&!G6QE2BNA&A*D9Z$J$WVG!NS4T\_
M!374J$YAU"6W%*+R)I^,0]2@`M&B\4(C9\4&M-6N.W&\/?M#5$U='151Q4<_
MHO(]@>SSD$J+\MITHULSHDRVLHIER%(#1>+C%$%7LY-24;\%-UQQP6RE.Q:*
M?+8R@2+\*BZ:2H"UVKW^HVM-/V<\,BN,TG5UJW4]XS7(KM"Z3+^S?+RNOW8%
M@<(Q\`Z.%F(/%QY1X;/HHG50>!>;ER,NK^!C(6KS5<]$S0`<-V655V:9MWA+
M@EFEE#*:&:&?[C+IY8@6TG:D`3,R::0KK_0P(I9VS@C6LKRMF=*CA0X*+:?_
M,WO::)^C&_!*+I?^2=F<?8JR9;'')KMLL\]NN6:EO/VI:K3?ACMNN>>F>ZFB
MZ\8[;[WWYKMOO_\&/'#!!R>\<,,/1SQQQ1=GO''''X<\<LDG)]PAV&IV^RBU
M*>>\N,Q=W1Q+FGG,J.?.B<)Q8KB`<LTA;_6"SZ"[*\>*I@A18JJ]TW??S?4#
M!]8IR!F!WZS-$'D'2C-[$6H8);9MO57WQBKJB_%&&UTJ;.2W?XK*:8M6$5WK
MO./>0+!M'`I[`4?N=_%BT6P3]D"R4XP%YF#<B:PK0(L=MO]<7<NCRK<]["VG
M:',RW?$R-D";Z&1VP*J4:U0D$O8)#GNBV8]K`':>_W)=ASR4L=)V;'8O!G*/
M6F]YRU0X=!D?^<04PBNA;&YRF;?`D$OA(4N.W@*V!P*N7`':27@(-IB`0?!>
MJJ$)KQQ2P1)*KH"D$9X0+]:>5C$0->4BS^U$]IS\^*I;BKL@^D"W&&)M)`K&
MVJ*0$K)&M<"*B4V,'!.UUYQ&_0]%<%Q-G!H($6I!CUL,49'V""<-[T5K+N0)
M5!%)XY/JQ*X@IRC0&_'8.$)YJ%6>T5YW!$E`)E7J>S9Y3LADQI`N-"MQA!*$
M^(QC(261\$.DR<]6H-4^O4ARDHQ3F&)4HBC&!.!$`3"=HK:G*(SA1R2(2E-'
M//-$PJ&0=*,$X+K<`I+W^/]DF4#:D&A@>$M*VL\E_?LFVUZ9QQI2$XXHC,);
MX-40(&U3@9OQI@DD&$XC<M.>]P1.%4N&SZ-(*GOBY&=`!3I0@A;4H`=%:$(5
MNE"&-M2A#X5H1"4Z48I6U*(7==!AHD&3'C9Q=ATU"D@35P(!^L:6&,V;7NQ7
MJ2OX,BC_*0V,7*K%)G:%?]EL3=LP:1?"T!"*CAL22@LZLDV2[U*>T2?RVB.9
MA33O6H#D4*KPI3@68(1*^1.0($`#MLU`KX4HL]P>1"K4MSU1>FFD8*%B6"TR
M,H1:VHN2SMYY4K\UDH,!.(_X!B.M$F"&*KBQ4'6:4U*RXHVHXL14M88&T`'^
MJJG_'KJA.PGER,-!AU#]09,&IUD0\<7JA(PM;%EYB5CC<6I/DVS+.*>JIPC^
MA`\K!.W?\(HC7:I6FS6\G&KG1,+4%36T<3OLS8174F82<*E[=*M(_%@;#_D6
M<)!!R_*PT5EMWHT\_>E.(Z\SUM^.S:P`C=0-8]LYAB'7E>==C2@=Q3;"#JZV
M]YJL&!%"D^LN1'SU66]W]19<\8#2?'`4)*'..D<]_J2SAJ.I=F+55>_XR*_8
M1:M@Y8(C_=)-I0'8(10QW-[PG+6XO`M`6+ZY5]BT%Y4NL9]"OCEB^`1BO!6&
ML=S.:EJ()C4H"8YQCO760^X6M,=7TW&0A3QD(A?9R$=&_W*2E;QD)C?9R4^&
M<I&=]N/DC?7%58YR/G&4D"OLZU)EB<F5":@SOG!Y@H`$9-'TXA,Q\ZT5!U8P
M5-K[WZ8D-LN]BR[!8-@KQLRXB6MYK]'R_#]Y;2>%+?K78>!\N&+9^"ASALBB
M[QPJ]F$H/L?E)Z2)Z:*XV@>I[@Q<&-MGI)[XST[^FQ%5I*$6%J8:-GO8CH,!
M"!\+^:_-DP9*55]3EO&P^=:GF_,F"8S&>DIZ<#^D241L9:$R?7`BN3*27F9!
M$%-8A(A&;9^I&E+;#&9I(9W$M5.8>2#H.!6]DYRSI=/:6K.L^K20]F%?_<?3
M?`UF6#LA]V)&DYF<'N]`AA3AO?\$M,1P/R4O72/V.UE[SW6N6R9O+9``F^/<
MOQ$2B.ZI]96PHFXCI7-@ZST(?-!UHQ_I!-I&E<U7X5WP&[L3J8KYUU[.C4?"
M[@\H;U4O-@(%S<UX^7`7#,0B2_0H2.I\.A1:.'GJA)YCGB<\!E.M,%D^%"8N
MTW7'4E$K9)#IHDE=X6II47)76[@?0K4EF%VF5>[4:S\QN[;ZZ0[&0#9+E!]R
MEU2>.KRKV!Z*-[:YC`VA8@MMS)D?F],:U*R#P9-;6MT'=CE4R,YAH][FO-!1
M#4$.;/3RIJGW$]0R.OKE[XEB^S7)ZZ#OBOVH^$UKXKUPY/YUYRU\>KHB],-2
MBKT%TU+_3]GWWO=DDJO5?C]\XA??^,='?O*5OWSF-]_YE`S*-9X_-AH2^BFQ
MJWW)K#]],A5,/($>_..A<!Y3G!Z.0"KG5!CES?0O>'*YE$K?A9)][@.-Z0UD
MGY,\'7!^:E$09S005R"(HGLXSI$X\/"(G``=+!$$5M@*F(J.U!$:W5"IAY@9
MRY&@&LF]SGNKQ>`\Y`J;V%DY*VJ=R*H2<9(_LA.F8L(.SK`<L%N>$LFNAS@9
MRP(86,*/BI`,F:,_V1,U]Q.]KYNX#>0<;B.L+$J(]L.\R2F[IP(0:RDI*/`R
MJ`O"-+*0/0@9(<(,ZB+"<%,6]@`?#LHBO**[@*HAEW*X."NF_X6#G"=JE(=X
M%$W2-G[)+K:Z%4$PA>X0'VW2.-OJPDD[,;0RB=):CQMI#D=C(/_CD@JZ+,J1
MN(/(-Y(!P@C!/I3YH_H:)SZ,#VE0NC^<-+13O5"$DUQ;O(`J%NF1ND9DP@/1
M+M&+PYC9#),C(2K!"D>JPW0IHOBJ/ZEC'_8A-/,C0;&SPS_"083PQ!UC`?ZA
M$]NPMU@"'1]1"U0AB&C0D"2D+S,S%SQ4L*^`1C9,0=\KF.WCC[N9N!)[E<\K
MH;\J,>N"%M@PM_OCG&3+C*`!,E@4OI.(.WI$&J`!L^"SO^=3F@_41P,YD7WT
M#M=#GNAB'0[Y.XP"QOH#DP3Z,HKJ*/^$'"@`A,B,U,B-Y,B.],B/!,F0%,F1
M),F*4BDHN)'>H*PE%#[?")WENP*4M!]"K!::24F6'*@77`[VVR9,R9'8.3/K
MB;M6V@W"BI=O1(H1)#X[$X^ZH#5-.L;(D0AE&2]S.8S_44H+.A"\&,BD29Y4
MNQ3.>!,PFXFVV;6%V*A+H4>+S#&F#$OQL#:#BD2A@(ZPZ;,V?!\5TQ\Q-+-M
M([;+^;A^^2N'H;LM(RS,P@P2LT;,TQ]8PX\8P36/2*VS+,!],L7X<`C'Y(EB
MY$RD])L+RI]2G"SZ(K:E,@]CQ)?]4)@T))$**9`L^:+U8+G6D!I%.475XZ.A
MJI:+$4>?C!/_IT-'P;$XL^L)::I%=BS&8;D??O&5!P0*+C22E0P1XUR@.UN:
M(&&F1NG![?&:A.._XQ"(5RM#ZW$1O_`+A93$\5RZ66I-?)$&CEL3X5&D/B&N
M\WR9AXPR:JF@IRLHK\,>?S(4?D%$"U(6QRH)(;+$]02[]FR\CZ&43C22@7,_
MMV!+'1L:X:&ULK`Y;!.H[N3,@I@%7O3.Q>%*HX',RG#*="DFKZ"WFXR0E`-.
MM3B3ZH&(25F-0ZM+&@U,Z-A.(B,>'*,EK:A-WN.G<O$)*X`/<8S%14*)?XN<
M5UM)+@.DR60GW#B%'IF/K%L\=X/&IRFSFQ&$+,32EC@S&-F("@VR[*]JRI9X
M)K`;J&34DO=04A+2,ZU!TY(4,E!S2XO:4YK!TS\%U$`5U$$EU$(UU$.%2)YT
MID5E,49UU$:%U$>5U$BEU$FUU$K%U$O5U$SEU$WUU$X%U4\5U5`EU5$UU5)%
MU5-5U51EU55UU5:%U5>5551%1VFR58F0)E/`58G0U5OUU5W]U5P%UF$-5F)M
MA5[=560MUF)55EXUUF5UUEMM5FBEUF,=UFE]UFO5UFK]56S%5FXU5F_-5F@5
M5W"5UFT=UW05UG,UUV1%UW85B')5UWF55WBU5G:=5WQ=UWR=5T3UUW\%V(`5
(V('%J(```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g267791mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791mmi001.gif
M1TE&.#EAO0+B`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````"]`N$`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`%MANX9-($&#!0<F/*@0(<)H#15"9$AP
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M`_J77X$!`L@?@<Y%]M:#ED'H8(043FCA7Q)B6*&&%V;HX88?=@CBB"*6R.&)
M(:)(HHHFINCBBB^V"..,,M;(XHTQXDBCCC;FZ.../_8(Y)!"%ED64D>2A>22
M2C:I7))/,AFEDUUA12544E8)I9998GFE5U.&R>675HKII9E@CHEFF6JV>::;
M:;XI9YQTLCFGG75N>:>>>799TX3>)2=HH(0.:FBAB!ZJ:**,+NIHHY`^*FFD
ME$YJ::687JIIIIQNZFFGH'XJ:JBDCFIJJ:B>:A%$K;0BB*NPOO\J:ZRTOFH*
MK+?:BNNNNO;:2JZ_UAKLK,0*6^RQQ@ZK++#,\KJLL[,"B^RTR5+;K*_7/HNM
ML-)6ZRVUT3J;[;CB<OOMN>"6N^VZVBH;;KKPGDLNN_.Z"RVZ^!9;[[[JTMIM
MO`#[VR^_[+Z;[\$&$]RN*1.R$@`+`93P<``F3"PQQ!5#?#'%$P<PL0DE0.PQ
MQB%[_'')(W.L\<<6L[PRQBW#_++*$;ML,LDBGYPSSC?3O''&-<L<M,\V_QPS
MS2F#O#/%*.O<,]!&SPQUT50+'?733?.<=-9$6UUUUV!/+?362RN-==E'BQUV
MVFQ+W;'39)_]=-M#JVTWW5?'K3?<7]__[?;?==.]M]9\>VWXVH!?G7?A3)>-
M\DNG1I[JY))73OGEEF>.^>::=\[YYYZ'#OKHHD?^&F^HM];;ZJF?KGKKN;'^
M^NRNUQX[[+O1?KONN=O>^^Z^V\:[\,'K1CSPR/^N_/'+&^^\[,4GR*"`!U9/
M_?4*(KB@@=A/G[WUWW?/??CD>V_^^.=+C_[ZZK>_O?O:QP]^^N_7+[_X\,_/
MOGY%\NA_D/\C4@#[!\`""M"`!#R@`A/(P`$Z$($/7&`$&PC!"DK0@A2\()'X
MA*<.<O"#?O)@"$%()A*NR81P$F$)1\C"%;KPA"V$X0M3B,(]Q9"&-[3A#'4H
MPQ[B<(=]`J)/_S)(Q`D:$8-'U&`1D<A$)29QB4YL(A2G^,0J2M&*4<QB!I6S
M*J1T\2M?Y*(7QPA&,HJQC&@\HQK#R$8SMC&-;URC&^<(1SK*L8YXO*,>X\A'
M._8QCW_<HQ\'"4A""K*0B#RD(@/)2$,V,I&/7*0CZ4C%*UI2BUC<(C:H0Q"V
M;')$OJG1)RN)R4O299,*&>5O5)G*%QGGDZ&$)2M+F9A0X@B6-)HE*7>9R5Z:
M\HD_[*%8PI+#((9IF,,,IIH$<0467&$/OH'862#6BM^$1)ICN<@U!!&`*TC'
MA,C,"C98T0I6<,6&K3(G1;C)@G8^C`4#B<85FGD%00#G&O-D02#4"?^35K``
M"@IAIC.AF99V0HP%)?`F#\.)SP`(0B?1N`8Y!<**=MZIH:>$$D.)F4UEBC.;
M&ZTAF$(*DNCACGDH?=Y)53H\EKX&&U=(6<@4XC&!M%.=FL%&.ZLY.VP$(@!6
M<.GN,E0[G0:`%=`;$3>A4$M!&#1DSL2&*2CV3X]=82"MH*K(^+D6*P3`+3'M
M&#P)\DXHM/.J*S+I;R`6"+P\B)U8=>90$V."L38OJ7==*5Y3NE>AYE5U]M-?
M_O`76,+>KWS[^T]%CWJ6A]GS&A"+**6\EQ9N*G0[D\)L8KW33GO2;U&!L*AT
M'$O3J$KT80*Q@FACJE"49/6AXZ1F8UGP6(C_V7.RJ8HI;`V5U=:"2K>%1>Q@
MA1O<SPJVN)N]'B]_R5Q:+A<M63WJ0.H*6XJ9TV/V=%@)?HI:L@;`(/X<V6,+
M$E:Y8D,0=;4E1L*:4%36=)L/(XAM=7N69CX,K7MQ&`L62Q"GC@RIUWA8Q4HP
M$/^B5B'VI2V$R#LRA7J58P#^2\5N&V"'$L04U,2&5^$)4]&>,J8\C:XZJ4M6
MTQ(5NP?EIWU+8(6S9)6V*?8N1>-KU,>V0K7W'4A,12:(:%`L+8M]F#FQ@6+L
MJJ6;NO2E<Y7\W"9SB*1UBF0PH;PF*2_THSQ9;#6I@TW9OA@*_C0M-HFLS^C:
M,[R"$`04+&Q9:^HX_P![8`5]R2R0T(YUQU`(A#T-"ED3!)4X+Z;M57?<BM!^
MM55GK>:+TTSCG[(@&K;UB&W]^U!Y[E0@JPJP@DN,5OV:TZ#^L2A$M"PHV[J9
M(>&]@IQI?(6ZMJ*9\%RLGG=<8G,Z]<X6)G(``A'FJ[*"FU9XZ&+9XEB'?9?,
M+'BUJ-]\SI]8V9A4KM*S5<C1G4A[DDMNKI.UC<6LFH"K;JFI4<VIWTW&-!`R
M/N_#-FE9\MYV#TC^:5`3\V*"5)3#XG884XW:UH(&P+TLP)!^.[G-*PA$UP>'
M&%)AZE!S!\`4/D6R5"/SZMNRML#=C%!T&>9==)^W8@39L"<W(_%K>!O<)?^^
M&8=H?`V);3+#.C5!-6D<W4V^=^#86'-;"]U6=2L4KB9GM<2!F^%Z(SC9V\ZV
MTI-.2DE"$MM.C_JTIP[U0)*:R]^%;-8U#1'5HA7DUYBJ;X.#88A=5>Q?845Z
MDR/D\ZXVUR7^ISMCPO4G.3H`D@W98V-JUC7K<R`I=D_9,^[397^%M!#)<="3
MK5/#B[&B\XYMUK$^3T'T^TD5(W;`R>Q9:H87+31N^ZW?O-OS;GBLO;7WVV'K
M=<Y+5;1O/B75GTY[J5?]]K6?_1V9SN3><_N*(AY(('A=ZYB?N:X$B2DT$:YN
M@'92(8L5Z%5'_Q>C/U_79VFS\7USWWG.LY:M0/[_;\)Z<ODR-N;.]#Y/U8WD
M6D:?GAAO;60FW,F(P=:_$-DQNRT/(1][T\4>HT[#MV4YEF2:=A`>\W);IW!U
M%W[_9E0SMGF19G)F]U,*90KB9W07UU![EG4#!U;'MG2^)X*_YURZIU%8%A77
M5GLH"%)4L8)11U&R160F0%!=EG4^QGCPIW5GX3`_-T\%@4UMIGT<,6S3I%`'
M1GTQQ3"EE1;EI$TYB!"MQF%CUEFDMTD391PL8`)791'\!5][0!!VUA&S=7F*
M]V*?]G8<]A#+=G44TV^F-D;A16PF4'R?YT\$-EO%IX2Y=F#-Y'P^J'IY.&=F
M=54/`W&C-Q$Q948M6&TJ_]@3T]:(5,9!D2@E(:56F)@\?*57G-A2?2486PA-
M:C=YXJ9PXR1T'D<Q%#53#">*ZY9S\094>K%3ZH9O7]5\YO=8TW1L.)<7'W@6
M7O58XE9CFP1O5S5N#$=N0-46Y99S7(AQ`*5>(N869I=\R!=QCX9^ZM5.=K&%
M;36*!&AB*Y>-H^APCQ4R>GA>+J=K$,%.!`$%)O"-"<AP/_>*1@=7R&B*UM=R
M\[:)GMB)F?A7`>F/`UD:MI=[N'>0"JE[#&E&\)4S'J=U$,&`.3B1[><Q;H%C
M!R6#$U.-VD<<[&0RU'A0[T1Z'.%?!S5>$U&1*Y%@$[-EK?8P$;6%$Z-0X962
M)?^Q6"2I4$&FDG3H69*7,@O7"FM6,6`7$P[#A`]I,A$)-!F#:0T!-&RE>AUY
M53<Y,1[G3@>%:P^E:1UI5Q/#"L:F$%I)>*2%7GD8<6W5D`C9E@N9D&SYEGC$
M>R5(ER1((I;W*K`T3P(Q3^;T:C\(6]\'?<RT<"X6"*KV:M]X!9=';X*P!UW)
M%HCY4/4DAJJ64<S48Q("F'O!3-Y4F&YA"O7$%J:`F`>'%IEI$)AY!;?"F`W!
M3(W!E\'!"GL0"!Q'%[^69A<">]FG9Z<)4X@Y3X@Y&?%5<;@D9WJY>!)UF6BQ
M!Y7)F):I3H7VG%UY%J:)3V$(?8@Y9/AT!1%5<6B!4.K_=9=V69XC6".3&$)Q
M*8E8!H,G:(DIZ)"&-"C;@1"G%B;_\4WY$4>'99\]<9_Z.5QM5%%H]1W^:1.?
MEQP'&EMI:1V9A2B:)2C<M&40!8EP>2;19J%NJ289ZFS89IYU>9XB&J(D2IXC
MFD5N1201LWX;$F!U6*(7TA@P>J(@:J*N%)<X>J$;JJ-RV:,YNJ-`ZJ,\^J.*
M5$Y`64?1X"I#FI#20:1.NJ1!^J1M6:-42J-6.J-8:J-:ND57NJ5=6J59NDOO
MZ23IZ:%!RIXN6*%1BJ'QJ:9".E)M:FU06B9E6A7K"9]I"A9$BJ:.J*$]RJ<=
M^J9TFH(%^8D`J8E^19"(:JC__]BHA7JH`KFHD*JHD5JIE'JIB9JIC/JHCBJI
MG6JI<RJE@BJJI!JJIKJFJ#JJIZJJJ5JJK;JJKLJJLCH18.JE89I$J/1\NIJK
MO"I+K;2KO@JLO]JKPQJLQ"JLR'JLRFJLS%JLSIJLS0JMS[JLTQJMU"JMV'JM
MVFJMW#JM7_JMMPJC=>J>"0FH+^BG8WI,'Z5:7L<"[?JNSN2N\0JOS42O\EJO
M\YJO^+JO]]JO]OJO^NJO`0NP_$JP`ENP`YNP"+NP!]NP!ONP"NNP$0NQ#$NQ
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M'ZA[M:T;H<B5NJNZNH1B'J\+';1+NY2UG[@WMF'[N[YK(JP`!=[G?1HVFOT%
MA):)7U\+O`_DF0HAFO_'"E:`O-89;.SFFLYK0.-4O&GF&]__AYIY=A"!8`4\
MU;QT(;W%>W97P%0'$;[U97`G<@W52ZNR67"J]A978+[)QYH85+=R&TG@Y+&#
M&T@#;+AM^[<O)!2!()7K5HT#H5^*N&L@&T.!>A65N,`MD8-I88SR!<$3"3'Q
MI\#"1,!R>UHD*9XE9A`[9I6!A[>'B\%F%),DV6+<)``603$V=F`Y,8/H]6^)
M-Y48H6E<":3!B[Y(3+8_0E,F,%Z*%X1X-TW[-9Y'K,26P8#$"%E\EA90H'<^
M]8Q)?$`_[&\$Q:L8B86R^$H/8JRZZA9L[,:Y>DI))B&D)88B#(+'J'\4HF'/
MB`W&N$F!-E:`1XO>2,4!Y+JGF\BR_[O(B*QUNR7$'YQ=F=>DBMS(1GM6@/=5
M00=KX^5.TT=XC"RE+\;"`;!OW565(3G%VV10ABE-S:1.MX9TF1QF`0=D!@5;
MH];"[9$16`Q?+PH18\B!:01?"M5._<9-[EA:N\9PI?=L5;R]T/S,FF:&8$P0
M?[Q4<QS-83PA[89S@B``>F9A]?62%FC%">1V4:R-%69RCJ9JJR97#95G<?B5
M,]E->\"`7AE:)A"-^H68]N@Q_JRQ,6I_`35F)N=J6@Q@'A)FUP!I)0"3WP9B
MX2E@6<Q`'@6G"!RWU#9E?<M#%PVW%YPE<:AUV2D0HU>('9VG'XVV)EPFP[:#
M,14-B=AX=O^&=B!]KL9TMC>!PNI$:W2F@*'I831V;YELF#ZV;XEXQ]IGA1()
M7SUGA4(17H:9S/Y63ENH1@@A9!R<R1W6A=@0,@WLS[`UB8_;N:+[N64=NFG-
MJ*['::'43I"V=6<]UVO]N3I5`@VU<"50ARVW>=>P9G+&A>*(UI.;4MRDR3DG
M6AB9;J>U;R_F??,H;A?6?7K<:&F,SQ&5?.WDG&RE2H=1QU\LT,GG4&*'2J9]
MVLS<;K-5$*`L3085C[84/;$[VX=E7(9U7+6=7,25VP*J'B,-R:1'8[:]V[A=
MW+>-/S_%3J.&4`(U>9WEE;XUW-*MV]DQRF_V?SP<6?TEU`AU5GG_:-`O!E6J
ME<G91WA>3!P[!E4L4,;U63%3_6.^T5M6F#,<<S-NYTR3=VO-75KE-#'-G%S2
MO,T";L[C:(;ME1>.-M@#KLT?$EN@MI3B=84'Q;P$OL08YMR*C=>UUH-#_8IF
M+',!Y>&CE(3[K(!#%@A[T)?+;-HMBET%C=CA"570%0T3E:2M$IY;F(WXM-<>
M8P(@SH-:UW`+)%(;[=%&GM-'7N1(ON1*WD%Q_<@K[H1A>9\K74Q-3N18/D;^
M_<''3'A6Z%^7E>19+D3VJ5\&$8PK3-[;#9:,=]AJKGG6O&X)NM1_!^3MQF]R
M*M65Q7(KH962<GIDJ<ISYH=Q>-$!7N$,_[Z]`%U:=67,F<QXB7[HB;%5)MY?
MZZ9U3%A7D1?I.'+8!L7#B\U\*(P6+3S/(3C.SN3>W@7,LGA:@MW:W20R"KA;
M>Z'#"L%=!E7+W`3&+@)ON>9CB+V!V.1MC7G.MQO*E7SLEOQ(9J64\,J$^93L
MTH[LR6=6;.&NJNE,J;5I&/;?U/ZF_D1/P;96!C<09N463N5\6%6(%'KN*'%O
M_V?NM5Q1V=G0^<2$$"'3Z1?HE\?+LBQ1\4I/,OCO=Q1FTFE>%%C,D!Y:AGF0
MDO[P"UZ>L\2KJX3H$-_@%;_'&7_Q>SSQHS3Q=H%+GB0A(N_&'4_RU%%1&+]@
M(,^]V2S'&,31&/]]TTS.ISJ=T8);\S&<TM4F\S3_\V,.]#P?]"R-\U9>]$)/
MYG%:RTE_Y4,_%'5-UX6MUE,_NE9/V)D;]5I?]5AOUEN?]5PO]6`_]EY?2[Q-
MV\9-W,>M]FP_W;W]]FB_]FX?]VU/W78/]V>?]VD_]WHO]W=/]WQO\1$_^()?
M^)QN^!R?^(2O1%!"Y60HYD<?^4H_^3X$^92OMT%O'IEO^96O\TX"H/\90I.R
M^9[?^4Y/)OGY^'62^J5?Y5\"*+]"?"G"3!2J^(@OX-NT3P\"G1["3+2*(H]9
M3JQY$)!98/UF^QI4$,.74?E[(GIF(K6)3X$P$;1O<I=Y^R0J9_ST:[+_;\V/
MB>+561"6=[X#@;T4P@J^&=_0V9N&C.AJQ`("$`#QSWAM5,C?KNSX/^W1$6B7
M[G8RG%4``07;-6S1!A8\:/`:E`#8H+!H>(U5`"@$!06X@I"@0HT=.7Y,&'*C
M2(\D08Y$63+E294M&;*P$D`0P6LP6UZ[$N`:S9NM9+8R(9,@"Q:!!N;<V9+E
M4I--5SI5"I7I4ZH(HQ$]"#%`T"LT(08-$!%;(!8E<G8=>+&I(*T!6&0DN"?H
MP4`!C%:=&A6O5+X[:2:U:()%JYH!K&`[R!-QX9F(!P)VS#/I8\64+4N.G!CP
MYK^=+W/^[-EO:-*C38,^+1KU:M6M2[-^3;`$_XO%&+'Y9%4:XN/%D0'[S'B%
MJ%%!@I-"*:$0=NK8S9D_7Q[=]7-L$W-CN]AJ+.W6P'M_M\QPI]L20P.8VME*
MP.'ITIV[A]Y>_GO1.0EC=SL0(BN"87L3].XVH7SRR[.K[+KF(A,(2S`LGHB*
M!CX)YXOO->T`3.PBM%II);>:6$COK:%8$*25MW+3CA6RKN"/-J)8864P`-FZ
M8@^$6(`B-U8>&HBL5@01[KX+;SMH2".+1!+#E(;DB,DD.W)222*E/)+*)ZN<
M$DJ2HLRRR2VOU(\[;&R#@KTL+[PF@#UH$@ZGAR![*+>'W)(((YI\:LS+)<&T
MLL\S^?QS3T&U'!3+.O^3NHB5:'3BZ4C[!FIEA3U8$:ZQ"P6[#:*BL"%*D!L'
M`Q1+44,EU4\]"45U5#^'M/.H5HF":[?_TO140*,"X*_+Q]PR9:"P&B-+K#IS
M7;740(_E,MDM"[2,E:`:XRDL[2ZBC5.W<-PJQ;"N*,&MKC1URU.@,()H!<2D
MK1-$AP2S@J@`&$R-V0+CI9<S>>?M[-YY*=.WWWKS_9??@/$%V%[3L#'%6Z*N
M(2NTI!X=D=S\:,(4FYSVFTC,#P46V&"/"P:YXY`)%KEDDD\N$*(KSAJSUI,G
MKBZLMR""MB[^TB3*1:$&FFBFCTW&%^A]41XZ:*+]_?ED_#PER`JS]-O9VW#_
M_:IK9:S>XFW?<7-EI16%+M(I,:P&-KKLHL]&>N3$.F(+(P\'"FJGB=`:SE7^
MZO)40\1@S=`V3DWPU*W<V.(NIUKKQHPCGA0G:?&U4W(\\<<[BGQMQB%O/'/,
M-Z=<\\XY-X@5MGP.($++$\M);%Q]9>%K7)N>>3##'@15<MM/O[URW3V__'/?
M>P<^L1CW\%1$SUN]!K@1X1I371-E>K?3@^;&O?K=09\\^-QYS[[[[6FZR/1K
M]IB]>1O3Q*C==^^TX@I/Z\H=9Z;7#G9M"*WG_OO?O<>_0IS".M^8WH6?:M%L
M)RP`G,5,0)R*[:<WPLF(Q>QB+6VI"R)W,9S_)D0?_PYJD$(;]&`')=0;F13D
M9J"1U5`2"!00J9!-,CG+PMB4G!#6$(0W_&`.#X(8092G.O<Y&/4(DC%7-4:(
MZ/L01-#C%[_94(=.%.$3W0.QVX#%+27$SG5H=IF"K(Y#0QJ-3UZW&?R$[6&E
MDV(:H_@99=W)+0(IC-Q>1:*"Y(0_Y,O;'.?WO\;PC5?8&5L&.;6I-J+J5(<T
MEJIT)25$,O))C5PDLA+YI4&)*"?;JE+JO+(^GX#*66;RH\HX0A3M*!*2A3PE
M)5,U24>V4E<F,H48W6(4,.+)C598GJN2\CR+:4I<5103EE(YJ&$:DI62).8C
M>\0HA/SH6UB3C`&S5).,:/_%)DJ2WVV2AY#ZC>1%JBQF.(\9)=#`R$,^69``
MIY4?:_6QA!D3SNJL=4()GL]P%$Q7TQ981#5"T9\X7.,_^[D<_/S/*UV!#%*2
MXL",[<0^9S3*Q;BS$RN8`*`"#>A%08@UO]GL,K89(ITDR#1VCD<GBY)F\A"D
MT8&V-*/3P<_;DG<A`_ZHC_O\2R\'&=*[%*E;N0K+7<!FFK&Q]*4=5`FU``01
MD_),CW:+"ZSF)SW7&>5O@6/!X`*Y,\3IQ:MY`6M?OBK6L.[%K&,]*YZPL0*T
M_.]QV=DD85#:'W49I%T9:5M;QZ37LJ+5KWT%+%F=TL/J)+`_>3H(1=QX!8/P
M;0__=%QJ1"XVOT`D,+!GO>Q?!8O9QMD24NR47EVXLQ_)$.@:3^N/7L<#6=)N
M1UA[Y6QL-1M;UFAJ3H<18(VV,EIO76R=6>V:=JS5J\>THEM[N*1YK";2G*T,
M74;%:'2A.UV7+A0N<U,1%DT#TJO&C#87Z>G_`C&B%B[MJ-*M+G6=NE`2F0)"
M9"2?Z1)6.*'LID`.0EA8EHB-F*@7O>>%;E$+<X4Y,=$P.4D.O[!HN%8PQ$.`
MD:BF_#+4@UQDC_[%L*H(ER,WDE*/U&+:AZZ(->F-A%+>.HA[,4*X(@8+/<B$
ML3"5*5N6%%*1-YYQ)#-[*D.Q12,F(F6CLF)&B!"FDZU(_QU''G)=C"A$DU[%
M<;&D'$DN[?B8Y^%)/*]02B0!^;.X'.1X$=1,^PZ2:9ZM2I1C;"Q(6GG*6,I)
MKTI)/IAL9DXL"HGQ"!(L/$/.O9T:23?#M,HWCW.S4/*78V9%D.],9H<'X=9U
ML-$M1G-1T96YM$-*8%6AI:W39$,;J#U]-%&7.FEFT]?C'`TRG$T&TYJI=&4:
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M[G?'>][UOO>]/P5L80%\X`4_>,(7WO"'1WSB%;]XQC?>\8^'?.0E/WG*5][R
ME\=\YC6_><YWWO.?!WWH+;\:(W-HIJ5'_>E5_\75FY[UKW=][%,/^]G+OO6U
MQ_WM=4__^]W;GO>_]WWP<P_\X0N_]\5'_O&53_SE&Y_YSW=^]),/_>E+O_G5
MQ_[UM4_][5N?^]_W?OBS#_[QBS_'F$'_Y-*_?O6WG_WO=W_\X3]_^=>?_O>W
M?_[QOW_]]Y____>_``3``13``B3``S3`!$3`!53`!F3`!S3`45NY@Y$,>9E`
M"P08DX$V]\LU6%LV"N28]6.V7?O`$AR8M5D,R*A`$#2-"#'!S(`IM4$_9K$V
M"C3!;DLVT5"U`?0+,#(;+II!$61!]5/!'3PV'-RV#*S!I+G`7^,U(4RT%'Q"
MHYE`(CP;*_1`;:/"J4"?W%`<:KFB2DF)2\*=&&&(-AF)]1&)_[HH$ID9,34$
MB39)+,2*K1A1F?(*'>&`E2HKN(;S*\*!%2_$#CU\"^9I&@@2Q&MPK[Z`)NQH
MET!\G,<JBY6AG$"H)G!)J4%LKK<QD?D1.'.[F!&#"YP9L=D0"R!Y"S-I+(9C
M"97:);)0&4/$!N3:1))8F?_!1#-)$'<)$O!YK4\4*TK)F4W9'><*,J=8E/N8
M"B`C%V6$BH1IB,Q*GK>X%@A[0X@0@)D+Q7";0X>C"H*:N`@:#1_3#*SAC049
M(--`P[1`HW-YL"QKH?$0KEA##1];J/#:)6A!C76LD_M@B[=A"Q=DN8$\F"!Q
MC`ZQB'0\BO+*JL5HG8&X"N>@Q`/:,O_'Z!FQ&:_%T,>A((B*7,*W$*Z8";8N
M*CF,`I5K@XS>D)%I9#13@".+<1G84,,8V:,KL*C4X@E!$(";H0Q0L8*0?)Q&
M%!"7F4B4XZ)_/$AHLI>BN!,2@8[U60Y^5*O8(!%UL2%`FL>)8!#PL)B[0*%Y
M]+4Q(9;IR@L3X0^Q4(B)$(DT`0RU;!\EL4>-4(O^$)(,H0WMB`83"#BHD,/&
M@I:.T$-6=*J0&(O#Z$0D(3`ARSH_K#%5@C,P`R/]Z"F#N`HYJY:.;(P5F#>G
M2!.^M$HZBDP,`1*.I#F.Z$N+X:L^M#$^Z3-CZLBV$@2C,`A.X;?4?`JGG#'(
M.AT]@Y3"B<S_"_$)D9A+7TE$/US-I2K.FD`1)($"U6++RH&"C.1"M-R5\VL=
MM30ZE7HKVCB)X*2*UNQ.L3A.GF,-<B3&"HM'G]I*R&*F\:"G'DR*U?$,X4A!
MJ)2/N*P)KQ0-)`-)M;%$A)FHOV`4HQ2YDYP<<V0TT^*4ZZ@)[7`?_^E*ZD#-
MM-"8"6S(F@`0\4$-Q)C(Q"+(&YJHT(0,$S$2=:D.@;@*"C&CU;!/:"/&A<J5
M>+R/(M'+M;D"]HB+MB)0.0*-6_PH-*$)*#@?SBB=)H2TB>(-W3P-3LF;],0H
M<CP8O82.$-U!%AC)CH.WK+((JQR(A(E$[HP9-F&>&,'+IE!#R8A+_]RHGCCD
MTA*@P\\!L@!:DH;T4<6Q4L;LP[ZJ$TV\10'%LQ]YG8-HSA,9Q+-*DS)-"141
M$Z<$Q!=3"!/9%1K)F>I1U,>A1&!,NJ*`()!LG$NML$T=""O82ZJ(R\OI1,P1
MQI"($:\(A"7C5(,@"Z]\"$0=DSP5++,4"?I$B><$3+3X0C"M"NW$C)V!G(DD
MK-+,'ROP1+JHJRW1U)FIR)'P46_4"-A8U:R`%T`2MXF3H:,8TWB<"-AHGK+(
MF=D@M_LJUQ)XQ\NPQZ'`1]5`C(F(",A@"^)JQ-'8E`]MN179LIVPL`<2#%+*
MFLLHK]CHS/D<QMFD)J>D*"[54I6J%79D%O]"/,G1H$1]I8^I#(S48(7RF`[W
M04D=K)'3,!%3S$C:Z99X9!.F693&X"$SRA3#0![>@$J,/1@?.4@(.ABV6-+A
MM%AQ7(YVF8R2U4_>B$N>/2J:#(V:30V-Q8Z;I(D8,3E5"1)!$!WZO!#KL-H2
M81R9V%J?N`\RA8H!VDZKN-"U@3/G85+%/),>`ME=?=4(%0G=+*:JB[K8@JMJ
MC0@T,Q&]`B-/>JP2`1,">1*::%F"6(%F/<0A:E9:Q8F,N)QH<%.X#*:@T[%X
M<QPK.%F$4%>V?53N<"^0-11*-)3M&-7/&DNTW,S7)(B'&,G'ZBGM:$^HDS'.
M$H28",3;I1SC*@G_2U3,/=!%^0-$*Q"(0%4<[QQ,A2-4*<$)P^23$>6OS47:
M3T0:344N2X19I,U`MD"N&ED9.#K4>A%+CM%5>4S"=LU/DR&<C+R,7BP0](U/
M@B%!+9S"4`,DCF'*L+$?A,HID&6+%*F=CIE7M!D@*,"XG5B4CI33H"&+U@A?
M2./?')3@)%3?`.TE!SZ@@8C.'AG%?>E3>KE@HU'0#]87'Y/#,%)(MIS@$>PU
MQ`A)W!R-9!28HOS9'DQ%"&J?,HDVY13@X.J:Q^J:^IT,I`P-!:7@7:0,J17B
M$V2)$\X*:/%9RE%2`;F0&YT<9CI3N0RFU0FKQ^*)%7C3`Q(1R3&1R9P>_U#A
M"%,0`&K%5*\:CRMNA0:F'$$P%\51XF8=S<9I2.VAHVE%B("LU?3[F@I%"24U
M8#REULJITTPYW5$R,HW!L^XD9,K!3F?%RSWN'DK<E*Y-75N5+<>YUI28W(Z`
MP\2`U-X19+OL'&'<U!A:73=NSC5MF>NIGD46-V2EK=904CE"S^X0EGMTR/G9
MFP@:WX)46;*E1]%H5TYYU]L`2_`P+EE[&($0FPMKN9(DL$>3"U]QF=J(R3<>
MBI`4A"&=3W'L(4>[7_>,M4WYSR.M-`'Q5X]5-/C]Y6N6CD#PH3;<RL<M#9A,
M#S#;F]48DZV<H$=S4YWZ#CE<1)I@PTH#V^VHC/^+R+((+DG6<#2U:EID1LWG
M2,?E$)]X/5,R>C0HG9"&!(]Q;(C8D&-]!HS:(<O&J624*"%%I$X,X<VL%4]N
M`9*Z6)/$JDN&ODL!<9^A!A)B`<QF)5;`!)*E)NI>8NJE[BD(NEW0S#$^9..J
M!A3Q<A].5:FW`!)!\J;-`&-+%!.6$):$N3@]W`R,&&H6.)^S-0CA4%;G`@RT
M;FL\Y*^_%+CQK!(-V>J&!$YFXI+;#;0:^4=T\V.I<BXH9FM4?,D28+@&N3BB
M&$GA,&!Q^R::*-*]=DQ3;NRN:I#?:.Q6:6)?]<RV;L>0@MPD&<XJ(9]=2@Q\
M?FKWL1&%F.G=Q3)VG&S_3%;$RBT45BJGL>0)&`&0]P0,05".SJ@W1I,(J_6U
MY6Z6L12$Z:;NZ5[7'MRCK@F-ZN9N3Q&=[K9:TQ"=R-[1D?MNYMZE[P[)T2#N
M9A'<^,#/V[!N'6P%4Q#<QP@V%?R16.(BFQ)N_)!"FXV.>)UNYDZQ;$T-6DL,
M^R8H+/N-Z?9!%X;PQ?GO(2KP`$^>Z7ZQ)+5F`6\4"`]PT?&,_<XIYH#AY;`I
M'_17(-H,A-S052TG\+[P#">-'T$3`G=9-TJUZ((WA3-4_FG%_,L+FDME]M,>
M1$9R/>6?(N\?O?A/[.$<(H<*QT$RJT[R0\-EOR)R#(6_(Z?E+\^0<O-D?*/E
M_R,_B9HPG2&?<BQ'LAZOOR"'\@6]ZEVUYSKW\#NO:#NO:`PO[\_@<SWO\QHR
MTCSO9T`W=#R'#81"=$"W6U.2.J?[;:UCND?/++ZVW)W#.D*CW4F_.J*+]$VW
MNLN=ND]O=*R><RJ[=$X7=4C7]%)W)2NO],Z6]%"'=:FXP?E%0A8^8EWG]27.
M=5_']6!?86`?]ELO=OHU]ETG=F5/]EYO]F5W=F27]E]_]FJ?=F$_XBL_]3;F
M]C'O]FWW]G`']W'7]G+_=G,7=W0G]W-G]W1/[D6'=T*7]T"G]T.?=WNO]WC/
M]WO7=WSW=PNANH`G]6,2IU<7^%8G>%-W351?3%=G^/^%5[J#=_B"?WB*=_B(
M;_B#YS'+M7B-5_B)5_B.S_A9K_B0-WF#-[IWA]`@[/?SJL(E9/D5=/E_/QB8
MY\"8'W2"BL&`0L&6%W2:+T*9%_J@QT(6W/>@WU`*R?F8UWGG*/JFIPZEUT&.
M<_.O\5Y+U.XL#RPS4?133YY`0*XT3XNK9Y&*DT7145:9(G,D"X1`<,9UA^EM
MO5YQ\Q2.N%I!&,E_`Y*WMYB^V(-:JI$]$/LQ#.,X]H@:J5:R]U05T7IW)XEQ
MWK)6!)+'0;+WYB;!Q)RNKXZE'E4DN^7*61.+P/J98_OQ`I^Z=WQ4984`.MX:
M,7UXXQ#FX4+97_/I3GM9%GW_%JGUOYANW5]E4S#CIXB&:)@4E&CS.8<-O!=0
MZS8%5A[(@=:/ZV:IA[#:/WN0LH<1LC"3<&6OK7T3?PJ3YM\1'3UT5C"%YK?:
MK@EI'-G:=?Q'_E1)XQ:V1HP1*T!_8SN8]BDO?-7'7KK,L0"(*Z98#13$ZAHV
MA%>L)$1X[6%#AQ`?2JP8\2)%C!,W.@S$0I!!CZTV8A/$(D"KB%"NM&+U,2$V
MEQ8S9F1Q!5M#FP9-LH`HR,055B!MTKS6JJ?)0#MMPD3H,BC!CPY1:IS)L2K6
MHM=8K60!A2:VHU`%!0B$4^NUK@$:9KW&PI36JJP"C&71,^Y6G4*M"&IZE6*@
M$H%8_[&Z(CBB*9M$_T(,9.4*TXJ1VUJUFA+AY831KFQEF3``JZ8)7V9V&!9F
M--$(4YM>#3/`1-2J3V.>G;DT"[.FB29<J3IRJ[6IKW!N.A<;:]K(8=YF_K(U
M\^BUIRO/G-RZ].70%08R'4`0=-8]85HYB.T*^.K2!95`':@T-MZ9^9HTG5IF
M4_3LFP;2/3LU"^91U]R`V1&HW'6R3>?1?\;U!)M#@MSD$`OB'=A<?:^EA]!Y
M#%US17((?=?:%69!\5M?")D$7W*LF%`@C.K%B!UUUYBDW%SPH12C46M="!,+
M>\R(VC4[YL>"=K0%%YMKU"47S6:B!1=::0O)J!Q"4D473?^`V278)(+,4501
M1*VL*.)(%XW85"N!P(61*8*D25.;<Z*9D)P-I6BF@&/:F*>?$3%(9H59"CGF
M>4C&!!M.STUDIT1I^N4G<;/YR1&BEY*)%J=7+0E3I9-2A"2'Z,5DA:81001A
MIFS=:-J-KV9DJD\,[7$70N6=I:I#P565Z:6\8MKIIH^NU9JF/06767^[KH6-
M%:;\FA$V`H2&&6>('G?5>1..^E=\V;J5HFH0:9DJNL&F&^BLBE(DB'\055JL
MBL=R&A:NP`;JHD5DJ=J0D?0*BVQ-X"'JF[Z(AHL1-HZQM6["8-F74"M0C!14
M0M:*9M*UB0852*7#0>$F9.1Z%!3_9!U#B(V1)DF(<I>L>00O9$PN]];$)$Z8
MWXG71'-L22:0NQV;-G6W79%ZMD*C:"$JV'2#X44]<E,F4&FF:BZU-.AX3H.9
MH=<`"QC3>!Z!22K%Q]XH'BL57P'%V!1*FS/44MM=-]Z[F1532[-!^'-L'[7-
MPD@21LTFT'3;B*371<YYWH:BY9B02WI"J6`K[8&I^-.<;Z[@H$E"1[CGOMYM
MXTUAA\T;9KG-9C;?'9_>>4D5JO;VX7HCO?+GO8N>%39?C392D<0%LH='PE-D
M'DXL8_8L9L3CA]-<'%)5Y+7!17YC0E9R6-],UX/[4O.M[,'JDA`EIE/S>.%I
MU]"+NF43_V1W478_7HS-Q(KF%,'V&''L4IIH'*\O\9$=8[HUJ9(0)V5G>8@)
MTO0JF(!L3"N#C+-LLK2CC&=6-\&?_D!8F8A\Y&0+`4U-I+6HR_@$/0\Y"OZZ
ME3_YF:8_]<L4X2+R,J]DAC@N`>!D_)>_$0XQAF\KXD*(B`U3V`LKYPIAN]"C
M08TTK#ST@XRX[D?`*]RJ.&!Y3!'-M3.:.(J(4#3*TZ+Q(0D9!#ET8<5@0$(7
M,*D17BO[#GS<(KOXI.>.$AS/94S',M$<\&D!4&.2JA2`D["@!/-*V^\D1)>4
M,.TV)BD1Y2;9%'\YR4N>["0HPX0FU[@D8+7;8X2\M<<$G4M)@_\!F?W&=1K8
MM2XS)9B3(%;@'OB`43L3_%(BGU9)81+3-7:)%\O,`X4-%0DB85O90<!4I9LP
MK3!H<XA0"F,EUE2N-B%)BD/.Y\7NH2TEO!,E.H<IS<XQ")@]BIP[CZ/.YV"I
M0>9[BU`"(*0P68$%'@+2.(&9G%>ZK$964N?-X`FD]`CTDZ($%W2H`I-&>;$5
M;PM*<%CS(2BP[R%V^>A'/RA1JU$LEHO"27!`:A<4<H2>$HO/WCATD>K-!B=D
MN184NP<;FDJ$CPL,XQG-:!K<;8150\TB16#XH0`>;2:8=%])((3)YLEJ<3!9
MYJX89*F'`.ZH0!6J"+-2QO<Q<%>M>-'_3POIDCTX,"Y<?.!0NS23B6(P2]$D
M6B\QJ)KKX41\8/WJ_?0J,:]PJ(C^:@OI6LC%!K*U4BXB%TYJAI&Z%I5X?VU>
MD.`:O`\6<6%%@5:\@@J\)Z4Q(21MDNF6Y9W96',TJ%R.'Q&2F!"9+FE$(VTO
MFP22[NV,M#X#VMR2Q!O?^@4R5B!>XFX6T-+2D;E)(NYUJ!(BZ6Z2<:(Y%JT@
M1S?B-+=)'PE._6RR@H^FA'11#>E*KY!<UQQEFL]U+G3A*]\L,10F.1*`5Q1S
MDBNLP#P#/50Y<^C;7U*L!/6]6WN7V+7.V7:"WAD;T.+;W?=.>,!H2\ZM5LE<
M01(W+6;1Z$[X_R0G@RS5D`?&!ELW]Q()UXW#Y)PO3#]GW@K/5[0/V5%L,N2H
MS_24+2^AVD92P[*4))-RI(+(<3Z#4\PPYI!%,5)NW)<^MX16@7--B$<"U)JQ
M8B^L@`4JM,8(D<=HEGPU"8WSL.DAC@CR3QB9,E<?`CZRD4F-"L%5FR[2L"./
MTLLV_G->_)*HAE@V1\#BDHJ\%1]($9I5[]/7;GO*/X60:P]HSDB&$IP1GI;D
M*X#V\UR3&!ON_A1<G!RA5E\*G7FU)@#!M2"1RW1.JX`(+*(V#1C/N-D%'N6O
M9_Q1C4`CFIEA&6V2]-^<JG?C#:DVS4-6T8)[!!.RF$RN6-)>(-?DEO_494?:
MJ1%+F0(AG.S`$E!)<M'.GF*@=<<(F,"&)#`UZ=%QIJ0_$4*;>0E$SZ<8Z\2I
MH>531;F?UMFO34!+28:&I/`KO9M`AD&DP6.CT97A)C4`DB"]HZ-E2!*-WYB9
M2S2M^\[,N&S:]$Q*4TC#;H:O_-W7:">H.,O:-I9F6RNG^,IOC#%H6_<]W$1A
M6$`>(7*5YJ8][%*5&!(B./ZNE9?9PS\;WO*(7661(%U)T3\*'HLU9"%V$==#
MWE:"Q?19KKW>])'#$M[N3.M#5A@[2VK2U*MPVD8<-9JZ&%@:==WJZRQDE[H"
M#_C!^TDJ^JJB7<IC$:4B.?&6Y55,7C010?3_$^Z/]].K$'TOLTW^[K2:B%\'
M)GJ($6OT#^'*UU/4*DU')+MA/Z;`>M08E8*T(_VDG[QB2I$`?EVCV`II3QTL
M>*K'7ET<!.EEPJO2"6EO3+1'(**J.JR-L#6DJF=9S[A:OY4@:H[JVLS;_<GV
MI(Z]]E?M(-E4^J@2$-_T[,H;[8@F_]_-_[:6RMW]?5=_^.L?__V?G>^HCO_1
MW_V%S?[MG].0V@$2H/T!H*60F0,*8`0.H`3RWW(8H`5:%0+F7P9R8&NT&0%6
MH.<PX``NX/QYC?=TX`36GU"0H`.:X%8!W0B*(*C5X)=]V@WZF@[:(`[VX`[F
M(`\JD67]H`^VQ=\%_R$2`J$20E$K^%X2%F$T/2$13F$0-F$1YJ!;E!H5WN`0
M/B%"-50H?:%#B6$8%E,PK1,:GJ$:@F$ZF2$;DF$;IN$;NN$8TF$9RF$=XN$=
MKF$>\N$>SJ$>QJ$?4I@@`N(@,@UQP:$BVF$A]J$A/J(C1@?Q1.(?4F(C5N(2
M;N$5;J(F=J(4?F(F@B(GBJ(GAJ(ICN(IEB(JKJ(JMB(IOF(J@B(ALA@MPE@M
MTA@NSJ(M[F(NWJ(N]B(O_J(P^B(Q!F,Q`B,R#J,Q+F,R'J,R-B,S/J,T.B,U
M1F,U0B,V3J,U\B(KPF(WQB(X?J,XNF(XDN,X>J,YIB,ZKF,YLN,YMB,\_O\9
M).ZAU"W<N\WC);*</;:<)2YB&M:C/@;D@>`C0@&D0?)C(/JC0"+D0F)B/A[D
M/D;D(3(B1#:D11*D&5:D1O8C13*D0;8?Z4U?\1%>Z87D2(+D\)5D2HJD^Z$D
M2;*D2;:D2K[D2<ZD2]ZD3>8D3*YD3>XD3<JD3^)D4.ID3Q8E4!IE3"8E3QXE
M4RKE3SIEJXQ@`UH@#0:@!\;?54HE!6[E"E(E5WKE`F(@#+Y@5H;@5XXE5E:E
M678E6EHE6W*@6D[E!KZE6X*E"MZE5M*E"UZE6HHE7L+E68K0$?6+%W'$SI'B
MMLW$#O63"U4$9$#!2F`,1FQ1;AQA/*JC*>()1PG_!,%0#A3`Q:,8CY0@%;@H
M14:TR6,$@I"=IF.4"")MF@%)B$Y<133`45-1C*>](PZ&Q2493)E0'G'$6F-@
M'4WL@>H1T7%%1#1(B&7Z3&$8D%98E'T)0O;UU,N]S6#`!/)HUF5>1$L@3UR@
MIFL2D5"0YEP5!F"920,))Z%`IG%%IA9B17!ZIRDT)A%9U$)$#GJNHLLEQB-=
MALV1E@P^)!T&T(E!QD@<!!PY&<"TQ%:T0C_UQ650VT%DV40F9$=*Y$!R)+0)
M2=NT%6W,#S4]6DLD#M*M7*:=QS)M!;6Y1LD\:,$E!%]D3E"PJ)$@''%P%);<
MR$8Z)!S"SU;(Q'!$&6',_]'-M(U;O(E1E!.[3<86B5N:#%0`19UL:)F'00&C
MU-QW*&C``5V/7NARO(R.XI94#(XS26(#^4C+O45`_AN1@MM#*>A6C`O=#!-;
M,2B.&I<^(NC%Q$RXU&F&:D<(X5/:01M><)G-N`\1!8CP:>!$3="R2(FPW5AL
M>)9N8J8/6AM"<)Y$](3KY,1$&6=D#8W^\-6MF`:/*01#E$NO($F>/*KFB(9@
M001,N>-EA0IT)-Q";6I,#9)''1Y-5%7*01]`A2?ZA47BG!Y:L:IMV>I$#=I%
MX&I\9@03<:=ABMD()<;H<!9$T5E846>700>9944*.D4'N<7E7:$NXH<I74.U
MTO\-T!%7>38A<Z2':5+8<7!)<(G,Q&C-:YSIIHX'V!!)-EZC-A8L@\V:KR1'
M#D$@<J`?Z;""TCF75;%&&S6)J>#'W6Q<OZ*?Q5Z8?3&*P8ZLR=E-9J'6L4AL
MRF5)E#K7RH2(XRA.R(#.'LA&W;',:];-(Y$L,A*8QN*-;[G8YOP,T"K(S@+,
M?-%3+7*%B$C<BTW8/R4'[R3&P5(8%,W+H/C$N4H&J78J>@@%F]Z82YCF7&D)
M=TT>G^%$UO[,)&8$E.509W:GW.*@9*&4MFE7C*F/X$!@+(50P!361MS%O(#$
MXW`5KCRK6]2LK1WNF6&J#LX+'(V-X=E'8BT$V(:&?0+_CTS0IEQ=!5-H1+YD
MTD5PCU#XIFF<G>,RS*WQ%IZ0V+1&U<-<!:[F%,)4!(YE1=;^E8"%7JZ8I^8R
M+MQNHH0UT_.DQ,]YTH!F1I395PZ=%9-2A[_>6)(@Z%;4IGHY$_$J"#UYA",1
MG4=^;R`:;$'FW%SPGJQZD6]<!QR9B],V%^`4$_;0UT7)YAB!C)+HE_=VA,C1
MAL,@+#WR8X!8P6-0WLDJ&W-@Z4;$'0/=38C,+'7<J'2D8`\5!\EEZ?N,K11Y
MAFN,6S:.;XTPB/+6YTK0KT-M!0=3F-)2;/HPAWH]#H%D;SUF%X,V\,3FXHHH
MQ\9]:1<&BOTVSU09ZE^4$:Q=_X3AX5BQ*%#S\(4.T<5CG,1Q(JMEL@QH2H2$
ME$#--N520B518O&EV,1!\$3C[<:AO)2I\*83^DEML0OU>I2PI9RW].W2$(9'
MS`VB4%9LI-A0YC%2GL2EC89ND(5^0(8IF,`9CP8V01^B6,$8MQ0B9PG8C<J2
MO9"]*`1=R&KH^I50(J6\N`L;]W'BB@JF37*Q)!:U(&[[,%$@!PCOUO$CLZ25
M*1GDU>Y.V@6R@!8HZS'%,M(B[?(F)9?4^I=?K%>E1&J'L8PN,Y*+*D^8@<D,
M-\6DS@8M5RW/2G,T]DCA^DNOT55OR8:$T%?UX<VG.(U'(%,KI<8-5Q#M_$S'
M?"P[[?_O-#NCEB2'KH)$W!&MBH7&R7!,=QVM1)A2`W,;-KFS_%27WSS.RVXC
M,H8.@"B424B8T(H.FWXL%BD&%I$<<XJ(<R6&\<Z7@SD;QO;,+[)'RQJ30F&C
M_B391)W<UI)0U_(8$:<([UP%]\B4#.8NRT"GV)*$LO6-1?QMZLXM6'TNM7R$
M>GV4U3$2=XY'#JFM;E0=IK#.1#R5L7@43G%GW@Y5;EX$U3CK#%E!:,D>JL;<
M9QE.Q<A4W]:0[Y[5DA$QM]K5_DQR[23U<3H:4(-*5E^#5[^943',J3D13L?Q
M!K5-'),$!:%*`KF.K^WR1Y4?8I.'[YXF8@?Q6B_ACSB=BF+_4X3)QH`R;'UQ
M26AP"2+Z,>B@C61E6U$Q2<S6#G:X2&C[KR!^*1M*V,`E2;OBA,-ZU[6@7S?+
MR"-Y5,ZV2+0MLU+%1'%,UV?SAT`[#OA>26S+U\\B!/?-Q@W3%JG`$)$)1+<E
M#7$9B6\=[<\F!Q,Q\TBWV=HL-QQV&,R9*W1$]^D:QPD32#?5$P/;EP!L].:4
M=UT^$X<DG1HB'-Q:;6;[+]VM\LJ`#[L@ZK*UCN(2[U\H6VQ\BJ-N,G.(CYE\
M1U9%F9P)#5=?J@C9130MIR/%169A1+.HB/"P'EALRRAI"D*<C\%8E%+?5:),
ML7\N4,UDBK#6M?N\J%%P%(7XIGH1_ROO/$?_<DMD2P27&`SDD5WW-'5%J'A2
ME<4+D<7C^;2SWGA&[('0O)!D&46-CJXH5X6F7JUONGA^'&?\,DQ]MFVI$BO9
M^<0^O2^ZG,<8)R&%45[G0*Y7,/::;!QQ>1UVUQ(AEDASK6C#+-<:`8E=8&G`
ML1=/?!="4[-K7Z,UT<](:\=;-4D6DI)Z>49\:0F,+[;6V5>6*1YQ@PD<?51V
M`K=^F=1!3_HV@JT&G>ZC^QNTY.SB!%PB1I`O65VGDU(CW1Z^`6Q\?!W\3*]A
M9/IR**"D2Z-+M'ILL$+?F?I]T!.$`L5*/0YIZ2J+F8G6V3?+%/=YC)_HD$7[
MBHY;1+NQV_\%<H^*J'M%@0?W-280\(2U3'U9^ZBKO1,V6.R*$EGK3W,XO@,\
M6X`0P3]9%)JR51]\I0*/O^>$;VZX&3U\OWM9OJ/:2M\[OU^\P[,JXOH$``3\
ME7F\QO=8Q<?MJ#TVN##\OL\$)RO1R-<RP^S*`QT%L2[A-'NP1=YCI"=B1IKW
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M%@=FM%@QHD:.!B-^U.AQ8\F0`J]E3(ER8"N7UUJM3*F2)DN;,U%BNRF39TV<
M/WONI'DM6E"@/HTF1;I4:-.C3I5"]:D3_V;,G3%=MHI6U*-,EJR>_L064^Q,
MGEA?:DTHLRA*LB#/FG4KE6[8J'95ZM2*]*U/JT!;U?U[E^I>H7*)DDVJN.5=
MQTR!4FT;>>Q@IB_K3GZ,<FU>@9J75L6Z>:!`JSOU6KXJ&N;*OJ1Y?BS(*@"+
M*[99Y/:Z,'#$WF,-MKH2^'?QX,=;FKQXTC9)WQ:-)Y<.?'ITZLNQRU;^FS?R
MZ[\%Y;Y]VVN`\;C_8K-MQ8H@D(*N9#<8B$5#5GMJLY`HR`KN\0$$D2Z0^*ZY
M8H7S5BJ(/O^*8\$][4Z*\+KNJO.NN/-N8^B\_A+$AC_<)"JAPPAI0R@\%@*P
MZK?;<+,-I(,",/^(1199>7%&%MH3J$0)(92(.PM/C'&Z:P0IX;ST?B/2OQ+`
M,JF5`$;$#J;;S/-M02&_`ZD_#`G,,J(39Y3HFCW\8R&]A6X<+R-!L+3.S>`0
M,^O)TG3R4$BS>HH3SVN@Q),E/0$]*M#'!AU*T$/S1-301!E=U-$_#\6&ML#J
MI,VL^NJLB86"=#+3-/W\]'-./`/+$+$Z]:H/3U59"`152P<BSZ#P%N*SMT8A
MQ77/1W<UB+8:ZU3108,D37$@5O1+U2`KP-*53U)38J%&C62MT]25!NQT#ZJ*
MO96%;3-]*SRX0MTS5UYG(J[/GUP,-U=L,LS4P5Y3"H`K=!4:B,Q<`]O_\5%,
M43T74G@![M0*D+Y%%2:AKG"/6[FN.+C<B4_]"-G`:@W`%#%?'*EC@3SUV+D7
M:\7H8Y%/)EFY'EE>V64>7Y:OHROBJS7A:%5N*=F"&AX(5.6N&;9D)8$6>K[X
MZ'N(9DDW=8AFC0*!`N:I9:Z:-VE/W@.*A\8ETM72,`UD#ZKG%=/6D0*HD3<3
M,!;HBAIE;:@]GP,T"6NJ6Y80)BPSBICCCI[LN)42L+,B$+QMO&+DO>6+9KB/
M>QS94H&LZ-+CBLP<.:&[K7Y(J6CZS.G9C(3KKSF<!($BMU9UNLT$%$T9Z,/<
M@!VS/A2G33TW*%8<CL7,%YPWUBY9,;VYNF"#_RQYY)5OWB;Z\CI;4HE-:1*G
MAE/UN7:E^"171JF3\O#GF4*^"9L<_?YIU)5"QXOY]R,;EUMN-0;,A(P\]3"^
M5E1M?EV;HG&WE;2K-(*X7T:0Y90K;`M9&J&*5^#C/@EN9G)F@=+\WI=`H63.
M>3^Y5DU,$2.H@(H5S?+>!,5GF@L2RRF>*N&MJ*6XY:7D3<BJ$7%LJ!)5Z4@_
M!=G#XWRF.)#%<"W&@M=M_F(JIDTK$"4(1&^>]#:4A&YND@+B$9^#.*K]:#H4
M\M(7K>/%O)UO6*T(C_7"<YM`F"YQMJE1(.I6H>0\S3O72!H78>05F/30(J;`
M5-FNIC:W=>E-<IR0=__&6!!I":<$N8FC$C,20M=<P4@$\E0A!3(N/!IQ(>:I
M$2O(HY',+6=TX]):;:RP&VS$R(N8Q",>$P(ZAX1'22B2HAB1,ZPA)="5WJE<
M%U6H'&31K'*Y"2,B@<,*Z`VOEN8ACG<"0!^:7<&(*F%ES#ABE">M+C=5,A\/
M%8(IG#1K=&,1IUZ$Q":9\.]%\EL:2RZ(OVDM;24@:6`'9YA/?.[S?8$00.4`
MQ"WZ<$HG21.+LE@8EBM\+2CQ>LH[<2*MJ50KH$.IGXQDR,\):A1'6'.;O4`F
M1+<9,Z&M<X_(&AH?\P5M6J(3#TE]U;^;A))@9;L&;0)4SQ3!;X9C^9\=<73_
M.)T@BZ%,"<])4_I`E"*%8"<LENAZ\B1*'2N>=#D1BAQ6($?6R8!(I0GKY!4[
MF<2SIQ9KFD;8)$B86`$*-!-2X$["O][@M&%UW2D=8V4;^.Q52&N$"]]6:956
MH15#FL/F8;78N<1&[DEQA!?;I&0TB'@*/F[$#B"Y]K.*M,($%6&%U!Z"TX;8
M]"#\:RG1$HE8Q6+#2!'!:Y"P%[I:\4<@TNP21^AIMFK6UEXZ%&*!7%6R-(($
M/WKLGD8XJ=HQ,HY:G&O)3D42M"MRI&NE;<UHL.*TWXHI<)%SB.$,VQ$98:H_
M29*4``H2N1)U,DIY4\J30--4<\K0G,<"%5)"=T93_PB"%?QEXM96HM_^OI"9
M"2(K2X>G0J%BPX\\U:@^'1QA"VXOKTJU"5AQHIXW"M&TJ,FM6$)9$_5XU6TD
MYA^!9$+/=:XKP1*&\%%TR9)1?8R6>0+5L,1G%"P&)8#32DF)+,RZ:QPP)^KY
M[4JT9N&@(7657'&Q\RHXD`9K*HX]0:*2O3(@G/"/FQTUI@?O"T(1;K2V87[?
ML*+F/9M&A;,T^2ELM&-#KJW`;5^;XIV'9DXH$@YE=`Q,ZE!FQX-UTB$EL`H4
MZK9;0!_2D+UL-'24NQU(/_IBR(&K5WH3X][0-FB$/<FB.W)'Y.R(.L<%SAF]
M0\OK^!ED)UWM1QP-1BP>1__50RICH7^\-4Y=86.`X^-TC%BJ<_8F0PL=R8RE
M(\N(]-8TA$MM%F5=K^/(%3DF</75[`Q,TOTZ92/[I9?@RN@O#C;:JL1&6YE&
MD@Y'I*5SY1LO+13OQAQJ3O/C4Z*!13EQI@^=,UFA=(G%/]F%><G<4K6*!?+3
MN]%SI^$<G[GH!7&)4TQ1`HLXQ9T5T>T*I+5&II-6;Q)`@T`AWX'(MEQ87$_Y
MBB5M(,YH"DLZD&\//$G*SGBA+#[Q.`4T6!6MW4B]9X78U9<J_0M5P_7HW'L'
M;%)!@Z$&.Y:2>-7I=`.!@E`OCO.L/[<F<0-ZJ/*74(@+$%_UA*17@.RH0/S;
M3GC_H6':Y@>K<XL49!*SR:]0]21RCACCO,I9L?S35@"1+IHT,Y.(UM0JPR/,
M-AL3CH,,OQ*\HL0V"[5-;_9ES1<9\7AI]#QHQ1OZOXT^SZ6'W.DOA_J_+XZ,
MMA&\8V>TI8^U3ST__+"8QL6;B-D2?`;1S8O6#3+77Z&ME;/S;8K)NQ>15O2F
M3_WS5P\7%D"AF"SH-1FK;[F#:'E6;:6/5?(<M9$,TSR(UN'T(T;-F%17D>FO
M7%MMRB;B4[)N!6FSR9JO>N>DCIJWL5Y-B<]%,J(V,BF:VNH`_2;/:@W_&$*Z
M&JERDB1JJ.G[$*CE=*3\QB.]A`\C@@8*BH]#FLOU!##A__CHL]8#B32B@?0/
M_[B'%5K!!4N(+US"-`!C!FGB!7G"!9-D8<H"!Q^(,6A0QN1DG<@)AI[L",DL
M"7OJQUBA,T#B!56#AA0C.&RP*;#!VO[DA5[0>FC(R<S"A*2PA&`0!]6'G-!*
MII3PP3K(-)KD)EYP,FZ""TG'")\"PZIB#/N"#0<#"&%B#&'0!8OLA6Y"8Y#0
M,5P"#XW+!6M"$2OC#_^0*8YGHZ#P$,\""G4P0;A0+P!1+$SAY7J0$<LB&@#Q
M[@9#1U0#='SLP3`)98Y)V\3-NUP1UCYF%9')%5]ITGP$%UM)WJ(M%Z$-EZ#/
MO&P1%]WD<83Q[V")`37B&'\#E/\>[1G%[19_L8ZHT167<19Y,97R;TAJ<?18
M#R),85N@$9.`\3JN,;$"C1>'8QRQ<1NC;V;:QAIY\1R!KQT%P=6DT1<;4`T+
MD1_3L!\!\A\%\L4(TA\+,B`/<B`-<B$1DB$5LB$A\B$EDE!.SB$3DC1>+=(6
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M5M`=7]/YWA$VH6\V8],V:Y,V<?,V&9`W?S,W@5,V@],WB?,X=;,W=U,XF=,X
MD[,XE],YA_,YD7,ZK;,YHS,[E7,[H9,[JS/JE+(H,\4K,,@HPY,I)7(\IP(R
M3B@HU;/(/LZI/",L,@4NRO-DW+,\=4S)WK.>)*@_^Y,GL,R!ZB)`"90^!W0I
M#W0_8\XIVM,A#;1`V=,?'[00G]+(+O0N>X2+BH=F-O&(RL2Q_^)2'T>T1,&2
M1$_41`G+-@Y'W2ZF(_P(>Y+C'NFQ5D!)(EBA$__O5@R/O]ZC3'(+BKKD'KDM
M,(KI/-`(2+MDE%2T+*4)2$]+.&Y#$)Y)ZIYF)(P1%R.(.J34&LE$C_1'KRY"
M<1*B2\W1CM1(K4RC1^V/P:Z@23-4W&@F'DL-2$'$%9GT1/?H_RA$2M]F9)*Q
MOW8H24!I2LTR6AQKA^!4*Z/B1%HT)XVK)DXL*[0L)<Q/*US""<U303DU79P)
M)M@DI_2E1\GEZJPT.,3IO79K0-1HIA8I&L+#SA`-*Z*!#S6,*!;("L9,)C('
M4^_EW*B4-3PUOB;25['"@%C"_[2"5O]X""LX"%XJTGQZ#"&FB6\$=$"0KE[6
ML16R99R2Q4^M54F"-3P`+%K,1"L"P01:ZDK/$VK4;REJM59;8[!TK*W2D,M0
MS">0R"6\SNVJU;R&*2OP(Q6;XDY_K'W<$T(<)-Q$+QU/0DV>S[F6#TRIQCN[
M[6)M\B5;9O">$+`&0EW'#\#<9IY:2B1NU2(PBVB6,62D"/I4D/!0%O5:-F?8
MCR8_9I0*Q.X\9H?VZ%.JID!JYD4J2$P:C/9HSSEDU%>JZJ8\EIX@B<'.R=#"
M:R9E)Y74%6AB2D)4;;E82SV$BKK&9]8JMIP0Z+1R3$K4PW%`*R'23&,]!S)V
MQ/IV0A!^Z`7_D_8^_E3':BFG0"*W+"R`%K0F[E&IN/4]&L:\S&BAGLX]N'6N
M%HA@-W535XE@I>HF=&DE/HM;5$5&HZ+!4$/(9.14)*K3/DY`DU;*[L0MZ`XH
M=FA`1S<BL6&-9H+4(H/79L62'@/99,)?;A!4C,5G7`4\/\/,F/;"@G?++HB^
M<**:I@P]Z^ML'B/&(D/IG`=K1I#EXH2#G*=R[<*GHF*A8O?AG.XH,8G<6$U)
M7NCWZ(9*O0Z/E$E,!Z)/H@&.3NM9J`1[^K1-^$Y\J'2X@JA_EZ94(@:\B,J,
MBDL6X=(OR=*+TK7=<`2:ZJ9W^$NB$N@9@]0A2,M-/"6`8#4__@]G_VPT1@CU
M=EC`2$IV4]B$=JYQ\O*2*R]I?^\1'PG"0^=4/3`MWGHFU2YH!]=%MD"JO\;&
MM>IO5G9XD*`I2OKEK,SIAA18*Y?8IYC8D(C&.GH6*@^IBC)8:8?$"K:E+^O%
M-:BQ!!S+.+B/A<]GC%.T*@-%SZ9HG?C,]^H&QP9BF?Q..-)&JO1JC4:)-GA'
M9_(U)Q;(5^['>XE%;EL#83)B[1SFB(@%-%!S-1]94G-C0>@04;T'5G-*Y$8"
MX@+K4(2,DY$%J6K#QZH.6BV,34[9/-J"J*9(@*KNQPBN-7..D?&GLNYQ`M7G
MB6(EJP:&75)13NXDHIJ$>^>$14\D2;374__OKGR$[Y=I[L)$%9(CY1H0;8HL
M`U"JR5QD]S)C5Z6,3"BJZWI4:NM\"H8PESUP1ZGDXF4SSRRZ9C1'<_6JBY:[
M>20,AVD>9I5JTY9=PIDZ=B:RK=54AEF!5B!^Z$6XKR4*-72\SH]:5#N[,Z*_
M4ZMT,#>N3R.8Y#4W17::),^H;62L3?3ZH]T<BV["B8O";2U<36=NJ*3WU[[H
MU&+SC+D,HI%6>I5<6G8XK(14+[E2<&E?NIP$00#"-CPVC=NHRF/"HSW$QDR.
M%D,[YO8F>O66)B$$H&1/;^;^)IPO5LK.B=Q(0FOV3[/TCVR%UHR*I*.!KWPB
MYDLPY3J-,RJX*3__#BA^:^>>4KC+0D9`K<BRT,G"Z+GKQMDKYB7<C"<W&HE`
M8E27B<RO1N)$F"5RT;.B,!?NV(7$0,P]0ID^BLHFLCDO0/<GPD.LYE,FNH;3
MO"*$H&HJS*\T1#O,=%<GY=B2\T+NM@Q3:$80EFF#ZK<";0*B$HY2&':`5`IG
M=S>8`TYQ"1E;/$HL6CLI4Z<^F8TI6&&0Z9-=S0G^V`KYSO6<YNZ$+DV41)4N
MN#=\.MER?R-\U;."$?(6%]"NMXV2VGK@\EERBB1I?T-_96Z[(*)FM^U\L`Y\
M1885$._.F`D_(_$L%Y4OM1*5(^+;.FF(IV-+QT>*N"C&,`>-I;0:KT/\_\X[
MA%&T;[3O-V3WU%(IC34T?$F"M&:CLY3&/4Q.)=ZX.R1*AY.#?VHCQU$$=YY%
M:?1C`<&CB$//H)A&'.NHFN,T3@M"QYE\!"_\MNHH@18"+*C\IFZJ**AIQYN\
M(Z`+81X$+,M)&OFM-T)(R\U\CK8KR1G5)SXY\7@H8*QIJG1BO&="MP,TL`4"
M"^$HGW^7S0D:YLQB8P1HN0]Z)N"0*%BL4WMJ:,%&^PIN*@3.G`"YRMPU+-J<
MC8^B$U]DQ!@,?`1W5V/EYX+[&C3=@6*,TR/7LE?,)N!%8F1B#[XF:?79*-[Y
M!JTU8!(NAA[&5E`]JL)UTV?L984"=)P7UT$*/O]-FWB-`J3*(NIPO?::PF^(
MA:O9<W"2A)T\IL]9'562ILC(+B!)2;:"8Z>01<<7]@*'^6EY8V&R*],VY<\$
M\$GV`"SZ6<+WPSPD@J3V!BS>V:TD3XA\R)"#YFMMUFV9H[#%)VP#0V.<K%9(
M[B!R>`%KQ:R3@V-K&3BRR_Z,"=XMZ<OSI7BO/9J((ZUTQDP*PG_;V.`UA*S7
M)$5B`I18'MN?6#B""SJPICO4B2C"O3S^]`4'S]1POD]^P_I&W@(KM]T[!+P*
M7F8LVX@["?R4@XL_DMQ._HE\S\+QPW#;BPJAI"\&%BT"8&Q,PPK.9+P@(J4+
M7L<BJ*%<13@&PX!J9T;_+EHF@D>O^;9X',F\*NM;],0FI-8F*LM>J0),X(8L
MX`/X%F0=T=,]WU<\;OI$5&?Z['-P5Q3K:-W,P&1W4"+R]?HM8+Y5?$P;_V1U
M:*3(!L0VQ#XG/C\0S%9X?%+@PD(X5*=E>4(;4\RRC"I99H)%(E\.6>)9=3HW
M@CAVZ5SJNHP+3[^:+T6O6:"S[*M==V*CB;O2"66G>,J4$]GHPE3`Q\L+O8+W
MA?\)]\!T]F`*Y2Q^M$][V]LOX_?07QH9NYK#\8@>S2NAS5$9]13%S[*%OZ@<
M`;4=`0);-&S7L+4B*!!AP8('&2J\<L6@PHD%!RZD*/%B1806,V+<J#&APY`-
M_[%9N3+28\F5"%F"%`FS9,B7+B?6+,D"I<>9*EMRQ-BQ9$>>0WWRW-B*A2"C
M/5/6#/HS)5223&\2;!7@FM.J7$,6?:DUXE28%V5B-+LU)8M`:3V.?=M2JU:"
M<N72K;M04`!!IEBQ$L2"Q<*Y>`D7OEL7L=W"@_'2;<7J"@N+AQDK-NS8LN;*
MG#-W3KS9LVC0GQ>7QGSW<F/2HTVWQLPZMFO9L&?;KHU[]6W=N0V>Y@U<M?#0
MM(,3WSW\=_+7JZ/U/O[\L!7ET(U3O\X<J/:9UP0)NN*=\,2O9*..WWY^9JLK
MK(2BOT@^_GOS\.>#I8__OO[R^^5[M<]?@/ZE1V!]__\=6&!^`@(XH($)]L=@
MA`@Z2*&"#5HHX8,+3H@AAQ!Z&"!1&5;XH887ZH>::ZF9A@U%*;[8V(HPRACC
M8@K-J&*...Y8(X\T_JACCT("Z6.01`YI9))%+HDDDT<^J6234D+I9)143FEE
MEE5NB2675WZI99=B$ME1F>:9*1538UG5EGMIOH0F3'&ZZ5973=U))YUQ[FE>
MGGW:R6:=;\IY9J&#^MDFH'_":2BA-"T:DZ*)/LIHI8Y&2BFF>$JJ*9^6S@GI
MFIP^I6:CGG9:ZJ2;'FIJJYG"I2JI*K9(:ZVVWHIKKKKNRFNOOOX*;+#"#DML
ML<8>BVRRRB[+;+/./@MMM-+_3DMMM<PRJE<`VIJ@;0`L=,NMMM]NV^VX`83K
M+;CEJBLNN^F2VRZ\[YZ[KKSFHGMOO?3&N^^\^+J;+[__V@MPP00?W&_`_NH[
M<,(&.XQPPQ(S3+'`%2]L<<88;ZQPQP]/K+''$5\L,L0F@\SQQR2K'#++*8_<
M,LPOG[RRS"6C?'/-6?782C3MM0(9T#X#'73//Q<]--!'+TTTTTHW+;3322,M
M==50&WWUU$X7S?76/VL===96/XTUV6"7W?75:9--M=ANFSUVVW"K[37=;\N-
M]]=QZWUWW6S[?7;@>X<]=^%K'P[XX&CS;3CC>=O]-^2"]TWXXXM7[C?BE%_.
M^>2-_V,.N>:R?D3Z4:6?;GKJJ*^N>NNLO^YZ[+#/+GOMM-]N>^ZX[ZY[[[S_
M[GOPP`\O?/'$'V]\\;+=6!!=S$>7777#*;9<<=-'WQF-RUN'???62P\^=M^+
MCUSXWI=//O3CGZ\^^NQSOW[\[LO??OWPSX^__=7G;]REIOQDA:P@)``Z(1'P
M!*.@BPAB#Y42!"O0<R)L7*$5UT!)*Z!0'@R2IR![,(7L6$"0":)N/9<ZE0E=
M54(4GO!3*FPA"U^80ABN,(8TG*$-75A#'-Y0ACKL(0]_F$,@[C"(1!PB97KD
MEX@L!"*"*(@@`A$1@@CB(%)L8D'^\L!K4%"+%&3%-;S8'?\P&H0M(+1+-,+#
MQ5:PQ2`3;`C0'J,5+WI'(6_\XA4%81$Y+N6"['D@";'AG8$`9BG=(:04_T+(
M.+:"+PCYRT%8P0(&9O&,%,2&'L/"@@=ZIR%>"A.8.@G*,7ERE*'\I"A+2<I3
MJM*4K$QE*U$)RU6Z4BMQ<F0!39*4$+*"+;L$9!.GB`T0@N>+K(B&$DT1"&P$
M8`\]BTADNI-,P#ADEQ1$"10?",*_&+,@921((/Z7R2\JD8W<E"`%YU@"+T;&
MG->`@E:L(,&P'`2$QIPG(%%RC7`F1"E`$V8UL4F0Z9`P/!"QI`4C(ICN'`16
MJVHHHHJ(PX<&*E`,-6*C)#JJ5`G_"J(PQ&BL-*HG'U[*HPX%J4AG2-*)FE2(
M$8642D<"&[XD4H+47`\)E1((:7[Q.T"S`C"?Z<MX2C`0.15,-[M903?F="GF
M).%T=FF7"5:P116TBSO#HY3OH"2*4V5/,-G8(E,(P@K5M*1/OV,*=[9HCDO,
MRU+^(D*U@M"G18UG.5FQAWL"4Y:Q?"5?_^K7P,ZRKX,%;&$%2]C$&E:QB#7L
MI>ISA6@8$X.FB(@(G1B(@4R'(<]48B_+Z-6VAO`BD77B$RN)$C1"9*%2!"==
MZ$D7B)3S(F7,)SM18DR3.-&UX4%(-P/A1=_.A3W3`21`JWI978Z6A`Q9X$F?
MR]+H<G2Z_Q:5;G6I"UWL6C>[U^TN=[^[W?!J-XA%\FI.P(I7R(!G@H!9Y"^W
M"AFE!/.*;9Q.3A<9`,2T,;6$W&^+"DI:"H+0(!AT'A2B2%0U-G'`N<RI;2-C
M4U.P0,`4M$)[]@L9GSIOM<^$0GP?:%Z#`LVR<\DF?Z/AX,LR]K`L7K&+%POC
MQLJXQ3&F\8Q??.,:O^BEEI2+'^<2#<C0I8F<M.)5O/A(C@AY($$#,D*F>,6Y
M_+@@^+Q1DJ_H$]9JQ<A9M.21*^E'H&G1DI4T126=V+.YS%.AG#V(&\5L$"%?
M0[("*?,6C6QD[UHJI1EMBYY'ZM(^-_3/H,H4CWE,Z%`)^M#@!?^TH1=MIT2_
M"M(?%6^9UJ<]C8A'TYQ>D:=#0Z/U-'$YF5XQ\T)X1"@]+TKTNY_^S-?J_;TZ
M?:ZNM:QM#6O^W7K7N9[U^WA-:V#_NM>X#C;XQBOI\3HHV7]>=J.9_>QH6UK:
MR*8VM*>-[6IG^]K:[C:W5XAC&XL[W.36L;ESC.YQGUO=Z2YWN]?M;G;+>TNG
M<O:>`UWIC88404.DD^S00D-[$RA.#@)X62B-*O$:4%3Y?JC`!T3PE3;TX*R"
MX<+1PV>J^%FC$(>@HN^=[XJB\.$2KXGN_-TA(F9\52FR)`/EDM>%^"6P1E91
MS$UYC63&R"^RI*E<UA.(/8!1G#=:H!7_N\,1*UX!BCD]-96'?B2HNX;IF=VR
MJI4H'K:H6\Z-Y&E!=`XF"0)ID7<Y^H\@PT5`LF:H2]?ZV4<=I#=B?4SKN<@>
MH+C7R!`UN.+<JU^E'DJM"TG,JD0Z/@V32'@W!LHZ?J(5@>Y@@XSZB6YW363P
M*'E`;C$UX]11X@7[6,DXAR`(I/*H(]ZZY!JH]"$"$,5;CZ#UP#;R>QAU3O['
MS2V:>#"[ET@M)?,ZI&*D!+X1#%`-:*,EFJ7CL@/N1>XKP286=S]'V31,*LO[
M$4:$F4E-SX1W\I%HP)/Z=K4^\_?@TX5\WZ;1=Z(%,;B>+D<P),)'_NH,CI#-
MGB[B4+5^W7<W_W\3466^$R>3$60@%'G/U`KPQ!Y:,6%@<07_8U.VA7^J\W]Z
M!B.1D5L.6':&9!=X]1VFM0<6-'Y/!$D3='D#^%6U1V491E3XM'1C!7<D=`6U
M!T6^9%NDAPT'=G>CMEF&84ZA-4=@55G;A(.$P5PA!%:=-EQJE$5$]1W8@$PM
M"!@107EFEX,^AU-;E443]H(`M1XCN&;7,()"!T@O"!%=.!@Y%8&`1%<Z051X
M=Q>'MT]/!![8`$61Y7@,E!0+I!,@I$;7=!=_I(/&%((Y=W?)Y$@Y`71/='.S
MU2(=-%HQF$RMD%>307I:M%Z6Q(B@-8(@9H.=9Q@@=%3-XU5L94[81_\KEK=T
M2@2%5CAJ$Q0(:X&'4/B!.>%%2R=T9/@=2\%$W[2##@@>0(>"C"AJYO6%F1A;
M=GB).P419\1/.=%$>7@0Z^5!<>B!CH=05<1$PU1!1740`=!TK9B+Z^4=ASB"
MJH<0SE<7J&AB[4=5F)&$6D&#`F:'8-AV2Y%30:<5&+185K%9(G1!#K&+1C$7
MP`54ZK1&!%40XR=^"G%5A`1<S+5)"-9EZ]1TJ;@41Q5,HP="4WB'&T%/<'@2
M@1"0Q^55'7&")@E\)UA[I0*(*+%.::1$<P2(DP=WV%`"3.=,.K%)>;5+,SF)
M%4%BP!5"_T=0!F60(-1;J;5&#2@0MC44T\?_E/`$59;D0'"X%--10)7T2#D!
M17M`BK[E9?5$0LP4?2W">OG4BN342PLE&#=58ADQ1SK!E0UA3?U%0<17$B($
MC.UD!2897`6IB98TBU[Y$WAY85?1"LCD30`E5BV8?6&D2SI1C:CU5?_G1B16
M5:/U?7@%3>LX><FT51Z(3\37F==`5K?431V14`2!EG/ED3X7C/G4D'.!05*5
M@^Q10-,Q5@_Q0!V1AR9)00MX%2?Q/U#16X,1$=-AA'5G66YD%X)AA(-B0VN7
M%#6H%!SH5ACA'8C42PO!7(XI4&NQ=].)A\$565=)4$E4%[DE5?&$562I5CD'
M8:=6A8$@0*CH@",(_P71Q%1S%F11)!#P1(B6,8O::9]V$9G88(;NQ`H^57M9
MQ(%T5).D.56:V(9C64X8Y$Y45D%](4(H45MAD95!E51&64@*,7U>QI$.M*+O
ME*&?]54U,H\8E%7.=UK9!*#L5*-S257Q5()3](ZE%4]!^9(BQ*'Q%)_Z-QC!
M!!&R]5429!&H")4<!'?M&`CK44]VT91EU8O0QQ!_Z'B$U(OF=$BXY5DYM4Y*
M2I;=M%51M9GS95!29:!1A%-S=$;>.(*?EX>ZY(MXF50M6*,(Q*0/!%0D6J:G
M1ICGY($&M1A$M2+S.*#LY)#;6%LMPJ9V6FJXYBA-5T[14)_PN!+%%8%(.?^@
MIM=]M;44%N%.II!7T9!)%#E%,OD3G95%*)A,991+W;0>6#<0KBJ>$1%Y3[<0
M<E5BXI1]QY<:%M&56T40?L%<=QB35W1F7Z626CEGV_E%F>A/AEE5>AI9[-$S
MKW5Z[&1;D8>".G&E\`A%J1F1Y.1+EFA:MN55BW01JLB!O]5+HEJ84A5:""2L
M=+2=1BFK<Q81'VJ;9=1TF\64_55!N>IF"B&4";5^[.I!D#J3ZZ1EMA6Q'FMF
MTPI0"7EF#YES9@IGPI2Q8PE4O`I/`<ED<7H5VYD03=E$%C00&HA/_JBB(<M-
M/G.43Z9<HC=?Y>1\1:M6\2E,]*A$[)5%HZ9E13O_7\5ZG+CT=3FY1+GJ01@D
M4#K163'J>-RDB=CV(EAG7/E$C7]Q3UY:>W.T2,-TAC)UAA244R^'$!>J@?BJ
M4(T(MW.63%L*HN$A:FTJI]PT@SH'HFH+<W;!?1(T@LZA1G?!%J*:ATN17^*)
MN%6U2VQ5IN<4$8&(A5PE%SI'=E;;'<,H=J<;BUNV=,Z1CWCJ'&OH'4!I13_E
M>!3J?G`[3E887+OD8"@6K;ZX5L5*CX\816VG%7MG040FBYA)6ND(@PSQBI*G
M%6TKD^`!N!`61=^Q1H!K5PD%HC+GBW/A0&;%1%+&1*2'NY6U25^T5%*$O<[Q
M1(;I8&JV1M`$H]YAE%"(_Y8OYUEMVT00=K*Q:&";9UKON[QP>U]'Q[T'07D4
MA$PP*G/O"U::]W6"Y'C5N(Y$M66/-&H,=$];>D_Q&!:R=0UBE1J]A(<UZ$&Y
M%*DUZ$?36%9AD;H9/,"`*XI\-40:L62NQQ2O5X%T:4$N3"`*1CKR>[]^]WI`
MG'*HA[4I9X%GP12L`*L!`G!%<5KBI%Z/U2@7EQ+_AG&OPWS@9SI!S!-FC'2H
M!WL!,DY!O$%27,8":'WDIW&6Y)@H1\=D3#H`)V`#Y\.M,W-?#,>DPW,;XL<@
MLG*RTG+<P<CO!B14Y4"<-'A=IB)HAQ`D[,CS)B9<-TK!ZV:4'&^AK'BMY'2B
M//]C9Q9*G"S*W6'*FIS)17(ID=1VYL&L_.9QMDRUI*7$A/*YMT1^:F0%=\?%
MIO-MUM9H)+=MQIS,R^QMRJQLSES,)1+-S<S,&-@CN?5?Q7D5""L1>U5SY:M%
M6F1DBR2=:!=EW>E%9K9E%B9%)?$75[2=6Z10865)4B>$613(!A'(7>1$?-?*
M_SS*KBS0`/W*`4W0`VW0"5W0,O(4%&A;7PJ:LG6^,=D>PM2`PM0>-DFN2L1Z
M39<3A:1%#[NGYA09V#2VL'JZ.X@2^JI7+4&N(%1[6[R3N:BL":=O"$=1$L=0
MB8S3G++3'U=2#2=H/SUI0FW4@Z;3)=?31TW4-LUH1YW_TQ7GU$L=U'?2U$&!
MG9%$5,X1GA-)8B[W7V1(1;+X0&BZ2))Z63*9N?/KCQ28L.<X8:)K5_`$IQ[[
MHPM162B!ED`:3PB$=Q(V=+X6:\0F;(-M;(<];(AMV(G-V(OMV+I&V)&MV)`]
MV8)-V8T-V>EAU_5*TO"%@SM(I2"JM%:;6_K'%ZV)AS<;L^^4F7(Q?OM$3@6T
MI:4WJH84&48*B1SJMGH<0;T](E`,W"7BQ2;RV\(=W(8\W,E]W+X-(LQ-W,U=
MW,B]W-'MW,IMW-<MW=A=W=/-A(8QD$AHE1,&GW'4M,[A3C281635M8'J6X(G
M1;LJ%S$YPFWJ1<[W@`]+=*68_Q?[M6!CVW11^*$3&+T+C=`$?M`'KM`%KN`(
M;N`)SN"F$5*M>B.\Q$5:E+.59$C>ZT%.)!!JJTD/$;7%E';A+(5TX;U:Y';D
M[)5LQ7?EJD#ML8Y\AV(8GA'AF;I37=0WG>,/==5)+=4]_N,^KN,X3N1`/N1&
MSN-"GN1!SN1'KN1`O>1.WN113N50;N4[?N5%GBJ+_&DS-A$@6,HU\A$X$N9=
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M^&[O^<[OXU;E6"[P6C[E68[D!O_D`W_P"I_P!"_E#Q_P#A_Q"R_Q"%_P#'_Q
M%8_Q$&_Q'+_Q$]_P%`_D_T[R_F[R_8[R^W[R*I_R)=_R2&+H?B[S@S[S,4_S
M-V_S.4_H.U_S/(_S/D]>*^_R+$_T0V_T0H_T+Z_T1:]C(J\MU+.N\5'_ZJ,#
F\AD_]9F>\9Y^]2$7\K*NZDX/]:\.]K`.]6._]60?]5J/TP$!`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g267791mmi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791mmi002.gif
M1TE&.#EAEP(,`7<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````"6`@P!AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G!DRFJE6K:+1W,FS
MI\^?0(,*'4J4HRE,;22U:6/*8BM!3Z41%"0()-6#3T%F3;B59=>!7R6&%?BT
MU4"H9K&5A5J5;5FS.*M.38N6K-R#=S../4MP+T:J:57ZQ0NUJ.'#.TW164K'
MS>*+`2*S"%`B;620)@((%!3@BL#+'5M%]CRU\V?-+2<'%JBZ8NN"+%@,O!)9
M;F3*M2.7N&V6<X"[HF5CFTSZ=>D`JR\:'SB9^&;D#8,[I)W\).VF"$67$$@=
ML??O*O<@_UV,%.DGY:A%DS8IB,7ZCZ+S;BY1'#7+R1[Q%Q0=F'9LL*K!-1P+
M@<5F&ED'&LB=?6>5H)]&M!G477?#O:?0@0S%5IU)%"*$(7@@AAC28FTX5J*)
M3$%6&6NH@69*<Y:Y%X`)_8UV%HRG8>/?;MB`IJ.-G\GXVT&T'<A9<Z5EIMED
M[6%8I'`22E9C``0&6>055[+8I&TM"KG>DVFU0MQDU\`&987_,;<B<PRZ=P64
MK3BX('W#06?0<E,U)]=D>^Q&FIB=X?FF6:^98B>`M:E%Y66MO48<==+5"=MO
MSFV&8YU-UD<H=!0VR4)5P>W62J>7TN;;F2*FJJI`T;11GJNP(O^%T8-4!OG9
M%:.B%J!^G#WU7YQ08`,%=)1QYQZ+S_DJ').`&M1K>[(]U5ER[=4'%:^_B8DJ
M-KUJFZRWF`)ZK:[9ZC>L0,..^]RUPEW7+&SK"5("5?:].Q"582)WQ9KJL1:;
M;!$2R6!IZOZX1ZX+%HS5@ZV8(!^^O2J*ZW`KLD"CCG1J.."M!9F:JU3QO>OQ
MA)R6#%>V`0=GUA4.<VM:K3K^Q\*\J]:<ZB=+N=%&8XOI3`=&D:7%HZ21WMLB
M:D.#!C.;",HUM'Z9"12UI),BZ[*%$ENMW];;5:UCL%1O3:[6Y&ZJD]B;LE9Q
MV7T=^NR0+*[V8+=V1JK:;QT2A"=9:37_"IW?9@V[X8_8L69AFF#!3/+*)KN,
M$]RS-;[XCXQ73OGE."T8H^:73YZWS:`?]@D=H^/\JAM[S&J?TEW+"[G89",8
M0.JV<GMLV&/C?F?NHO'A;(*Y-[?H[L3K;CSLQY,K?.P$,U?EZP-K_*-:MTL3
M`-@SY_I@QP/WY1]J`8</?O<(6@@%JH"^EV"5&K=?I9A7<!:EY9Y+;G^8WUM&
MVIM5\1]S_Y_Z7^@&"!Y3Z,P-)AH<1(+&O`619F@01!J#_&,USNPI>!@L'K:P
MUJ_DX21S7@,A\D:8P>3%[8,-%,@U7K<;*D%I.0\R$&6$$Z=V:49,HCK(WJY6
MITWYL(=`W,_2_YB#-9?14''WN]R`$!<Y^B6Q?I8[$N:0Z,0J$O"*HHM5B3)"
M*^'`C'81(R&RRO*CJL!,7O5A'O+TQCO(W2B-QGM3E*P6,#$:[UQ4PZ-^PK>L
M\=T)2IV!BH/@LKT>O4]#32J?OPA5R,@MS(8+BN3T)EF0(3:M((6)#\<&1*B*
ML6]-1\+:Y"(&Q<XU;F:<,R2Z:+:OE57)?_N2#Q9GZ9,3]>QG0*//EG*DLM90
M*7Y(!"9IJ"2([N@G.&9$32`">2#0#*TTPGP.!XEI/,Y$$Y/,)(TUK:E&79D`
MF'T\V]^@L\U@-BDY<G297/A@)Q@&0"<6Y)S=H".:0[&Q.L@LT@];0_^;^.%I
M9O'#$EVZQR13J:4$K/S-.:^V4$79TUA0:,_%1!,%>;4K-NU943]]8SEB<E0@
MNTE==]0#+<Y-J$JT3.E,CK(S6!7.(O\*Y+UHN-&XN2<P>\`H0=Z$4L2AD6K8
M"(1.T84:/&(R"@&\I+..92[[%)-F>#'H6:0ZR2CX45@$<H]<Q"=);E'U?_(3
M8F_L5*VN+E*`BJJ*]8J#TH#-$2^Q`:8DW?HFN7;,0+3BX#:G>D-3M6>@5$'I
MQN8W5*].2W.%C2LIZ1F;B)(U0OZCWNT$Z+_"JO2R+<%9SW2F$Y;X"+.I<BMH
M=TJ^T-!I?@WYW&A7>UDMRJHESV1MB!1X6=K_9D0R"%&MP&PKV][6C#$F.D]+
M0.C;XAJ7*USA+=^.RUR;F<*U+VVN=*=+W>I:MR.W+%$;KLO=[GKWN]Y=RJN$
M"][RFO>\Z+UBJS;K!O*F][WPC:]\?;('\K1TOOC-KW[W.Y+-DHB_``ZP@`>L
M$-?BDL`(3K""W_M<$RTFN@N.L(0G?%S3P6J[%,ZPAC?<6O\>F,,@#K&(P=,*
MG;T*PB-.L8I7+!-0[`Q%RF6QC&=,XXVX%L,USK&.=VR15BWEQ^[EL9"'3.2"
MF,(F2(YQD9?,Y"8[^<E0CK*4ITSE*EOYREC.LI:WS.4N>_G+8/[RJ(I)7.Y<
MQ2YWF1BW!,&',V/R_Q2!>8J:L6&*/632S?&CRA5.L1FJ%+,P5&FS+,-,Z$+G
M5C)`<BB<&!@ISC@HT9.Y#=B"`Z46GJQ*AKI-FB)]&Q9Q6LF&#K66N8D-A,KE
M2/5R3@=Y&C=%18$U+0-4`&5-R&U)57K.ZPTJ1<UK0^]K?W##*-R"$P!I-#I!
MK)13&16ETVK1TY)%^Z>=J-397EO;RZ36J;8T23T'>>9`K%YVMH^E+3FZ!ZF$
MC%Y2#0FJ@91@HHW$RK7G_63_2/2(GDF3>E@&KFP/J9]$!54@*_.ID>+K+$/D
M=#NGO2TANK`N](XXAWL#K88;44'<H9G&O-49<*?)H./V#,<CM/%=4R\`9?]R
M'J[N4O+2[F=4D]D-%'`%:HG;'+VMV,.;6JC5P?TZB/XQT,F"%71IJLTS^[*A
MP/-=*X-#">#WG-2E:QZ-G.]+,A$=],VW[MW`<CH*\8LQ-SOXK_.1^S^9,I;2
M>3@@D<OL[>F>J4$.3I"#Q\GE$/&Z9-K<BI1S_>_&E3.G>UYS!XX19OTB>YJ.
M])0<'BFPS_9,/)W.R)6?F4F"2(0@7!$N"H:FF)%V4^$!3_KOG`):FLZS1OR-
MJP,U*U*1*I)D[N*IEC%;43^LIZ<U':3;#&E1HQD]1`1_&X$*O_3(EXG@0Q]V
MD]CV^0_94)R]@Q,L:3JBQT^^]D426-E#(>M0?@K_ZC&J]>V;7RN@3SW$L^PK
M1#?__/"_B)R+!`#R\QHG,NP,S>//_^R`OH7ZUPJSL'75)WL]UW_;5X":]BGE
MQUK%E"=U%2]8LA_M41BS%!<\]7`-B("&1GR+8GS5]28)%U=00#O-\1J.1AL7
M`UJ"D%/,9X$<*&:C<G4:^%TPQT3[@DW18@)]=#)%A%EZ%FGTL7\Q2&7_IQM8
M`H.L%1S^H60=M$C$E2_"`1AL=USSIW[95X04IH"[$1MMIA;-)2[AUA`615I=
M>";:(DNZ985RQG,,J(4J%A<&TH7O9UV)!SR^QWN*-!O8(UB)AG`_:%UZ]TM*
M"(<(5H"/YB!V5G7EY2W@_[(6D$A[3$001I5Q[Q$<`_A>RH(;(&B(^?442*4;
M!PA?TB$:8!,='R)"]"1W"")8\R5X/%>'GMA="AAS6@6&G_@K'[<HPN-3/H5$
M1B19,[6!\:6`DO&&LXA9HD6!YZ-^?#9@=_@G90%G4'$3B:,^+*!SS51P`>`[
M2^1GQ(A?H/>"69B,0"&"236#,B1ZY=B(M5(T#"%%`$(<86(@:<:+UT-A5!&*
MCU)FE62.0Z$]/)A_HPB0M)A^DE&'KC-G!CD3VH*/`=*0I#B#"S@L)RB1,#$J
M``B`D8:1^B5G+B0\\>.1*Y$<`P@5?/!5)!E?GH*/M=&.*QF3*19T2>AGIN!G
M,O^9DT\&DSK9DS[YDT`9E"I4)D2)#45YE$:9E$BYE$K9E$SYE$X9E5`YE5)9
ME51YE5:9E5BYE5K9E5S)E1EV#5_IE60YEF99EFAYEFJ9EFRYEFZIE'[G$=!P
M#=9P#7-YEW1IEWHYEW6)EWRYEWK9EX`IF'A)F($)F'_IEWFIF(:9F(.)F(OY
MF(P)F8T9F85)F9@YF9HIF9QYF9OIF9UYF'Y9EQGFF*!YFJ(9FJ:9FJBYFJYI
MF:P9FZ]9F;29F:H)F[-IFZV)F[Q9FY\IFXL)$G1I#<0YG'5)G,=9G,AIG,RY
MG,ZIG-"9G-+9G-%)G=/YG-=9G=AIG=RYG=ZIG>"9G>+_V9WA29[C^9WGJ9P:
MAISIV9[F^9[H"9_E&9_T.9_VZ9[UB9_W*9_ZV9_6$!)UR0IY*:`!.J`&6J`(
M>@T$JJ`'RJ`)NJ`0VJ`1^J`26J$4>J$.FJ$3JJ$6RJ$8NJ$@VJ$A^J$B6J()
M6FT21J(JZJ$L.J(M:J(ONJ(N.J,P2J,R6J,X>J,ZZJ'"R9X^^J-`&J1".J1"
MFI?2&:3&2:1*NJ3LF:1,^J0_:J3-::3*2:50>J58.J3KF:5<RJ52>J1=&J90
MZJ1B2J1?6J5@:J5ENJ;$&1(">IEO>IAQ^I=S:J!P^IAU&J"()@"=89AUN0=4
M`IR^>9M^RJ?%N9N#BIK68"A\_\JG5U"7Z'@%>AD`?!H9`K`*O:F;@JJIN0D-
MI$EA><JIF?J;G6J7D\$*=6D%@5JJB"JJB7J8UD`;@7"<KEJKL4JIN#JKUU`*
MJBH`+!"8E3H:A%JKI(J;/9J?_)FLV!FK0L4"5A`(@6"=R_2HRKJ?VQD(I="?
MU1J@V,H*JKH'U[!,+,`*DQ&MUL`*@8"N%M.DR-JNUJJ=6_JNVNJNR6D%`F"N
MJJJK]+JM_,H*I4"@\IJLZ)JN+"``I4"7D0&M`6`%PWD]I;`*L[JO$AN>_PD2
M"4JGD7FQ#8JQ@JFQ'DN7ITJKJ\`*>"E4#!N@K!"G*4N@Z)J7(SN7`KJRNXJF
MUG"PQ_\)#3;;LBG+L1F:KL1IKC%JI+3AJ<L$KJP0`/K:L-1JHT'+M$S+D^:U
MHTZ;HQEZKGUZ#2LPK@.:L@PJLS9KI*R`J;1ZK@OZLPK*M2DKMBU;ESY+E_Y*
MI1%K#=$*#5R+H3X+#4#KHL=))L09J"O$`L?IJU(ZM5)KHL?*KQ/KGI2:LP4K
MK')[M5:@)(!K#8`ZJ]!`)>?:N-]$E^)Z&ZBJH)Q&K9$AH)0:>M]Y#9/1JY/[
MI58ZG#S(M@)PLE,:"/?:NHF+N.&YI;@[K_MYM+_JN\/9N()K#:HZ+*/+MIRF
MJT)U&[JJJA9#):I*J9(Z&9A:"@N[J\F;JK-S#<Z;&5HKGGO_"@6L.[;*>;16
M$*"9T;H+>P56\*B\^[[D&1*.V;&I2;_S6[_X>[]\&;+7\&Z86K`'&P@FP+#B
MRKT##+J_*L#1.KHK)``"VJSA&AL@&P"H2ANHRK<A.QG%&:>"224+K+7I&L+H
MBJY5"L&/RU/C.K8:3*OZF['YZ\(M;+\P+):E.<,R?,,OC,,QC+KC>K3-VQFH
M:P+1:@7.>@U0(,2@BW+DBG+00"9+3)>5>ZM[0+>8Z\.W>L%,O,++)`B/NP>W
MRL5=&YE4@JF8>[8B+,*T&KF2:@V7ZZPLL`*ZR@J9<059*[L[?,<VG,-V>:P!
M>[OT>0T\:*ZGBJY`/*UT";/]5)<._W(-0\N>2SR7AB*ID2R6D<&MI$O!_1L`
M<[D;#QRHSKG"D^&I?*HDN'J]R&G!D.JK@6"OO\J>9>S'?6RM\0J_L)R=C$S!
MD6NN&YROMQRMLFJ7?@NMJ.JWO%S,2*N@GBS!L=&WOQJNZ<J]Q\S+OVP-E>R<
MGNS)M!&LI&R<P_*YOKL'RXNJ<HNJOEO+NUNQ'U&XZMRT1LJ_BS+*!%S$5NO&
M)[M,*P0%Q]E/5/+`$FS"?-O.`4"<H!S0;&P%II"@^_RW,:N7"QVA"=W%=3DC
M"VVR5$NX[(RA*!IAZVS14UL*SDH;@2FNL3'$+$#2T?K$M(K2J+Q,L\K2S%R7
ML4&N#(O21O_JTC:-M*GZS`M:QF6LL@PMQH#;L,T\TE*Z"DY<T4A]H7S,IDQ=
MG(L[P5]JR(9LO4LK`'4UP0*JQ87<I]9@`@)@R:CKP&&=U0X<G<L9RJA+P><:
M"!"+KJ70K0/*@WE)NR>[PL2IJN+<U'K-GK.\UTQ-)8M,G+\\V,<LJ_-,G",,
MO-Q;NU?`V+7+"L-KOFJMV"/,R([MR[4+IL1IJ-8@`"7@MM@:PFT-M(:,V'Q*
MEX8="%>`JI=K`F3JUTPJO\-:K*]:JM;@SE_-R"4=K@<\(W]ZP!$=LD<KJ2MD
M`OQ,P,#-MRX]T`)-T`SJF`GM(*0;K,%*K8^KK]/*S'^9T*RZJ;3_3:R?.F'?
M/=ZS'9K$^TMY6<868](&?-*>39=X#=F??:N>>AU?_-*FVM.G?=ZH&L4N'<5A
MO-U!7<;V>AO4G<]J+=0PS0*8"@4"`*Y&_:MW.N%RBJ<63N'0L-2[N^'.V<#*
MZT)EO$P,&W29<;ZHC;GGRJ?.B\DB'JX+R[;0R].8S,`,7,"?K,EI[:EBF9=B
M.;9I+<Y)'&FZ7`J^&LNTW,>SS.%&SIU%DM<G6*Z]W,O:RP+#8N+.6^7:.\3'
M#+QW3>5Y>>4O#LU:/N8(2]#*&1EESN-J7I<]3LTFX)P6V85N6[K'N^2UC,X>
M\;$+RK-\OK%^_K&Q:@4Z?M=7,+>[6NB<__NLK*!S<XWH`@JQ5H"NJWT-JX#H
ME0ZN=0GI=1L(^"RWG<[IB`T%<?SED]Z^"TV_$+H',SV@@O"L7WNND9[227W1
MM+Z@4%M>&SWK-DJ\HXZND5[IT:K:P8[H;+O*GUOLL>ZV4$#.RUZ7HGZ<RW3L
MSISLY]KLK&#MS6[$>W#J1JRK);BBE2ZI9>NMT`JW[+O!NI[N>,X1PZGD1WZ=
MMCN^:#JE/E[O9UKO=C[O?PSO_.[N_HZ=NFO.`J_OXROO^'[PW:F@IE#D]*ZL
MMMO'\=[O`W_DLJW#>8S'%I_Q>HSQ&W_Q'J_Q'!_R']_Q(#_RCAF7$2;R);_R
M)-_R*H^_)PRT+_\_\R9?\RQ/\SJLX1/_[_G^[CSO\SL?].J98>S:\S]_].VZ
MXT(/]$:_]$D*H+6N[E&?ZU0_]5;/T5*/]3N:T0M6]5I_]5D?]EXO]F`_]DK]
M$62ZYFSZVDRJ]$JJIF8*VSZJ]&T^IN(I]T.ZXVZ_G'5_[T':UT7*YFR?I8/_
M]D]:^$"*^&N_K(??I(HO]WK?]WM?]#\JVR7;'"4PQ:-ZFPG>JI?_JH'@Q:+:
M^=Y=WG,I5,@KPZA9Z<=YM*7O^<.ZO,W!L'^9M7'*Z9U1IXD9WA(6JH5)S2<X
MZ,]=X10>J^(;JLB?WNA^IS"]_,2/VL=_X<^/L<PO5.G]N=1?X;"^F`'_@*G9
M__UV.OWA+^"\&*#",^K77:!WJ?/V#.M?;>?/3*_6WYZ!,-_P><Q+;PHE@)P1
MRY]'N\$`$<C:-6L%"1HL.##A084('3:$R%!B`%8-`UD)`&U@((K7`K&(N-`:
M-I(E39Y$F5+E2I8M7;Z$&5,FRH0A#;+JR(ICQ8<21?9<5=%GSY_6!/`<"K&C
MS8A6K%Q+&K6HU&M7K"04A'2JR*I7#0ID*I7HV+`&]SRUQHH%P:$L6`1B6W.F
MS(&LV%X1,!#:M0"F%%ZSJY?M7L&$!Q^N&Q<Q8(\@V09FG/@C9,J*[5(4G%BS
MXL*//4MF8=APY<UV)W^VG'HT:LA_24=F_-&P_S4HJU@$MLH6,VS(K>;^!AY<
M^/"YI3];VVWMRMK6AYN[=LZ;M><`"*7710[M]?,]S&&OMBMZ^F9K'Z^?APRM
M.WK/L]E#WSZ]^L8KT`=:42OP,W&5!QERC"L`N*RQPJVUZC)PP&L*9,$KON`2
M,*$`5@',P%+8*A"*`GU:T,"]EC.!A2L:JZLZ@E@1H$$3`H%FOFO>$NFCC][J
MCH4],'0+BK\8W+"\`$Y,4"&UW*JOL12?"L0$!-U24$`&:^)01HS`^JM*GZP8
M,2%3KG(1QH'>BNLA_L8DLTPS4R+KL0G9:G`C`P.SQL"K"(*"2#:?6HXM*.J+
MDTB%DG3*!#C_?#,M`_]U1(ZG"`ERJ\#ZP"SO0(0$O**$*RYR2\A"&16Q38*6
M8O!`@D(M:#DF!]I-3H6LFG%`HAYDD$,K%S*/H(O*LR[.%UUMZ,R2*MO#!(U8
MN>+'M(S-+<X!._IH("CTP\P\:UID%"Z<[%KN/L<@:W;!/=Q42)`23C26+Z$P
M`Q/%\-@Z[;15!-BK6RS!O:8[>G?#%UJANCVV6H($H+#/49\23TC,</*L(KL4
MOL8P%_=B3E""UANH!/TZT^@:7S?FN..6Q-MKMD0K6HY"M4QS#(IO=U4.+4AS
MLTTA,.>]9@6_D)/0((<ULF8%W6XZJN&7T<K3J2_U<_A<O\Q%E6=D#\P3U8K_
MI(VZZ@.E_9="HUGN$.6_0HY+@"S330NPLI$BS`JX]BI0[>0"@6L%I`?;F*$_
M`W`K@"P7A*O"@HQ-JR`L@?S49!.3_1$J%BZTXL9(P_R[[X2:I1>G$A42L"HH
M_(9(D!4*HKS%@<Z""IK/J\J2E1(*,F5UHWC2KJ",E3W1=1)Q/AI5_9R"2NV(
MNK6\,0.'OXU=D+Y"*Z.Z!`AD2^:E\CAZZ3N&<BJ<\G;,&ML..A[2LHNO]ZEK
M-(1JA?#F`],C)(]__:$&H6+H*`F%LOA+H7C'_;:'Y$^TH'1-@%_Q]->5^;&L
M(#SA"8'F9)6%=$1MMEI+8\AE*[1,1"A@,A7Q6#"N_X8`+BU]LQRJ%*<@N6QL
M,WA17)$(U*EB>20OL,G1<DR$+XT\ZQJV$5';F$:BXY0@73RTABD`9RQ!E`LS
MR%F0"F/C&.!)S$`RO,R^0G.['Y&&(\628F`0=C*"1.UE4*N@%H>8*\[$Y8<$
M6ECQZA*($>WF-=&87ASE2!SC:"91@"G7<O;$@N?MAC!$JA.R-M>R>A6I!([*
M5&[V4IW5*&=1BYQ6A0*6+H!U\4`PJN)A7.2B$BA,;R+JR^LFYAWT6<LSJVC;
MU;QC%`K9;"-*2B*]]J#$P%0R3HXKXV9H1II*7BIW^_&5W4!GK!"^Z`JL0*8G
M)?(B_"0351=23AL/2!%G\O\E8-*JB4%6D;G'5<Y$E+O&BA3'Q6Q*2UHA=$HR
M`P,I<S+'1!#1T-$(4@I1-4MT]RD2C&+YD*\<[UK6@1_\$J*ZFK!B17`3D%88
ME<!L%F2.#X4H71K:4)Q,<D"R<6:<H,F]0&0TEC=<"Z3>HLX%S:E%@S((IS`'
MIR/J+SOW6>"ELI3-I2P%3$E2I]0&DIM/V<5+?SD-3Y/UMXI`"F'*.=!1H=+0
M'>ISJ0%=:@&G@AD!P:U!5$H(Q\`6KQ?&B6@5M!:\N@@7WYU(I^J[%1Z%1"$1
MT0ML01E(*;Z9O4!PD%I_TXU0KM#"SG2K6^]BFPI9$5AZ=<M%4%"F[NC5+VBH
M4:3_`[K"YD`V0;SZB`5XP^QE&\:U@:P";J98#I^T=Y`?;?4Q`XEH:E6+DG6M
MAC#]Z]!BD?FB?0G$>Y`E&%]P5S.A(+-?J+H)N_(*W.6M<T!?).VE4*,\OF0,
M,W?U2$%LV$VF[?5$+KNF*@/$UMW-:6N!Z&I[LN8O[&4V`+!D+)LR%CRX=51O
MIMP+*^I6/0!MQ$0&K4B=<G=4=!YH3:AZX)?J\\]_]H@A_XQ:,;=9PW>^CR,#
M:I%7(%+784YSFB3S)V8*Q#H3&8W`$RH/\RQ,KW@6<U'DJ\K%^EFBUX;E6DG9
M[39]JN*0K-;&JZU>3UX\K99.;3[FP0E<[!6G?(J/-ID"_UWW7":0R3@$&B(&
M+T\$L-$(/7BG2EZJ9HM24YX\UD<H0V:;B'H[+\%(+7,:LDY#Z"6*'75+D-NA
MW,IB$!M-N'M[HS,)LVI"V`#O&IV,JQ7DO-E8:6I/P[75N`S3-H2P8@7'G*)F
MAI1;'^GG(T_A(&#V8#-?^JLR;(S7%>*KQB&-B#".O@(J32-J6^EM83<L$"O*
M6FE#X>AX8Z7@P#ZCEH-DNI&;K;5Q6(%8=L7:/K#QS8V5/<<ZPB8YI'/6^Q1B
MBJL:;X#E`>L9'?W`A5W!?/B!#C2N^.I`U.E$CR:6@I:#'U%MK3*W!@G$A`*-
M8AUSB>S>;+S5-T"V-8C7=BG0<?\#MFU3[C6NCMGP9U@0,.5F1CKDC(RC;?AN
MH6AFOF7))1FY@O&0P+E*K^*XK-BBUH[/RN,GGY7&,Q[RK:2IY7,NN<A?OFR:
MQ]'E(.>,QG4>\XWGDBHI!WHN(25SGYO<Z#D_^L=Y7G2QP!SI,M_Y03A6F?B*
ME^K2J7IBLLZ8K:_KZE^W>MBU#E+F=GVS8!\[VKF.=;:KW>MB7[O;SP[WMZ?]
M,"%#;<WUKM6[`WNS8,-8WR<[>,$7/O"'_[O?3>MP.RT^\81'O.,EG_C(4_[Q
MAK]\Y0&?><Y+_N(W=_K+FSYZT9>>GUH!/>E3;_K0K][UK8<]0?8^>U_E./:L
M5_WM7]__]%SM'O>_]WWP=3_\D?#Y-;^.3[.3_Q[F+]_YXVD^])^O?.E7G_K7
MCS[V(0-'VG>?/]I?S/2S/W[QE]_ZY#^_^<&_?O1O!OGC^7Q1^#E1^M??_O?'
M?_[U/U'([3^;PIP__[,]`23`^P-`IJ`_[U/`X2A`B&C``!3``WS`")Q`I1O`
M`I3`"M3`"\PFO@,\`<BL"IJ\S0,\`!E!Q0,V$[2\R3,*!2&,(L(\L#$?S4/!
M/UJ;Q+N($X2\%RD%AW.\)"'!%11"$D0J4?$?0<,/SA.*!63"N6@M\8*8#;HL
M>QL[U_*[=6FKM;-"*ZPH+81"S\C"Q.C"*OR,B_A",AR[74K!_Z=X0C3TPL?9
MO#;<H2T\PS>\H3U8%$()+Z^+/]VX&&G+/8FH%>`;ON&R#GX1BW#2LZ";*LE!
M"&QBQ+'8%8_+E6+:"DIT,5D3+;ZXD*K('J)HPE","=N[$E')EN#K"DP</9X)
M1`4:"N;".`9:O3#Q1#CCG5:T#EEDQ,(1OJ30#N_IK/KB)XXA#[&)C3V<K5.+
M%\Y(IG))IHA;QHT(DP'1B6J,+U8(&,;PK3,B"&J++KTHC\VREB!3$#B!"[AZ
MC-E"F6:*C!7JJ+0P#78)KHWH+7),QU?;"&B@I^4;QV-[#:321E)S1M1(-E$T
M2)7`ODQ!--`)KE4X('STB(^BQ\1P2/]X/!%\G*V@Z"BP\(B*$RXUK`M!T8E[
M;)C98J/;R$8MDD;#>,>2O*KUNJ'E4$>%&;AR/!$%*069S,:6-,?F\D?`&!:3
M.;_ZZ;,7(HV+FXB^J44W,17=.(MBJ8D&,16F!$2]V2LGP2)P48Y9TJR/""WC
MN<J*ZR>WL;1MF8]U.Z9#;)#NF!.OE#:.F!>@L@(!V`.X4)4@"T..J)%264N[
MH*=UXQXL<0NJN+1UZSFE*ZF_J#-CFKF#=$R:@#D#V['E\$J%L((]N0)Q.A:K
MD#:<X$S+%)'0$DQ7B99+N:R*T)L-FR;.K*":"(`]DI1\B1012:#DPI+Y0([/
M%!ZXB8L92<O_(I))KSK%"KG-J2$21=%-I+J(H-F*T/K*I&.(H1NH<OF)J5,X
MQ$*HWJHI:'H>(H,@6_$94;JC%OR7`<&?NO([=`D8YF1.,,FZHT*BWXK/'6J-
MH[JKA1LOVED-?H'*L\(7I4&5I:&=.*&0;&F,.(P+^"RM:MQ(G1`$4[*&]3",
M3M&/]/B[O'O,#-W!*.PHMJ0LW?J2!7(,?<I"$M6/+(PG'E(7,WH*$_TEF@$;
MM;`H2?(7ZA*-[@23/7G1(ID-K)&1B?DJ2_I.ZJ(9?3(BC]R\A`.OC7A0!G50
MP5@!0>BK%R+!/@0P&>(05A"B<[F@E4D?:2D7(^52`8,*1&RK^32S_TP[(HNX
MM:"AG&+R$D$TR[_),ZC(PT=L-]%Z(=291A,EK8'@FR2J'3I3H153JR3:*RQ)
MU(M!'5KIE%O;B@R55&P@19$(.(P8E)L<()Z2EDU=,C>!"J%""_0D*D)9J"%5
MHZ'JH(R)2^6)DZ7110N2)R^IE:B1B%OT$>[IP6N@)Y$XLYURD`>JD-N!+;[R
MCW,REHO8*ZM8UM8$1LH:1N,+FQMY,<A@$DCI3OSI3O1\%\M$"\V$%/R!P5<Z
M.,P2@*>P%T^+"V^,HK0(3VI9)(\4(]("#(E1CD$:.F[)'D5"CLN:PE7I)'Q9
M&K7`K!#9H=.PA@?=M3&"SE7QCH^`)EM]H_])?<R$C""B3",6**)(RD+*8:3Q
M*9+=Z!8=_2C@P4__]%>\(2Z0+0U[S1/\$AK(6J7(,($9!30>HAG-\-'L25G-
MPA:IU"Z?2MF\`+*#951L:<OP,CG(P%AV,4I@.A,`?!!GV1S2LHL=2A5]`1>E
M$M.S6DS*00YJ3!R!<C3=<$@YQ1P*`1X7T4PH65LZ_:4(:2AJ,XA=>B>!2I_'
M^M`LHT;V<4!O6AAU4B>>@:E5"2/^L3V*K=C_FZBH$:*;R`GF/,^("0S\8:<#
MP9]DP2;FDC8"#2C_X8EDL9O=:-4+ZJZH<LTNLZV+@II!@A)=W"8V44H<V:FJ
M/<4!A9]!7(K^B]#_I#(6[1#<9TP(Z9PFWBT^7UD\$T@=%S%0\@Q;.@G2\O"9
MD\K/[LS640U/6WVRP#"%L#(NQ%"=GPDB#II//P(V_C*6]CRN&P0;_JP@%X&;
MWYK:^6TL+2*KMIRBR9+/*D(D1'H?PL":RS08)<10Q0U%.7Q"%M"1"L$M\67,
M>G&,`)#2!W91"BZ2)C(-]'J1I?&L+YG@G`W(RAT1F!U0B3T[6P(3?:(9-20,
M"06BH4(+YFPGV:T+/CE2*UF7[WJAR^P4__V+*(6.)87"NN$0N64FT@J$G/Q/
M`2N1CE+(6+/5`-C55+E@=PH$C=0<A*K;M\A,*F$7$V`W/FD1N,$(.@,W_[0]
M5)D<,F9B*'*9K;AL#)VP5]JDS-[9U,79B<BYB"XI5'+%(\AXJJ>JBR'AR!7`
M#RN#'@,VR$I%"`/[JX.JDZL]3V*JJLZ4XB;3G"X:U2$JJD-6&$%Y,#?^"-?M
M(+5!(?^1*1-8FH]`QP8Z%VNY9)?:B4S%*8VH+P9&Y,NT*OR%*W(,U]LHD(K$
MFH1H,^H4*($ZH$NKS>Q$/8>25H6HR]A@5-]1V/*XIG+D3;!2+@"^IFN^+EZ]
MB+.PM&@6#+C!XOITR#.VBU6(9C8$##.4M`H"JV@VC$N!R+0`-X75(BO("JZ[
M%9Z\E8T@9PQI4%NQ2<'!$.NC#3:B0H^H2^N86/]%#D7LBU]"BR2=@(OZB!>A
M*(6+D35D4C&U(;=]$8H.?F>`"V<)$^D$;:8*?0PF$\&J$`1Q$THVVJC`Z"A;
M@28"R>E][BUV2;4;<FF=<)!X26("$<>&XVF,O(J.,NH@KE!&_;5X$6=*8Y4S
MMKA@FK^5:T648^2E`[J=BSJC\SU5/$QA.L"G.\Q>Y+^V1CD8VS.);D((_+FQ
MYEW>V\6SSNNTOL2DF\70N^N_56NH(^N-ZSW&K9[`1FMG]A6Y,[O';CNZFSN[
MH\$-'<(:Q&S+#L+-SNP8O&S-[NS*]FR\TQBY9D+01NW1#NW.^VS53FW1AFW6
MYNS7ENW5UD'7IANM)D3_7"S$W?9MM@;NW@YNWB;NXS5M!?SJXA[NWQ;NYE9N
MYV;NY\X]XS83]E._]L/NZ];N].-NZ^[N[/[NY>.^X_8^[S9O\#[O[4[O\&;O
M]79O](Z_#93O^:;O^K;O^\9O^R/O!<SO_O;O_P;P`,=OCM&8`L<&`T?P`U?P
M!&?P!7?P!H?P!Y?P"*?P";?P"L?P"]?P#.?P#??P#N?PTM[O[H,C$/_P$S?Q
M%$?Q%5?Q%F?Q%W?Q&'?P$:?Q&K?Q&\?Q'-?Q'>?Q'O?Q'P?R(!?R(2?R(C?R
M(T=R\FZ%*Q"$)'?R)V?")2](**?RV1.B*ZCR+-?RU2J6)M_R+[<Q01`1,"?S
M_S+?F"*:<C-7<X\!SC5W\S>?B2Z'\SDW$W'!<CK'\SS'!C37\S[_C5;0&S\7
M=#67\T$W=)80\SL_]$6G<CYG]$<GB2N']$D_\D*G]$.W\TO7]"!W]$W7<S''
M'K?P<D\G]1$'=`T:]5)_<_-R"U5W=?(NEIY]=3@O(@,)@#2?]5S/T%8H@1`1
M=5UW<UD']F'/T/(B=C47\P"0X&-G=E&L]4!O=C+'K&BG]@7T5URO=BB?PFSG
M]KW+3!;H=BTOHE0/]W)/+4`G=W-/\@!0]W9/+0#`=G<G<D67]WJ/'G"W=R2/
M]WSG=_[8]WX'^(`7^($G^((W>+D6<9-(^))8>))H>/\%1XF'E_B4F/B(I_B+
MM_B,/XF*WWB,/XGQ/GB:FX64&'F4*/F3.'F32/F26'F2:'EL>/F8)_F9-WF:
M1WF;5WF<9_DY%_">]_G^?OB0CZ,,_/FB-WK_<W.=:>W8OFVF7_K:INVFAWK,
M$_K4FGJGGVW<QGK;?GJI=[RZB[O32OKE)GOH+GOI-KV@K_KH05VT/_OHAONW
M=SDW1^^Z5V^[;V^\-XZUAZB\O_N_]_O`?^_72'JWAVZNAONW7FNSA[D"YOOI
M\8^XOSVFDWS*'VS&S[VD1]#-OT++0V#+2PO$H@^U$<S@XGPZ7)4]P9+<"C4(
M';:>]OS8/_TZ7)?'GR.NSWK_I[\/_5B%JXZL><-]%`RB'#J+WF)6?FL810K^
MJ$^\L<=\W./AF\2)9FIFXBZ%9&K>:!N14;D-CF@QPT]$VY<CNP%_TZ,G]NFH
M.O&L3/UM9`H*=3F@V_"HV:S\WZ-[P#?OHV!.Q0DCU%A:Z`,(:]>L7;DR<"`K
M*U>L#+06X*!"@:P.3I1(\:+%C-<J;L38$1O(D")'DBQI\B3*E"I7LFSI\B7,
MF#)G>N1HLR9.C3<%$@Q4\*"U/0]Y=M1(=&?1I-9,L>CH\^C!$JP>(JV:,ZE5
M@3.W<NWJE:2UL&+'DBUK]BS:L*R:L@@D]EJ`*VFOL6`5R(3<M&8#C*5K+>*U
M0"S$_Y9JJO<PXK+7OC)N[/@QY,B-&R:N7)DNM$!6WEHQC/9*H+50*B:FZS:L
M3Z!A`P<J)8"RY=AG)=.N'7,UM&NY<PO<K?N@;]Z_??<>#OQW1,%`63`4[ARN
ME55P31&M?EP@X-REY"Y$.#0PB^?$C8O_77Q\\(.VU[-O[_Y]Q]PWY5^D;]%^
M?*R_)ZX:[-!\(`\)=]\UG05R#12;`;4@5&L1U1D+$:YFS6!3U:<??A-EN-^%
M-EGS'HCLO37BA"7R9")E*9)XHFD;^2=07-<@1!I/`1SXET%K15A"A"P$P()!
M8K&PRH1UT2770&UM!(5G)SJI(HHK0LEBB%5:>266),DH)?^747KYY(B:)<G1
M%2^R4HJ)5T#AW4!6_!CAFQ$"905#8J4&WD!BWM4EF%].^>>'60K*E7XZ7955
MH;\)")<UO#%W4`![:!0`*P*Q(&E'$VFHE(4506.8FA1=L<(>>PR6***IXC0H
MJZVZZM6AL1HZ:U)M6>K60$)U).%%@`EFT:::F@=7I?JQ(L!$0W4J*ZK,<O0J
MM"J1!:B??/X9B``]FG`C7))ZV>)?=3(H8XJ7$M56I5!<`<V$,BK7)[S4QMM7
MM/7:>R\V#<F[K[4KLF!"CX85V!2@W5D3X+A;+OAKNT11JAEJ)DS;;[45!XKO
MO8T.NZEP'%_8L7$$\O;N-0OQ]"C_R+Y1>FM80#+GLH$2&=E;F66R4,(5'.5F
M!:[C>2SRQT$3B#'115LY;'KG(1TR><>-9XV%,E>$,%'C^7JJ%4R6V=G6)Q_H
MVQX4"9#9RVY&MS1Z3"?=M-*Y&5TOQ?-:K"*Q8DVU6HPSJBC`C0K-R`K@@0.>
M9Y,'R>CW0-MNQ!>_<U.\V-N12QX9;(W+?3F"##5D:\DO0E,IBV4.)(BR@IL>
M%C1\.0FDC*(?Y9GEL7,YN:O-TJHJK:M06A3?`PFP)HQ(<A0`=4=:-R"DQ>[4
MV4']K:#D[<Y*3SOUU=,4/?:V%\HZ3\P31!5=`D"5H$#85CWN1$!"!<T5/#+$
M$=3@9X^[__;6"RH;_I;)V]>*A\%FUO[RES_(V:^`!BS)_P0X0`!.+(%.\I]>
M5#,Q!2KP@$=KF]/0IL'R/*<X'ES:!SO(MA&N380E5!L*TZ;"85FPA0?,SWPP
M),,8QC!E&Q2:<6B80:38T(8Z)-`/87@1%X(H;K)S'!(Q9\0E)O&(5"(B%&FW
MI28R48E4O*(5L^A$%46Q/=JC'QBE-S\Q?I&,8314%]-H-#.R<8QN+.,;SPC'
M^JFQ-A.\8\,:!JAQ,5`Q?;3.B"3((#_JL8&&Y%\`3:25.K9B)(T,22L>"4E'
MBB22(J&%)"4)24UB@Y-IU-<?^8?(0`)2@J+$8_^J,\I5WI&/=/\[9"I-F<JP
MU-&./F-:1>RRFHD$PA0<645K$!((002BF(*H(0Y_MA%B"F(/RENF=.YC"FXI
MDY?$-*:GBCG,8-GE.(%@EVZ@MC%<_D:-K7@3)`,0`)"<$PKIY%%(?'2%>,8%
M)%<(@""P03H?L>"1Y^QG)^^ISGS6\89*@UIHBC/,KRWS1CT)33%+0<(4@M`N
MQ@Q.-XO#"F)F4*.L&>8>0F.>C([T-/LI%GY.Z)M:TF:)<'F4S%8F$)NY"S39
M>DH5I^00;9K40,Q9C>Y\XA\HF:!2/'4=07A63#M=JDQV>]$U"F-%`D9QGP#M
M9`!PAE46A$00-^,J2'Q$4)#\""3P_*?_(/;)SK)BXYY7\"H^"WK*/S')!)0Q
MVY;Z$QZH[:%,-LJ9%KL$)&TVA!4FX)FMH#98F3[);ZP(:3%7EB302)9"E,45
MA9R$+,>Q5#))`=D'*?2K@9B"20SERW=@A-E$025Z#KK(6G:3LR3="'I)`0Q1
MH(!9T#!H9N\R$D<XIRHUWI-T_N1G-+!13WN6P+AA!9)([MD*K\[3JV"=;DA^
MU,@(-;(5IO`D$<6X$"MHR!HX`YYIZO(@@K56*<SZ%/QHVY"A7(I--WDM4:1*
MN/TF%5(#X:U%1IN]SD;F@;.$T53`2=X`$,E%=)&H6`00)#\6Z&"Z=>#_UB)!
M,9%(=8'9C(EV_Z=9T-%E(BG:W8<+Y%"[J>Z4TU(C"Z)P3H+^$Y__C&<_X]I6
M':\52`%XI'8=R5:W$CB!&,;.0G"EF8((R2YU"@M2I=0:5C`9E:LY%6Q`/)#=
M599Q9+DP66R;V+L5*&P;$5]_Z*9>1:Z(P)#)(`>3M)T@B0]ZRLD.7'IVG235
M916]*R51!`.A*Z^V?*=:2E,&I.$!*<=166-!\>)GL\\U)V1*6J%PTMB*""EW
MGIT$F'27NVFN+C="GL;Q<K=Z:K)>]9Y7+:A*AY54:)3@OSX!WG_Z4YS.G,^#
M]PQ-J`!-D9>I]SJD2U(TX0).X7B8V<N13FZ^LX*%*.D[`^I.$"?BYO_'N/1A
M3=&P9&VEX=7@I;`HLI&,6"<8)G6&W?YA6(`L1:<(W2@0*UB-@%=CLA258+6)
MM=%;1.J7*1(%-(]+(^GRR6FL7J$5.(.G/@-P"FPL/`H\!LD^.<E/?[(5XP.M
M)<'W12<*5:HI(P_,FNKV7\^`KEU7@W*[7\;N1JEW*BWW3K%\A2S5'"N0)L-;
ML1QBDV(5^TF%"?GLMCT9^EE#<0_AF6C/S)NB=@3@)1-Q4:"'[3.Q8A5<][K.
MY)QGB9A`.@*.6E%(QI^9*<6K[JT03H&BG.%VL69,`>BH*2Y/D$0!2*/>+G0K
MN?"1P#6[KW[NJJ,H7K9TO2FNX]E_Q<7K:P3_52FNZU37N0ZX4G1=UMB>+TH1
M=#/2::PWR_(:[Y(M63*Y)2'/#,MW$*7TQECY2;L;DI%6-I4>6=T:$B[L_U2N
M/G)9A^!X.Y!MB0<UNQIZ6E46B\%0Q+"WA'0MK4GL3)$42JH2T4?J_'@[([YP
M[V<UKL45,E@#^DBQ;A7CGKZQ&D%)2,X81#.IB8A#>`]B@K!<,2=73L(,$G;L
MG\TU4.H\2=2P6+FT'-;)C&4E!%095BB)Q>PQAL;T$$8HR1ZXB7SA%LGTWH5$
M7;@$Q@;:'\_X2I%(%.=$W;%,3:(!R`O"R"YM!#A!S0H<QRILQI#X%V\`6'[8
M4!H%@#OI$\"T'\4M_]=R69?>S5,F^4A7E=6F_1BK-1*/5-?@=9%!A0RV14BE
MA,K9+<KD81#_L8DU",()FJ"8D%A_(=A!L<EX6)MI>!#DP9ZLU06'T84@\(3;
MQ9K;5*!7=%NEI`Z2[,Z?08WX6,J$L8OMH<F1;`1//>(`R@B9`:!#$)J,,!@"
M'MK!0%7\$-J(A$>+N,B),!:U<%\+J16K&:&KB9_A'>'W2>$_29)`J=/[914[
ME<#W'9[BS964T$FZ80U#N$[B1%.4T0W^P=LC\M3!#(70A<6%$5]/I-MIK`Z1
M2(2(X1O!^**^\%8@I-R#K084F%F_^"&LA)U&#`BZB2#`-9O*69V;@-:?9?^-
M*WF0UG@804R;\LU7F:S6\`2=DL"/*<1%7&2$#ZX`A$`8>(Q1%TU7)N73=(V5
M('17PT%2/J551*95=Z65(V%7=`U")5D2R+F1ZXQD4X#@\/%*Y<&/ZR!,?`&2
M8!27-2J$RXA%7`S?33!9KMR@1A`;_&C81$`(ZU0$U0T8.7*%%I$84JK%B`P.
MU)`&C9B;1/!BPWR.*:GA+GW)N$&-E[3<B433+@5=RR0;GRQ2498EY2`1*RCB
M6*2E5L*&4]H-B@".1("EW'!E4PK.44AE`"@B5Z:(7*9(-0)'T$6>Y9CE]8`0
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MQF"J"\QX3)R)8<@D1"!`VWX4T[#X!'E!)E,B!*0%VD(,)HNZ7-!EQD2M$/7\
M"(^RP%B1WW*U#X]VG#IU_Y<ZV=/%8541BM^0YE.0[9@Z#1[XL94KE%_'2=&(
MYJA@B%1N"%7-,%26\F%#*`2W](9H5<V6AAUO',RP#%_+;`U#V<5H*%0>'@28
MPAF>9BA*T.:Q.)/Z"(0`D!?@F)1PVHE46!]060%>O`473@5FE4B+60I,#0S@
M<(Z']D>QX!39X29O$DT4>AQ8H2+[D8ZGL=^G&J&I$=Z.-.%5P5_&':%#F@`2
M@A7[^<@>5$_E+!%S)(3$M$E1@9U4!I;-)02NS10+O(:0D)>'HL@*!H6/#%O@
M[)(`<![KB")E));LZ.E)?)9'@)9\P1XX@:"WMN0X&8H5@).`$::F'!K:!1>N
M\/]2-R*)KB%$K?D>3_CDJ7`$8(31CN*=$T9<J4*7S7B<IP59WNW86-F3CTJA
MX4E2D`TLPK+:.AVLCT@#.R%H=GX@KC")=2!*>R'%4IV9L%C?H9E"K>V,]CG%
MH;G(V0E,#W++4$!!LFE*K[Z1MIK$<59B]T33[_4+L6P-O\A=X;AIYS5?PXQ-
MD:RA-2#D:"E)F968*=FCQ9"EY/RK<H$5D6$#%,05J3)7J<(B6XW>2'!7JL&?
M$9).%(255OT3=+$5*MI/@@8M]@5"V(PAYB@5%VK17O)$,;5KT$4?ZME):'P'
MW082Q%!>4Z1&(&%?8=ZLEECF9)K/N%B=.=:A8=B6L#'_FYZM86\9Q(`PQ4BQ
M!:9XT*3VB*2D1@?9UF=F&NW\R%L!3*B6FL!&B'6MTQ1VTK^>'R1Q6JI=[2.]
M5"-!K.[&19DH(<:Q'X*N[IY9W]),WJ8<3ZZLC#`R)D2D[$.DJ\.$'HP<Q_4>
MVJB,BI'L#!089,DM9C>^YG$X+EA0$=64"%V\B<3@&UT22[KE19S<K_#XR#16
M[XIX3XITQT&HE]^,B/>X[[C1C<$A4:=BS*C)TU@)+]?^"*@=%]BR@,7^RZHY
MU^`Y7/JY:I#B12?!DT"F'^Y>Z>0`Y^4THXI<0;8$0"'*I<LA"</`">_UB)#\
M2*"Y!;9`">.J1?R63XX0[H$D_^2X#-63I%FVJJ](;&=@B(]^@&!%3&H4WXC!
MS-""K*"Z`H7H@-;Y"D0I*(A-KERW7L,-"E6D[1>_MBX+N`)_RNX\0>Q(&.S"
MZ>YS^9B/-BP>0S!!U9.KD3"2)E[DL)%A4=-!,(G"\,0]61[P'%NV0<2I?$KS
M)07E`L7I&0GV0LH,6DI:CLJ[SA<9*;%("-#=V(U!7$//DB<;&H]`D(O"'+)W
M],6?KD8!.U]>J!C@T$D-SG)?**L`[U_)Y(7^T$X46NQ(9.W65F3OTE./A=7%
M?16<T%C'>;"G;2T30F%6@163@(0TF'`@"Q#V_<5$1%EY%HCFO,LJ&P[QG1@O
M"6J`U/^@"$[+L6Q)-WY.O.U%7WZQ[Z%)OF6E98!R2%P@GHHA"R#DY%E=:2K.
M".H(DT3(^+*.N,QK#ZHFR806R<@D^-9)(-3KTCP%VZ46Y&%:!O6K)Z'5.9G?
M%>)8PT'P6S&DJ$GIJP497$V7CP!9VNH=UL:%(&0ME@;T"(V@1.Q<&#*-KQE&
MU(`O"S1TCP1&D1Q(0;B,A"!B9'Y'4]O,NPT/>0S&':Y@HR63<?@S2,PF>%3*
ML0PQ]Z1(0IT8KE1KM*[UK;2)EB&96!P@"B\.49#+`!O6G[S6R\U7L$+)`N-+
M29N$(,CJCQ#4*I+$+,!)QP'I"!O>+&"5[4)V5WG?'1NAV<[_(B!W<T[97)+4
M23&JQ<T-H-&*M5Q&J]W>!3HO+;(2,;Q@KB1^1[4^"F6,AK7"ER<FL3]SZSF.
ML5]=VDOUZ(W\"$;\&12@EV)2V8^\CW?P4SC+*C^Y)D>L0"=#=8$(0(_&H&UU
M1ER0B8*D\>2`5R51$GAW$GF'=W>5]R1=;";-)R6%MWMC+!,+1G('L'7S$_`\
MJTH:!DNB9D8_=5)([E_TZ$!>1#="!8#3A?Y61QJ"QX\<B*:,S2=[]7&F]H*X
M\CF3R%QSR7B6DH4KDM2N)X2"^+7"S]3^M5<;9MRZE(@#6B'IIG@JT88'<&A3
M*"G-(_0DT8F+IO)"+H^C;X_ON'D(_T*R`7EI=A.1J\>)4Z>/+_F1_[B./WEH
M/1:30WF!4/ESG'BA&N=P3GB6<_FW)+F2;[F8=_F8:WFAYGAT,G&:KSEVJGFL
M@/ETMCF;<Z><U[EV8OD"+:@J41"%H05ZZL\$/JA.!3.<^Z8#(09Z5BB?^WF@
MA_@X&]A9R-*AQP:6@_1!45GH`5.]@09H5)JEY^A(`=:P:/JP5)\&J2&F5P?[
MO"AJI*7<!4M'@7JA&SH&`LU,<:EN%"[4<+IF:.\/<O738/J`K'H.\[JP$$>)
MB+I-3#=K"`MJ".8'55-72W@3R?=;M,^I-+@V>7DFOM51LXB;E'+\%-/.^4LU
MTAOYE(^-;/\IO1;3FCG(O3*?`L]Z;^:JQ5@W9JT%U1F(-@5FEQM(F8!.@`@5
MZ%A49,TOCA`.P8_ILYY(O[%[R_1%97&65^NVQ5<$=3EXGM7KI'[L/-I.%5=6
M0E1QL9F*47#8`<L4X6:[G2+)#5Z;<BLDO7<F&44;R;2%ZB2RQQL%L\1/`"/)
M4+FIG:ZLITC;E0D/:\?AF6ER1K0KLV"Y[(#'X9*L:L4-+^^OAN^!(EX#0OL%
M_CG)`;^%/1K./V+6;YF8F!3=+FEB"IOXS&];BOM)"Q[:D``U>U5+W[JIGYPU
MYR+RDP5NN_0PE`G,4C!C?VU98`#SM9:IQ>0X$'6(W-W@4/0ZQP?_R62JC,%5
MUFG>ZW>L`G>H9@#K69<J"'&,\A7+ZU&+3LA^D&2)*=6^?5&"N@CQA7JE#J,$
M16HMR'B8EO%\//*T?O*POF.&[X)H_FCQ!M=0RFNEAQ5@RJ?#)BCGE'+LH!UF
M.^]-B*N/2#HZ5L!T_XKMU)882;6JA:TB'8?)LJPBDE-A_[K"RT],%>RC^!%!
M`[*D1E_Y7CA_%6-I9>@81D"N'$"P$#A0X#5K!J^QL&*-X;5`)@*P8GCPX)4K
M$PTRA!8`(<-`+`($NI;1&BN.%`]"6W60!:N1)`VR8@$38\V&UK#EU+F39T^?
M/X$&%3J4:%&CV*ZY/*@T*4*F2@5QM'+1_X0U4R<5.D488,_2K1(3=DU:DJQ$
MB2@#"$*YPN`5*UH9AO1Z<.K<I($X0D-HA85=BE8D7@E42JM%BDWM/KUVE'%C
MQX\A1Y8\F7)EN(@Q,X5F+8"U57T%7^ML[4J)CDT%'G99UV'?L6;+6M/+\B)F
M:";!IF2Q*G-2UW-Q>_VHNF.@*PY#S[ZV2D#BRTPK1Y<^7>A$Z]>Q'QPN4V;K
M@W*S8[\F0.0U*V\/CSRH?B)XNF"A7+S)T"3V0.BMCV0A4OMO^X%,&HR%XR;:
M`[_PQ*-.P049;-#!!TE"4#S<$I))MHC,FRE"FR9RRZ!`3%L/(?78NP:*A;)K
MC:123L+.))KZ(_]IE1:OZ\X$`*^8::(7)<SNP1^!#$JV:Y33RTB$CK0F$+:L
M$4BM)0W*JD@DJ8R(I4`8LL)`M[:$`JP`3$DIRA5``JDVD?22:<H]:I.--[WV
MZR])(F.::;0HF6(A3#K%G//((`$-5-!!+5/.I3D/Y5,TAG)<:%%K]CBI*>6\
MTHNUX:ZQ2,NI-JWM/#&UHQ-3E^+4*LWFB%125-?T&E51J;!L2R27C",.43KU
M(E37!3F$$:7^Z`J@5=="(O%7FHJU9BHB`P$P$$&<!="\MTX3,3[U`B",-!UO
M8D4`A##E3*F67K*I+VN@X*^[B4PXRU<8%]M5WGGI!92]8WN=2`"76.3_;]\,
M7XK0W0[1PRNF0$R)UEG?1*0/PX0(3$K8=UM:"L,F";2XHX:L$$D0#47+3<MW
M\ZW7Y,=Z<VXN@TLZB66(^++"2M%J8VKF%=JLMB,!!NP9+*7X0N@SA73$K$DT
M,Q2(/[P:'3#/G_FZ8N:29E),Y:9.SEKKK1E[SNN4.&OHSM&DY@N*4EE`U:L!
M@=7Y,&5Q)CK6CP1Z:[8<O_X(7('.=NIL@7Y&CB*FY=KJZY3CY5KQGO"=K_$>
M7V.%E<TFHGS#'3=N?'+)):]IK)J@F<WQY7XS:+..;KM-<I+.0DFIADK(;70.
M#UK<]MNUSHCDV66GZ.?4)1?]=92$WWTIX%>G_^ATU_/CD%S?C^5\\FY_)>NP
MNF;/'B?<;3>UMS0/M_HTQ<"_.E'-=#[?>ULQ`PQ47-W^?GR'8JU4?NBXSU__
M0.&?TD]%#T.I^/6)2O\SH,X.Z#]%M:I^!43@:0[("D<=28%3VA_7\J4]XVTP
M@X_CH`8[^$$/AI"$\TG<!5&8PNC<2X0M+.$(01A#&,[0A3(DF0I/5I+P[=!\
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MP1E.<8Z3G.4TYSG16<U6Z$00K7"G((RRSIW(TRC2$`H]Y\D3?&)CG>Y<9SLG
M(T^!\O.>1-GG/@,*E'VV$YY#0:@^"YJ3AS9FHA#-IT,MB@U3M`*@\63,07U2
MT:.(-)THE)I$6\$"CB*Q)RS`QA7PR=&C=/0G,/6)0'32BK3H!*<<_9A,)2/_
M"'C"DZ/^#(I+@>)2H<[S"D=I:E"6VI-6P%003U5I.TG*SZ&&-*LNM6E0&RJ4
MITITK$=%*C:BLDX68#6K\VRK1/G@UIY\%:I#6>I9(W.%60REK"]]:TF'<E6>
M`N4*4;4"6L/Z4I5RE`_O_*I0]\#/'/7S"JR0J%"CRI.URM,B\FSG6(':DSU,
M%:M?+6Q#IYI:M$ZUJ0`E[65ABE?$-K2IITCL3]WYU*IZ=JDI;2I''XO9Q`Y6
MHCGIJT\PB]93R-2V4[WL;-G9V]86-2>W[:UGM6I3YXXULL"5ITJ_ZE+OUC2J
MG?4K5),KU'^2%:"?U:IK8?K8[/Z3J+NMKGJ!FMSW__YSG3#%[DZ2.]:XZM>_
MGJ4O;87Z5.U6%;"/L>E99<O.G(P6&TJ-Z6^1JF"CRA2@"WZI<?F[$Z\:M[S&
M)6M-_VG5#_-SM`BN\&H1:UL37R$:_,0K*^C[XLQ*%JT9KNZ&FZK@'P.UL/RD
MIW,UJ]^Y#AF>06ZH4AEJ8MKVUZ\R-458B;SBUII8ID]U+FU-C-@/:QBM/(GO
M?BNL9,WV4[S31?)0?]O0TH*XJ+HMZINI*U.O]G.K'Q;$*;`!!2WOQ,X<=N>)
M6PMF@0;YNQ_.<H,94P*A!D`GE/[)9ZG<X0YK-2=K/>ULAPI/$U25U'+N\V!'
MW-&T?.RY-[TOB,.:(W92^?_*JRUL8:.PXA<#V+YQ?NFF.^KII6*VJ106MGJ?
M.UQ!F[F?R,6G>HO-630#.*4\!JA+\4KJSA:UO@QV+H3Y>>6G+OO%33UVF44\
MYO-J%\6<+G>F\&G3CFY7)T&N-8E]6N_V-EG7$@U$M1OKYW?F]`I[(+6Z05WE
MA@8<LP,6Z&ZU35=(.W2L2(UPIW]<[H'*U+E(#O-VJ:P35DS9U5/-]5(?"VB/
MFSGCY:[W8TVA8_[25-=XU2T\+<Q4,?=[K$$.<\MW7.]%[_HG*^_R>5_LTX&2
MF=%H+?*LS?S;R#J:WR!6\8J/?ER6L_:\%R?TB04>6AA'%=J7Y?9E&8I:X4K[
MK-3_]3._N9[NXB:7W#[OJ+GKK6N[_W7B.BF!B-=I:6P('K&(4*F.A[O8IQI<
MO;NUB&3?&>`$AWHGEEYKU]/-X)UC?.=M-L5O3WMX*)]7$'Q@L'"SW4[1;[[3
M;E][Q)T.ZOY.GNADO76G;]WD9Y^Y[*;E]&D%,8O0\SB\^P1^?S7L[40+U:L)
M7F<4,*M6V==^UY<_O$4.+G&;RECC3F>P:9.;TO`[>=A-#K^G<TMBJF)VSUH>
M;FJ_:FEBZ]ZO@H`"1[N0_?C2?_^_[GM03>;0)$,`!VFXB,(`'43K!@4!#S!K
MP,TQ%/#_+HCO'(0"B\Z0+!!06F'JZ"4#M\:G:*XHW$X"_TFP!$WP!%$P!55P
M!5FP!5WP!4\P]Z2#``.0`7D"`6.NKAI0JMS-H41*SCRP*$+PGFR0H-"-,=J+
M)W+0HW2P,A`0"&$PD9!JY080M)B00:SP)R[.ZXCKGHX+R?Z*"]<M`3]*K$(,
M":5/[HQ"#*E/,B0.Q(PP"@\)W#90\U8M&F[MP)KLM((,"LSOYK*OUPY.WWIK
M0"*OKPKK668+]!:1QV`,RD[O\O)0LI@/P![/IX3,](9-\:(*$A,K1_[PR"31
M](JL#OMJK>SKK,QM\GH-^"@1P^A*SYPOIP;DU\(OP6X0V6RJK'Q+_$(1K9YE
MJ"31OF#OY6X1V5#QV@8KSO!+$O_5;_:J*A'DD(\&I-=.S`0XS\CBJO[`S-$0
M[<?NC@HURQ&1*K.L4-H^K.U6[*Z,\`KL:<0P[@&KJZF$[[[$3KS`3*F6B^3R
M3A[',![!SA$WC?AR#.'\RLOPCM?.:^7LS.I>+:>L+0T'"\EH#.,H2_HJCNA2
M#[;RSO>TJ^E>3:]<#B"S<1KQ2+;T!!E+DDW2J]$ZSK^:;*.:"OKT:Q#QC1%]
MD:9RC==:0=#@3^=@+-%VC?P$02;SCIT`+<WP2RAQ<KI`+_H(3N_HB<S\*AF/
M[.:(SN?$#.1L#RK[2L^.$@Z_ZK"LDB>;+LB*3,AL<=^&$AMH$JMBC=`6K>=T
M3=#HLJG_KJR=(DO([A(=3?(DF8W3D(K<<`ZE_BS,$M*Y[H^WABP;.VH%^&D;
MSRJL[F[%?&P*T[#(L*WU9*ZZ-%(AL<Z=&,\BA4SX&/$(<\(N&TWH:H[HL`PK
MY4TK.Q'I$K+,^@KE*.OK8&S,^HF>VFNZJ*_-@(XB,1*[O&PC;2TW2['ION_-
MZ"_G7HP.__*.CHO`HDOMA@T=44[R#@XJH?(ZY>PZ<]'4O(T\<\*V=!&M#$ZW
M(NL[A6LG-DH\R^P]L<'T'NV]AJO\WB_*/!.Z`.RYE*[J\@L_>2L\YZGJ4//+
MCE+-$(O#^I/@0LL[!6$03&VV"M2ZD,T_77&_MBI`.<T\CY"H(G9R.C>IX\21
<1(%D".42187)J%A44$@J"%]T1FFT1KDF(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g267791mmi003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791mmi003.gif
M1TE&.#EALP+#`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````"S`L(`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O8,.*'4NV
MK-FS:-.J7<NVK=NW!D&UP32WKL)/;4P9;.6FS410=/0R%,0B0.$K+%H-O!)`
MD,)6K1PG9'P%6ZL`E2%&5HQ-4`D6)%NQ8`&EI&'.+$6SR.Q2$.:!D5^VXA.@
M!.J1E#7'ABGH=L9KO4GV]LWSB@G6#H-;+MS2U*<Z?3%]^J20+G6#;?Q"Q)M=
M\,++JZ\P_VXL4+QDA*Y!)Q1TQ7'ZB(<%MA)/,@!FXA_MOS1\!7]*]I)=5L)+
MC+%P'DFY/>0:<BR]QU&!"+X&%(`0.8B-?B_-!4I!K4AS&UZ"H1:-)-K!YF%"
MGRS3AAO>*418`(LQ)Q^'!2$&FF*HY2B?A+[E")EEC`6'(XT<XOCC8P694MB1
M!)TXXY-$PF;9E`*=-M`I-/IH)$'^12G0BTSN=5"/7E()&V<Z?KGDD#-VV>./
M74(IT&@,BFFGF7(:%&2>>=IH&9,Z:CEFD4;B%UD`4:"IJ)2&1D,+;`LN"EF:
M91X9)IT)L3DEI7EJZB.?>&8I):B']K<<C*2.%$UW`YF2779N1/\C$!UM[$%7
M&W0,E)VLV*SZ:JX)T=5BIO9QYAFJ\5EFGV&.L5""8>056RPV\:4W7@"<%2;9
MM(45AJV%KMFWVD#V(5;NF-Y:&6ZR!)7[+)W+GG=M"9E1UJVRJ";8V;+C[BL>
MAI>)>R!LZ:I7H+8&"6+"LF@6C"/`5E++[[:-+>P8A*Y]AAF$V.A+D,/E;6S8
M0=>2=^%H,M:XK(02B[MGR\R2+'+$,"=&;0D:G[*DOW.BB@T4WK+`RF(3[SA:
MO'I"&VUCS^((<LC+9M:M?8ZY6VZZJ%UK8,_FCGSA9SL75+!K6%)-]:GB<I9@
MLE>+*U^Z`X<LM6%!)WUTU:L]2^]`"D?_+=**UZV*B6)U2`(L7I\HYH8;>UB6
MG:Z!8?.)&\`>Y(8DPZ(7MKDA;[OUSH2I=W)BDC'&A[);<RZQYVJ;'+K1BF&Z
M.F0T#X2P@Z)A>Y#%M(_K9\<2UG:QMLJ-O"!L5F)J[G!5VCRMV+H??VJHN4\/
MO&/@S6GS[T'.`IYBT.XF??7-:Q_WGNDIMOP@Q/E)/K7]%@3%R+DK=GSZG:/>
M_GWPUTO>]QT;S9?(DQMI>`U3+QI@?P)FOYUY3#Z1XAKS$"A`X&5&>):)8.[<
M$S/919!;`JR?]BKC&S^I;G2[V5/V`F@PD_'G5+'3'6/:UZ_#@,]F!=&@M@YE
MLX#E#R2LZE4T_WB%ETP()!-MN(ZKC(B-QV'#5<#R54)HE;DQU<98&$H6P@@B
MO0OYK#Q[\XQZ?+BZ*NGN9WO;E\'2Z*`KHFXO7I,8K]QHD&FMT#6E^9/MR+,'
MEE6)7G&TX`!!TT6!/"MNR!,=ADZ&$`RVRS8]L]]K7D;'G3U/;D;;8PP/4AM-
M\@PAA<%2Q]+XLB+9K@07^U\<*WE&@A@G,VT\(^AX]!IH[4LR"\L6>7!6.E6N
ML4YJ)->`$GG*+?5,,GW,S!T_@\F;];)9+H0D\!J7-.RMLI5>]*3TG)69ILT)
ME3<#)M'F1C'BB)%<J#*%UZ3W.B!*AR#1H`-=Z'"XO`AD#X;K%8D$(O^X-I#(
MB0=94143EC+5O2QW6U.3(G&8O\LH4T91<"$.7]9.Z?WN6;#C4,H"8`(<+0R4
M9U17!8T6,\3DD5Q30TUZH/71WQ$L9@1=J-.^R*7:=%0^[X(6.%MA`M!\1I=3
MBQ9#/_D^PO3'CV_SF95<:I#//'.$ZTGI]91UTJEYZWPF^YU5S^;2TS0F,8Q!
M*4>A!<V@5J:B2!7(*7CTT79ME8O02NCX9&31&L;U7*.1#$:A:A"@G76DM6LK
M_(;70L\]E5H60PAB,C,_UB6,1S):H;FL&I(@2@Y73VQ#'6:51($@3B#940P4
MAQB-5O#J(%1L"`,'F*_X=>9>P32CRL[J-3+_YM6,NH1E`/+XRD'B]HT<,HPT
M(FG&67"RAWO%'<(0YC'P'%5T-IK4CPK)MW,%=XP0&VH.V88MZ>[1,ZQA%IQ^
M.Y`]]!2E!#E.*=VJ2TF*LXR"A*]!$GN[T^A+O).2F6XO:"#O?O)GJX$1O0#;
M&.DJQJF0*6TFXYM#9LH6-DWS[P;AJ["%^C:^=/+O%I^WWNJ"E667S"9QMWD<
MXLKW1:)SI81NZT5SKM)FIW!PI/S[D;D$;BX",07E/&M/;.QAQWS1CN`$(HU/
M5`X[+&I(`LLC(XIF:USM/-EM3*>LAR(KI!-U70796<&-:O=]$4L9]#@CTL(:
M,G6N9>1@%?@E^C"U_S/9,L'`E*34,8J92Y+964%-I<96[AEO!YKK%PM$TZ3:
M;GLC-0B+7R8[L=E5;=U*\9^KR6307&//ZANIN2I3H/#BD#`Q5%M[7JL>ZK*Y
M9P6)(V)^Z-13D\^A3)Z;J)OU:+X^UH8HO8V7,\U;B3XUA29SI5T=FT/(HNHR
M4,BTG4\'Q!Z[*E8Z[BPVZ$`YR-#J.@#M"RA:@<3KH+;']_Q$YL"S!T&\2&II
MI-J$TQ.<18+QK`CF&#?GX\U1;@UWQ9KPUW#D8.AQ^IKX<2,9\?A-3C,7J=G=
M47?KBQP&BE!L](H&QZ(12.0%P!0\U=W\KN`*CED&9RDNT&PP%.($.==8./\3
M9WPX1IOWID^=9^PPU^83,]$`4^2T*30+,9XLRER#,<-D]W`O(^?.U!MXI,.0
MR,.UX"NDL=C]W??'[B/O$B]OD.TNM=<2E+YPQ7!;TBQ0W&P^W%1CDS+2<+K6
M2<=-0](K,MY4]Q953$[RPC7JG8SMR7HS=X\D0=K3;D,2,+&'%0D$$TDP!:V2
MB".`MH([@`]H&S:DJ\0_MC9TDY?)Y@.`LT&M:F=_S8(FBZ9X7?)H^_+9BV`J
M8@`J.M(6;V1(HU?;9V%FY15_WA99`;>0I1AM13_(T>)'QKTXB_63_;W;A$TW
M=`::9>M"*2(%$@78^]Y%04,-N[@8-!4J[85,;K[_S-A3KJQ9__.H+A]<RQ\C
MNF$158%(JT"`ICMW`REJ:,+9[5EV--JARD&PY6.11F;!<T8TATVOM3(N%&SA
MEVC=%P"!T#S_$C_#!TSSHQX;AH#AUQO9U3#=\EYP$8(B"$HFL!.$<1Y]-X(O
MX1HHJ($5$38J&(,RV!/5QX`W<1CF=D(SV!*99VZU<Q&LMX-".(0PL1K31Q.1
M82.C1H0MP1XL$`5+N!&C$2=,6(56>(58F(5:N(5<V(5>^(5@&(9B.(9D6(9F
M>(9HF(9JN(9LN(:`HEH7\2DJ$28208>@(A-4B!!YV(9\V(<9,2U,IQ`>)Q'R
M9H.FX8(.04>Q5Q.N-QE1_^AY?AB)DOB'JD>%^441:Q-\*&%_FL&)7V,3*Z00
M<V>'DUB*IE@0I\`>MV$ED1$@"Z2*7V)N7-(>/:**YE=WL(@-J8A(K3`("R0?
M2YB$?).+S8,C[`&,@4:,C#0?#4-3YG:$[>$]M`A/SP@I[B&+]X2-QUB,D/*+
M/)10TQB+?%8>[G$%&'>*Z&B&D59;&.(@3B<N#)=4=0,UWD)-:T-`*V:(ZW(V
M`T<_\'A-3<>.=,..*&-=$;./+B@N8P5="JD[X'$T^5A.'^<SZZ@[*%-!NC>0
MV#60\I>.'JF%W"-1#:1U4N,[6Y:/?W5L2T4:\R=1W,@E,G(-R8-FM)9G6#:2
MI__&8F'#BLP!9C8396XE&#L#0*_33BNDDS?)0LW$>BMI9E)&:A\9E5W86/+Q
M([.0<!A&'ML$3AG4(RC33,YBD\!54_VU9"PH8I#B2%CY0(<"2<5G225@7.ES
M*#J7D1RTD<!E6POX,+^W',.&3E_W;OBB5A4GE8;)A(W&7E#Y2<I303(7?ARS
M6,=T3T:H@;FC@'QY(:R!4#OYDR>YF8?1F3-E/>"Q+'N5:EEF35:VF$?)`M0D
MF@-A!0.I5PGUE+*3(&5VF+I9A0<E)&OYE]NT><H1'SRE'LDTF54277#4EW-B
M`EW`E>JD'O8A2EBY!R<IG0Z9=S=S0_;3;PFA>T5W3H/_N4)ZZ5BM<)IN=(_G
M,2TODQL"<F&[&9\S*)E3]91H59(&YY35TE8.Q6O4%VP'@RYUAD4I@Y1DYIDD
M:3XF5EL]&5D,6I=9]C"9H3,P$F5Y9Z#<2)^,04U,B6C^XUA`*9\B&H(!\R_2
MM)81253/\B\J22\!FI7GT3?3)W8K:G%591A8<%4/YEQ`-S>KX2T/PQ^PM4@?
MF()_%!X9"057EQX_ZF"=!J3*,DRT\:/@UVF_5:*,<5/]R)PCVJ5L(1Y1-R>F
M4E$)=5M\0'Q&U7`9MAK7$$#U,E0_R$6+-3!/>![S882@-B?)EF-TX@HL$(%`
M@J<X!&6KX30I1AA*ZA^G852!__:$?/8Z5P"%L+%8D7%3U/*HX2$:,5JHV/!3
MBX$8RG&I]@,T7EJJ(QJB4Q%BWU&8IMJJKIH2RV)<5Z&J+N*)KWJKN/H1H7H5
MV.@0FY&KP!JLPCJLQ%JLQGJLR)JLRKJLS-JLSOJLT!JMTCJMU%JMU@H?"IBM
MVKJMW-JMWOJMX!JNXCJNY%JNYGJNZ)JNZKJN[-JN[OJN\!JO\CJO]%JO]GJO
M\'J$U[JO_-JO_OJO`!NP`CNP!%NP!GNP")NP"KNP#-NP3;&'5K&'9((D_RJQ
M7/(=,P&Q!-%'*ZJO$@."_\HO#*.'MFH2,R02)XLOF'%:B)$UADAD'0D103,P
M;U:!A_^FL1UA(0_T$W'*$2F#8LBQ:GN4$+3AL8-Q?NW",JT0488Q-'X)$91!
MEW'RF`(+&2+7):[`JB=A;C@;$9>QGGF&7;Z1:!_#I3);8*IF'T_WL6R;G*EQ
MFD;J$[WZ$8S!*Z[Q,)+A&<$%3+!F$=]C(=H3;/D6-E_[$"R&C<Q(CIEV5AW2
MC<;2&<&A'$DX90&BC6>UJUWZ9ES[4F?RBYW!&IL;BX%VN0-3C9,*C)"QC8_Q
MBN(45@.$1<LQ=AJH,/(B"-)HM(8F,5/F6@XJ.J[1$K?U/HH[C'H1CJA;BP?"
MC,(()&JC'*H[N:Z$3,-AO.@QO9CKM@-D.R2D<TZW/]8(N;C_^TF!9"/]@FRV
M1K:"6)@9Z'O#QUJ11DA*\V]Q18`7]H\O&Y\ZJY$+AI"I-#<*=WP4\QD+LY%0
M6D9:<W0'D3$021Q^E%>NT3AI=FBO1Q#OTKX1$6*F!D9V&K,C<9P6$E0M9%5`
MQ2[KJ%M@`X_Q,93KI)`XE$5T$X`@15G%YK151G/@8RB&J+3+(IOW2RPI5@)=
M\)AB=K</(78JYEC5Y[\2,T"E,U+D<Y9JUDZ]:ZJ_0W%KA#TR`E@W\AI].X76
MLY.HTE-!VI+NI:#KL6*U^25<.1!!;#/6F1!>[%9!:3W/6,<YR'UI1I_;15,<
M+!+50Y]0S`(WI:&T]YI:Z9C9B9]0_PE>HX3%_Q<\-H.4"R')*L,A)Q@[TW>>
MO[=6H/G(]6+'YE9NS.>R:U9LR,')%;)\C4Q<C%9_CYR@^^LU[5B`:FRVNME'
MZA%C!D)^_)5#]*<]]<DW0/=-8ZR[53F9]Q@G%F6#4&Q%Z7L;JC%U#S-,+*53
MES0>I2M_,`C,+,$<VQRHM"=K#,89+3>9XNE]T@D:A3%TBW0D+DR_Z4LQBJ9S
MBW%2QQ5<&YR@`9-3`_Q%W1(@,F2#H;@C("M\B.Q8])G%C]S$G7QJZU1!>]6W
M7OH[#TDG)%2@S+)UV.*Z]P>%"GV@9[8_95S*Z('&I9O&J88VV!3'Y((</$G/
M\2QL=2*;<?^#&;*J$C,TOMIR6X0L2>?3+R>[3?>&R)J9NZE6@MC04XX\R65:
M:!Q-4*G'/Q+,?0W]7P]A)>*588H)DP7=9H!9GTUF,CMCG;MUD#I<:@Z67++\
MRJ;J(("[8"]-T!0X>X:4G5<F:@JZ!VGTS:;\0\@S?=%"343,S64KS8,)OJ!<
M.OYSJ$BULVJV$DS*&LGL8RM6=$X'2V.:HLO,0<KT&5Q)GE?`H7?]8'`<34F#
MPX?R9.W"(!1'3<#EGHE=C1121@5YD=\%1^%;&Q<=T`@]+M*0,J@TCF[*N;>D
M?EKER51<04?)Q<P1"!44G7LD5Q*R9#N)U,&;=T%MTIOR6"4Y,-'_K"?;VR[K
MZ=HQ@AJ&H1?DLU53<]CKI<=6_=<N$3Y#FZ%`'<[:@Y/`(Z$*:J$I\\0BN6;O
M@Q^47%.(A&;(0S3$T=]TQ<5W15G2\X,L!C_D7=Z^FBZNP\(!7=O:\Z-+Z#'[
M*#KJW3P0&;X?Z7$'PX[4S)$^,QX6=WPD%P!#0T8!4\`')\Z#>&$RE[)$0S3T
MQY`!%UYV[1`E\WL>,U8K,]7`ZVY!(]_E#%]F%=W)XHY:F;;(\>'HM*!A'``3
M#E^>B+YS?3>GE,`&J-%=+3'>4B<4E:T!@K[?08>M"+GV$[DYTAB]`2&[6"1C
MASW8V)/7*Z*F.XPYTJNR'6C0_*OB$Z/)_RL(+;(;LV$L0H*^OPKG]\PEOL$\
M!%W2CFZ,))ZZ!V$*<UO'D=[,+&$*GIY#I;ZY;YY!.>3FNP%!F9Y!FN?=K9Z-
ML:CI.V).SLN+2"7KSZ>H8X2X?;X>I!BZX-N*K3.'5/.,?7S5,.VP0'@1PJUD
M(*BZ*TCB6<$>@H41U"X1RM@044@R70L2B3N'8"H>X3X9MNSL%''NRRH>9:[N
M\![O\C[O]%[O]G[O^)[O^K[O_-[O16'A^!KP`C_P!%_P!G_P")_P"K_P#-_P
M#H^N8S<J9D(I%"_Q%0\E%S_Q%K_Q&,_Q&M_Q(/_Q(I_Q)._Q)1_R)S_R)K_R
M*,_R*M_R,/_R,O^?\C3O\C4?\S<_\S:_\SC/\SK?\T#_\T*?\T3O\T7O[TB?
M]$J_]$S?]$[_]%`?];QQO?,!()Z;0\$.N='>,6.2Z.WQ]=ON2AO+[G_2'HB4
M@V2/CDEH]=$N"'NP]0GLW9@+]G0/0;B:@U9?Z*&-NY$^)9AK]8"/(^_.%+='
M4-+EA'5$'P0UO9;Z<<[,-XEA8/Y!&.W"[I<<&0SUM:FK75X:^336"E"0;)L?
M)^<II[]+*/E%@=8NE;1H8)`_'-\-QSE2[J@_*:?_6EFA)!<"U352Y:!1:)1?
M4Z6'+BJ5[C!9^0F,TMQ71^2B46D_B?.1$-)`PVJB$/2,B`0#D\]?BF;_*QJ*
MQFPD`TPL`/X)(4USLOI'L3T,$OS+;SOJPR`ZA[C,>1G'GQPIUNR$$05YKFCJ
M<SZ#[Y$`T8H%-H(%#1[$UBH`PH)7!#'$%J`5Q((L)AJ\<H7B1HX=/7X$&5+D
M2)(E#RZ$J!!AQI0#&;+<"-,@2I,U;9(4A%+@18*"7&*T4M`G08$&AVY4B;"H
MT)\=DQ*4R+&5SR@/-[JTJ+3I3:Y=O7X%^U&0H%976,A$2&LGQ:P,HU(\>G!K
M6+IU[=[]N##C69[8<EXL.[>A580L"#-<>]`A7L8@6?"IN,>HQ5:5!9DU:+@B
M8;2(360$#=J$086A-<)M2M/CE0"'"YXJ<5%U_\&GC6W?QETR)V&%?06R`-X7
MX>R92(D3;)M;^7+FP]N6/4TT0``6K:\*;QB=H>:5VILW5EU[M\,KE4DOI"4]
MN]2%$]W[3>[S/7;2J>EWIWQ0H/;DQ;__!Q`O^HY#SCO:!(/J/FRX0RBV`!^$
M\"OLN#.KE6L2NJ($BMXJS#72-&0HK@C#,FLO*#(D3,3"SC+K1.L2(O!`Q,)#
M,,34./*)P8-.%*Z_G@P<,4@A1>*PP?MB#$`:B%3,3,$AGX12,8TPTX]`'3$"
M$BJ*%HORIL28`K,EX02!8C.$CJI-QC`]JJU(VLSRD+8`7+&QPR[O'')`@BZT
MDR$HCJ2OMY1BQ+/0YO^P8\E-Y.CKS,SM((/(1T-!8A(;!^';4K"W%#KLJ:6J
MG(S2U-(;R90RV3J,RDE7;>XLN1X2%*,:!0G*+8@:+:@J5G==3CZC4!($1%DI
M$E;*&2GZE%>/%,7FBM$PA8A95;'9XRQKST/L4K^H*_':8PMBEDQKNSTQ(N"Z
MK;`@/L;-4EEWZ?*IV[[V*K'=!(TRBUOMT@SU77_O"JS>^M"U5\6SJ&/A5*)*
MB//>?Q^&.&*)<V-6I"\GQAA`7$>Z,F.//P8Y9-*X<E)DD\$RKZ96HCFY99=?
MACEFF6>FN6:;;\8Y9YUWYKEGGW\&.FBAAR:Z:*./1CIII9=FNFFGGX8Z:JG_
MIZ:Z:JNOQAK`DK-^>6N0O.8Z['^K,[!2:.VJ+D[JH&`ABBC*S0RX**QU;3^Z
MQ=Y5D"BN@()MU\2M\22>`CLN,+;+$XI0O'$C/-!Q):V/IP#,FALX.<'.>"'B
MS.970HN.VWP%C/Y.KLAI%^^R,YDN,ELN4T:.:,RFOFP===LNZEA%!6DO.'"0
M%[N2<]]MTDQ;<+%3+7>7&FW8]CN9K+TG!),4_"`1.W:>8N&2[8C+'SG2M6M@
MM^+\V24SXG$P5EBC:)#E#01]].UDPSQ[*%VU?GCOJZ>M6'`_M%^K7%.Q:"G&
M*@WK7,C6=;Q^G:E&:&E+B3@B$^)$!3#]P1X4K/(;_\0%$$_029<#.X(D8_5I
M41Y4CIL6<@JSG*5YEY%21B[#`LG(I7X/HU$#055`?!&$;R/LX4Q*!(7/=&<[
MG?J-PE"8I\I`!SO1X]Y,Y@4D'1EOB8RYTN1X<SJA>&=_S?(.Y#Z6$WIEB"?"
M6])6EK*QADRN6R:8A7^(,A?L80]&-[QBK^8"120IJ8OS:U(>;5.D6`72B$`T
MR)]<YJKWR`2-WPK3%^WT'AW-9F\[4AM1GC@\0?YG<[Z[F!1/8JO,=+(Q63PB
M8C@Y&TY&C%]/,5OK^L,E-IYM3;'C'W(\1"$ZVLN4MH%A_LZDQ%LUC#CXJXAV
M@OE+N[BI414SW9F4V4J(8?_ODIAJ8D+4DY+%3.4GM606@XA3&Y9,9"PFF)=A
MFHA,9C;G1&2I3`AI,Y22S69EG-)F0=BV3M>(L9TJJXPZT]E$>4IS,N4):!CQ
M^"ZR(&:#ILF(>YI'%(?XIGE361)G0I2BR\CP/E,9RT+_&1;H-#2&'762B,JR
M!]#431!\\)`D1VJ3DE[&0S;=VI5*>LB9]C1H8[F)*7SIT^_XDS1#)6I2E;I4
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MZ0P%`U*=/)`P0BWA8_BK39CH2$3!C*)EGKMAJ8A33R[V_^&53,#@LT)'3K-$
M4*/>Z4TZ3A1CS*,)2B<R/E0QQ:;D>7!?)&M3J^SOQS^AB6(?,F0B(P9NCMIQ
M+L&HE3B/E2^C1`@Z0^0=-Z4IP!.[@F9GHJ3.<+F80HE"EV_Y*J,H$<@_T?-@
MVAP27$$ORH>IE&J6*=8/1^0E0$H6KO"KIA>7#26$I(GQ,+J@4XA2*+CS37]6
M;68+HUEZC)[TLA046H:<@L#]S.^"\OK4UG7!.]=`TN"N>^M%GK>[(>1N6328
M/(2&L$*`*4&U%:93O@0&SK8$,DWXLE@KYQJ,W44W3^!T&0(NJ)_.9F?T3"P1
M='>7*>/E8IS)^.P7(0=F4SE%@O^Q8QFAZ&?5UC/XW^#25KO6K>`%<85)BVON
M!0,\P29]M=<4!4]ADM4R%I_*$R>.I83;E06OHWC*:^)?C*N\(RV'2[E=/G.:
MU]SF-\=YSG6^<Y[WW.<_!WK0A3YTHA?=Z$='>M*53C0X'8HJ?UT0"TP`',LI
MO3+7E%7"IM[OJ`-GZSB*CBD0)G5V@M&%082J@J7)HB<*K",LX--OJ%Z"/;H]
M(25F56OP[I27)Z>#95FZ?N!;&"?Y=XX8::VZF\+FD8;437<N4&9XTVX&`1Y9
ME8^.O-U%)ER"Y5RH09;AB;YIZ+(E)#I29+2$@Q;_.965!N).QV*$%M++V803
MBPKT0./_S3?)$$>'(_R69&YYH6PQHM9KJ4&BT(I94`F$,I\JDPBE^<-CMN-Q
M'G54J5<15BA%)Z0$/W-)B\B)Q24Y`B$,@^*2;ZUP1R7>!.I@<@1Y`0\N@M&!
M">^2^7?SU3ZKS[0;M"B+>#F[2.D1&0LO'Q*TBI`+J6*EFQ*CC>$>*!`J>2D(
M!^DH4T"48;N?U<*N_[D[&ZJK$EB(>$&<J;B4JINC.'&D4R&^$P(_=OJAL=(=
MKHL+[T*.8#,D<,&T9ZFCOC"?IT(U,5/!HVH7U=F*2VD-A((_`YJ8WKBX#-L7
M$*D7T"A"ARK`"QLM5>*AB/"CO3$-9&HO\A`WUY@;A`(K_UN)_XF"G-F((SO!
M%?\)K)XZ#BN0%^1*O?WZK>+8C]M#K5V9K^YBD&[S+C5$C!*I&\'P)P*!H662
MJ;L[#'&[CQGZ*LT#)_I@LZ'@/`&KLZ::PS/;&D/TC^.`(`X4DE`ZBLOXN$X<
MD$=<$%+:)(H8C?@PD"W;(7>+"=%SJD9!E`TB,?K8-$RT"N*@O<9BJCGDD#\$
MP8<;K=F*1$!3Q(>0CVPB.1XDB2]I!89!#D<[K2M,P#O"Q9Z``DFL1ACD*A41
M.]Y`)GEJA24C%F4[#!5L1\7#,^U#"$'#)W-<#?ZP,`Z1P43[P&H"QH$H*?)0
M/[MS#N"@.X7TNPSIC!GRFQ%J.Q8Y*/_$^::_`8WEZRJJ8P&Z(T+@B+]YHCJ8
MXT1\R3:H8RXMPC6GR@FJZS?H<*.38)OJ<,GK,,("G(QS\8TYQ+WP"Q+J"SR/
M`,J8V+NRZC2+X<F).3O+4$;E,*<_"\JHM!W+"*DG&4"IQ,JLU,JMY,JN],JO
M!,NP%,NQU+GJF(ZS1,NT5,NU9,NV=,NWA,NXE,NYI,NZM,N[Q,N\U,N]Y,N^
M],N_!,S`%,S!),S"-,S#1,R[1#G;>@_&O*WYF*O&#*['G$S'')S*G,S+E$S(
MM,S(I,S-Q$S.S$S/U,S/-,W21$W25,W.9,W1;$W1A,W0E$W0I,W37$W7Q,W8
MK,W4?,W9M,W_WMS-V]3-W\Q-W^3-X@Q.X"3.X3Q.YA1.XWS.Y$3.Y81.Y6S.
MZB3+[-3.[>3.I3/%[@1/"%G'0%-%Z4@5\I@([[&\)0S)E4C*9G$2@8"IQ6A/
M',%$VR`??$N(6L&)PMNBU4A/'[H/&3H^I$`JC#HXDI@<2?LCKD!)ZX&^+;D5
MDNDW&AI#W)E/_-L#410)7:04*RO*AB`X_8A0N@C1C!D+_),<`571AH!/Y?,W
MJ;@"5A`TCDN9=3I!DOPFOUC%Q7P=D-*DNS(IEPBY>6J%0;A1BP(,D$J1>#(*
MWIB(@8@_:20*DY+&ACJC^OPKXN.XA-B#BRB/R]*(JD0\HR@X>\,0_[]XN")=
M$/JD*-;A404ABV\2,P0*R1%54TW2K013#'."TVA812%-4-:1!CZ`T]N"E4"=
MN(&P-8HJ/<"+OXECTX2PTC/5##REC54C4S:51O,P#S[UBX9"+TX-56:LTJ)(
MF:KT/3X%TIZ(5)+DN!3A48G#*((L4E(-*3;%U(<AR#*K#&F`(4C%'6EZMM-H
M#9)\M5=,TV995L!#',1I3\LKBF"R2!;MB5*%UC5[46:%5LDXC=F!%6D\C6JK
M/@&MOS2%B1/4",V0!BE]B--H3S*C+\O3B%;XT3&-TA"+T2Z*OW&EQGI=5P;$
MTGJ%E2F9"!RCI?38I66-5^5R*W_K5VQ`A/\#>M?T=`]E>IV?D-)G=5)A*R5?
M68QJ];?C6YY=A=0P2PB8VM<7+=`0N=AF*=AMK59I\%?)ZUB`O2N/95:@THQ9
M\%5ES=:(N%(?*E-4#5@U7<]P)5HB!5*ULKQW)=JU"%FB*!-!45>8/:%G-=>'
MP2F4R(B`JX@N4+NY0,.`.B$%.5;@(5%7Y5%W(P\;,JD.:BAR35%7)3Y&559F
M!4AG+=4%TQN9?4'M>%"-S=OHP%N(;=65\-2B,`R'<$$18UF"V+8^S5)F#57.
M`SS"I=1I+;.\/5S+K1MT`MDZ30D%8ZW3J%5=2E%ULUB(W2"HW=:H1=V`);XR
MZ2!6@-H$!2,G$S;_FV+`XNNBCS+4SR5:HJ79]T(WC/"A#2W/\LS;[IH(A0DY
M%H@CG/4WPB4P!D30BNK;]]&R\:)4E,2I.+7>`4R_[G51P^V)@'HVB$D]H$))
MC619=8M=R_.=D!P(J)/6*2E>I8@LBA6_C^U89LU?%X7>@,2&O1W3`YK4V<D\
MV'W%V4U?@87@OMC0-XG=%W76?)79/C6@Z-5>R2!<_"M5OAU9$=T.;0*JEGM!
M%([@BU"2*:W8O(50S^U;^*W/5XR_B;7<$2['PN`Q#K9A@?6C%NY?C0#((#97
M=XT4MO7?Y[4WE^C7?"6^HPU5+W+1P*V,&BK90R2U,CT^34735[3?]!U6__C4
MW7]YP?Q=3*QU5)CUO2UU"2VBSWAD7;_8T'$%L_>ZW&C=B@ZZ`I2S@C*SMQ4^
MX($(.'L#LS+S(D$$7.3MC`'DDI_0D)^HM[S5BXMUWJT-P5:`*1@:+U">"#ZP
MXC\F4/<`%H-,4W33"T>^2G?=4"'&"K2+8`+M6TU399A567>C+^[=8Q0N"]QE
MXE)MW):K6@F6XL'[JV#:-#GVM#=F3_P;7Z@+Y5ZMVP%L1WT=KR\M4TBFU"@&
MJ2G1UCZ^KP6NRL4;$YO2D/;RYE>6OP1#SZD`WRJ=3V;;7YA5L%>-8A#$X7/^
MSI=!5N;P4#H[H1/EFH&NT@?992-^B:WYNQ(=B76`5@Z#]N((>5!SFU2`@J=H
M@.BII"D(@=Y0M+))_6=D@1"$1HJ.Q@N5#L^6=NF7ANF8ENF9INF:MNF;QNF<
MUNF=YNF>]NF?!NJ@%NJA)NJB-NJC1NJD5NJE9NJF=NJGANJHENJIINJJMNJK
-QNJLUNJMYFH4"@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g267791mmi004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791mmi004.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$N`L$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBB@`HH
MKS+QO\2I=.O)=+T3R_/B)6:Y8;@C=U4=,CN3GTQ4RDHJ[-J%"=:7+`]-HKYW
M'CKQ5%.LQU>YW'Y@&`*D?[I&*]D\$^)6\4:`+N9%2YB<Q3!?NE@`<CV((_6I
MA44G8WQ&!J4(\[::.DHHHK0X@HKR[PUXI\7ZU)IFO1[+K1]0OGMI+".U`-I$
M&($ADSD]LYXXXHT[QIJI!^V:@^7\6MI<>VU1LP_+B,\KM')^?YC[&@#U&BN/
M@^).BSZG'8BWU!"^H-IOG/`!$)P<!2V<<]L9/J!5/3?'T$-K?M>/>7]P-8GL
M+6VM[-5E<H%.U0&(8`'.\E?<"@#O**Y/_A86C-ID%W#%?33SW+VB6,<&;CSE
M&60KG`(')R<<]:R=9\=->6WARZT*XD@2YUZ'3[V*:%1(HS\\;`@[3TZ<^]`'
MH5%8^O\`B2S\/);">&YN;B[D\JWMK6/?+*V,G`R!P.I)`K.M/'VCWUUHUM!'
M=F359)XHPT04PO"`760$Y4\]@:`.IHKCW^)&BQ6SW$D%\L::H^E'$08F95W$
M@!B2IZ#')/:DN_B1I5E@3:?JX9(1<7*_8SNM(R2`THS\N<9P,G'.*`.QHK'U
M[Q)8^'O#4VO7`EFLXE1O]'`+,'95!`)`_B'>LZ;QWIT-HDYL-5+SW)MK6W^R
M$2W1"AM\:G&4P?O'`X-`'4T5YIX@^)C"#0[C0[6\D2?5%M+R-K==ZD'#P8)X
ME.1@=/>M^X^(6CVNJ-920:ALCF2WGNA;DPP2OC:CMG@\C.`0.YH`ZRBN;C\<
M:3+X@;2$2Z)%R;/[6(OW'V@`L8M^?O@#TQ[T:YK<MAXN\-:8EP\::@UP'C$"
MN)-B`C+E@4QGL#GVH`Z2BN-T+XEZ+K]YIEM;VNI0'4A+]G>XMPJ,T?WEW`D$
MXYXR.<9SQ6OKGBFQT"]T^SGBNI[J_=EAAM8O,?"C+,1UP!Z9/M0!MT5Y1X;\
M>:K-H_A.?4+JXNKG43?&6*"SC9KCRN54$%0A[#`.>^.M92?$GQ++X-L]0"7?
MVK5-4^SQS1V<9C@CR1MBR?G8XXWCJ&R>E`'ME%<GJ'C_`$C1KX6-X+QV@2(W
MMRL`\NT,F-GFG/REO8&K*^-+"3Q+<:#%::A+>6\R12F*WW1H&4,'9@?E7G&3
MCG.`<4`='17*Z7\0=%U?4ULK=;M1,)#:7$D6V*[\O[_E-GG&.X%4K#XH:/J1
MLA;:?JS&^AEDM<VP'G-&,O&I+8+<?3/&<T`=O17&_#/Q/?\`BKPI'>ZE#(+D
M.RM-Y82.4;CC9@\X`P>G-7H_'&DR^(&TA$NB1<FS^UB+]Q]H`+&+?G[X`],>
M]`'245R5C\1=%U"\:WMXKTATF>TF:(".]\H'>(23R1COBIX?'6D3)ILF+A(K
MZQDOQ(ZJ%AB0`L9/FX/..,]*`.FHKDK'XB:/?6E_.+>_A-G9-J`BGA"//;`$
M^9&,X*G&!DCJ,XK,N_B)%>+HLVG1:G:P7=]:Q>9-8`K<+*&)12S#IMPS+G!(
MQF@#T"BO-?#OQ)GE_MB36=/OU@AU<VD+B!%$"LX54D^;[RD_-C/7O7;Z;KEM
MJFHZG901S!M.F6&5W`"LQ4-A<')P",Y`H`TZ*YG2?'6D:S?FUM4NPKK(]M</
M#B*Z$9PYC;/."<<XJM8?$/2]5CT46L%ZC:U'<M:F1$&SR=V[?ACC[IQC/OB@
M#KZ*\V\#?$B.\T+28O$$MS_:%W%<2_;)+<)#((G<D`C`)"`9P,>^:VK'XBZ7
M?75M;I8:M&]XH>T,EIA;B/NZG/"@<DMCCUXH`Z^BN/LOB3HE[HT^L>3J$&GP
M0"9[B:V(3);;Y88$AGR1P,]>M)+\2='M]"U'4[BTU&%].>-+JREA5;B/S"-A
MVEL8.<]>E`'8T5RFJ_$'2='DU]+BWO6.B"W-SY:(=_G8V[,L,XW#.<?C2'XB
M:'%)J278O+(V%NMRWVJ#RS+$Q"AD&<D%B!R`<D4`=9161H/B&UU^*X,-O=6L
M]LX2>VNXO+EB)4,,C)'((/!K+E^(6BQ:R=.*7C*+O[";M8<P?:?^>6[/WOPQ
M[T`=717$>`?%VH>);S78;ZSN8EM;^6.%I(501H"`(FP3^\'?^=8]U-XQ7XH)
MX>C\7;+2:U.H+_Q+83L3S&41>IX'WLY]J`/3Z*\CUGQMXF1/$FO6-];PZ=H-
M^++^SWM@QN?G5&9I,Y7DY&*T=4\1^*-9\1:Q8^'+J*S&CV45SY+6PF>[=TWB
M/)/RC!`XYS0!Z716"^NW%EX'?7=2LS;W4-D;B>V[JX7)7\ZSE\5-X?L]%T_6
MQ>7^L7UL\W^BVZMO=0&9`HQTW8''1<DB@#KZ*Y)OB)HS:+IFHVL5[>-J9<6M
MI;Q!IW*??^7(`VXYY_.IIO'NC+I6F7UH+F_.J%A9VUK%NFE*_?\`E)&-N.<G
MB@#IZ*\_F\;OJ?B?P>FD7,D=AJ$MY%>02PA7W1(N%8$94@D]#^=:EA\0]%U#
M48+:*.]6WN97AMKYX,6\[KG(5\^QZ@`XXH`ZRBO-Q\07UKQ?X6@T9KN'2[V6
M[28SVZA;D1J-K(QR<!@W0@^HZ5U^O>)K/P^UI%-#<W5W>.R6UI:1[Y92HRQ`
M)`P!U)-`&S17GEWXYDU#Q#X2&CW,D5A?O>QWD$L`#AXD!"L&&5*DGH1FGZ)\
M1K8Z#H3WJZAJ%[JJ7#0FWLE5I#$Y!78KG!QTY(X))%`'H%%<)%X_L]2U3PS/
M9W<T.G:G%=221RVR_P#+)"3N;=E-I!Z!@?UK2T;Q[I6M:C;6<=O?VS7D;26<
MEW!Y:72KR3&<\\<\@<<T`=317)6/Q#T;5+^.RM1=H;I9?L5U)#MANC'G?Y;9
MYQCN!7(>'?'&O7*>");R\>X74(=1DO42&,-/Y.\H!P,$;1T(SWH`]<HKGM.\
M8Z=JEQH\%M%<EM5M7NXB57$:+C._YN#DXXSS4.N>.M+T#4);.>"_N'MXEGNG
MM;<R);1DX#.<\#Z9..:`.GHKEI/'NE)9WUR(;MUM+R.S*HJ[I6DV[&3YL%2&
M!Y(/7BF:A\0]%TW4;BVFBOF@M9E@NKU(,V\$C8PK/GW'0''>@#K**\[B\=RZ
M9XWU^PU62>>S6_L;&QCAB3]T\T;L23P2,KW)(["MN[\?:/8W>L6TZ78DTN2"
M&0+%N,SS`E%C`)+'CN!0!U-%><>+/B`Y\#:S>Z(USIVK:=+#'-#=0*)8=[C&
M5.Y2",X/-)XO^(3#PCKTVB-=6&JZ7+`CK=6ZAP)&&&"MG@KGJ,^PH`](HKD]
M0^(6C:;J5Q:S17Q@M95@NKY(,V\$C8PKOGW'0''>M/Q'XELO#%M9SWT=Q(EW
M=I:)]GCWD.X)!(SDCY3TR?0&@#9HKDE^(FC?8M1GFBOH)K"X2VEM)8/W[._W
M`J`G.[G'T-(_Q%T>'1]0U"Y@OK=M/ECBN[2:(+-"9"`I*[L8.<Y!Z`T`==17
M&W/Q*T:TT[5[N>UU%&TJ2)+BW>`)+B0@(P5F'!SGG!]JS?'/CN6ST+Q+%HLD
M]MJ>C26JR3/$C(?-88VYSGC(.0*`/1**Y/4/B'HNFZC<6TT5\T%K,L%U>I!F
MW@D;&%9\^XZ`X[US\?CW4I-6\:VTMO=V]OI<`DMI#:HQ@PC$[QN&2Q&5&>0#
MDB@#TRBN(3XCZ;9Z;8M<QZA>2_V?!>7DUM:96!'4$/(`2%SUP"V/H,U;UCXA
MZ/HU[):R07]RZ6*W^ZUA$BF$DC=G/`'4DX'(ZGB@#K**YBUUR:3Q98HMP9M)
MUC3OM-F"@'ENF"W.,D,LBGG.-IKIZ`"BBB@`HHHH`@OFN$L+A[6/S;E8F,29
M`W/C@9/`YKQ/2OAOXCDURT?4].VVIG5KAVGC;*YRV<,2<_UKW.N7\;>+H?"^
ME'RRKZA."+>,]O\`:/L/U/XUG.,7K+H=F$KU8-TZ2UD><_%C4H+GQ%;V%N%V
MV,.QRHP`S<[?P&/S-=O\+-,DL/"`GE4AKR5I@",';@*/Y$_C7F?A#PU=>+]?
M9[@N;5'\V[F)Y;)SC/\`>8Y_4U]`111P0I%$BI&BA551@*!P`*BFG*3FSKQT
MXTJ4<-%ZK<?1116YY!XUX$US4M!L=&\'VEGNU5-2==1BGMY,0V^XDR*W`Y`.
M#S]*S(/^7;_LHA_]EKWBB@#P>#_EV_[*(?\`V6FZ2PT[Q'!KUUN33;'Q1JB7
M,P0L(O,CC"DX!P,J>>U>]44`>4:IXSN);&UGM[4:#INH:I-"=76#>QA4#$H&
MT%6D/`)!Q@URNCA!IFEB-YWC'CY=K7&?,883!?/.[USSFOH&B@#@?'C+IWBW
MP?KMUN33;&:Y2YG"%A%YD8"EL`X&0>:YR_UZ*?Q'X0\276G#2]*2_OU$P1OW
MBLB*DC#:""Y!XP>G6O8:*`/`[*59X+*9`X63X@[@'0JP!"GD'D'V-:7BVTMK
M/QQXJ?5KS5[6#4K6#[)!I_'V_$>QH\E&!.1T]"37M5%`'G'Q"M%L/@9-9K')
M&MO:6<025@SJ%DB&&(`!/'/`JUXWU^XTIO#]B+IM-L[YF6YU18O,:`*H(1>"
M`SDX!QQZ>G>T4`?/5C)%9^&H-08W36-CXX\^>>9':1(E5,O(,;L^N1G)]:LW
M>G64M]XCTO4;K6VN-2UDSVNF61V)=12,&67+1L..YSQ@5[Y10!Y;_::Z9\20
MFB1WL5Q?ZAY.I:5-&=CICF\0]`.G.>?0&M;Q?_R4[P#_`+][_P"BEKO**`/!
M_!7_`#2__KMJE=OXTN$TWXC^"]3NED6SB^UQO*L;.`[1X5<*"<DG@=_PKT&B
M@#PGP=&\4GPQCD4JZ7&J*RGJ"*;IO_))_`G_`&,L7_HR6O>**`/#?%FG6X\9
M>*[75&U@?VFUF;*QL&5?[0P`&Y9&!V'![8YKL/"41_X6'X^B7K_H2C)_Z8N*
M]"HH`\)\!:=;+>:!9W#:Q-J^F+>&>U9E6WT[.[&X%,_."",-U]J=X/\`]7\*
M/]_5/_0C7NE%`'GWP<N(U\$)I3[TOM/FDCNH70J8V9V8`Y'/'I67-J(T_P"(
M;0Z''>Q7.H7QM]2TJ>,['3;_`,?B'D`=,G//IFO5:*`/#?AUIML-5\-V5R=8
MGU;33=FXM695M].R6'S*4S\X((PW7VI^@:%?7-OXST];>5FTC3I])L5+EMX>
M2608SWQY8^F*]OHH`\)T6VL)M"U6YMYM7O+JT\)RVUS-<NOD6K[#FV5=@.5(
M)')P*V=0_P"1+^%W_83T_P#]!KUVB@#QZSM%OM*^)'AYU=-2>_N;^&)D8$KD
M-&X/3EE&.:Z[X8+/+X/_`+6ND(NM6NIKZ49_O,0N/;:JX]JZ36=*36M,EL)+
MJZMHY<!WM9-CE>ZYP>".#4]C96^FV%O8VD8CM[>-8HT'90,"@#S'PMJ(M_%K
MZ5H<=Z-.O$N);W3+J,AM+E&<$'H%<Y^4$CG-<OX,N8VO_A_8XD6XLX]52='C
M9=C$2';DC!.,9`Z9&<9KWZB@#YYT6*+5M'\$Z24N";>RU5KP1PL6CBE#;6'&
M&R#QCOQUK;\$ZC9ZS>^'I-1UK2Q<:3I\EK96<(D69F,80^9O`&X*,8&03R#7
MLUS`EU:S6\A8)*C(Q1BIP1@X(Y!]ZYJQ\!:=9BQCEOM1O;;3Y5FL[:YE4QP.
MN=I&U03C/&XF@#SZWL+K4?V9HH+.!YIAN?RT&6(6Z8G`]@"?PJAXH)UW3/B%
MKVFI)/IET=/$$ZH0)/+VB0C(Z+CDU[U10!X'XKO8-2A^)=_:EVMIXM+:)V1D
MWJ&1<@$`XR#SWK9O;K3]:\9:S?-I]YJ6E0^'8[2[CAA99%=I5;&UL$$#YO4;
M?7BO3O$F@6OBC0+G1KV2:.WN-F]H6`<;6##!((ZJ.U::((XU09PH`&:`.)^'
M&J75[;ZE9&[EU+3+&5(['4I4*M.A7)4YQDH>">]>=ZGKTOB&^TB>]O;A+^+Q
M%"&TA(2D=G&'*@R''S2'Y>2>Y`'6O?**`//OAW<1VWB'QCI4^^.].L3W@B9"
M,PN1M<'&,'ZTMS_R7RS_`.P`?_1SUZ!10!X+KQ>RTWQQX7E@N#J^KZN+FP@2
M!V$\;2H^58#'`'/-;ESJDO@7QIXEO;N%Q/J&G6XTS]P\D<\Z0[1&2HZ[EZ9'
M'>O7J*`.-\0QZIK7PEO?MML(=3GTXRRP1J1M<#<5`))[8QFL3Q1K=C'X^\":
MU)+BQ:VO)_,52^$:$$'Y03CFO3"`P((!!X(-8(\':5'JNBW\`E@.CK,MK!&P
M\O$B[6!!!/&>,$8H`\F\-*_A[3OA[KFJ1R6^FVIO_/G9"1'Y@81YQTW9XJ7P
M]:S^&;/X>ZOK$,EI8VIOQ<2NA_<^:&\O<`,@'/\`C7N=%`'A&B6LQ\7>';HQ
MND6I:SJ]U;&12I:)HHPK$$9&=IJ+PMIEI)9^'=&N[G7)]9L[]I)-*5@L-FR2
M,PD;,9^4C'\7)8X/I[Y10!X/X,F5KKX;V6R5;C3Y]1BND>)E\MVW,%)(QG`S
MCMWKN?&TBZ5X[\(Z]>9CTNT-U'<7&TE8B\6%W8Z`GO7?T4`>/W.J?VUXO\'7
MZZ6MA!+=:GY`"E3/&(D`E(*@@M@]?0<UE^!O^/KX6_[FJ_SDKW2B@#YRT>SF
MU#0O!EE;KNGN+'6HHU]6:*0`?F:[KPYXMC71]`TO3M&;4[[3]-D-YNC*/9O'
M&,)\R_>=AMP".QZ5ZG10!X1INJG7/&'@_4)M4FO;QQ=_:H5A,<%FQB)$2#&-
MW!SR2<`GM3_`PS<_"X'^YJO\Y*]TILB>9&R;F7<"-RG!'N*`/+_AII5S;>+M
M=CN$VP:,&TZSYR-CS/-Q^!3\,5C^+;2VL_''BI]6O-7M8-2M8/LD&G\?;\1[
M&CR48$Y'3T)->JZ#X?M/#UI-#;27$\D\IGGN+F3?)*Y`!9C@=@.@`K5H`\9&
MA2V?Q%\/:)';7"6%S!97\HDER4>UB=`K8`!.?+S@`$@<>F5\2M<EU2W\26=[
M>7%HUC=1QVNF10D+*FY<SRL!\P.?ER0`<=\5[W10!X-XG/D^-_$%XX(M[37]
M(GGDQD1QB*7+'VY%6I?%$EGK?CC5M))$=Q=Z=&+R6W9A;1LC@S%"`2`!QZY!
MY%>WT4`?.E\J3Z)\0UM+NZU!9)M,V7%R#YDQ+'YL$#@D\<8QC'&*O>,)TU*W
M^(VJ6HD:REDTZ))6C9,NFT,N&`.0>M>^T4`>"ZCIUI%>>*])U6ZUS[5?:PTU
MOI%BP1;R-W5E<%HV!QU)S@;17<?%1TM-)\,2.&V0Z]:LP52[8"OT`&2?8#FO
M0JR-?\.VGB*.P2[DG06-['>Q^2P&73.`<@\<GI@^]`'CVJ*^IZ]KWB*SCEFT
MNWU_39WF6-C\D*2+(0N,G:7&>*9XND75=,^(.O6>9-+NY-/CM[C:0LI3:&VY
MZ@'O7O=9'B7P[:>*M"GTB^DGCMYBI9H&`<;6##!((ZCTH`\<\6%M8@^)&IV,
M4TMF[:>JR>4R\Q[0XP0#\N#GCBH/$][!J-E\2[RU9F@EETQD9D9-PYYPP!P>
MQ[CFOH&B@#P3XE:Y+JEOXDL[V\N+1K&ZCCM=,BA(65-RYGE8#Y@<_+D@`X[X
MK9U6YCL]>^*%E<;XY[W3HYK961L2HD#!F!QC`+`=?Y&O8J*`/`K6=-'TC7(K
MQ95?7/#E@FG!8G?SW%L(RHP.N[MZ<U<U"SFT^_OK*X7;/;^`!%(OHRE01^8K
MW&B@#SC16$\WP\A4G_0M%-[,0>BF!(US]2Y_[YKN-%UFQ\0:3!JFFRF6TGW>
M6Y0KG:Q4\'GJ#4T>GVD6H3WZ0J+J=%CDEY)*KG`]@,GIZU9H`****`"BBB@#
M%\3^);/PQI37ER=\C?+#`#AI&]/IZGM^5>(VEIK'Q`\3LS.6ED.Z64CY((_I
MZ#L._P"9JY\09K[5?&-\1%<200-Y,0V$A0HP<<?WLFL.RGU[3D9+&74K57.6
M$#.@8^^*Y9SYI6>Q]#@\,J5+FBUSM=>A]#Z'HMGH&E1:?9)MC099C]YV[L?<
MUHUY7\+YM<OM:NYM2OM0EMX8,".XE=E+,1@X8]@#^=>J5T0=U='C8FFZ=5QD
M[L****HYPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**SUU[1V1775;%E9BBD7"$
M%@RJ0.>H9T'U8#N*MR7,$,L,4LT:23L5B1F`+D`L0!W.`3]`:`):*9--%;02
M3SRI%#$I>221@JHH&223P`!WIP(8`@@@\@B@!:***`"BHI;J"":"&69$DG8I
M$C'!=@I8@>O`)_"I:`"BHIKJ"W>%)IDC:>3RH@QQO?!;:/4X4G\*I2>(=%AN
M+BWEUC3TFMEWSQM<H&B7CEAG*CD=?44`:5%51J5BUS#;+>VQGG3S(HA*NZ1/
M[RC.2/<5:H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`J*ZB::TFB4@,\;*"?4C%2T4`>1
MIX.\0/;Z,G]BP6S6:0Q2M',FZ0H]EF1OFQR()",<[5&>3BJUEX!\26WAU;*"
MT6UFWL^%F0!6;3C$6X/4RDJ2.<G/3FO9:*`/)=6\):[=2P+8:!]D@&FW<&Q;
MQ7V>9'<A(CN?"C+Q<*"N3R<(N.GO-!U&7Q?8WHLQ+!'IZP+/]HV?9G`E#\`Y
M;=OC&,8.W)P57/9U1UB+4)M*GCTJ>."]('ER2=!R,]0P!(R`2K8)!P<8(!Y3
MI'@3Q$+"Z6YTX6]RNFSP6K/-&Q2;R+6)64JQQGRI0#V'7&174VGA>^?PYX6L
M+ZU27['J37%S$P4+%$5GVC;N8?+OC4`%L?09K1\)^)H];>='OA/.B[45(&2.
M41G9)+&2,,"Y[,<#9G!)KE-*^(>M.TRW(M9T>Q:XMPD>)/-:*WD2,MG:1NN0
M@^4'Y1DDYR`4T\$^(I+"0G24@N%O9WMT-PC>3YEH8Q(&+$D"7:Q).\XW$9K7
M\,>%];TO5M"GN;#*013)*[3*%MT9Y6"*BL=I&Y!@%E(.#@HIK)T_QIXG34-9
MT^]NGD.E6]Y<I,(8O]+6&X1`,!>#\LJ'`'W@>N#7L%`'EI\):Q+X^;59=&3[
M%'JD4ZGSD;<H,X,HW-NR-\3$'!&T*H(1:U]?\.:C<ZYJ>H6U@LZ%]-FC3>@,
MWD3.\B#)X."OWL`\<UW=%`'G/AKPKJ^C:GI0N=-MKB-+.T22Y:0'[,T23!@H
MSDL?-4`@$8W9[5Z-110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5X_IFNZSHOA;PO<RZA,U
MSJEQ$66:X>Y^T(6B4Y:7_5G#L=B9S][=A6!]@HH`\D@\7^*%U2&WFNI,)?M9
M*KP1_P"EM'-;QN.%XRLDS\8^X#T!%:GAKQ'J\VH^&(M0U9[@:G8">2+[,@)<
MJS9)"CY1M&"IX/#`[U(]'HH`\E\4^,_$&BW6NJM^\2:?<(D!:"(K,7228(6(
M&`%"+W)Z#YCN$=WXQ\0V^JZE"VKM%:"\=5F-HC_9D$MVB@`*"P)@B7!R220"
M"17KU%`'DM_XN\0_VG=VL&IM&QNS"Z);QYLU^UQQ1X!4D&2-F;Y]V>JX%-T7
MQ=XHN]3TJU>\DN%O#&[.((@%/V6"Y9.%Z$/(OKC'.>:]<JM)I]M+J$%](A:X
M@1DC8NV%#8S\N<9XZXSCCO0!Y,_BC7+BQT2YBUJ9KJX5HY7CMU01.\MDKIM(
M*.4,LB@E3C)!^8$GTGPC?W.J>#](O[U]]S<6D<DK[0NYBHR<#@9]JV:*`"BB
MB@`HHHH`X3QA+J`\660MKR>"WMM,N;V4)/*H!C:/#>6A'FD9^X2`03R*Y*+Q
MQXKFM";*[>ZW27*0OY<,A)A@CG`;RUVDL&=?E^@.?FKVBB@#RNP\3Z[>S7<<
M&O![:VL[R>"\:WC=;@HMOM+;$Y"M+(/D`^[@Y(-3:QK^I'PUX:UJVO[EI@;H
MGY$`N)%@FV*P488%D`!7`;=D`$KCTZB@#QBZ\9:XEKHEW-JLUN]S;7:AT$)$
MVV=!&S$YB4[>KX8<D*,L*>/&_B-[)YKG4I+4+!:2*\<$(61KB$2*-SC"!2CC
M)#<<8+%2/9**`/&;+QUXCN3YMQJ7DV\\,!D<01[;53]B+R+E>PN)#\V0...*
M?)XJU^'74^SZM,\4D]NT@-N%64,E@I&QP3&#Y[G"D'+5['10`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%<\GC+33>7,,T-Y!#!/\`9A=R0'R9)?,$
M>P%<D'<P'S`9'(R`34%M\0O#ERERXO)$2`(X+P/^]5EC*L@`);_7(,8W9/3D
M9`.HHKG#X\\-+$\IU$B)-F7-O+M^=!(N#MP?D.[CHN2<`&I;OQGX?L;B:WGO
M\2POL=$AD<[LQC`VJ<\S1]/[WL<`&]145K<PWMI#=6TBR03(LD;KT92,@CZ@
MU+0`4444`%8?]NZC_P!"GK/_`']L_P#X_6Y10!A_V[J/_0IZS_W]L_\`X_1_
M;NH_]"GK/_?VS_\`C]4O$GB^7PYK%G:RZ<LUI<Q-)YZW&)-RLB;`A7!):2,`
ME@.3G&*J'XD:>L-Y<M87IM;6*.21D569"S3*X<9VKM,)&=QW$@+DXR`;']NZ
MC_T*>L_]_;/_`./T?V[J/_0IZS_W]L__`(_6=+\0]*BL;F]-I?M;VL@CG=8U
M81G+ALD-QMV'/KN4#).*8_Q'TN.\N[0V&I-/;SF!42)&,Q#2JQ0!LD#R)#@X
M)P,`D@4`:G]NZC_T*>L_]_;/_P"/TCZW?R(R/X2UAE88(,MGR/\`O_6<WC^R
MA\0/I$]G<^9]L%JDL6&7!$`#/D@C+7"K@!NF:ZZ@#F;:Y-E<2W%KX%OX)Y@!
M)+$+)6<#@`D3Y./>JUO%;VN/*\`7^Y9#('<V3L&+*V0QG)X*)CTV*!@*,=?1
M0!R<Y2X4A_`FI#+%BR/9HQ)D$C<K.#AG4,PZ,1SFM#^W=1_Z%/6?^_MG_P#'
MZW*#G!QUH`P_[=U'_H4]9_[^V?\`\?H_MW4?^A3UG_O[9_\`Q^L/3_B5;7+Q
M"ZTRY@1W@A>1&#K%-)@%&)`'!9.F2<D[0%)J2Q^)>EZA#&]OIFJO(^6\A84:
M01A(W,F`YRNV5.!EN?N\4`;']NZC_P!"GK/_`']L_P#X_1_;NH_]"GK/_?VS
M_P#C]9-Y\2]&LXKJ3[-?S"VG,+>7&GS`"8EQEA\H^SRCU^7IR,I-\3-%MK<3
M3VU_&O[P8,:DYC:0.,!CG;Y9)QV(]\`&O_;NH_\`0IZS_P!_;/\`^/T?V[J/
M_0IZS_W]L_\`X_6)J/Q*M-*F87>D:BBK"LACVH)E.9]P*E@N`+=CD,<Y&,UV
ML<BRQ)(ARK`,/H:`*]A=S7D#23Z=<V+!MHBN&C+$8'/[MV&.<=<\=*M444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5A^,_^1%\0_P#8,N?_
M`$4U;E8?C/\`Y$7Q#_V#+G_T4U`!_P`(9X6_Z%K1O_`"+_XFC_A#/"W_`$+6
MC?\`@!%_\36Y10!RUCX/\,/>:FK>'-(8)<JJ@V,9VCRHS@?+QR2?QJ[_`,(9
MX6_Z%K1O_`"+_P")J[I__'[JW_7TO_HF*K]`'+2^#_#`URTC'AS2`C6TS%?L
M,>"0T6#C;[G\S5W_`(0SPM_T+6C?^`$7_P`35V;_`)&"S_Z]9_\`T.&K]`'+
M:KX/\,1V<;)X<TA2;FW7*V,8X,J`C[O<$BKO_"&>%O\`H6M&_P#`"+_XFKNL
M?\>4?_7U;?\`HY*OT`8?_"&>%O\`H6M&_P#`"+_XFJ6C>#_#$NAZ?))X<TAW
M>VC9F:QC))*C))VUU-4-"_Y%_3?^O6+_`-`%`%+_`(0SPM_T+6C?^`$7_P`3
M5+2O!_AB2SD9_#FD,1<W"Y:QC/`E<`?=[``5U-4-'_X\I/\`KZN?_1ST`4O^
M$,\+?]"UHW_@!%_\35*+P?X8.N7<9\.:046VA8+]ACP"6ER<;?8?D*ZFJ$/_
M`",%Y_UZP?\`H<U`%+_A#/"W_0M:-_X`1?\`Q-4K[P?X82\TQ5\.:0H>Y96`
ML8QN'E2'!^7GD`_A74U0U#_C]TG_`*^F_P#1,M`%+_A#/"W_`$+6C?\`@!%_
M\35+6?!_AB+0]0DC\.:0CI;2,K+8Q@@A3@@[:U9]>M+?Q!;Z,Z3&XF4,'"C8
M"PD95)SG)$,IX&/EY(R,T[C6K76-!\1+:B4?8?/M)"ZX#.L88E?4?,.?Z8-`
M$G_"&>%O^A:T;_P`B_\`B:/^$,\+?]"UHW_@!%_\36Y10!P7AOPKX=GTN9YM
M`TN1A?WJ!GLXR0JW,JJ.1T```'8`5K_\(=X8_P"A<TC_`,`8O_B:/"W_`"")
M_P#L)7__`*5RUM5Y<I.[U-CF;+PEX:>[U%6\/:20EP`H-E'\H\J,X'R^I)_&
MKG_"'>&/^A<TC_P!B_\`B:N6'_'YJ?\`U\K_`.B8ZY*^D\10ZGXR6,W[QS6L
M:Z5LC8JLODN3L(&!RO7IDJ.I`JM6]P-67PEX:&M6L8\/:2$:WF)7[%'@D-'@
MXV^Y_.KG_"'>&/\`H7-(_P#`&+_XFJ7AO[5MT_[7]IW^7>[/M.[S/*^T+Y>[
M?\V=FW[W/KS73TI-KJ".9U/PEX:CM$9/#VDJ3<0#*V48X,J@C[O<$BKG_"'>
M&/\`H7-(_P#`&+_XFKFK?\><?_7S;_\`HY*O4<SMN!B_\(=X8_Z%S2/_``!B
M_P#B:IZ1X2\-2:+8R2>'M)=VMXRS-91DDE1R3MKIJHZ+_P`@+3_^O:/_`-!%
M',[;AU*?_"'>&/\`H7-(_P#`&+_XFJ=EX2\-/=ZBK>'M)(2X`4&RC^4>5&<#
MY?4D_C735S\VIRZ=J,JQVGGK<ZC'"Q$FTKNBB&57!+$#+$<85&.>`"1<G?4"
M;_A#O#'_`$+FD?\`@#%_\35.+PEX:.M749\/:246WA(7[%'@$M)DXV^P_*GR
M^);FVTRXO;BP@58+TV[-'</)&(U^_(6$>0%(8$;<`J<D#FM6+_D.W?\`U[0?
M^A2T7DDP*?\`PAWAC_H7-(_\`8O_`(FJ=[X2\-)=Z<J^'M)`>X(8"RC^8>5(
M<'Y?4`_A7351O_\`C\TS_KY;_P!$R41D[[@RG_PAWAC_`*%S2/\`P!B_^)JG
MJ_A+PU'HM])'X>TE'6WD*LME&""%/(.VNFJCK7_("U#_`*]I/_031&3NM093
M_P"$.\,?]"YI'_@#%_\`$T?\(=X8_P"A<TC_`,`8O_B:VJ*GF?<9E>"X8K?P
MZT$$:10QW]\B1HH55474H``'0`=JZ&L+PC_R!)O^PE?_`/I7-6[7J1V1B]PJ
M"\O;73[5[J]N8;:W3&^6:0(BY.!DG@<D#\:GHIB/+]4@T#4K^]NF^(.C(99(
MY(5WPX4I*LB^9B0>9MV[5/RD*3DGK7/WVB:'I^CRG3O&FD7EVL=O'`J3P(R%
M3;!Y!NE"L<6P(4D#D@D]:]PHH`\>M]/\.7_A=K2\\6Z-83S2(WE)=Q2"%%MO
MLNT_O#EC'EL[B`QQE@,LW7-.T*35)=1T[QGHC^;<PLL#W$68AYEOO<MYHW`+
M;@[<`G)YZ5['10!R^D^(_">DZ-8Z;'XITB1+2WC@5VOH@6"*%R?F]JN?\)GX
M6_Z&71O_``/B_P#BJW**`,/_`(3/PM_T,NC?^!\7_P`51_PF?A;_`*&71O\`
MP/B_^*K<HH`P_P#A,_"W_0RZ-_X'Q?\`Q5'_``F?A;_H9=&_\#XO_BJW**`.
M&\1S>!/%!B_M#Q/IF(HGC4)?P8^9HWR0V02#$N`>.N0<UCSZ'\.Y=.:R3Q=:
M01.B(WDZA;+D+YV?EV[1GSWS@<'&,8KU&B@#S.\TGX=WFE7>GCQ7900W5Z][
M(8M1M\EV381\P(Q@D],@G(-.GT[X?SW,]S_PE]M'/-*TOF1:I"I0L\SMM/;/
MVB1?4#&,$9KTJB@#SR:W\`S:RVJ-XKLA.;A;C:-2AV[@T#`<\XS;IW[M[8Z?
M_A,_"W_0RZ-_X'Q?_%5N44`8?_"9^%O^AET;_P`#XO\`XJC_`(3/PM_T,NC?
M^!\7_P`56Y10!A_\)GX6_P"AET;_`,#XO_BJ/^$S\+?]#+HW_@?%_P#%5N44
M`>9OI7P]:=94\6VD?^GR7[(NI6^UW=T<@@@X`,:@8P<9&>326VE>`+..-;;Q
MG#"Z*(S)'JL`=H_+CC9,XX#"%"2,-G.".E>FT4`>:7&E_#NYCO$;Q79JMU*\
MC;=2@^3<LRE5SVS<RMSDY(YP,5#=:=X&NKZVCD\1Z,]A%'>EF;4X_-+W)^8#
M&`%`)P<Y_4GU&B@#S2]TWP%J"DW?C2&:5HC$\KZI`6;(G!/3`/\`I+\``#"X
M&`0>MB\8>%(HDC7Q+H^U%"C-_%T'_`JWJ*`*MAJ>GZK`T^G7UM>0JVPR6\JR
M*&P#C*DC."./>K5%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%8?C/\`Y$7Q#_V#+G_T4U;E8?C/_D1?$/\`V#+G_P!%-0!N4444`4-/_P"/
MW5O^OI?_`$3%5^J&G_\`'[JW_7TO_HF*K]`%";_D8+/_`*]9_P#T.&K]4)O^
M1@L_^O6?_P!#AJ_0!0UC_CRC_P"OJV_]')5^J&L?\>4?_7U;?^CDJ_0`50T+
M_D7]-_Z]8O\`T`5?JAH7_(OZ;_UZQ?\`H`H`OU0T?_CRD_Z^KG_T<]7ZH:/_
M`,>4G_7U<_\`HYZ`+]4(?^1@O/\`KU@_]#FJ_5"'_D8+S_KU@_\`0YJ`+]8O
MB.>WMK>VN+N+S;:*25Y8]H;>@MY21@\'(SP:VJRM:MHKQ["UN$WPS3O'(N2,
MJ8)01D<]#0!6D\(:5_:5O?VL*6,]ND@A-K!$FQW4J7'R$D@,>#E3QE3@8BDT
M&RT+P_KXLC/MNXY)W669I`I\H)A=V2!A!Z^G0`"2_P!+\+:9'')=Z1IR"601
MH%L5=F8@G`"J2>`2?0`D\`FJFJZ5X;^Q:O:P:3IZWEK9&9@+-5*!E?8P;;@\
MHW0\8IZ`=517-7UEX7L+E+:7P]$\CJ"IAT=Y4Y)'+I&57IW(P.3Q7+Z)?6&K
M>!=)UX^&]#CN+N_AMI8Q:+M5'N1$2O?.#W/7\J-`.G\+?\@B?_L)7_\`Z5RU
MM5ROAO0M(GTN9YM*L9&%_>H&>W0D*MS*JCD=```!V`%:_P#PCFA_]`73O_`5
M/\*\N2C=Z_U]YN2V'_'YJ?\`U\K_`.B8ZJ^(_$=IX;TXW%P=\KY$,(/,C?T'
MJ:S7L/#FG-J$MYI-J8Q=K%&L=AYS9,2'"JBD]<G@>M1ZOHGA:_==%^S6]G?W
M$8DA:&VV,O#$9(`'(1SM)R0C?W21:4.9<U[",SPCXU.NZS!#J`BAN5BE5&7A
M9-S(0H'J`I^M>@UP'AOP);:1J,2ZFEO>S30RDHZ!XU"M&!@$=<,>??\`/K/^
M$<T/_H"Z=_X"I_A55_9\WN;`B75O^/./_KYM_P#T<E7JP-3\/Z+':(R:18*3
M<0#*VR#@RJ".G<$BKG_".:'_`-`73O\`P%3_``K*T;;_`-?>!IU1T7_D!:?_
M`->T?_H(J+_A'-#_`.@+IW_@*G^%4](\/Z+)HMC))I%@[M;QEF:V0DDJ.2<4
M6C;?^OO#J;]8J:9:WVK7-S-YWFVMX'B,<[Q@$Q19R%(##CHV1^9J?_A'-#_Z
M`NG?^`J?X53LO#^BO=ZBK:18$)<`*#;)\H\J,X''J2?QIQY==?Z^\"4Z5I.I
MI<6+V\IBM97C>/SG57:0+(Q(#?-G?@[O5QT8YN1?\AV[_P"O:#_T*6I;+3K/
M34D2RMH[=)'\QDC7:N[`&0.@X4=*BB_Y#MW_`->T'_H4M*^]@+U4;_\`X_-,
M_P"OEO\`T3)5ZJ-__P`?FF?]?+?^B9*F.XV7JHZU_P`@+4/^O:3_`-!-7JHZ
MU_R`M0_Z]I/_`$$T1^)`R]1112`SO"/_`"!)O^PE?_\`I7-6[6%X1_Y`DW_8
M2O\`_P!*YJW:]6.R,7N%%%%,1P.L^/I[36=6TRT-H)+26UBBW1O/)^\DC61C
M$C!F`\U0H&"2".:;_P`+!NHM7ETRXMK=+@6\>U,D.LKS(@+H3N52LL;X/(^8
M$Y%=9-X=TFXEAEELU>2&8SQL6;*N9%D)SG^\B''3Y0.E.GT'2[AI&EM%9I)3
M,YW,"SE`A;@_W0![8!'(%`'+7GC;4-.U&33KFWMY+A);2-9+>*1XCYMQ)$Y9
MAD1G:BD*QX8D9;%6M.\3ZE+X%LM=N/L\EQ=36@V+:2P*BRR1HPP[$MC>V''!
MX(&.NRGA;18T95LAAVB9B9&)9HY&D1B2<D[V9B3R23G-.M?#6EV>EKID44S6
M:/&Z1374LH0QE60*78E0"J\#CCI0!E6?BV<Z#HVIW5K')_:%K'(8;5\S;V`)
MV1GEU&<G!R,=#3=0\2:I97]Q`(+9D,L,$;!6/DO+,D:>8<_,2K%]HP0``?O`
MUIMX4TGR[>.-;RW2W@6WC%K?SP8C7.T'8XSC)Y.33QX:TL-=DI<L+MM\J/>3
M,F[<&W*I;","`05`(QQ0!/H6I_VUH&GZGY?E_:[=)BF<[2R@X_6M"HX((K6W
MBMX(UCAB0(B*,!5`P`/PJ2@`HHHH`XEO%M_>:;K,]A-813V<YC@AG@D9GQ*\
M*@C<H.]T&'4D#)4C*\Z&K^)IM)UZQL)1`$G\A3N!W3/))Y9$?/\`!PS<'AAT
MK3C\/:5%/+,EF@DFF6=SN/+JQ<'&<##LS8'&YB>IS4G]CV/VF.<QR,\;M(NZ
M9RNYF+$[2<'!)QD?+VQ0!B7GB>]CMS?6\$+V4>I-9R95RP19!&[$CA`I$K%F
MXPBCJV15L/&5SJ=C'-9QPS3W3J]O!Y$B.D11G^8-C=D)@.."6QCCG<;PSILL
MDK3Q-*'F>4*6*A=^W>G&-R,R[BK9!)]AA\'AO2+:9YH[)=[QO$=S,PV-C*`$
MD!>.`.!DXQDY`.>B\3ZUY%JLL=K]K:<6D\+6KIY<S8.&99'1`%=&&7)?.!M-
M=3H^I1ZSHECJ<2E$NX$F"MU7<H.#],U2/A;2E4&*!XY5'RR^:[-NY*L=Q.XJ
M3D%LX[5IV5G!I]A;V5LFR"WC6*-?15&`/R%`$]%%%`!1110!PUGXVO&O=/T^
M_BAM+V29ENTFA91",P[8\JSC<1.A#$X)PI"EN-1O$SQ^,TT218E623RHT/\`
MK6_<F7S1S]S@IT^\.O:KD/A/0H%@$6G1J()/-C^9N#\F,\\@>7'A3P/+3`&T
M8M6^CV-K<13Q1R&2*,1(7F=]H`QG#$C..-W4]S0!@'Q1J4MW;/;6MN;*YN[B
MSC:0.-K1ET#.X!509$50.K>9P/E.83XJUB>U:"PM8KC44EF!7[.Z;D15^;RG
M=2AWR(,,PR`2,`@C8'A+1S).TMMYJRR/(4=CL^9BQ!4'#`,SL,@X+'&*GC\-
MZ3%%-&MJ2)E"R,TKLS8.0=Q.<YQ\V<\+SP,`''M\0[N*6;]W;S):PN\X$+(2
M8HR\J@[V4."K+Y>2<#=N(KT16#J&4Y!&0:P[GPAH]Q;R0BV,8D3RW*NQW*1A
ML@D@LRY4M][!(S6Z!@8%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!6'XS_Y$7Q#_P!@RY_]%-6Y6'XS_P"1%\0_]@RY_P#134`;E%%%
M`%#3_P#C]U;_`*^E_P#1,57ZH:?_`,?NK?\`7TO_`*)BJ_0!0F_Y&"S_`.O6
M?_T.&K]4)O\`D8+/_KUG_P#0X:OT`4-8_P"/*/\`Z^K;_P!')5^J&L?\>4?_
M`%]6W_HY*OT`%4-"_P"1?TW_`*]8O_0!5^J&A?\`(OZ;_P!>L7_H`H`OU0T?
M_CRD_P"OJY_]'/5^J&C_`/'E)_U]7/\`Z.>@"_5"'_D8+S_KU@_]#FJ_5"'_
M`)&"\_Z]8/\`T.:@"_5#4/\`C]TG_KZ;_P!$RU?JAJ'_`!^Z3_U]-_Z)EH`R
M/$/@V#7(E,=[=6\ZS-*KO-),JED="51GPK`.2I&-K!3T&"S4[62VN=:N;B]B
MDEO-*=(X$MV3"0M(0=VX@G%PH/3)&1CH.IK"\3Z7!>:;<WDKSK);6=PJ"*9H
MP=P!.[:03]P<'CU!XP(#=KF]4^P:>\.F:5I-C-JDZJ88!"JI$J.6663`^5$<
MEAW+'Y>22-#_`(1^R_Y[:E_X,[G_`..5GW/A^32[AM5T`RF]./M$%Q<NZWB`
M8VEG)*L!]UNW0\'AJP%;PM)+:17&CZAMCU6*>>YE11A)%EF>0/'G[R?/CU!&
M"`:Z&N7L81XON%UN]$T$$#RP65LCO#)#ABDC2,I#;R4(V@X`'<G-:O\`8-G_
M`,]M1_\`!E<?_%UYU504W9FRO8S;^RBU:74-,8V9FDN?.2.\M/M$3*L40.5R
M.F]<<@YQUYI;+PO-:ZKIM]+J;3M8VWV;YH_FD4;PI+%CR0P+<?,R*1M&5,^D
MZ1;V^M7UW')<F2-S"!+</(-K1PL3\Q)SE1SZ<=AC=J92MH@*,O\`R';3_KVG
M_P#0HJO51E_Y#MI_U[3_`/H457JA[(91U;_CSC_Z^;?_`-')5ZJ.K?\`'G'_
M`-?-O_Z.2L#6?&XT@7@;3R[6U[]E(,V`RBW\\OD*<?+D8/&>I`R0TFUH(ZVJ
M.B_\@+3_`/KVC_\`0138=3,NOW>EF`KY%O%<"7=G>'9UQCM@QG\Z=HO_`"`M
M/_Z]H_\`T$46T#J7JHV'_'YJ?_7RO_HF.KU4;#_C\U/_`*^5_P#1,=);,9>J
MC%_R';O_`*]H/_0I:O51B_Y#MW_U[0?^A2T+9@7JHW__`!^:9_U\M_Z)DJ]5
M&_\`^/S3/^OEO_1,E$=P9>JCK7_("U#_`*]I/_035ZJ.M?\`("U#_KVD_P#0
M31'XD#+U%5KG4;&R+"ZO+>`K&96$LJKA`0"W)Z`D#/3D4]KNV2[2T:XA6Y=2
MZ0EP'91U(7J1[TK`5/"/_($F_P"PE?\`_I7-6[6%X1_Y`DW_`&$K_P#]*YJW
M:]6.R,7N%%%%,1S]_P",+"QO+VS$%U<7-H]O&T<*K\[SL%15+,!GYE)R1@,/
M6F1^-M)DGD@_?K*D`F*,@!)\WRB@YY8/@>GS+SS5&_\`A]::CJ4E[-=NS3W`
MENHG4O%.@EB=4*,Q486()D#D$Y':GW7@&SN-1DODN7BE:561`#Y<2(L>Q%CW
M;0`\2,3C)P1Z8`+G_"9:>OFK+;WD4D+V\<D<D8#*TTS0J.O.&1LD9&,$$YJ6
MU\407'AZ#6Y;"\M;6X>!85F\LNZS,BH^$=@!EQU((P>*R[CP#%?WQU"_O5N;
M_?;2)</;#=$8IWE*H<Y56#A,9X"C):I].\'O9^$K?0)+NT\NWEMY$EM;+R=W
ME2(^7&]MS,4Y;CKG%`&U8ZS97VA6^LB0064\"SAYR$V(1GYN<#\ZSYO&.EPW
M;VY%P<1AXI-@"3G,8VH21DYFB&3@$O@$D-@M_"5G'H6D:=-)))+I4:+;72?*
MR.J[=X'(SC/!R.:AG\,7MY<7;7NJ0W$<JP^43:%9(FB970[@^TKO4L0%&<]<
M`4`;MA?1:C9)=0[@C%E*MC*LI*LIQW!!'X59JEI.G+I6G):*^\AWD=MN-SNY
M=CCMEF/%7:`"LK6O$%IH7D_:8YW\T,W[I0=JKC<3DC/WAP,D]@:U:P?$GAF+
MQ']D\V?R_LY8C*;L9Q\Z\C;(,?*_.,G@YH`L6?B&TOX]4>WCED&G3/#*(]LC
M,Z?>"JK%LY&,$`GL*6V\06EQIL%YY<T?FW)M?)=1O64.493@D?*5;)!(PI()
MJHOAV[2_O[Q-5Q+=KY6?LR?)$#*RKCH6#3?>(Y"@$$DL8X_#+6>F:3;V\J22
M:??&Z7*^7&`Y<,JJ,[5596VKS@*HSWH`0>-M/:SEN?LE^%A8B93"`T2!$?>P
M)X&V1#C[WS8VY!`MOXGL8UO"Z7`-K>?8W78"6?8LA*C/(V-GUX/%9T?AG6%L
MK2"35]/F:&Y:XE+Z<^V=N"&8>=]X-DYSC[ORC:*GB\,746JWU^-2BW3SRW,"
M_9O]3*T21*QR_P`VU4/IG>>E`"VWC.PN-7BTO[-<17;E@Z3/"ABVJ&Y!?+<$
M'Y`V.^,&IM#\6Z9K\[069E641B4+*H4LA5&##GIMDC;VW@'!R!5M?"UTD%I!
M=:A;R102K,ZP6AB,C*^\,6+LV2V2V20WH.<Q:%X,31->^VQRJ8ECE"JH(`+^
M4H4`DX54@0`9Q\QP````#K****`"LK5?$%GI%]8VEPDS27C;4,:9"C>B9;GI
MND0<9/.<8!(U:P]<\-IK6I:9>-=R0M8R;PJC.?G1L@Y^5ODVYY^5W&.<@`=8
M>)[#4?#YUJ$/]E+%4PR.SG=M&-K$9)(&"01GD"K#ZW!#!;23P7,+SJ[>2\>7
M0(I9BP!/3&.,Y)&,YK&/@QY=-O+.ZU%+A;R5)Y]]JH5Y(Q"(CM!`P!"-RCAM
MQQM&!4R>&Y[/^RS97,8FM(;F#S63Y8Q+ALJF>BNB`+G[O&>.0!S>--.CFMK>
M6WO$NIYY(!;^6&D5DB\TY"DY^4K]W/+`>N)F\56J0J6M+WSS.;<VP13(KA=W
M.&Q@Y09!(RXSCG&0O@6Y,^G73ZXT5S9.64VMJJHQ*R`L1(7;>3(2S;L'^[G!
M%B'P=-:6]S]DU"&WN)8W2(QVNV*`NRF38@<8#!%Z$$')SS@`%O3O&.G:E?+:
M117*.6:,M(JA5=02RGYL\`'Y@-O;.:L:#XGT_P`10QRV7G!)(VDC\U-NY5D:
M,D<]BGY,OK6.O@*-[EIYKU(I'MFMRUC;^2R*8S'M0LS[8P/FV'/S_-GM5KP]
MX4DT._B=[MKF*WAG2*1U56)GG\UP54`#&U.>Y)X`P*`.GHHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`K#\9_\`(B^(?^P9<_\`HIJW*P_&
M?_(B^(?^P9<_^BFH`W****`*&G_\?NK?]?2_^B8JOU0T_P#X_=6_Z^E_]$Q5
M?H`H3?\`(P6?_7K/_P"APU?JA-_R,%G_`->L_P#Z'#5^@"AK'_'E'_U]6W_H
MY*OU0UC_`(\H_P#KZMO_`$<E7Z`"J&A?\B_IO_7K%_Z`*OU0T+_D7]-_Z]8O
M_0!0!?JAH_\`QY2?]?5S_P"CGJ_5#1_^/*3_`*^KG_T<]`%^LIVN%UF_:UBB
MEF%K;[4ED**?GESE@K$<>QK5JA#_`,C!>?\`7K!_Z'-0!S`FUR'QO`]S'/Y$
MD@,H@>XEABA,>P(!Y8C8^;M<OD.`6!&Q<U?TJUEMK?2_--UF749I$2ZGDE=(
M_+F"`F0EA\H4D'H2:Z>LK68#<3Z5&'*'[;NW`9(Q%(>_TI2;2;2NP-6J&N_\
MB_J7_7K+_P"@&IOLTO\`S_7'_?,?_P`35+68)$T/4&:[F<"VD)1@F&^4\'"@
M_E6?M)?RO\/\P-:BJWV:7_G^N/\`OF/_`.)H^S2_\_UQ_P!\Q_\`Q-'M)?RO
M\/\`,#"\+?\`((G_`.PE?_\`I7+6U6#X;C:32YF6>2("_O1M0+@D7,H)Y!Y)
M&3VR3@`8%4)?&6FQ^'8M<%U?R6<L\D*&..(D^7O+-Z;=L;MUR1VR<5YK<FW:
M+_#_`#-S?L/^/S4_^OE?_1,=7JR[*%S=ZB!<RJ5N`"0%^;]U'R>/PX]*N_9Y
M?^?R?\D_^)I2F[_"_P`/\P()?^0[:?\`7M/_`.A15>K+EA<:U:K]IE)-O,0V
M%R/FCXZ8YS^E7?L\O_/Y/^2?_$T.;LO=?X?Y@0:M_P`><?\`U\V__HY*H7&B
MZ'K$]Y!<6OF,TXGF_>,-S^6(L\'IL&TCH1G(.34^KQ2IIY87,CLLD9565<$A
MU(Z#KQQ[UD6@O(+L2^7<+DX=@F3@]>HKDKXV5*48J+\_0#HK;3;6TN#/$C^<
M8([<R/(SL40L5!+$Y.7;D\G/)-,T7_D!:?\`]>T?_H(J;R)/^?R?\D_^)JGI
M$+OHMBRW,J`V\9"J%PORC@9&:Z^>5OA?X?Y@:E4;#_C\U/\`Z^5_]$QU/]GE
M_P"?R?\`)/\`XFJ5E"YN]1`N95*W`!("_-^ZCY/'X<>E"F[/W7^'^8&I5&+_
M`)#MW_U[0?\`H4M3_9Y?^?R?\D_^)JE%"YUJZ7[3*"+>$EL+D_-)QTQQC]:%
M-V?NO\/\P-2J-_\`\?FF?]?+?^B9*G^SR_\`/Y/^2?\`Q-4KV%Q=Z<#<RL6N
M"`2%^7]U)R./PY]:(S=_A?X?Y@S4JCK7_("U#_KVD_\`034_V>7_`)_)_P`D
M_P#B:I:O"Z:+?,US*X%O(2K!<-\IX.!FB,W=>Z_P_P`P9A^(?"NHZGJNHWMM
M<6A%UI%QIRI*K*R&39C+#.5!#'ID9QSG*ZAL-0N/$=I?7-I8K;P1M@I.QD$F
M756QY8W?(Q`Y&WS'^]P:UHH&CF>1IFD+*J_,!D8SZ`>M3549R:U5@L9WA'_D
M"3?]A*__`/2N:MVL+PC_`,@2;_L)7_\`Z5S5NUZL=D8O<****8C-&OZ6=0:P
M%VINEN%MFCVG(D,9D"],?<4GTXQUJW:7MO?1/);2"1$E>%B`1AT8JPY]&!%<
M._@S6[;7X=;MKJUN[@WCW4\%Q*8D`'G+&B,L;'A9SDMGD<<'C2D\,7K:(;0M
M:RN=3N+UX'8^5*DCR,$8[2>/,5NAY0?6@#I-1U"TTG3Y[^^F$-K`N^20@G:/
MPYK.G\6Z):RWL<UXR?8E)G8P2;!A!(0&VX9@A#;5)..U8EKX(N$\'0Z#<WP>
M1[UKB\O$`\R4>:TBM\RD%^(P<@C@]<"LH_#K5FTZ_6;4(9[RZMY("7ED$66M
M8XA)LP0'W1MD@9VN>3@"@#M(_$ND2W$4"W9$TI"A&B=2A)*@/D?(200`V"3P
M*UJY2WT#5H=6.H*]G%+<W0N+DH[DHN%4QC@"12J#J%VMEAGH.KH`****`"BB
MB@#$E\7Z#!]H\S4%'V>3RY/D<X/S9(P.5&R3+#(&Q\D;3B_/JME;7L-G+.%G
MF`*+M)')P,D#`R<@9QG'%<?-X)U4Q:[%%>VI75)#G=O&%+2MNP../,4&,Y1]
MC9P9&QJ:CX;O-3UJSO9)(H%CDC,QAD_UJ0S&2(%2GOSAEP2?O"@#5N_$&EV)
M<7%V%V2&-\(S;2%#$G`X`#+ECP,\D4A\1:2()YVNPL4#A'=D8#)Z$<<KP?F&
M1P>>#6%)HFK-%):1VMM<6QU&>>;[3<M$9HW82*H*HY*@MM*G&?+`Z&H]'\):
MMIGV:)K^.6WLXV-LLTLDW[X(460@XP"';*`X!`QUX`.@'B/23#;2_:_EN6D6
M+]VV2T89G4C&05"-D'!XQUK31UEC61&#(P#*P.00>]<='X=U.Q&F2Q16SQV=
M]<7KV_VAW8!X778KLN9&+R,Q+8ZXKH/#NG2Z1X9TO3IW#RVMI%"[#H2J@''M
MQ0!IT444`%%%-==Z,N2-P(R*`,A?%>ANT"KJ"$SRF*/Y&Y;*CGCA270!C@'>
MN"=PS;_MFP_M7^S/M'^EYQLV-C=MW;=V,;MOS;<YQSC%<79>`]6MXM&BEU.*
M2/394V!BS;8U\CIN'.3"YV'Y5,H(/[M<[-OX<OSXNBUVYE@5M@\Q(I&*@^7L
M*!2`#\WS>9]['RXQ0!MIK%A)J?\`9R7`:[P[>6%/1-H;G&.-Z]^_L:CCU[3)
M;2&ZCNMT,TDD<;!&Y:/?O&,9&/+;D^GN,X6D:!J5GKMI<.D/V:UDU$.[2'?(
M+B9958``@XQM.2.<^G+]&\/:G91%KO[*9(EO&@CCF8H7GF:3+$H,8!5<X/5N
M*`-9/$^CNMNRW@*7$231OY;;2K@%<G&`2"#@X..<8%:U>;+X&UJTT">S6Y1W
MN-.6SE1+EV0M]G6W`"$!=H*B3=][J,=Z](1=J*I).!C)ZF@!:***`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*P_&?_(B^(?^P9<_^BFK<K#\
M9_\`(B^(?^P9<_\`HIJ`-RBBB@"AI_\`Q^ZM_P!?2_\`HF*K]4-/_P"/W5O^
MOI?_`$3%5^@"A-_R,%G_`->L_P#Z'#5^J$W_`",%G_UZS_\`H<-7Z`*&L?\`
M'E'_`-?5M_Z.2K]4-8_X\H_^OJV_]')5^@`JAH7_`"+^F_\`7K%_Z`*OU0T+
M_D7]-_Z]8O\`T`4`7ZH:/_QY2?\`7U<_^CGJ_5#1_P#CRD_Z^KG_`-'/0!?J
MA#_R,%Y_UZP?^AS5?JA#_P`C!>?]>L'_`*'-0!?JAJ'_`!^Z3_U]-_Z)EJ_5
M#4/^/W2?^OIO_1,M`%^J&N_\B_J7_7K+_P"@&K]4-=_Y%_4O^O67_P!`-`&%
MXSTGQ#J_AC5K&RGLYC<1,L4*HT+XZ@>868$X&,%5!SU6B33=2NO'>GZL]@8K
M>*W,3N95.TCS0<8.2&W1D#&"#EP&1!700PWZ01HUS`650"3$S$G'KNYI^R]_
MY^+?_OPW_P`76*J2:OR/\/\`,9SWAR%+C0;N&0$QR7^H(P!(R#=3`\CD5GW7
M@724T-M.:YU$V2S-,D0E#L&<R!@"5).X2E.3Z'(;+'0\-K,=+F,,D:+]OO00
MZ%CN^TR[CD$<$Y('8$#)QDZEO%-<ZCB9D>*VPWRQE09"..N<X!SP>XKSG.;E
MRQ5FWY?Y]#5Z(ATUUDN-1D0Y5KA2#Z@PQUH5GQVCV-_<P6YCCCF;SUW1EL\!
M2."`,8''H15G9=_\]X/^_)_^*J>>5[..JTZ?Y@B"7_D.VG_7M/\`^A15RNG:
M5>VFJVL\FA70%K-?3I)%)#\PDEF:./F08!5^@'+;,D!*Z25;C^VK4&6+?]GF
MP?+.`-T>>-WT[_\`UK;QW;;1Y\6`RD[8RI(!!/.X]JIU))?"_P`/\P,-=+2Q
M.I78M(;=KS4X'`C15+*)(QN;'4EM[9//S<UTM4=6_P"/./\`Z^;?_P!')5ZK
M;NAA5'1?^0%I_P#U[1_^@BKU4=%_Y`6G_P#7M'_Z"*70.I>JC8?\?FI_]?*_
M^B8ZO51L/^/S4_\`KY7_`-$QT+9@7JHQ?\AV[_Z]H/\`T*6KU48O^0[=_P#7
MM!_Z%+0MF!>JC?\`_'YIG_7RW_HF2KU4;_\`X_-,_P"OEO\`T3)1'<&7JHZU
M_P`@+4/^O:3_`-!-7JHZU_R`M0_Z]I/_`$$T1^)`R]1112`SO"/_`"!)O^PE
M?_\`I7-6[6%X1_Y`DW_82O\`_P!*YJW:]6.R,7N%%%%,17BO[.>8PPW<$DH9
MU*)("<H0'&`>JD@'TR,T^2Y@ADCCEFCC>4D1JS`%R!D@#OP"?H*\Q;P9K]GK
M=SJ-FDHCGGNY9HX+A8Y&$EW&QV-D89X$P.1@J,D&M:_T#Q+>'P]<R202WFEV
MT?GE^1/*[*LVT[AM8(K<D$'>0,9.`#MX[RVF,0BN(9#-'YL6UP=Z<?,OJ/F7
MD<<CUJ:N*\,:7JL,F@/=Z=+9'3M%?3Y?.DC;,G^CX*[';*G8_7!XY`R,Q^#=
M+\46>IWUSKTMU+$+:%;>.2\\P&4*?..`V,,^67/164?+C:`#JY=;TF!XDFU.
MRC:61H8U>X4%W4X91D\L#P1U%']LZ7LNW_M*SVV9*W+>>N(".H?GY?QKS)?`
MWB8;EF9&66TN);@6^Q%EDF$`EM_G+$;O*?YQMY;.1R*UAX9U222X>33)`EO/
M>21A+B-7G\V[2>-XSDC*!,@/@%N#@$F@#T165U#*P92,@@Y!%+5'1H9[;1+"
M"ZAMX;B.W1)(K9=L2,%`(0=E!Z"KU`!4%S>VMGY?VJYA@\QMB>;(%W-Z#/4U
M/7)^-=#U#6?L?V%<[%ECDP5&0^WY7W?\LCM.[;\W"X[T`=(+^S/VG%W`?LO_
M`!\?O!^YXS\_/R\<\]J;:ZG87MHMW:7UM<6S-L6:*570MG&`P.,YX^M8.CV]
MS9ZMJ=T=!N('FF,:L)8=C1!I7###DY9V9CD`YE'4*2&MIEW9Z1H"3+NDCOTN
M+]8U+!G?>2?7`E=6SV"YZ4`="FH64GE;+RW;S7:./$H.]USN4<\D8.1VP:CA
MU?3+B.62'4;25(9/)D9)U8(^<;20>&R1QUKD[32-3C_LK=I,J?9_$%W=O^\B
M^2"3S]K</T_>KP.>#QTS+INB:G%J4:2VLZ:3"S3BWDNA.3,JLN`S-]QMX(&%
M`,?(&<4`=4NI6#O;HM[;,URN^`"5295QG*\_,,>E/M[VUNRPMKF&;:2&\N0-
MC!(YQ[@C\#7%:;H.JC1/#-E-I[6\EI%;+=-YL1!\IN5<C+<8W)L;&6^8`9S#
MX.\-ZCH?B4>8)%MEMG0Y`&4"6T4.[!(+8@D.1V.<+NV@`]"HHHH`*J7.J:?9
M75O:W5_:P7%P=L$4LRJ\ISC"@G)ZCIZU;K*U2SN+[4=,15_T6&1[B8DC#,%*
MHI'7JV[C^Y^8!:&J:>UE+>B^M3:0EA).)EV(5.&RV<#!Z^E21WUI+;PW$=U`
M\$PS%*L@*N,$_*>AX!/'85Q&@>'M3T[PQ=Z7?::TIG*L?(NA$V(XX4"A@<C[
MC!.AVHNXAB36G!9ZE!=:"]^LMPL<=VC1GYV#-@Q!F).2(U="Q."3UYH`Z)-1
MLI&A6.\MV,\9EB"RJ?,0?Q+SR.1R*1-2L9((YTO;9H925CD652KD`D@'.#@*
MQ^@/I7!+X6U.Z\-:!IT^FRV\]K9K#-(L\7!\MXG#$9;(1W*%6(RYW`8K1T;0
M]8CEN+G4XO,&V6:.W547]X\:1A<;V`(6-OXL?O>O7`!TDOB+1(9%CEUC3XW>
M'SU5KE`3'C.\#/W<`G/3`JU9ZA9:A"LME=V]S$R[@\,@<$9(SD'IE2/P/I7+
MZ-INK6>EZ/YUFZRZ5HHA2W,B'S+G:JD9#8X$>,Y`Q)]<6M(TN?3];L80SLEK
MI7E7,I7`FE9U*MGN<K*2!TW^XH`Z:BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"L/QG_R(OB'_`+!ES_Z*:MRL/QG_`,B+XA_[!ES_`.BF
MH`W****`*&G_`/'[JW_7TO\`Z)BJ_5#3_P#C]U;_`*^E_P#1,57Z`*$W_(P6
M?_7K/_Z'#5^J$W_(P6?_`%ZS_P#H<-7Z`*&L?\>4?_7U;?\`HY*OU0UC_CRC
M_P"OJV_]')5^@`JAH7_(OZ;_`->L7_H`J_5#0O\`D7]-_P"O6+_T`4`7ZH:/
M_P`>4G_7U<_^CGJ_5#1_^/*3_KZN?_1ST`7ZQ9[N:U\07/DZ?<W>ZUASY#1C
M;\\O7>Z]?;/2MJJ$/_(P7G_7K!_Z'-0!SB:_<CQ,+,ZDIB_MPVGE-Y>?*-CY
MNS@9XE[]>Q)JM8:Y+?>-8;8ZC%?6SSO-;_9ID=($$3A0X$892X;<I+.&`)&,
M<]W7*_VQJ4\6AS76@7Z7!D#NJF%0SF"3(4-)D=2<-@X'//%)R2+C!R5U^9U5
M4-=_Y%_4O^O67_T`U#_:U[_T+VI_]_+;_P".U2UG5+Q]#U!6T'44!MI`79[?
M"_*>3B4G\J7,A^REY?>O\SHJ*RO[6O?^A>U/_OY;?_':/[6O?^A>U/\`[^6W
M_P`=HYD'LI>7WK_,SO"W_((G_P"PE?\`_I7+6HUG:LQ9K:$L3DDH,FN;\-ZC
M=1Z7,JZ+?2@W]ZVY'@P";F4D<R#D$X/;(."1@UK_`-J7G_0`U'_OY;__`!VO
M*FHR>J-O9OR^]?YCM.BC2]U'9&B[;@*N%Q@>5&<#VR2:T:Y^RU*[%WJ)&AZ@
MQ:X!(#P?+^ZCX/[W\>/6KO\`:EY_T`-1_P"_EO\`_':=DM$@]G+R^]?YDLO_
M`"';3_KVG_\`0HJO5S\NI79UJU;^P]0!%O,`N^#)^:/G_6XXQ^M7?[4O/^@!
MJ/\`W\M__CM-O1![.7E]Z_S)=6_X\X_^OFW_`/1R5R.K^'-9N-7$UE&!"/$5
MO?'=,`#"L"*[8S_>#<=?;%;6KZI>?8`?[#OU(GA8%G@P2)5('$A//3\:\4N]
M9U&^U%K^>[F-R6+!U<C;[+Z#Z4>TY$=F%R^6(;]Y*WS/9M,LKAO&EYJDND7%
MFDMHBB5Y8V\QCM+*VV0D;=J@`#:,2$'Y^=G1?^0%I_\`U[1_^@BL;P[KNI7G
MA^RGN-'OKB5X_FFC:$"3G&[#2`\_05/I&I7::+8JNAZ@X%O&`RO!AOE'(S+F
MCFNCEE0E&3B[:>:.@JC8?\?FI_\`7RO_`*)CJ+^U+S_H`:C_`-_+?_X[5*RU
M*[%WJ)&AZ@Q:X!(#P?+^ZCX/[W\>/6A/1D^SEY?>O\SH*HQ?\AV[_P"O:#_T
M*6HO[4O/^@!J/_?RW_\`CM4HM2NQK5TW]AZ@2;>$%=\&1\TG/^MQSG]*$]&'
MLY>7WK_,Z"J-_P#\?FF?]?+?^B9*B_M2\_Z`&H_]_+?_`..U2O=2NS=Z<3H>
MH*5N"0"\'S?NI.!^]_'GTHB]0=.7E]Z_S,6P\9:C/KTMA<I;+!:SPQSSQP[@
MXG($.")3MR2.1OR&4D)R!HKJUW?6'B2TOD2.:V28Q(B#!@)D6-MP=MQ/EMGA
M2"",="9M-T[2]3:\2Z\/6,(M+AHHXI;:(LJO&C/G!8?,7.<'D'GG-7]3M+:V
MT75GM[>*)YH99)6C0*9&V'YFQU/N:M2BVK(F47%V9J4445F(SO"/_($F_P"P
ME?\`_I7-6[6%X1_Y`DW_`&$K_P#]*YJW:]6.R,7N%%%%,045Y=I_B&_LM5UJ
M4WAD"W%W'^\N'N$A(NUCC,D9*B$!6^4!@&4,25QFIIO&VLZGHIN+<VNFR`6D
MI#Q.[)&[6Y>0GA?+_>NISC_5-@GDH`>ET5Y@/B+X@DF*KHT:*L+S.K!6=,/&
MA0XEP"GF%F+E"0.B=:?>?$/6[>,2+IUJ%6U\XJREBQ"W+Y#*Y7!%L,8+8\S.
M3CD`],HKA=-\7W1UK3M-:"/9=75S$X8N7`$MP%<,S'(`A`(`(&\<J`H/=4`%
M%%%`!1110`45Y/=:MJL4NMRO?WH%M>^9%!(9<3E6N-L`,;`Q,X2(`?=(\ML,
M9-IZ75-6NY?%%JMG.WDAK=(D60@2/Y[I<J0#ABB`'GH:`.SHKAY-6N!J6E23
MWLD#3>(;BU:`RX5HEBE5%QW!V1MCU?WJ,RR1W]^(=1NK:UDNI9&E>ZDF\J&W
M3]XZAB0O[YPI4<87&.U`'>45Y;9ZG>W-TOV76'FLYWA-IY=\92BM(5G5G#'<
MRQA9.?NE^#Q7?>&[VXU+PQI5]=KMN;BTBEE`&/F903QVYH`U****`"BBFN6"
M,5&6`.!ZF@!U%>3Z?K6OW%GHDRS7?G-=QQ3QM/G?,S6S/@$`E%1KA63G8Q;L
M@*]7!JMIJ'C:".RUQ'`B$KV_VD8D1H\JJ19YZ^87QD<#."<`'6T5YR=:OI-4
MYO[A+B:WU<"UB;+*T,JI%L0GEMJDCUY/K5:QUFY?27;4-2GM[6T:2XGGAO"Z
ME2$1(TE8@LK%I/F.-K*<?=!`!Z?17D_]NZI;VNH2&_:Y>WM9)K*:VOS*C!8O
M-&Y0,2('!B\S.XE<=S7JZ$LBEEVDC)'I0`M%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%8?C/_`)$7Q#_V#+G_`-%-6Y6'XS_Y$7Q#_P!@
MRY_]%-0!N4444`4-/_X_=6_Z^E_]$Q5?JAI__'[JW_7TO_HF*K]`%";_`)&"
MS_Z]9_\`T.&K]4)O^1@L_P#KUG_]#AJ_0!0UC_CRC_Z^K;_T<E7ZH:Q_QY1_
M]?5M_P"CDJ_0`50T+_D7]-_Z]8O_`$`5?JAH7_(OZ;_UZQ?^@"@"_5#1_P#C
MRD_Z^KG_`-'/5^J&C_\`'E)_U]7/_HYZ`+]4(?\`D8+S_KU@_P#0YJOU0A_Y
M&"\_Z]8/_0YJ`+]4-0_X_=)_Z^F_]$RU?JAJ'_'[I/\`U]-_Z)EH`S-:\7V.
MEM"D$MK=2&X\JY59S_HJ!6+R2!%8@+MP20`"1D@9-1:EK;W$OB'2);7R!;V<
MC0R.7S<+Y2EF4%`I53(%.&)!Z@9&=O4=+L]6MA;7L1EAW;B@=E#<$$'!&002
M"IX()!!%<YKZ:=HYF`MKJ2XN=+N(UGWS7!4(L:X(^;&[*[G.,[%W$\83:6K*
MC%R=HK4Z^BLK_A(;+_GAJ?\`X++G_P"-UGWNHRZU?VNDV$U]91RI++<SF!X)
M/+4!=L?F1]2TBG(Y`7W%2YKH:1H3;U5D<G!+J]OK.B36@O&TJ._UA[\0(SJ0
M)Y2NY5!).>@ZD].:V?")U?\`M77?[2%WY7GDPF?>%_ULV`F[C'E^5ROR\C^(
M,3=U+2H?#<$&H:9/=11I<JMQ;-))<),LLJACM))#[F+`KR3D$'-7/[>L_P#G
MCJ/_`(+;C_XBN&I>+Y6:JDY)2AJO0SM1UDZ*;UX[?SY[B_6&&,EP"WV=7.2B
M.W"HQX4]/QJ['K$LVIZ=!##;26M[:M<B9+DE@!C)"A<,OSI\V[^+IZY+76GZ
MKJ+V,MM>G[1J&4DV3VK1$6P.X/A2#\I&,@D,>W7H++2;+3A&+6$H(X_*C!D9
M@B;BVT9)P,G@#H`!T``EN)$H2C\2L)+_`,AVT_Z]I_\`T**KU49?^0[:?]>T
M_P#Z%%5ZI>R$4=6_X\X_^OFW_P#1R5DW/@3P[=Z@UY+8_O';<RK(RJQ]<`UK
M:M_QYQ_]?-O_`.CDJ]0U[J+A5G3;<'8:B)%&L<:JB*`%51@`>@JGHO\`R`M/
M_P"O:/\`]!%7JHZ+_P`@+3_^O:/_`-!%'0CJ7JHV'_'YJ?\`U\K_`.B8ZO51
ML/\`C\U/_KY7_P!$QT+9@7JHQ?\`(=N_^O:#_P!"EJ]5&+_D.W?_`%[0?^A2
MT+9@7JHW_P#Q^:9_U\M_Z)DJ]5&__P"/S3/^OEO_`$3)1'<&7JHZU_R`M0_Z
M]I/_`$$U>JCK7_("U#_KVD_]!-$?B0,O4444@,[PC_R!)O\`L)7_`/Z5S5NU
MA>$?^0)-_P!A*_\`_2N:MVO5CLC%[A1113$%%>86_CC7+7Q)/:7:)<0-=7<=
MJN%C5A]KCMXE9\$C:Q<D@$X8'!-;<WC207_AZ[CB;^S=3L1-)$Q`=&DEMXT8
M<'.#-R,C@D\D`$`[2BN+L?'ZZC<I;0:>GG%LY>Z"QF,^1M8,0,D_:8^,<_-M
M+?+NRM/^)UT=,T_[5I#2WDXMHW>(R+%YDVPK\YCV@;7!(R2#D8(^:@#TFBO/
MY/B>B:<+P:-<!22X$A>/,7E2RY!=!EL0L,#*Y(^;KA\GQ$6"._N7LG)MD&ZW
M,XQE'N1(4PFXG%LQYX/&=@W&@#O:*:CB2-7&<,`1FG4`%%%<EXVUO4-'^Q_8
M)'7<DLDNR-6VJFWYVW?P#=R%^<Y&.AH`ZVBN9M[[5-^O22ZE:BVCW+:SRQ@)
M%*N\L,#!9541YR<EA)R!@!(=2U6#2=&2Z=FNKZ^\D2O&`PA^>12X``#F-`IP
M``S<`4`=''!%"\KQQJC2MOD*C!=L`9/J<`#\*DKS?4?%NJ:1I5B;G5;5I+S4
MXA#<.J1^9;!HEE*J1C&YVV]_+P221FK&F>)]8OQ!;F58KBY@AO#),BA;=2DC
M2(1@9"E(U.?F_>=:`.]EB2:)XI5#QNI5E/0@]13E4*H50`H&`!T%<!'KWB"U
MU*T6X>XFL[B>%+5C;+NF1Y-C&7:N(\#YU^[D'!R0:T/#NKZN^M0VFH74=Y;7
ML,TUM,D03B(Q`M@?P,TK[>IVJF222:`.PHHHH`***Y/Q7KE]I>N:);6MP(XK
MB3]^#&&ROG0Q_,<9V_O2/EYW,A^Z&H`ZRBN/7Q!?P>$KZ[=VN+V/49K2/8B!
MBHNC""`<+P".3QQS4T.MW4T>E00W)#S07<LMQ=1*N##A-KA3@$,X)*\'8<8!
MH`Z:.&*$R&.-4,C;WVC&YL`9/O@"I*\YO-=U_38#?SZB38HC&/>L8F</\L<D
MD2QEBFX%OE*$+UR014^G>(-8O[9;:2[FM+F*61YC+%"9%0+&$B)XCWNTH*D<
M<`'H00#NYH8KB/RYHUD3(.UAD9!R/U`J2O/I?%>K6MC]K:02>7HM_=&%HUSY
ML$J*I8KQD`D-M^7.2.,5LZ!K=Q=ZA;VDL\MPLEM.6>6%8V22&?RW#;25R=P'
M'!V$C&:`.HHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K#
M\9_\B+XA_P"P9<_^BFK<K#\9_P#(B^(?^P9<_P#HIJ`-RBBB@"AI_P#Q^ZM_
MU]+_`.B8JOU0T_\`X_=6_P"OI?\`T3%5^@"A-_R,%G_UZS_^APU?JA-_R,%G
M_P!>L_\`Z'#5^@"AK'_'E'_U]6W_`*.2K]4-8_X\H_\`KZMO_1R5?H`*H:%_
MR+^F_P#7K%_Z`*OU0T+_`)%_3?\`KUB_]`%`%^J&C_\`'E)_U]7/_HYZOU0T
M?_CRD_Z^KG_T<]`%^J$/_(P7G_7K!_Z'-5^J$/\`R,%Y_P!>L'_H<U`%^J&H
M?\?ND_\`7TW_`*)EJ_5#4/\`C]TG_KZ;_P!$RT`7ZH:[_P`B_J7_`%ZR_P#H
M!J_6=KZA_#FJ*<X-I*#@X/W#W%`$]QJ-I:7EG9SS!+B\=DMX\$ERJEVZ=,*"
M<G^HK*NUTWQ-)+#97IBU+39"8[F-"'@?+*<9&'0E&5ARIVL#RO$%YX42?5-/
MO[#5+B*XTV21E2X<W2[GB9<'>V\?>4D!@"/0D,+>B^'AH^I:C=BZ,WVMB539
MM\M3++,03D[COG?GC@*,9!)32:LRHR<7S1W,JP%YKL7V[5]0`MK6[E5;6VC\
MJ(M!-(@=R2S-RJMMR`"!D'K44?B^:[\)KKMGIR$-=-!Y%Q.8CCS3$I!V'YBV
MWY2!C)YXYN^&HTFT2ZCD17C?4+]65AD,#=2Y!'I4-QI'A_0-/^6R$5OYZS);
MQ.P3S5<R*0N<##'/T"CHH`\[XI:ZLVE-M:FE9QQR7VH,Z*S1W89"1DJ?(C&1
MZ'!(_$UH5SNB:[;W6H74;*T<ES+YB`\CA%7&?7Y<UT5*I%Q=F2G=%&7_`)#M
MI_U[3_\`H45/&J:>3`!?6I,[M'#B9?WCJ2&5>>2"#D#I@TR7_D.VG_7M/_Z%
M%7/R>']7.GV\*)8M)#J4U]\UQ(`0UP9D4X3!SG:<@[3AQDJ`2R:5P-S5+B!X
M_LZ31M-%<6S21A@60-,NTD=0#@X]<&M*N2&C7%GKFK:J]U;S07\]DJB-"'5H
MYR,-R0<!@,C'3H,9/6TI*R`*HZ+_`,@+3_\`KVC_`/015ZJ.B_\`("T__KVC
M_P#012Z#ZEZJ-A_Q^:G_`-?*_P#HF.KU4;#_`(_-3_Z^5_\`1,="V8%ZJ,7_
M`"';O_KV@_\`0I:O51B_Y#MW_P!>T'_H4M"V8%ZJ-_\`\?FF?]?+?^B9*O51
MO_\`C\TS_KY;_P!$R41W!EZJ.M?\@+4/^O:3_P!!-7JHZU_R`M0_Z]I/_031
M'XD#+U%%%(#.\(_\@2;_`+"5_P#^E<U;M87A'_D"3?\`82O_`/TKFK=KU8[(
MQ>X4444Q%.72=-G1DET^UD1PX97A4A@YW.#Q_$0"?4]:D>PLY);>5[2!I+?_
M`%#M&"8N,?*<<<>E4H/$.G3WNJ6QF\EM,*?:'F(1`&7(8$GIP1DXY4^E6HM3
MLK@3?9;J&Y:%0[I`X=@",C@'OV]:`&Q:/I=OM\G3;./9)YJ[(%&U\8W#`^]C
MC/6D71=*5U==,L@R_=(MUR/FW\<?WOF^O/6JD_B?38X(Y(GDN9))1"+>%,S!
MMI<@QG#`A59L$9P.`3@5+I^OV.HG4#&X2.PN&MYI'D3&Y3@]&)7G^\`?PH`G
M.CZ6RNK:;9E9'9W!@7#,P*L3QR2"03W!-)+HNE31O'+IEE(DARZO`I#'+')&
M.>7<_5CZFG-JVFJD[MJ%H$@4M,QF7$8!();G@9!'/<&D;6=+20QOJ5FKAE4J
M9U!!8948SU((QZYH`N@```#`%%%%`!4-Q:6UWY?VFWBF\IQ)'YB!MC#HPST/
MO4U96M>(+30O)^TQSOYH9OW2@[57&XG)&?O#@9)[`T`/'A[1`UPPT?3P;EBT
MY^S)^])#`EN/F)#N.>S'U-/&BZ:EC#90V<-O:PR++'%`@C5&#;L@+C&3G/KD
MYZU4B\5:7*FIOYK)'IR-),[#@HK.K,O/(#12+]5]"";0U>(6-M<S6]S`UQ*L
M*P2IB0.6VX(SCC!.02,#(S0`ZUT72K&U:UM-,L[>W:02F*&!40N""&P!C(*K
MS[#TI_\`96G#S?\`0+7]Z'63]ROSA\;P>.0V!GUP,UEOXNL8].-]]FO#$DL\
M<H$8S&(7*.S<]`1T&2<\"BQ\6V-_:-<PPS%?M7V1%5XG:1^^`KG'`)PV&P.E
M`%^TT+1[`H;/2K&W,>[9Y-NB;=WWL8'&<#/K2:?H&DZ5.TVG:=;6C,NW;;Q"
M-<$@G@8&3A<GOM'H*H6GB_3[VXTB"".4MJEL+F'<\2%4(SRI<,3[*&J;0_%&
MGZ^(S:;E\Z-I8MSHWF(K;6(V,W0E<@X(W#(!H`VJ***`"HI;:">2)YH(Y'A;
M?&SH"4;&,C/0X]*EK.U'5O[-NK*%K*YF2ZE$(FB,>V-C_>#.&Z9/R@\`T`/C
MT72H4=(],LT1]^Y5@4!M^-^>.=VT9]<#/2EFTFPGCMXY+6+RK<,L<07"!64H
M5*]"I!Z'CIZ54A\26<VAG5Q%<);%E$7F(%,V\J(RG."&WKCGO@X(($L6NVD\
M-H\:RLUT9%6,*"RF,'>#SC@KM^I%`#[70M(L1&+32K&W$99D$5NB;2PPQ&!Q
MD`9]<5)'I.FQ6[6\>GVJ0NFQHUA4*RY)P1C&,DG'N:RF\9Z2EIHMS(TJ1ZO&
MTL&Y1E46,R%F&>``,<9Y(JVNOQ&&!WLKR-YV<+$\:[L*A?=P<8(``P3RP''.
M`"V-*TY9XYQ86HFBB\F.00KN2/\`N`XX7VZ46VF65G/YUM;I$1"L*J@PJ("2
M`JC@<D].O'H*Q[;QKI5U#'-&ESY3VZSAO+!.3")A'M!)+^60V`"/?-7M)\06
MFKN8XHYHI0K%HY5`(*R-&ZY!()5E(."1R,$YH`U:***`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`*P_&?_(B^(?\`L&7/_HIJW*P_&?\`R(OB
M'_L&7/\`Z*:@#<HHHH`H:?\`\?NK?]?2_P#HF*K]4-/_`./W5O\`KZ7_`-$Q
M5?H`H3?\C!9_]>L__H<-7ZH3?\C!9_\`7K/_`.APU?H`H:Q_QY1_]?5M_P"C
MDJ_5#6/^/*/_`*^K;_T<E7Z`"J&A?\B_IO\`UZQ?^@"K]4-"_P"1?TW_`*]8
MO_0!0!?JAH__`!Y2?]?5S_Z.>K]4-'_X\I/^OJY_]'/0!?JA#_R,%Y_UZP?^
MAS5?K%GCOW\07/V&YMH<6L._S[=I<_/+C&'7'?UH`VJH:A_Q^Z3_`-?3?^B9
M:XR\\.:O-XK>[AL2EL=46X63S$4*,6>Z7`;(RL%PG][]YC&&8C1TVRO+?Q";
MB:R>U@N[U9E6;RC(9##/OR8\Y4+Y8&XD@AP"5VF@#L:H:[_R+^I?]>LO_H!J
M_5#7?^1?U+_KUE_]`-`$=U90VZWU]*;N3.9C';/(&(5`,!4/S,=OIDYQ6"?$
M>C(ND^8FK1OJ<KQ1QO=.&1ED6)MW[SG#LH^7=D'(R`36IX@TS1KMDDO+"&;4
M9%\FVGC@C>YC/)#1LP.W:26R>`>:R(?#%A+=Z3:7EUJB/81J+6*?R%655D63
M&8UP3F.+(!!PB^K%@-";PW9Q3:7,S-."+^]7Y)W48%S*!P".<#D]2<DY))IV
MO:&]U9*;0RO*C9V23,V1[;B>:F\+?\@B?_L)7_\`Z5RUM5YOM)1E=,VY4T<)
MH>AW4VI!IHWBC@?]X=Q5@<`@#'.>0?QKL/[.@_OW7_@5+_\`%5S^O6%SJ-EJ
M<=E!Y]RE\DD2D1E0XA3:6#C!4-C./FQDKR!4R6.JR^/HM5>W":>MA-:C=,-R
MMYJ$'8,_>VD@YZ8R%(P;J5)3=[V)C%(O2V$(UJU3?<8-O,3_`*3)GAH^^[/?
M_.*N?V=!_?NO_`J7_P"*IDO_`"';3_KVG_\`0HJO5FY2LM2K(RKNV%II<<(8
ML/MD3`G)/S7"MU/7KUK5JCJW_'G'_P!?-O\`^CDJ]2;NK@%4=%_Y`6G_`/7M
M'_Z"*O51T7_D!:?_`->T?_H(I=!]2]5&P_X_-3_Z^5_]$QU>JC8?\?FI_P#7
MRO\`Z)CH6S`O51B_Y#MW_P!>T'_H4M7JHQ?\AV[_`.O:#_T*6A;,"]5&_P#^
M/S3/^OEO_1,E7JHW_P#Q^:9_U\M_Z)DHCN#+U4=:_P"0%J'_`%[2?^@FKU4=
M:_Y`6H?]>TG_`*":(_$@9>HHHI`9WA'_`)`DW_82O_\`TKFK=K"\(_\`($F_
M["5__P"E<U;M>K'9&+W"BBBF(\_UOP/=QV\T^F7%Q/<W5R)KOD,S;9S,AC$C
MA%VM\N.A!)Y/70\/^"O[#66:VNG@FDM7BBC,CS"V9R&;&YMK`,!C"ID#G/6N
MFMM2L[R[O+2WG5Y[-U2=`#\C,H8#\B.E6J`.)N_`4NI69BO[^T,XD\Q+F"S<
M29*.A+-)*Y8@2$H<C8P!Y'%:,_AHB'7)9Y9+]M0M3;"%42,B/,C!<Y`+9E8;
MCC@#/.2=N^U&TTZ$RW4NT#^%5+N?HJ@D_@*CL=7L]2FFCM'ED\G&YS`ZQG(S
M\KD!6_`G'>@#D-.^'3V@-T^J-]ODABWN59@)1Y/F'&X##&!>0%;D_-PNVQ9_
M#U++1OL,>I?O1+!(EQ]G&Z,QP)#E>>"0I/<?,00PR#VM%`!1110`5@^)/#,7
MB/[)YL_E_9RQ&4W8SCYUY&V08^5^<9/!S6]5'4=9L-)\O[=<>5Y@8K\C-\JX
MW,<`X49&6/`R,F@#!;P-"8=5@6]98=222&0>7EEB=II"H.?O>9.QW8Z*!CJ:
MLQ>&GM-.TJ"&5)9;"_-V,CRT`<N&55YVJJRL%7G[H&>]:\>JV,M[>V4=PK7%
MDB/<Q@',8<$KGZA2:2'5K&?3K74([A6M;KR_)DP1OWD!<#&><B@#"7PMJ45O
M'"FJ6;(NH3WSI-8LR.9)#(HP)1]UF8@Y(^Z<9%6+7PQ+!K0U2:_6:9(RD:F`
M*H(!",0#C(#R`D`9W=L5='B72"D#_;5VSSM;QDHPRZOL(/''SD+DX&2!W%+%
MXCTF9)&CN]PC=4/[MLG<2%(&/F4X.&&1P>>#0!F6'A.:UTO1]/EU)98=/2%6
MV6^PR&)MR$'<2O09&2#CMDTW2/"DVG>(O[3GO!<MY4@+^6(]SNL*?='`PENG
M3J6;@#`&K#XATVX-E]GEFF%[#Y\#16TCJ8\9#,0N%SVW8S3M,UW3]7>6.TDE
M\R(X>.>WDA<?\!=0:`-*BBB@`JA>:8M]J%E<RN#':^8RQ[>KLNP-G/&%+CI_
M%VQS?JC?:SI^FW-M;W=RL4MRVV)2"<\A<D@?*-S*N3@991U(%`'/Z?X&&G:&
M=)BU#-KO255,&-KQ^5Y3`!O6+<W]]G8_+TJ[!X=>PN=+FM9(VDMA=+*[@@'S
MV\QF"@_\]%7C/0GFM"'7-/N=.FO[>62XMXFV,8('D;/'1%4LW!!!`.00>G-.
MAUK3[BRL[N.?,-XN^`E&!<;2V=I&1\H)Y%`'*2_#:.[TS2;.ZUFY*V%M]E=8
MHD5)4\N2/(!W,K%9,$AB#CH#@C5TKPG_`&7YKI=0F0PR1PJEOLBA+[=Q5`W0
M[$)&>NXYYXOQ^)M&E%H5ODQ>0B>!BK`,A4L#DCC(5B`<$A6]#4B:]ILEO%.M
MP=DKLBYC8'*J7(((R/E4GD>GJ,@'/V?@5[..S:/4U6ZLK(6]O,D#`"40F$2L
MGF%6(4^@/^UCBM+2M"N++4K2>YDMG%G8M:QM!&T8;?(&;*LS$8$<?.XY)8\5
M:@\2Z5<+OBN)&B^RB\,Q@D$2Q%=P8N5V@XYP3G':K5EJMEJ)Q:SB1MF\J5*D
M#<R\@@$$,K`CJ".:`+E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%8?C/_`)$7Q#_V#+G_`-%-6Y6/XMAEN?!FNP01/+-+I]PD<<:EF=C&
MP``'))/:@#8HK#_X2S3O^?;6?_!+>?\`QJC_`(2S3O\`GVUG_P`$MY_\:H`N
MZ?\`\?NK?]?2_P#HF*K]<S:>(K."YOI)+75PMQ.)(R-(NCE1&B\@1\<J>#SW
MZ$5:_P"$LT[_`)]M9_\`!+>?_&J`+LW_`",%G_UZS_\`H<-7ZYF3Q%9OJMO=
M"UU?R8X)8V/]D760S-&1QY>3PC<]!WZBK7_"6:=_S[:S_P""6\_^-4`7=8_X
M\H_^OJV_]')5^N9U#Q%9W=LD<-KJY99X9"#I%TORI(K-R8_13QU/0<U:_P"$
MLT[_`)]M9_\`!+>?_&J`-RJ&A?\`(OZ;_P!>L7_H`JE_PEFG?\^VL_\`@EO/
M_C55=,\16=EI5G:SVNKK-#`D;A=(NF`8*`<$1D'D=1Q0!TU4-'_X\I/^OJY_
M]'/5+_A+-._Y]M9_\$MY_P#&JJZ?XBL[2V>.:UU<,T\T@`TBZ;Y7D9EY$?HP
MXZCH>:`.FJA#_P`C!>?]>L'_`*'-5+_A+-._Y]M9_P#!+>?_`!JJL?B*S35;
MBZ-KJ_DR011J?[(NLEE:0GCR\CAUYZ'MT-`'35AZG9RMKEA.MPT2R2+&-FTD
M%8YR3R".AQ^)]C1_PEFG?\^VL_\`@EO/_C55;OQ%9SW-C)':ZN5MYS)(3I%T
M,*8W7@&/GEAP.>_0&@#:^Q7'_04N_P#OF+_XBJ.LVDZ:'J#-J-RX%M(2C+'A
MOE/!P@/Y4W_A+-._Y]M9_P#!+>?_`!JJNI^(K.]TJ\M8+75VFF@>-`VD72@L
M5(&28P!R>IXH`NRAM,U2*[NKB::W>,PF60#$#%@1G;@`-T)QP0.<47=Q%JMS
M:VMA<;FCD$TEQ"0PA4`CKG&6Z8.>"213/^$LT[_GVUG_`,$MY_\`&J/^$LT[
M_GVUG_P2WG_QJ@+&;X;MY9-+F9;R>("_O5VH$P2+F4$\J>21D]LDX`&!6O\`
M8Y_^@C=?]\Q?_$5SV@:W!9:=+%<6.LH[7MW*!_8]T?E>XD=3Q'W5@?QK3_X2
M:Q_Y]=9_\$UW_P#&J\Z49WV_`UT$L[.4ZG<2?:7D$-YE@X4;LP*,\*.?F`[#
M`]:VJYVVUZV@N+R22SU<+/,)(\:1='*^6B\XCXY4\'GOT(JS_P`)-8_\^NL_
M^":[_P#C5$H3;V&FBW+_`,AVT_Z]I_\`T**KU<Z^O6S:G!<BSU?RHX9(V/\`
M9%UG<Q0CCR\GA6YZ#OU%6?\`A)K'_GUUG_P37?\`\:I.G.RT"Z+>K?\`'G'_
M`-?-O_Z.2KU<[?:];75NL<5GJY8312'.D72_*LBLW6/T!XZGH.:L_P#"36/_
M`#ZZS_X)KO\`^-4>SG;8+HV:HZ+_`,@+3_\`KVC_`/0153_A)K'_`)]=9_\`
M!-=__&JK:=KUM9Z9:6TUGJXEAA2-PND73`,``<$1D'GN.*/9SML%T=%5&P_X
M_-3_`.OE?_1,=5/^$FL?^?76?_!-=_\`QJJUMKUM!<7DDEGJX6>821XTBZ.5
M\M%YQ'QRIX//?H10J<[/0+HZ*J,7_(=N_P#KV@_]"EJI_P`)-8_\^NL_^":[
M_P#C55DUZV74Y[DV>K^5)#'&I_LBZSN4N3QY>1PR\]#VZ&A4YV>@71T54;__
M`(_-,_Z^6_\`1,E5/^$FL?\`GUUG_P`$UW_\:JM<Z];3W%G)'9ZN5@F,DF=(
MNAA?+=>,Q\\L.!SWZ`T*G.^P-HZ*J.M?\@+4/^O:3_T$U4_X2:Q_Y]=9_P#!
M-=__`!JJVHZ];7FF7=M#9ZN99H7C0-I%TH+$$#),8`Y[GBB-.=UH#:.BHK&_
MX2:Q_P"?76?_``37?_QJC_A)K'_GUUG_`,$UW_\`&J7LY]F%T6/"/_($F_["
M5_\`^E<U;M87A!7&@%I(9H?,O;R54FB:-]KW,K*2K`$94@\CO6[7I1V1DPHH
MHIB/--=\,:S8P7]W#<&[?5+A3=*(FD6-%G:1%"1KO="A,;9)/S>F<:OA'PC>
M:/--/->W)AGMBBI(Z"5=Q!&[:@^9`"H)=_;'2NVHH`XRZ\%W*VL4-M=+*T$Z
MSK,\CPW$Y".F)9DRS'#Y!P/N@5/9>&9+.2^GOC;M'-9O#<O:Q-OO"P&9)$`)
M+@!@`"<[CP.!7644`>7Z3X%\111_;Y-2WW=S&TDL=PP4`N,-$0(V(7DD?,5!
MZHQ&39C^'VI+;3&22QDN<1K;%V8K"%GG<#[N"H62+"X`)CXVX5AZ/10`@S@9
M()[XI:**`"N:\6>&[CQ!]C\B=8_(+YW,5P6VX?@'?C!_=GY6SST%=+10!RFD
M>'=7T?Q)JVI_:;&[CU$H6!1HG`4S,`3E@<;T7/=1T!'S)9:%J%AX;\+V<H22
MXTJ:$3);R95U"-$3E@,@;P^,?P\9XKK**`.,/AG5Y-)>QD-BN_4I[U66>0^6
M6F,L;_=`<J2?D88)"G(QBI],T+51J27FHVU@KQN\P,-T[[WVE(EP8U"(JL_`
MSR<\DDUUE%`'%Z;X2O;>Q\/13IIZW.FPPQ/=1%C*HC.2J,5Y5QP1A<`GKQB[
MI6A7=GK6GW$V,P6MT;B16R))KB5'(!."0NP]0."M=/10`4444`%<UXE\-W.M
MZGI5S!=)"EH^7##G_61OD<?-Q&5VGC+!NJ"NEHH`Y#1O#NNZ1X8ET9;^"0&`
MPP2M([&#$:(I7(Z$B1]N<*2%&0,UIW&F2V^K:--9Q;H+2":U\O<%50RH58^P
M\O;P"?GZ=:W**`.!E\$ZG?>%=)T.[FM(Q:6?V=IX99&,9*-&Y52`K[D.`2`4
MRV,YK4T[PY?6U[=W]P\#32I(T<*RML$K)&G4KD#;$G.#]YN/7JJ*`//U\`W<
M^C6]A<&PMI5TL64MU;;C)+B#R@K$J-R`X<=.0!CC)U]#T&[T_7!<3G`$-R\A
M1LHTEQ<>:5'0G8%QD@?>^N.IHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`9+(L,3RL&*HI8A%+'`]`.2?8<UP_BCQY#9II\-A--:3S7
MD(D-]9R6VZ'S$63;YR`,<,,XY`)/&*[NF2PQ3ILFB21-P;:Z@C(((//<$`CW
M%`'/^%;^^N6O;?4;C[1.A699$D22+RWW;0K*B=-IR#N(R/F.:-=\7V.DVEWN
M%U%/%F-)9[*>.W$A.U=TQ38%W$?-G%;L%I;6OF?9[>*'S'+OY:!=S'J3CJ?>
MIJ`//?!_BS5=8;2FN)O.2?RX)=J*`Q^RB9I>`,'?E,#@>F:['4-:M-,E6.XB
MOG++N!M[">=0/<QHP!]C5B'3[*WD22"SMXGCC$2,D2J50=%!`X'MTJS0!YW+
MXAUF)IM^HK)#:2BZ9HFA66YM"BD%%"R!@6\S"@AMNW+`G)[N_OX=.M_/G2X=
M-P7%O;23MG_=C4G'OC%,72--4`+I]H`)?/`$*\2?W^GWO?K5R@#@M8\5W\&H
M1R6,TK6-V5ME66V\M[>8R1C[K#>&"&60[U"XV8[D]/H>HS7.@B[NP[/&\R,5
M3+.L<C*&"J.2P4'`'?@5=DTZQFGDGEL[=YI(_*>1HE+,G]TG'(]JFBBC@B2*
M*-8XT&U408"CT`H`YC4]=N;](H]#DO(+HMA([C3I(?-8],F5!^[`#%BO/3!!
M(!G\*W]]<M>V^HW'VB="LRR)(DD7EONVA65$Z;3D'<1D?,<UKW^D:9JIB.HZ
M=:7AA),?VB!9-A.,D;@<=!^5306EM:^9]GMXH?,<N_EH%W,>I..I]Z`,/6O$
M,44%Q:V\FH6MRK!//_LR8J/F&0CLGEEB,A2206*\'H<[2]:UPZ[:V6I!/,$B
M6MQ'$HV;OLHF:4'&<;\IUQ^-=9>6-IJ-J]K?6L%U;OC=%/&'1L'(R#QUIL&G
M6-J\;V]G;Q-'$(4,<2J4C'11@<*/3I0!!J&M6NF2K%/%?NS+N!MK"><8]S&C
M`'V/-<E)KNKC2DNS>Y2UU"]%R(S&DLL$,S(%1#&VXX`R!M)X^8$UWM4H]&TN
M*,1QZ;9H@F,X58%`$A_CQC[WOUH`DO[^'3K?SYTN'3<%Q;VTD[9_W8U)Q[XQ
M7)WWB:]^WZA]C:<6_P!FLFA2:U:)X3+<O"[E74-P%W?,,<>E=K55],L)+F6Y
M>QMFGFC\J65HE+.G]UCC)'L>*`*OA^]GO]&CGN<F42RQ%B`-X21D#<<?,%!X
M]:SM?U]A:SV.FO<6^HM*D,<UQ:2PP!BX!_?/$T>2,A3R"2``<@5T444<$211
M1K'&@VJB#`4>@%)/;PW4#P7$,<T+C#QR*&5AZ$'@T`5=&U!-5T.PU&,2!+JW
MCF42`!L,H/..,\]N*-;O)=.T'4;ZWB\Z:VM99HX_[[*I('XD5=50JA5`"@8`
M'04I`(((R#0!B^'+ZZO(+V.ZD,QMKGRDG*J/-4QH^?E`'!<KQ_=K:J*WMH+2
M$0VT$<,2]$C0*H_`5+0!SFDW]\WB>_M+RX\Z&0/):K%(CI&B,$8-A`5;+#@L
MV<'IC%='4,=I;0SRSQ6\2338\R14`9\=,GJ?QJ:@#SP>*]9CCTL-()6DNKA)
M6\L#S0FH1VRKP.,)(3QSE1[Y]#JG!I.FVL<<=OI]I"D3F2-8X54(YZL`!P3Z
MU<H`XR^U+6I'UVVM+^.*2VU*.*%F>.(B(V\<K*I9'!/+=5)^G;JM/NEOM-M;
MM!(%GA24"5=K`,`?F'8\\BHVT?3&-SNTZT/VI@\^8%_>L.A;CYB.V:N@```#
M`%`'*>+]4U?3%:?29/-E@MWN#:",$.J`EBYP2,@!5"\ECW`.-'PY?75Y!>QW
M4AF-M<^4DY51YJF-'S\H`X+E>/[M7;G1],O+V*]NM.M)[N$`13RP*SI@Y&UB
M,CDGI5BWMH+2$0VT$<,2]$C0*H_`4`9_B&XN+?3-]K</#*7"CRD5Y)"<X1`V
M5R3CD\`9/'497AR_U<ZQ/::Q<I/+)$7C%LZ/#'L*HXX0,K;FZ,S=#TP1707^
MFV&JVXM]1LK:\A#!A'<1+(H;UPP(SR?SIUM86=FS-:VD$#,JJQBC"DA1A0<#
MH!P/2@!;V3R;&XD^T1V^V-CYTN-L?'WCDC@=>HKA+#Q1K;:D+.YW^9:7$,,J
M,B;I1+<,@W%1MW+%Y;G8<98_2O064,I5@"I&"#T-58=+T^W\CR;"UC^SY\G9
M"H\O/7;@<9]J`+=<)JFKZV-3O;&TU*$)(5DM93)#'D(SB9$8K(/E'EK\Z[BV
M_&`..[JF^DZ;*9S)I]JYN"&FW0J?,(Z%N.<>]`#]/NEOM-M;M!(%GA24"5=K
M`,`?F'8\\BN-\9^,KG0_$-C86,L#,MM<7$]NQ&^8B"5HE7OC?%@X[E1WY[L`
M```8`J.2"&9XWEB1VC)9"R@E2002/3@D?0F@#)\.7UU>07L=U(9C;7/E).54
M>:IC1\_*`."Y7C^[6=\0_$<WAKPG/=6EQ#!?292W>7&-P4N>#P3M4@#N2*Z:
MWMH+2$0VT$<,2]$C0*H_`4Z:&*XA>&>))8I%*NCJ&5@>H(/44`<]HVI7<WB2
M^M[BZ%Q;S*\MGY,B21I&C!2#M0%6)8<%FS@],5TE0QVEM#/+/%;Q)--CS)%0
M!GQTR>I_&IJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K&\67%U9^$=7O+*Z>V
MN;:TEGBE158AD4L!A@00<8/'0\8/-;-,EBCN(7AFC22*12KHZ@JRG@@@]10!
MQ<?CEK+58]'GLKJ[=9EMC=#YF<[8=SLJ(%4`W">@P&Z':&HR?$BY-R\T.G0F
MSMK.ZN9U\\YD"1PR1E&V=UF4'MR2"0`6[MM-L&F29K*V,J2>:KF)=ROM"[@<
M<-M`&>N!BH1H6D+&8QI5B$)9BHMTP2R[6.,=UX/J.*`.2E^)D<$<WFZ/.TT<
MOEB.W8R[L&<-C"YZVTF.,8*DE1NVN@\>7FI:Q96=EI\42OJ/V>4RS$[HO])7
M(PO#9MF..>PSR2.N;1],=65].M&#,'8&!3E@Q8$\=0S,V?4D]Z<-*TX-N%A:
MYWB3/DK]X,6#=.H9F.?5B>]`''ZSXRN[?Q3-86\;"VM@L3@,JM),TUH`<E&P
MH6YQZG+8P0#619_$+5K&/3[C5+=KQ+G3(;@16HW,TDGG.3@)GA(2`.@XW$@E
ME](DTVQFN#<2V5L\Y"@R-$I8A6#`9QG@@$>X!IC:/ICQI&^G6C(BHJJ8%(4(
M24`&.`I)(],\4`<9>_$];*UN+AM%GD2%9G_=L[91))(E)81[5):)LAB,#!&X
M\5<_X6#&MI=7$FG,JV<<TER!.,CRWE0"/(&_)A;T(!!P><=/+H^F3JJS:=:2
M*N_:'@4XWY+XR/XLG/KGFG_V98;E;[#;;EWE3Y2Y&_E\<?Q9Y]>]`'/2>*+F
MZTW2IK2T>WGO;N6`I<!DV^4DKG[R[@&,6!E0<-G`(Q7/VOQ&O;W1[5#:/!?;
M;)IKE$)A/F26V\`LH`REP.,DCYN@"LW?G2K'[-;6Z6T<4-JZO`D2[%C*]-H'
M08)&/0FFQZ-I<))BTVS0D*"5@49"MN7MV;D>AYH`YJW^($=Q$K_8,![E;9")
MLJ[NL;Q8.T9#))DGH-IP6'S563XEQO/!&-,)628(SK/P$9K<(RY4;LBZ0GH.
M#@L,$]C#I6G6RA8+"UB42><!'"JC?C&[@?>QQGK4<>B:3#_J]+LD^;?\MN@^
M;*G/3KE$/U4>@H`Y.3Q^Q33KF.P/^F1AHX1=(5(D>U"%\*65@+D''&,'[P*M
M6C_PG5G_`,(_!JGV'42TMM'<^6EE.Z*K*&.950IP"><]N<5O#2=-&W&GV@VL
M7'[E>&+!B>G4LJG/JH/:IX[:"*V6VCAC2W5-BQ*H"A<8P!TQCM0!Q]]\0HK%
M$=M/\Q9+26ZCV3Y)54FD3/RX`=(6.<YR>`0"1'_PL9>5_LS#I.MLX-TH`E>:
M6%`N1EEW0L20,@$':><=9+I&F3&,RZ=:2&.(PH6@4[8R"I4<<+@D8Z8)I6TG
M36^]I]H>'',*]'.7'3^(\GU[T`<;>_$Q;-W!TEF$43-*?/P0R_:"P4;>1BVD
MP>,Y7@9)%Q/'@EU673UT[8\+R),SW*IL*2K&<9&"3YL3`9Y#'N`&Z5M'TMU"
MOIMFRA!&`8%("@,H7ITP[#'HQ]34=MH=A;M([0I/+)<-=-+,BLWF$!<C@`84
M!>.PH`Y_PIXW77;F&SDM7BS:+,)Y)E8N?+MV(8!5`/\`I"#C@D'@<"I==U74
MM&U4^;?)]EO]L%G!%;M+*C@;G?:JDG:H<]P<H,+M)?<.AZ4455T^V0*4(\N)
M5QM*$#@=/W<?'^POH*FNM-L;XDW=G!<97;B:,.,9SC!]\?D*`*&@:Q_:TFIJ
MLB30V]RJPSIC;)&\4<JD8]!)C\`>];-5[2RM[%95MXP@ED,K^['_`.L`!Z``
M58H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"J]ZEY);,MA/!!<9&'GA,J@=_E#*?UJQ10!QVCZ]KFH
MZ/H[O-IOV_5H/M,>+9U2WC"J6ROF$R$%T'!7K5F/Q!J%S>'18OL<6KQS21S2
M.K/$J(D;[U3()R)H_EW#!)Y..;%MX:DL-$TBTLK\1W>EPB&*X>'<KC:%(9-P
MX.`<!@<@<TJ^')H5%S!J`753.\[W3P;DD9E"%6C!'R[50`!@?D'/7(!KV37;
M6J_;HXTN`2&\ILJ0"<,,\C(P<=LXYZUA0>*9O[2UJVN--GQ9W:6UJ(]A:X9H
ME?:,OUY)R=H"D9((.-&PL]0L[I(Y;PW-MY;O*\H^=I6<$;>?E4#(VX].>#69
MJ/@V#4KJ_EG>VFBN;F.\2&YM1*J3)$(OF!;#(5`^7`())W=,`%RU\4V5[?):
M6L-S-)L#3;%'[C+O'A^<YWQNIV@@8Y(&#3/#OB"75-`GU/4;5K%89[A&WE<;
M(Y&7/RLW0+@^X..,$U5\'*BZ?&EQ:Q16DJS*(+%(F1A)O(B*X\M6R58'=E>^
M229+?P7I?V6YM[^VM+PR/<>5.]LHFBCF9W9-Y)/61^1C@].I(!7UCQA-;:8S
M6&FW!OVGMXE@F$>569]D<I7S`"I((`W`YX;;R1O7NI"Q$$9@EN;F8'9#`%W-
MM&6/S,``,CJ>X'-9#^%&N6\Z[OA)="6T(E2':/*MY?-1-NX\DELMGOT&,59;
MPQ96D\-SHMO9:9<Q%\&.T78X?;N#*I7.=JG.1]T?2@`D\56$1D#Q72F-+1V5
MXMC#[1(8XP5;!!#`Y!`Q[TR/Q9:SK/Y-E>R-'=R64:[44W$R%PRQ[F`.`C-D
MX&.^00*^H>$Y;ZZ\_P#M1@91:"Y+P!C*;>4RJ1@@+DE@>#VQC!R77@RUN]+^
MR3-!<.FH3W\7VJV$L0>5I#M>,D;@!(1U'(!XH`W++4[34(HV@F4LZ%Q&3AP`
M=IRO48((^HK(O/$-U;^,+73$MT.GE52XN"#E)I`YC4<XQB,@\=73WJWI&ERZ
M7*+9%M5L8K=5C$-NL7SEW9L!>`N"N!^I.35&Z\%:==R7EY*D+:K/<K<Q7[0`
MRP%"NQ5.<A0$4$`@'GU-`%#1/%]UJ&K1VTESIMRTM[<VSV=JI$]HD;2A9),N
MV0?+7^%>7&,TZ#QE=%]1\ZSC53/''IG4><KS&`%CD_QC=P/NLO>M[3M(?3=%
MFL(+H^8\EQ*DQ3[C2R/(.,\[2^.O..U8Q^'VCPQ6BV$4=C)!%Y;S01*'F(*,
MKL?XF5XT?+9Y!]30!8U/6=3T#3/M.J/I[(+NVC:Z4&*,1R2JCDJS':54YSN(
M/7CI69JWCR)#J3:1?Z7/;6L5D?M?F"6.-IKAHGWE7`PJ@-C(Z\G%;$WAV[O8
MPVH:JTT_VFVF'EQ%(E6&42`+&6."V,%L\\=@!3=;\+MJMU=W45Z()IXK1$WP
M[U0P3M,"1N&02V",CIUH`T-#NI;W3_M,FJ:?J2.Q\NXL(BD9`XQ_K'R00><^
MV.*S_$/B&ZTG4].M[:W26%V\R^D8']U"76,$<CG<X/?Y4?VJY;Q:ZEQ;"ZO+
M&>/S&,Q@M&B^3:0J@-(YSNP<^@(QWJIJ?@[2]:N[^YU.WANI+F!8(6DB!:V0
M!ON$]&W,S9&#T]!0!?;68AJ+6D5M<S^7(L4TT*!DA=@&"MSNZ,IR`0`1DBL/
M5_',-MX9_M+3K6::>;2Y-2MXY%4`(NP'?\PZ>8I(!Z`XYP#IVFB7=E<O)!J6
MU;EXYKO]P"TLBHB$J22%#!`",$^A!YK(_P"$#+V1L9=3)M4TN;2X%2##)%(4
MPS$L=S#RQV`/H.X!LP^(H9)XXY+.[A1Y!"9I`A1)C_RR)5B=P/&0"N>-V:R=
M>\43Z;XEDTX:KHUA%'917*K?J=]PS/(I1#YBXX0?PM][IVJ2T\$VUOJJW[QZ
M4\S3_:I9AIB><9B0Q*2,S%5+9.#EAGAA@5MQZ8(_$-SJWFDF:UBMO+V]-CR-
MG/OYF,>U`&'IWC*2:[N8[[39[>-)[>%6`7]V\L,3JCY;);?(5^48Z9QUJV_C
M'3]EIY,%U/-=0I+%`@17^?.U&W,`K':_4@?(1G.`5NO#*SRW\WVELW.HVVH;
M0@X,(B^3KSGRNO&-WM5'2_#$RZ?J;;5M9=0NGG^S7L27*)&<XB=0V"-S,^%;
M@MC.."`7I/$T<6I26S03LYMH98K7R@LSO(THVY9@,_NCUP!@G)'2&7Q?;QZE
M:(`/LDUK.[`C]Z)TFBA$0&<9WR%<>H'.*AA\%"WN(KJ*_P`W5O#$MNTD.Y(W
M1ICG;N&5Q.RA<C``YITG@BWDEMI?M3"6$2ONV=9WN([CS.O0/']WT.,T`69?
M&%E##<.UK=[[2(RWL0";K10"<O\`-@]#]TMZ].:M0>(K2>:*!8YA<27+6IBP
MI,;+'YA+8)`7;@YS_$OK7):SX5UA-6-W:QB]-VF;LJI$4DAX.Z+[1'\FT*,$
MR9QTXR=W2M(NI/%MSKM[:FU;[(ENL7F!E:7/[R1<'H0L:@D!L*>!0!J7NN06
M%[#!/;W"Q2RI"+DJHC$CD!%Y(9B20,J"!W(K/LO&>G7MI'<F"[MXYK475OYR
M+F9,JORA6)SN=!@XR6&,CFHK_P`'+?:R]^UW'\UW;W0+VX>5/**'RUD)^6,[
M,X`ZLQR<XID?@B%;+2K9[QG&GZ?]C1O+`W,'AD63KQAH1Q[]:`-'1-:FU.ZU
MB.XM6M5L;E8E23&\`PQN=V"1G+GH<8Q4.E:GJVH6=MJICM#IUY`)XHU5EEA0
MKN4LQ)#Y&,@!<9[U<T?29M.GU&YN+I;BXOIUFD*1>6JD1I'@#)XP@ZDU4LO#
MUQ9B"V&J2'3;0$6MLB;"H*E0KL&^=5!X&!T!.2`:`*&G^.[:3PY#J&H6MQ%<
M?9;.>6*./.X7#!%9!DY7?N&#SQTY&=3_`(26V%P(I+:YC"E8YI&V;8964,L3
M88_,0R],CD<\BLV/P0B6=O;_`&]CY-GI]KN\KK]EE\P-U_BZ8[>]7KGPREQ?
M3O\`:%6SN;A+R:`QY9IT"!&#9X7]VA(P<D=1R"`4SXVM9K"UN(K>YM_M:V\U
MN;F)3YL4DL49("OD8\U1SCJ"`PK8L=9BU"X"16MT(71GBN6C_=2@$`X()QUX
MW`9'(R`:Q9/!"26>C6_V]A_9EG#:AO*_UGERP2;NO&?L^,<_>]N=?2=)GTI8
MK9+T-I]NACM[=80I5>P9LG.T<#`7CKF@#-/C/3;35M:L=3U+3;*2RF1($GN%
MC>13#&^2&//S,PX]*=I/BV&\TS2I[F%U>ZM[9YYHP/)AEF52B')W9)8`8!QD
M9(R,Z=II(M;S5[CSBW]HS+*5VX\O$21X]_N9_&L"R^'UC926,BBRDEMXK=))
MYK!'F9H45%*.V?+R$&>#CL0>:`+6J^+A9*8H[26*Z,L'E)<J!YL3SQ1,X`;<
M,>8/O!3G'!%9^G>-]0NI;(3:+.!.;\-%'L+X@F1%(_>;0,,P;)Y9?EX(R1?#
MQ$:V9K^/=!&D>]+4*\VV>&;?(VXEW/D@%O\`:)P.AT[#PHUE?13F^$D</VT1
M((<$"YD60[CN.2K*<8`X(],D`DU_Q$++PBNMV$]L(Y3;&.>X4F-4ED1=[#*G
M`5\]1TIMEXCAAM1+?ZK97T3PS7*7MC#L@\N+;O!/F/\`,,D]>@/H:=-X:=O!
MMEH$-ZJ26<=JL=P\.X%H&1@2@8<$QC(SWZTS4/#E[K=G;PZKJ-NTD%TLP>TM
M6B#1X(>-@TCY#*6&<]QQQ0!%K/C%=.TNZG%C<0S_`&.::U-TBJDLD<32%,!M
MW`4Y.`#V)J\?$UF@G$B3;H+NWLI,*,>9,(RN.>G[U<_C6)J'P^74&N-]_&IE
M>Z;S?LH,Q\^*2/#ON^8()?E&!@*![U?O/";W%W(\6H>3;S7=M>31^3N9I(?+
MQAMW"D1+QC.><]J`(=<\:-IL7EV^F7379EA\N*4(IEB::.-G`+@CF0*-VT[F
M'&,D6T\4)]MO;06T]S<PW)C6W@10X18XG=CN?!"F5<D$=0`">N0/AV%2(KJ,
M2S0P"-)5LP#(RS12B24[LR,3"-QR,Y.-M::^%IH-5NM5M-02._N)78N]N714
M=(5==NX<Y@5@<\9Z'N`20>,M-N;G9!'<26WG0PF["KY6Z9$:/G=N.[S%'`X)
MYQUK:6\MGM7NHYXY($#$R(P91M)#<CT((/TKG;7P3;65D]G;73I!]LL[I`4R
M5%NL*A2<\Y\GK_M=.*T)-+N=2\-3Z;?2I%)<[TE,*;0(V<_+@'KL."<]<GVH
M`Q;?Q?J+>#-:U:ZLHH+^QA:XC@8':8VC$D6[G.<'#<CYE;%;]SJ4L/B;3M,5
M$,5U;7$SL<[@8VB``]OWAS]!67>>!]/:UU6VTQ+?3(=1L#:2QV]N%3=SMDV@
M@$C<P]3QSQ5E-(U5M3AU2]O[6XN+6VGAA2VM&A!\SRSSND;H8QZ=:`-B[N3:
MVYD6WFN&R`L4*@LQ_$@#ZD@>]9$7BNSN+<2VMM>73*',L4$8=X@CE&R`?F^9
M6`";B<<`U)J&CW.KZ-96UY/`;B(I).&@WP3.%(8-'N&5R<@9Z@=<51TWPE+H
MX=]/U%(;B4R":0VJD%6E>0!5SA2ID;&<CGD&@"])XFLTN'MT@N9)A>FP"*J@
MM+Y'GX&2!C;QDXY]N:S=)\:I<^';'4;^SFBEDM$N[OR]A2WB;.)6^?.P[6QC
M+8!R.#BRWA9O[=2_6_(@%\-0:%H06:7[.8#\V1@;<'&.N?48RT^'5J+6UBE;
M3[F2"U2S$UUIRS$0H6V%0[$+(`QRV"#Q\O&*`-GQ+XB'A[[#/)&'MI'F,^!E
M@D=O+*=O(&?W8'/K3[WQ18V,TT+Q7,DD0M<K&@.[[1(T<8'/JIS_`%I?$'AR
M#Q##;03S-'#%YH94'+K)!)"0#VXDS^%4/^$2N)[J6YO-362:1[%OW=ML4"VE
M:0`#<3\V[!.>.OL`"XGBFTEBA,%M=37$AFW6R*GF1B)Q'*6RP7Y6('!.?X<T
M^;Q!%]FT6ZBR(-2F"KN4,2IADD!!#8&0@.>?3'.1S&L>&-7@O(/[/$MQ`);J
M8M&2,-/,9&#*+B$[5``^\V[)RO2NFET:34;+1?M/E6DUC()GA@&Y-WDO&44G
M'`\S@X[4`4#XVM)=/M[B.WN;<W<<$UL;B-3YL<DD<>X!7R,&5,YQUR,BM%/$
MMC(;<!9OW]Y<6294?ZR$2%R>>G[IL?ATK!U/P?<)8:!;V;O<O80V]D3A478D
MUO(TC9;(XM\8`8Y<=@36DOA-TU*WF74`+2WO+B\2#R/F+S+('R^[D9E)&`/0
MYZ@`6R\:Z?>V#7GV6]@C,$,\(FC53.LK;4V?-UW?+@XY([$$[JWEL]J]U'/'
M)`@8F1&#*-I(;D>A!!^E<O'X69+_`,-6Q29H-$M5C:Z)54N,*H5=@8G(9%?D
M8&!@G)K6DTNYU+PU/IM]*D4ESO24PIM`C9S\N`>NPX)SUR?:@#$@\7:DW@K6
MM6N;.&#4+&%[B*!@=IC:,21;AG.<'#<CYE;%,?Q=>_V?>_9+S2]1DADM$CU"
MUB8VQ:>?RBI42'+(,-@/_$.E7[OP1IS6VJ6VFI!ID&HV)M)H[:W"KGG;)M&!
MD!F'OQSQ5C5?#+WR:@+:]6W^URVUQM>'>JS0NK;L!E)#!$4C(^[G-`%+4-?U
M?2)AI]X;)[B5/-2^C@<11Q@X=GBWEL*2@X?!W@DJ`:WM'NY;[3DGEEM)\D[)
M[1]T4R]F7DX^F3TZFL[^P=1DG^WSZP#J:@)$\-OL@1.<J8RY+`YR<OU5<8Q4
MEAI5]IUVLBW,4INKAKB_81;%8^6$`C7<=G*J>K9P<G)H`LZCKD&EW$27$%P(
M7DCB-P%'EJ[L%1>2"<DC[H..^*JS^*K2WL;J_>TO?L4%O)<K<+$"DJ)UVG/!
M]`VW/49`)JKJOA`:IJDEX]U$`\T$P+VP>6/RF1MB.3\J$IDC'4DY[5*WA=I-
M$N-#?4"-*>U>UBACA571&&!ECG.T<#`7WS0`S4O%36VLVFGV=C-<,=26QN6^
M4!<VYF!7+#L5/T5N^W.AIVOVNI7*PQ)*@EB,]M(^W;<Q#:"Z8).W++U`/(.,
M'-9@\)W#7+7DVI1R7C:BE^6^S$1Y$'D%-N_."N2#NX..N.9/#W@^R\.W0DM8
MK%$CA\B,PV*1RLN1S)+RSGY>OR@]2"<$`$S^*K5=0N[*.SO)IK>;[.`BH!+*
M8Q($0LPR=A)YP`%.2.,OM?%%E?7\=G:Q7$LFP--M48@R[QX<9S]^-U.T$#'.
M!@U4OO!EI?\`VQIS!.TVH?;XTN;<2Q(WDK#M9"?G&%)ZCDCTIJ^#E1=/C2XM
M8HK259E$%BD3(PDWD1%<>6K9*L#NRO?))(`MQXRMAI>H7<=M<PK;QW1AFGC4
MI*\&\.%`?)QL)YVY'0]<6H_$T<]Q>V]MIVH7,EHXCD,4:A6<HKA068#[K=3@
M#')&5SC6_@V[OM"NK'4[E(E:34#;HL0+1&=YE#EMV&^20D#`QN.3Z7[CP@)1
M/B[1A+J"WIBG@\R)L0+%L=-PW#Y=PY&&QUQR`0VGC:*ZUB[C%K(-.AM(YA/\
MA)E,LD13`<Y^9-HP.JMS@J3>F\66L*0*;&]:\EN3:?8T5#*DHC,NUOFVC*@'
M.['(YQDC.LO`:6:R(+\/'+'AP8`"'6YDN(V7!P-K2'(P<X'3O?B\-%+ZVU*:
MY$M['>->SF.+8LSFW,`55+':`NWJ3T]Z`+VG:]9ZI)`EL)=TMJMV0R@&-6.%
M##.0Q(88_P!EO2M.N>\+:,VF+J-U+#)!)?733+!*ZLT*$DA,J2/O%VP"0-Y`
MKH:`"BBB@`HHHH`****`"BBB@`HHHH`*R_$%]/I^E>=;C]X]Q!!OQD1K)*J,
M_P#P$,3Z<<\5J4UT26-HY$5T8896&01Z$4`>97%S?6&O7Z6][!-=#5W5+F]"
M!0PTO*EBH`7!`!(`[^M7;F[N[W4_#ZOJ%]'<V6J313QRQPAMPM'D`8JI5@5(
MY7'ROT##([:'2=-MHHXH-/M(HXSE%CA50IV[>`!Q\I(^AQ0ND:8EM%;+IUHM
MO%()8XA`H5'!R&`Q@$'G-`'`P^)/$BZ-I\X:XO)WTJ+4WD46L,)9U_U;F1E*
MQC&25RV6SD#"UK7FK:M!>SI_:"HUU*\-GDPF#*M]Q6^\LV`P.\,N[`'I752:
M9I\L5O%)8VSQVV/(5H5(BP,#:,?+@>E-;2M.>YFN6T^U,\Z>7+*85W2+_=8X
MR1[&@#*M=1NY/#&HM%<_\3&T$D6_451-DH7*^:8SL(Y4DKQ@]!6'<^*-1TVU
MWM)<3RI++8/!<Q1AUNF17@W/'\N#G&0,?O%R`0:[:VLK2SM%M+6UA@ME&%AB
MC"H!Z!1Q5)M!LM]FL*_9[2U?S4LX(T2)GZAB`N<@\C!`SU!XH`YRVUG5X->$
M,]Z;B(:O_9IB,2`%?L0F+Y`!W;QZXPQ&.F,6]UO4DCCUX7I^V2>%[N]2$HFV
MV?=`=H&.0#Q\V3D'Z#TK[':^9YGV:'S/,\[=Y8SYFW;NS_>V_+GKCBHO[(TT
MO._]GVFZX#+,WDKF0-C<&XYS@9SUP*`.;FU/5K*ZF#W<D[6=Y;6IA,2`7(F9
M-S\#(V[V"X(_U9W;NM82^(=?7P[:W[:LS33>'IM68&WBP)(A&0H^7[K;SNZG
MCY2M>C/96LEY'>/;0M=1*5CF:,%T!Z@-U`-,_LVQ\E8?L5MY2PF!4\I<"(XR
M@&/NG`R.G`H`Y?\`X2#5Y?$LD4=K.+2"ZAMFR\"PLLB(Q<EF$F\%R`%!!QCD
MGCL$=9$#HP93R"IR#4+6%F]W%=O:0-<Q*4CF,8+HIZ@-C(%2000VL"06\4<,
M*#:D<:A54>@`Z4`24444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
?`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g267791mmi005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g267791mmi005.gif
M1TE&.#EA<`+M`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````!O`NP`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O8,.*'4NV
MK-FS:-/*-(6I3=NVT1":HO/)(!TW$$VY-:6P50`6@`$+NMBJ\,=610LCCG@E
MP%+%#0$OYDAKL,``5R1"5CG9!(O)&UM9)NAW]$73!06Q0,WP"HO,I`VW`CQ1
M-8N$K@>7^#QQ]NV0T=S0:2.<#FB">NL6;-/FH9LVF9XK/^B;Q5_>%JT?S^CW
MM]`]`5@S_]2N-(#CR-XYFE_,(HI$09A5-K9,V^/ZU/$QSC<X^_Y#ZU<<9YY`
MM`0`A69_B2=08XA91]%LL(G4RG,+Z;6'010V%$T2RC''T%_;32291WY%&%1N
M$C6VU%\O.6B1:B::!%^('+E(6@`78C2C08)<L1N-"-E($(O8M+(;@@H*)!@V
M(.[$7%P"[<$<'7QAD]PGS"U&W$"F/-=&E:1]4N5P'P:PV'HNJI;@0%Z4\!=L
M`7B&&7RN@=A8>`.IN9J2X5EW&WS6!>`*=8'"1F>@/9HWFI[TA:<B-G=^]EJ1
MA0ZDJ'F9^3D@:9$NUI^:B!&Y7W\E&.HHGGI.5FB(=>[)Y'FC5O^*#9V-F3#8
M=?&E:M"F"6)JD'9^#M2J9>8!R.1O_>5'JZ*0_F6"8_UA1Y!U\('HYV)ZFM@I
M-IK>QNMJOBYXK:O"KK#FJ\;FF5^R$2:+':FL</L7D04QB!"CE\UK&JZ9)9AN
MLTT2U%B@"Q:[F+TV9HL-(O&55B1FW<V*6:">%@I?;QEBP]PGT62)S2?/10-R
M<QJ3W#$FIF32AC()=3Q=0@'[><5@W;6R'Q^8#1+KGG7:3*V:`M'9'V)1S#F?
M:',BY*;-+*K9X\\N=I?H8`-?D5F)3H>Z&IV72;8TMZ\=IQW0\@I"MHL.^F7F
MP+,">$4TOM4,MMGT"AMVDP+P-F*"7`/_2O?5:\9-WI"\O>F7"<?M)NFD`/I&
MLW:ANG?LWP^_9HJHDLVVPM`%>;;XVK2IS31L\P'-M-G':AU@G(@)8L+JY/(9
MX))#@U9BUU/CKC;N#)X.YK2QJRLIJI`/5%C@`))=NI!%"BTO[$J6<"MO@/;7
M;V9]F^D;I-2Z]EOW(T[TI$"?*(<E8GJ-2?*6V$@)91MT)!1RF6>:*:S]Q\YJ
M*NGVPT=S?D2*6GS(`Y[_Q<AX>.)6"21&K-_$J6!GNLU^("BOUB7010'L7P(%
MUBBM\0DQ]@J`>QRF0(E%B&NS>AC_$O<;_S6K07_*CX-02"0W">1V*2P(!K]W
MGFF=YW96"]H%_Q?8-146S$H`1%;#B,2:-`6`+[=S8?ZFZ,()[I!/!:.%O`RR
M!_XUBD?Q*2`6;?;%*1I&C`>QET$>A4/F8?$R<'+@@9J%&A0>Z85X=)$:640;
M[W'/B"[$(8MPJ!D/(0=+;N!+EW+4%H%D"$N?H(M;$(*E'"TD9CULEFO8-A#`
M7)`WFZ04#PNV20,U2X@&O*%B!F,;[SD&1J)\8V-**4'\X?%1\+'":[X%0Q!.
MBE!H@]4/PV,D[`'&E6TS4>-N>)W&2*\@S3SFPVXUF,L=<T`D3.+!#!2BOTB#
M27-D'301US;O,,U5-EKB-4MP/#A)#I;-DA;P?,G*/A[3D[+S)"OQ]_\7+1*I
M22Q@9^JH,[`RWB@SL]RE"0BBJSHQ=(,ZE&<G>;.]+>Z*HIX98T!=>1PIY@=%
M2VI2%/;4'^Y!Z#:T<9T$)]6*C!KI-BU-3T3&)Y#AI*P-<4E?3=>'%VS<A0Z9
MH,O+N`0_A_A'2('9)/^L=D$-IG**28U"$,DS*E,";$"`>DT0:1C.WWCO"E`(
MX@3I:%$?O>:L1:P@`_E#+?)D\$PS"\`W`176K4(48/][35@E&H!2A14*Q(IK
MZSRSR1@";I3JNJM%,_BK8<+&;4UE9@S/ZAH3IA6%$E.L'O$$Q&8&\5A:G1E9
M%XM8A&6RDYBQXFDM:];"WK"M/12$FRPSUGK_V=*'S'SL;=\XQ0<>2ZI6ZZ@Z
M"T8U^VTV@M,TDW)3&<@D&G$BT9`$R33F!L38%!N@:(-R&EDR@:C,>-21[D,P
M*;`>8@M50P1AJ69UQ[[R=INH?"X8V\7>J]UQL^#%HZ7\U,($3B:``O51$\^#
MP85B`PH]/*M7UWO#^AKD&B#"H18%E)Z#E>H\4O14`K494=0TB<,$\0QBMK<D
M%%F422/T;VXORV#4HJ8$`7ZF;!'ZS`9'K,'MXV?AXCAB33619^A<;13Q]]_"
M28MI%E30DGXET)?REG`]'F5%B\2?#9/NF0&=7H.>6=*89FI$VPME10$5,/'A
M5""&;`OZM.M(GI+O_TM%*FI!YN>0KV'#AO?+:UE?]\&U"M*K&LR4_:HJ4P3"
MZ97.91(1":W?!<UL,G8\#Y$0G.2"W-BM/#SO+P6)Z$5IL##WW6U`B1NT=.'0
MAER[\:9:ND_47/'$J!4(*P8H3/H(-'].WJ(I&,S$)3XUUF0=,K&(>,>B%;>,
MC%W0'@01HLW:6KC8P]'#H,58"!E1P`A1HVU'+,/5GMBJ]\UT:AA<'WN9-KY,
MTBV-E1CM7V_-(JTP)'7IT)9$8I<YF'"#).+7733#C\Y$?<LDL9&$-G03.\R[
MCG6^.3!]BBL`@9AQY?(ED&@H7)CHGE>0,.,KB5^ZAQ<'H2UIA3J!E,!S&__6
MFT!E:]77<GRS@3'OLU3%<3YCUGH`_0N"#\AR3N(.M0[W"Q\N,T>'`ZC,ER'B
M/W?;S+Y.SY.NJAJ*HQ?T1$<+Y[<>B`EBS,I0U\HR614@;?KJP5>!T#,]8LW%
MH_ZF@W;-DQ'T)#D#"O?*%;ILA'HY>[RMSX\+$>I@I*V;BJ9;+5/JY;0-]-\U
MB40>=K'D$P$JE$0FIE;0(2ZGN'PKRC<0NA`$%)G@F$%,\8G0AWZ[_%XC=C[+
MT"OL08M16@T9\_1HBJ+31'P0K:-;IWN;'9#V`7HM?6`CU=8'7W^@.284$A;<
M@8157,"W]!6B()KCY[[ZDV%]T)I/*=.(1O;`/P7_0GR/&K"FAONSA]0)KQ"O
M60%V.Y55/_1U^$K=JY_9TE(-8IZ__>.GG_]%\EF"\'ZJ5VH]MBAA93M6XWVB
M%7^?%7]@PU2KM8"S`6GRE'[Z<WP!&""J`7R3@8$,)5'&HQK,)BR_IS^#\4L`
M2'X'D78#D0@+F">@-$>E5H)!`P4C%@66,1OU]#A@]R;_HA9+\2B6)80G\2-E
M41\/TWY&:!.S08-NU(1%$2B`<4=22!)1^!7\%2Q76!-^H3C4TH5)41@!`B1B
MN!&01Q:S8#9)<H8N838:Z(9R.(=T6(=V>(=XF(=ZN(=\V(=^^(>`&(B".(B$
M6(B&>(B(>(5FV!"+"!.#_\(?5.:'(3)BEA:)X`4DC1@1QT&)I+$0F4@3G_@4
MF&B)E#B)#_&!I$AEIFACO4$=+K$I/1**9I<3PR)$YK$I>F@]:\0L#^,F;<<G
MQ2(M=9(?^L&+SW,CWF8IR?@0VA<2?D&#.1&+'E%;J-5#=V(>)0"-X`%1K1(A
M7`@HTW:+J\6+80@15_`L-79@MWB")&$V#:)8"F$*[%@2HH$;(C8B,"(:XK>'
M2P9-Y0@JB?)8+("##B4QJS%+&2$S$Q4C2.>/LF@0>#82HM&&,J%M&V%B_FB-
MDI$HWM%P$P4N?,9X[1,Z/],CC<4>OY0G0$(GH))C,T-IAV$[(S:3AV>#10(:
M-O](D\9C&`RQ&3N97\U#4,'39_9"0OS!DZ+Q@=O1"K^#.CQYDYX(=B,8-#MY
M'*[PE*K$4".&&ECYDPGQE)^RB:52'[M#<7C7+!>"8+1U@JV`",BADP1Q8=ZA
MELBH$*O&(]MADU*CE*2Q@U,YE4R)+7SIE7@)E3>TCZ/ADUF9&A^X@Q53*HM8
MCX!Y"K`'E=1H0@D$'MZ(/PJFC(L'*0P&CF6)$''2*%R)D4/2/^N%A)BE$>=X
MB_O%-NXU,$D4+I>"4@E6+,L(C(-SB[MT-9IR@K8!&@U)@H)@281#E+X86];A
M)G'$-M5BA0=Q=%05'IO"`L^"BZ^Y+O,"0`82)R`G*Y#_DIW>IB;WX6.6]D3U
M80KI9&2)%VWSJ":S!4=<J"Z)LI#^.`LP$W.K-R^N0F9&UG;F>4&O@TWH&4_-
M62='`HX&&2["TYP\5"W`&)&^N4W7PCUR]V77\97!F71RUSIN$ABLP2`?I82!
M\SI$V"1/0TKB`E-9:'*<F9+X$8<\>6X2@YP8\8P&F2]E6%:<B2<P&2<]6IT7
M(G'9EBNFQ#6#8VZ[Q2E!9C.`]7>P27]*`E--LW1OA"F&D3;$^"M[(ELHE3F6
ME6HL8EKOJ#7Q0AYJ:C]#5FBC5E&#4UY,PTP8-FIGB9#'N''O.&W,)EPV<VMX
M>D,1.9V#AEZ'542JQ@+?!#9O_T1W6VH_,(F0@'(-N)9HSY*>XN:H^P2?>#1(
M2(I0G[H@MJ(0U?F.QZ:.IQI1C%J$+85A9K(CKY)&F<,V7U@8XG%4\&@\J&F6
M]]&:.A(`^_A9=2-20<9,*9A)-J)AQL0:RGI+<M4UK2.C+<@B_LDL)#@WMG4K
M[69RR#)195>E%'E*<"2N4:)CT`H\\66G16.6%;A63&)@AE:E#4).5(IM:O(L
M@[,;.1*H!740):JM0<).4B1-4+:?T7HUBY$(*?5+'?AM`IF"TH(Y"/6EO[2P
M,,63S%-1]H)@<EI$M84B)84B*B5$9IA]>X*$(`5*0TD;`>5+M^B<T7,\#01_
MW>DLA_]WB]LQ.`3;%UUZCKHE1/.8(HI5-WBV1YH2'W43IPH3J"'8=F;Z=K>8
M)#.V=Q84(]18&I=33WVUM;HZ+]\Z;4%+'A$3IZW"M9DU&M4J;6\U10*C*9=Z
M(Y+SM`717H=U!59`C.482HG%E:*")W6#KNG&)]Z'B_[JJB=4*5*4G-.F*2+W
M7[NQM:?Z9_(E+S/G=FI%MD=+8`%#FP1355[4&E[KHWLZ6@BT3XB!,UIEDVCC
M0$WJ(V5(JV37E3]WEMD6-C?B'2K:I;_Z.VEUKED&HTEI4-BPKB9G*X1$J`![
M"L3$L;K3IVP5/"JJA.)R0-<$M,QF@V`*-EIS'`5YI);B'HW_L:AT=+W)]T\"
M*YG)1KBH1+[I*9"]9&F!LJ%=UI[O>5$"0CI[HKO[Y9]5RI!99[\.5C9.9J2X
MI4+D^[[-:QC[X3J'*EOO1&OC!FB4*B2EDY3"0S5A<[W<4T_]98:SYACG>"N#
M]DQ?$\+UTBT3>W<UZT#4XX`EZJ*[:6<[VWI-6E+`YJL7H5J]*[II-9'O.BT!
MQEGZFV</,T?7B+;($H>J@8.$6K4^.J)<.$$F"56"PK8-QJ!-7"1'0K;XDX9D
M1206O+9,Q#,)-,7QFD>K12M^5):_>Z<#U)^#"VA?FR>[836;92*MJA!O*VQ$
MYZZOAD,6'*=@''R>BZB)EK'==J;W_X,M>'QR^H4ZA4RZA$IJSF91:'0_5B.I
M?ULY=BQIK@HK#.NINXFK=62[6:R,3AP:2Q1'!4NP3#JZLE2H5V.3%(2GX`<\
MQQJN^/F[V)F"HXJI$3)<^2,-'Y8>_12XDEE>FTJN1G0[?,RD;\2\K]S,(@3`
M`211V+E-A>%$`FE,&O09M3JWA2-00ZQ&*8NPYRH(K$!A&#RQ*3QQLT%$O3G.
M\ZHJ>T)5%/L]?T*2,%P0[-G/ZG@CRQQ,.PJ.)@Q/1S,KM`Q5]ZRR$/O0_AAK
M?H0?M,4"@1"!&"V2>T"2V@,W)]F_E8@;ZT)J%ID1UWAK[N69BWNSWNE#%F0>
MSP*J,5(M6_\;0V"X@^(8(Q.9=G!(++ZIC,6BI_>#C7NGFZ&2231M/_,Y+05Z
MGK=UC2Q`J5>%+,O)RFK5J@YZTGDICAU$I<0UFDZ=TT-MC`BTCA/WT605O]C$
M*TS'<:OFFWV+LP6#)Y<3M7U&I^&RP,YU:G!M.[B2R#Z$KWB=0-=8:\^E-MXB
M:G!]K*1&T[5U8Z\B#3[G8D`;CO22+J)9LVUMFM+'ALO&AN_*U99]=QE!RZ:-
MDZG1EZJM2JTCF$?9VDKBCL96E?S!ACN=S(IYDT`BO4&SB31C&`L]*Q^X6VSD
M*>(1W`N=S%:R@]YWW&9XVAV%DZN4)Z;0VLY;F`EQVM21F*?`2L'_"]R+P0?T
MJI)4J95!J4I<^930;6E@*1O5+1#=722F`";8.VX'`I;'7=OLK90SZ7T6M)0T
M4X(Y^=Y4:<'F?4._S:R)B=M8:>"V>I/DRQJFL"A=6=VV;=O-$[RK_14!D[@H
M@31!^R+4VZ2)V!#V-Q7'VQ)F7.)1X3K+J<L?$=3..,DL'A$PGA18_(8U7H@/
MJ1$]ON-8\>-`/N1$7N1&?N1(GN1*ON1,WN1._N10'N52/N547N56?A1AMW90
MM^5;J.5=SI]<[N5B#N9?'N9D/N9FGN9EON9HSN9G_N9JWN9R#N=N'N=T/N=V
MGN=UON=XSN=W_N=ZWN>"#NA^'NB$/NB&_Y[HA;[HB,[HAT[:MOK=$2[IE#[I
MEE[IF'[IFI[IG+[IGM[IH/[IHA[JI#[JIE[JJ'[JJI[JK+[JKM[JL/[JLA[K
MM#[KME[KN'[KEG[EO-[KOO[KP![LPC[LQ%[LQG[LR)[LRGZ&?15SDYBK(`&"
M0)%AF^R%)[[LV*X3NW1,(8+#$@+M.V$;Z)831IGMYIX3U7[&4EAN_WON[L[L
MTK(JR52-3-PDH[(M=#*EW/.+'C6,-^X2!/UP+/4FY\(NQB,KW5$U_;JV"@-(
M;KV;[Q[Q(T$O=\MLGGIHQQ-#HPLY*04B9%I+?-%<X)SN-1%"@':L6F/Q+`SB
MW,KRDZ,V*A_0^?_C"AE%IMCS(]XN\3H?$N1U2AYG@UP*L.VS=WZ&I.SQ/X&U
MP^1.3)OV@]LL9>7FHE"/6"E%SDBO)!<R9-SV[SO?]121TL?2G>UD/"/%*ZN3
MF+19])F!,W4DQ(C%$Z\!JP434JR<XI(;N"6$]^&Q([[*QSGO]8"/$9BDX?`D
M-'K$`LI[/V%:]$,G]QEGU7`?&`C$`H,P([F6-B%I/*&FQ5(6;CACK.U;]#@:
M^*1_$?22TD[I:V]D&^R&1<T%JLPEQ)+C6SP!'DIX1XT1+WO=TIS6Q[$Z13X2
MDC1DI=N:XJ5__!-!7B4E<:[;-N%I*O^S0*_O\(B1"%:F]-%8CMM3._7_D386
M&TO;W_W08J+DHOI\7.[(G_X0@8O)PJ;QX0IPG9LTARMJ/]?*(LSJJQ/^H8ZZ
M>2OA1$0`(8A%@``LL!T42-#@P8(,`S!<B&W@080$&V)K%>`*MBL!!&$3I)'B
M2)(E39Y$F5+E2I8M7;Z$&5/F3)HU;=[$F5/GSI>M,)+T>;#54(I!018U6A1C
M4*-)?XYLBI3G5*!`B?H<RC2I*Z="D6I=:E1D5:@432FEFE;M6K9MW;Z%&U?N
M7+IU[>J\,K#K7;Y]_?X%'%CP8,*%`U\1]-'P8L:-'3^&'%GR9,J5+5_&G%GS
M9LZ=/7\&'1IPR)JM6$0$.9"%8HJGBP;8ZSED_VR6"3=2C%*0=<+50@.P$AU<
M^'#B.3W2[.A::`D6IGMS+(BZH_",MV4F#WE;=T>LVV$?C(*Z^'CRY8OG+4F[
M9.*+T#]61QA2_''1I(4R;4GPX,3L&!M>*>&]L;"ASSP##T00,Q9NJ\XB]:!2
MCB,3/A((BI$BW,\ZT`8<J"/F:B-*.<4RHO`X^`Z"0KP$5V2QQ<#HRZBY&%UJ
MKR,!-6SOH.E$*Y"%`"7ZKJ7^+OS.1O^L0\]%)9=D$JY6?CP2(O]4*RBZUR+*
MJ[G3(IIQI+P>O"Q(('5\"$@J!Q(3&RC*I$B@A4*ZL4TVFZ2S3CMIRHBIL1IJ
M);'$^OQSI!Q/TVA``O_%FRTT$ELKDSN0_O2S3R\+/.A#,@6TL"(P[^2TTSH7
MC9)`#5-RSB1!3.`20XZ:X]&HB:#;]$2*'*THSHH\Q3573V'<TR`WM]P2QX@$
MZDY8DJXP(3@.&_T.6&#9S!$D2HV4-4E=K\76Q1U/#"!3Q+X5!#'6NIQRU7$M
MI2B`/8*+\-6.I`$)W&]O.^T*0"$2I,]B6S&2H5&S!3C@XO(,-=J4<LR+H%%S
M3%0T@@DL4Z^5++)(6HH7ZDAALP*`5V"//V9WH:AZ,FFOI%C(-#ADT7I*):Q:
M?MDIIPP%N6:;,V--+DF)RY>NG6\&.FBAAR:Z:*./1CIII9=FVL5PKX`Z:JG_
MIZ:Z:JNOQCIKK;?FNFNOOP8[;+'')KMLL\]&.VVUUV:[;;??AAOLDQ*3-UR[
MZ\;[;KWSYGMOO_L&_&_!`R=\<,,+1_QPQ1-G?'''&X?\<<DCIWQRRRO'_'+-
M,^=\<\\Q;SITT4<GO7333Q<:ZI?^92M<G%COE-^13D$LJ9Z+@EWT>R',JW>H
M!$),)0U9Z5WFJ*'*/;(^1UVP^>.!LC>EQ/9S?D'K^EPPJ>@'"W?._6)C-2?3
M4.+7/IN\_VQ\GCB>=:-6HG"UI.!/MUN\VG]R-7KL47I.(O<Y2IE`EB*F^5GF
M6U%(SU-4A[SPE:P$2GG9`K.'$6LE0D5^$1?S8H,^_YL\4"4<C`D(.R/"F;AN
M5E[:STDN.+I6I$Q'L7%*_Z`20`1>""OSN9!FU(<2]!FD@27Y(4G*9,)9L::`
M@'G(#E=U/Y(TL!6F^%?YG!(H"BXH9R4AH5"8V*:>E>EG".&B[7QRN]TA3SU#
M&5?.ODA%,#Z**;V[HDG<)SO^(2^'VY-?'%DHGA6:)(@Z.HN.1A6\("Z0(YMB
M#!']Z!1"PC!W)@RB$K,X%P%*Y&1$P6*;[-7"$4$A7_QBD(S0(XWQJ8>$4N37
MNO:3K^X)13KOD5$E)2*0GJUF*$&ZQFJN(4N2$`N4#!E))4TS%$-Z9).JB\:3
M6L;#<`U%AD5!U"8-0L>2]?^Q:;P\I""B<,1>KI"/1EQ($(FHQ,J0$RH>Q-WW
M3K('/0)3G4*TX6%&A)H_JI.:$F$9@=X)H8FE))DYM*2@6A,_?&J2>M`LRR$-
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M+^4N_;`[7N'"EX,/X6;_<OL8O9["?B@#\):Z@@6.8M>0-NV+2_D:77NBII90
M&6(PI5K9:IXSA=UMS?3<>4($SVRZ*`2*@XVHR#FU0I7B\>!^I8OA)IYD>US2
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MD669-_<*S6,E<Q%&168U1RE+FOOSG$.3Z$+/IXX1<HJB?$36(E>YO`EIPQV:
MAIT-M&)O^N01/9IF7FUBP4;#-\RO0VT/X9N7+Z4FV:>U[VX<9[NUS)5QGQCW
ML5^?KI,)3?&,7QJRSZGNG\/%!U>6+TE;-^$VT:P28EV!#W)O\4NGF;OD1EW?
MO6G@0XB(UWAQ6+TDD>A(K8!A`@[K-I,E4&*#0D03ZIW!C;X-B5?,W0*B-DBB
MOAW6D1O_2&S`CX(+U2DL=\-2D[_7904*MSFA%LZ4T,[R40]>ZRGT)@VYSM&?
M]Z[2/ZS$`JKOB#X-<^1M_6T]G_R=:%<,'P6)4.C9$8B1CPBK[EE*U.R030<&
M]U#E:LU<5_CY*8^"U6(5Z9NSU+"EV9.I1\N^5UJH[[.T#5.G(ZH\CK@"*.BJ
MSV,3L4J7WEF0(5(CZYF5>G&>]1!!WYDHK]*(ZNF\HD@9%IB%$#Q`EQ&/D@HQ
M\MF(TAJ5</L_>YL?&7D3ZBM`L`L_.4*NG-F#"<L^VLL9\(-`K5*D(-.OA?`>
MK%M![/NPNZ(0=&NM\9F?Y*N_-HNK!U$B\*HC:AJ_';RXYPB7__`QH7NB->U`
M*41YE)<*O>&[0@C<'@L<"6_!M3AZ0KMB,;HAJ#:Y0P\;PZX@I[Y"#1H$(T7R
M+XJ@KSDDE2]TL;V0OSK+&9!#0ZEC#?V`L]8().^SC@!LPMX:J'<2A$SA/M8P
M!3YDL;'#$L6X@MARN0P$+8Q`)]0KE=<`NSN4I?DQI&=2J?8!N^J+Q1ZSOR1D
MPZZC1/)BM5,4,HO;Q';#(]:+,=<[".*YK*B"'>`9)&PLJ/AHP)P)O::`HR24
M1)*(!NLAICW\DBOZH^8QBE9K(=3[K');0VX:+Z_3P]]+)U>*GGS,GY)AGCIZ
MJV":('2<QH5D2)W@MVV+1.F!N(:DR/^*3(F)M,B,U,B-Y,B.],B/K!E`82.'
M/#:0')HR2H]C4[:E(,@I&HZ1#*.5N**5_!VCB"W)V#-`21.H.RN39)H`"`1!
M,`5AY)=3FA,W&21;,L$3!(UZ7![I8#3(:R(C6LJ$DZS*>"9-A(D@\\FA^:$@
M0B!KXJ"8@L=!E`W;@;*K-!6XXTI[^<J"^XL_>JJ#[#?%Z)B'.@C>Z[2]*,FN
M7)*46D4KC"IGM"QSY!DIS"37DB/6F9XUPTAY`J(AI,#$Z!\M@4/0VAOI^!8N
M43RI]$M<$34ZZJ,?X\KZ"D=V6:[(J\&>7,T@DL;`B,<A5#:+TA!T63RF[+Y,
M";7/O!9>`D/_I9H;UNG`?WE-R5@^-E0R/V2=64S,TWRAR1#&^6DI*F,O15*?
MI%*1MN--7*E`(\.&B`2A([3!0>I+F&(5\4S`]$0Y:!2R]G2,V-RPI[DETW2P
MZM..5(P:+(&:7]K.3I$ACQ(A$"K-5?+.^I@F%7G#Q7Q`BF#$YS3../I-!S0_
M]5(D*"K%?1K0_F011XL.YM@2ZZ(%PC0U>BJ.,D$?#@HW17*6TR@!,2G.N&0D
MXG,J^@S"%?PAI\,UPM-0.L$_X*0V$56H`N7)Q@#,<+(=XI*CFU1-TWR,*,01
M5-RRZM2_=+D[7-2B6]S1O[0X$N*@`[M-N;L"O>2,!7$%.',5Q;B^_SM<*.U:
M4./DP&K3S^AAD%WCHF#"M?TLBFURG_+,TO'(1^<13HE$R+P(CZ9CQ_9JRBRI
MMC4$-N[C0-@9-.CJTTGU"V%\":W<T!=E,4KEU$[UU$\%U5`5U5'-B6ISM:G@
M4U2S"9HD5<<`E*X8+<:;(I/AIL>LC&:2+!S,G6Q[2$0825N%S:[`U!""B2&-
MJU:5#(]PINL)@%,0A,&B#27RQA![,JH4C7<4!'1BI:SH3A6B2A904J[SNC7%
MR3@B19Z(2/]#UO(0,\F\T`N-J79ES\[@)?"*C<**5^U1/<J(1Z93-4)DR:Q(
M2?;",C1BKU-E&36:R9&0!E-=UP3+08/@IO\@HUAC7$\5HPSB/%8?/9:AFDG3
MR]@XDDZ$%*0,JC-QJ4R*>+P_8P73F*?V,3'DG#A[0=DVT4VEU-2'C8M&6LUC
MX<L8@U`\^SC%1"FXJ\(?;0U^A11]0;_LXZ61(E%W&B>V&J+KB;V>&C'=ZD.=
M+8Q*NB^B9<WHHL+A^*,>)==945*$#-'BBPS(\A/*[,2D55-\.D-\,ELT\J*%
MP$Z\E-LKC*GE`5:N;8MB`MM-I0CTC*XYF<#-&*:/0HG**\T>'5;!@,\(S%J!
MNM'[Q%.P:TQ(S)"GP5-V8K$NC#_'8TK!]8N'F=#5%4Q%XB8ERMG',-NC#5NU
M!(H20"ZX[(ODJKW_C0B^%CLBL7H/)%E"W1)0#?G=%3S*P$5=;U.R48'"GZW1
M'HM=QFC<DTA7?UQ/E>VCZK6+RF4(:9U2%97,YW`S->T9YD1`TCW=]FU>NKC;
MO=VMVOV\KVQ*_BO)+KU)TXU#I06B1BNN"3(?8"2^%=.Z2MLA-8P]Y%U0UU$?
M/6/>]\4)`1+8>90_2VW"NLO!*G/9`@VYF"G8I7I=U6&*:<HJBK""5`4,&?.H
MN7*ZB<55S_-'NW$Z&1:V-M$>.Q4*';UA5I5@M_C3WKF>0Q/48GR>P\6_-,V,
MY7O4.F4)%BC3DG6](`;!'ON,6E7A'TZ=+!;:)M'!EO#>Q=@ZTM+B,DXW_X?U
M83-6XS5FXS;>72[&$S=.$'JLFDL+3<AROX'!X[,J-^W%B'&+%X^*X+^H-"`>
M9#FVC*>Q+?Q!-M[*D*P@(#B>C"N`GZ'`74%)WRZ`M/8!5RSBUCH+X[MHCI5%
M9*,9T-NZ+@_KV^"(J=^4R7^)5_6<7,)(HD7^8T0,.(,5"B93-I0LY=!08O=]
M*?0IH,7E#(T59HZUW3_NV0PU#+'*J$/KUI`RA7%E"+LANWQ9(%G*G@[^96#>
MU3X*2@0<S%4>#[V]CVAES&\S+JQ$4^1%WJ!PJ/#M1:UED(/]9LX8RDT^B7XD
MD$C#4C71W<NX9'VR'L^D71U)V[/MX\*0I$T=P/__`8D:6EZ`^MM"SF=ZA9U]
MYN='!J4#,]9;'3M#43#UG-X+(<Z!-BP?H9*^BJ>HN1MW'2<@A+,NRNC/2%--
M].?X"$@&)HY9V"9\3JX@N]MZ:FC"N%%7/BTD)5</LM#V#>F;[EK&O"ACGD)L
MBT?M^\?M7;\A4YZ*D^=+0L;5*F?NTD##E>I]NZ!)NBTOE63(2-,CH@40ZE(=
M5<@\A@QA--\<(Y;4D.DG74$2AIJH3FO`("89669^'B;L89X7;+BL@&S!0S07
ML^NEJ$!,\B7(=FG)<-C8$Z.F$^3?:;K[6+:Z*^R\*C4<K@T1@^5#EMW!P[M=
M;N@&$JTNA.VG>=G31E;_8_9C3_GB)];MX!;NX2;NXC9N@_MH(!8?E3YN\4DN
MQCZV^CRPWZ:.<28O8]8P$11!!UUB!DD3XZCGF;@_UVYNFE#DCL4*\XG,T,(&
M4B(@\I[D0(.0H"JON8R&GU#?Z[V,<_6-J2#L+B[ONK#.:%+7(/(I!$G%]5X)
MD)N30(#ONT`?7HZI.6IA3]ME8V)),/*T*:(B]I@>93LUJ0CQ`"]5'$KL.T2?
MC;KKXB!+B/OBF,K>QAA0L$)<8]+@PEN5@Y"&(+$_L`J?AOJD!;K>-N2RUO`"
M0/MO$B_K8?Q$QRU%%3V05EX]V@#D4CSJQ5C<P$R][C(DL5@HU?TNJIT5':V_
M_],#6B6_"8Z&L(XHKWF&IG@V$"F'K/"P1/X1V;=^8QMLKRG$"BC!L&1D+CN-
MTL&<42&[<C0O8B&L(G7]W(\&;/,0A-$;"1,8JH+V8"9-:.4Q6G%DO_3"GOYY
MJE""*STC"K(Z"!5OA08%JC9%=)G@)6QR-*@""E#S:4C7()-FL,KC;>O-SH]X
M:N-=4F+,+D#W+@G=(0<V\:\4TU9_"?)]OV?G-0!_R5L_Z7$KZ1PSH`^\H4#'
M0-(NYPQDD*3ZCO-5:/.C(PG$<S275L":7Y.8-%8GC[\U\?;#=GS.6%LZ.]Y3
MNP(^19>=[._L&?O;S\4;^,$>*+[U=VX^F65G=G#3,_\F<S*ZJ:>JZ[.`=LZ!
M6<,UJGB_(MEV5S0+MPK?HDN,N"J2@+4,+ZBKBC25_]=[`?%,ZV7F5G)A(TN8
MG$H[%=D'CXRW'6J'Y<5^Z]F`2?*&=PPMU'E(+\F2%YAK)_JF=QBGA_JHEWI=
M.:R$I(H?>TBU./2FY\^M*LEH2DB,Y0R!A!ZCE["T+1YI;XRO//IYM>A0%IYT
M;VX_R<XC9M,=HR#'=N;-P%+:SK@%-XK8SL;Q9C_H]*VV=T^NIHI9;OJV3![G
M6W$&\PS\J[BXI]\I3`2W;]*N\!YQF74)/):#C^'W6KX/5UC<J7)ZE$4UVB*>
M%NU=3^LT'5`\RJTJIU=H]]S_@U%0A:PZQ!]<"$73`1P6W^OK;E>I]+6HLBYT
M!_9,=-\GK0M&6+J[&#QNQ[>L`@1DN,?)H*<S(-TIV.57895G'58B7VU"-OFA
MD:W",41,RV\3'07&1JLM\1OZ-E9SQ:<(1*`GX$F,$J#V@0&(`-@&$FS%@B!"
M@H*N)!QX90_"`*T:"B1X96+#C!HW<NSH<2`400VCB%S8ZF0K05"P+=18D>#+
MBPD/&AS8<F!-@K,.LF0A<N.5GPY_LL#X,J%$E*T"1,,6]"/4J%*G4JUJ]2K6
MK%JW1KW9\`I#C3D=\B3H,R+7M&HS7BF+<"Q;H0B]8BO:T*W=M7KO8D1H5Y!/
M08(%_SN5B_9PW;X#30SDZ;556)QNP>9-^%1AV,M'(Z8T-=AFY+VB1Y,N;?KT
M5<`:Z29LM=*L86Q'7Z.NG=%@;((E.+)V&/JR7X0R;6\%+AETQMX#-S-VJ+AF
MSL=NL>WF^U7NY;R;86HT3OP[^/#BP2MW"G&CV][-L<$=7UKUQO:M0V.>.YWN
M=/=1*[.O?!1R8WT!*-M<+YT%VT#522><8\+%)MU/E]%%F'&.T:<?AAEJN.%M
M^2$'E%S\`><=AUR5%QQ'VQ4VDV*5G5BB7T$)UM9S`0C2"A]EX0997H"E%%1,
M8-W(0E@Y&7320%9<!)@@%3')HT8^0;9'=GW1N-!Y=2UY(/^),'KY)9AJ_1C8
M7("1V>%;1`J28V@>AEF5C8-]AM-"9R87VIB$F144C7XI]J9"*:44'Y(-Y7:C
M302=0F="0@E:$*+LO56H6([B].>-TK0V:$%_`OHIJ*&V=B.I;Y&J9T8'SO5G
MEZ)^=.JIJPKB&4<N"AKIJHU>Z"JOO?KZ*[`;[CIJL,0-:-6PQ2J[++/-.OLL
MM-%*.RVUU5I[+;;9:KLMM]UZ^RVXX8H[+KGE4J741"BQAZ2Z[;+[;KKPKALO
MO?/:ZVZ]^-XKK[[]\OMOO@#O&S#!`QOL;\$('RRPP@TS_'#"$"\<,<436^QP
MQ1A?++'&'7/\<<8@;QPRR2/?NUK_`"FKO#+++;O\,LPQRSPSS37;?#/..>N\
M,\\]^_PST$$+/33111M]--))ZVPNTTT[_33444L]-=556WTUUEEKO35O9>(Z
M)YV>GKM6;@5=A5%L8H]&J5IRN:V5VI):=6A6;@O6%Z[LZ4GI3X,E6_9M\0V&
M4=R3-E1X5FSKC795BL_U5D?LXJ31'F"+Y1'CV4(6F4`I0=3*'IH^12'@4-%V
MFIL?#?>5;9R*>6`TIZ<.5=Z-(C[VW&"9I7>$905UTD&K\T03-K/<UM:K<0,(
MF4C)0G[7:*@Z=5)+L\?'49L=[3$10\>:FFY'UCLU>;8,1>8[>Y&93WAR-Z5$
MH46MF"#2_^:*71%(2;H7EO_=X_/)4DL,PI`9<4\0IPC+U_!W$6E`Y']M\5OZ
M9#(CWMEM?4,AX%!D$I*3R"A])OG,C]3&D++@Y39S6@C](E2__0F'>@[9'Z+\
M)I3NR:AY>GOAC&2"([:,;R!1L`A+((,1^N"*)\[S'V;HEYD58D%Z>VO@9Y8X
MN$$))A#<RZ!-9K2]]$&*,'Y+%Y\<92D9948PT>@@\T8WD0FBZ(7O2Z$:=U1#
M4Q'$%(AXX?_&%ZD!W@TWXV,>_Z2WK(-$RD:_NV$6G=*J(?9PC6#L8690A*@0
M*B1"_J,?HPC)2">)1$>1%%21+HG($5:2=<5#XG`.PA-:502!+O^L"QYQ*!<J
M,G)WAHJEI#@UP"L&,5"0!*!S(AD_6(YOBU)48A"]YS^C+$0F-$&F<(2$/-F<
MB)"+"J4N>^G*@@3&F0/9'J)64I:[_<0*V%B)^B9I0U194D_F2R2CVLB05M))
M3P?I0@]9$J-FOG-Z&-%D#XV8ID-JDG"=S"?Q!A66X-F$@\YI%F#`LE`N4G1Z
M!=F58$X!3N$`D9#2Y&A=4,B_7J*RDO`;3C^G)\:&_E%_NV3)1S=W#9C.$BQ7
M?"D2@2E,E2)2G"CT5$3U5\+##2F?HP2F3QYBI6@,R((Y_<U1NV=)]1E5(402
MZD"1I\PBOC`^5SW(Z9IZPZ3BRG44E>K_)'7W/D:F=$DZ-:J@#K)%6!9II0AY
MC4(;$[]V*M.6P?P?*'OY3+U>%"$-S.))&7DW4N;T5EUEEOHFXIAT_01`J304
M(WGB2"[NM"^3O50]IPK)=$&$D#_YH>]6-Z"5/$JO%AQ0BTHI-U@R#Z'$')1`
MDVG)QJ;*EMDS9?#`QRF`AM*7D4PK`%G5BC/BD)<X/1(/NSH9M!W4M58B;'>&
M"#KA$D6;H,4)?;:I/^V6BJ[Y7%*A_`A$/;(5GMA594>[NE;K1@8[P0GE1!%%
MP\<B$KR,!1!#&X/<B4XVF\VJ;W7_>-6P2$.BW+,?"#N(C<JUA#"`!"D`KR`Z
M002"IOH][V<J_VR2?&Z5@,R5$?=.$2F1`G![;_3:/[\98^9M$:]H3*%>?T0_
MVK@.4260*#&/\A#XH/""-.2@]"3H0+8Z&(C9+&-+?GNL8\'/KTVU*4F)N>`?
M81AT-#5R^@KXM5GN]B93+,F:G%MA(77702HA*4WF&,TK&*^NC>R@.[7)FLEX
MD(\B3FZ;)=-DNP#2AON["!G?>N$\"Q)<CD--HZ^R.O*4CBN/]DBEH]>W(TYZ
M4W8VUNU&<\2.H-2A7#NU>T)-.U6+YA2LUES_.&)6HG9+$)K"RJ-FC>I=\[K7
MOOXUL(,M[&$3N]C&/C:RDZWL93.[V<Y^-K2C+>UI4[O:UKXVMK.M[2MM<[O;
IWOXVN,,M[G&3N]SF/C>ZTZWN=;.[W>Y^-[SC+>]YT[O>]K[WM@,"`#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
